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Abstract 
 
OBJECTIVES: In Australia, diabetes causes significant morbidity and mortality. Whilst the need to 
prevent diabetes and its complications has been widely recognised, the capacity of health care 
systems - which organise diabetes care - to facilitate prevention has not been fully established.  
 
METHODS: A series of seven population-based case-control studies were used to examine the 
effectiveness of the Australian health care system and its capacity to manage diabetes. Six of the 
studies compared the patterns of care of patients who had developed advanced diabetes complications 
in 2000 (cases), to similar patients who remained free of the condition (controls) across Australia and 
for various risk groups. A secondary study investigated the role of treating GPs in the development of 
the outcome.  
 
RESULTS: A strong relationship between the patterns of care and the development of advanced 
diabetes complications was found and is described in Chapter 4. In Chapter 5, this same relationship 
was investigated for each Australian state and territory, and similar findings were made. The study in 
Chapter 6 investigated whether late diagnosis or the patterns of care was the stronger risk factor for 
advanced diabetes complications, finding that the greatest risk was associated with the latter. In  
Chapter 7 the influence of medical care during the pre-diagnosis period was explored, and a strong 
relationship between care obtained in this period and the development of advanced complications was 
found. In Chapter 8, which investigated the role of socio-economic status in the development of 
advanced complications,  found that the risk of advanced diabetes complications was higher in low 
socio-economic groups. Chapter 9 investigated geographic isolation and the development of 
advanced diabetes complications and found that the risk of advanced complications was higher in 
geographically isolated populations. Finally, Chapter 10, which utilised a provider database, found 
that some GP characteristics were associated with the development of advanced diabetes 
complications in patients. 
 
CONCLUSION:  A number of major risk factors for the development of advanced complications in 
Australia was found. These related to poorer diabetes management, later diagnosis, low socio-
economic status and geographic isolation. Strategies must be devised to promote effective diabetes 
management and the early diagnosis of diabetes across the Australian population.     
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Chapter 1 
 
The health problem 
 11
In Australia, diabetes causes significant morbidity and mortality and has been 
formally recognised as a National Health Priority.1 Whilst the need to prevent 
diabetes and its complications has been widely recognised, the capacity of health 
care systems - which organise diabetes care - to facilitate prevention has not been 
fully established.2 
 
In recent times there have been major improvements in diabetes care. For example, 
intensive insulin therapy,3 new hypoglycaemic agents4 and new treatments for 
hypertension5 have been introduced. Improvements have been made in the 
organisation of diabetes care, such as through diabetes centres, patient registers and 
reminder and recall systems.6 Yet, despite these developments, diabetes 
complications continue to occur and their prevalence may be increasing.7  
 
A number of factors may be contributing to this trend. Firstly, the prevalence of 
diabetes has increased over recent decades leading to a much greater population at 
risk of complications.7 Secondly, people with diabetes generally receive poor quality 
care in respect of their health needs, because the condition is difficult to manage.8, 9 
Thirdly, some of the most commonly used treatments may actually be ineffective, as 
only a small number have had their efficacy established in conventional health care 
settings.10 In the face of the growing prevalence of diabetes and the factors that may 
be contributing to it, and in order to reduce the burden of diabetes, the capacity of 
the health care system to manage the disease needs to be established by robust 
epidemiological studies. 
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In pursuit of a greater understanding of diabetes management, this thesis takes a 
particular perspective. It begins from the principle that diabetes is a public health 
issue and not merely a clinical problem.11 This is because of its substantial and 
growing prevalence, the great pervasiveness of its risk factors (such as impaired 
glucose tolerance, obesity and physical inactivity) among the population,7 and also 
because the key metabolic disorders in diabetes are preventable through relatively 
inexpensive and potentially very accessible interventions.12  
 
Diabetes represents a somewhat atypical challenge to the public health discipline as 
this field rarely concerns itself with diseased populations, focusing largely as it does 
on preserving or protecting health.13 Yet, arguably the epidemiological and clinical 
characteristics of diabetes make the condition an appropriate public health concern. 
In a sense the disorder underlying diabetes – hyperglycaemia - is more akin to a risk 
factor for disease than a disease itself,14 and the concerns associated with diabetes 
are in large part due to its complications, such as retinopathy and cardiovascular 
disease, which are eminently preventable.15  
 
When a medical intervention is considered for use in clinical practice, ideally this is 
guided by whether it has been shown in clinical trials to be effective.11 However, 
clinical effectiveness does not necessarily mean that the intervention will be 
effective in the community, or in routine settings of care.11 Typically, when an 
intervention is shown to be clinically effective, its efficacy has only been 
demonstrated in ideal or research settings and with particular types of patient who 
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are suitable to be enrolled in clinical trials. This means that there is often doubt 
about whether clinically effective interventions will be similarly so in the broader 
population.11 
 
Indeed, there are many examples of interventions that have been shown to be very 
effective in clinical trials that have made very little impact on population health.11 
There are a number of explanations for this inconsistency: the group in which the 
treatment was shown to be effective may not be typical of the broader group to 
whom the treatment is designed to be applied, or the treatment is not generally 
delivered to the standard at which its effectiveness has been demonstrated.11, 16 
However, only interventions effective at the population level reduce the burden of 
disease and are therefore of greater public health significance.17 Such effectiveness 
has not been established for the management of diabetes in the Australian health 
care system.11  
 
With regard to examining the effectiveness of current models of care, the thesis 
evaluates them across the Australian population using population-based case-control 
studies. Case-control studies start with the identification of persons with a condition 
of interest (cases), and suitable control groups of persons without the condition 
(controls).18 The aim of these studies is to identify factors that differ between the 
groups and thus can help to explain the development of the condition in the cases.  
Population-based case-control studies are a special type of case-control study 
 14
distinguished by the fact that they source study subjects directly from the population 
of interest.  
 
This is an important feature as other types of case-control study obtain subjects who 
are only indirectly connected to the population of interest. This means that there is 
often doubt as to whether such study subjects are truly part of the population of 
interest or whether they are from another group. That subjects of population-based 
case-control studies are directly sourced from the population of interest makes for 
more robust findings than those from studies where subjects are only indirectly 
linked.  
 
In population-based case-control studies, study populations are defined 
geographically and temporally.19 In the studies in the thesis, the population that they 
are concerned with consists of all people with diabetes in Australia who made 
Medicare claims between 1994 and 2000. The cases are all subjects within that 
population that were treated for the first time for vision-threatening retinopathy in 
2000, and controls are subjects in the same population who had not been treated, nor 
developed the complication in 2000.  
 
The thesis retrospectively compares the intensity and quality of diabetes 
management over seven years of cases and controls. The principal research question 
is: does a history of poor standards of diabetes management lead to the development 
of advanced diabetes complications. This question is examined from a number of 
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perspectives and for a number of high-risk groups. These comparisons are able to 
examine the effectiveness of diabetes management across Australia.  
 
To conduct this investigation the Medicare database is used. The Medicare system 
funds most of the activities of GPs and specialists in Australia and is the major 
source of health care in the country.20, 21 In each year approximately 90% of the 
population receive at least one Medicare service.22 Thus, it has a greater likelihood 
of affecting the health of the population than perhaps any other health care 
institution or program. 
 
The thesis uses a specific diabetes complication – vision-threatening retinopathy - as 
the outcome of the studies. Vision-threatening retinopathy is a relatively common 
advanced complication for which there are a number of very efficacious preventative 
interventions, in particular, glycaemic control3 and screening for retinopathy.23 The 
complication develops after many years of exposure to hyperglycaemia24 and has 
been used as a sentinel indicator for poor diabetes management by other authors. 25  
 
Furthermore, the research questions addressed in the thesis may be relevant to other 
diabetes complications. This is because diabetes complications share a similar 
aetiology in that they are all associated with hyperglycaemia and the pathological 
processes that are related to it.15 Hence, interventions that slow the progress of 
retinopathy by addressing hyperglycaemia are likely to improve other complications 
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as well.3 Similarly, patterns of care associated with retinopathy that are investigated 
in the thesis, are likely to also reveal themselves in other diabetes outcomes.26  
  
There is significant epidemiological evidence that particular groups within the 
diabetes population are at higher risk of developing complications.27 These include 
low socio-economic groups,28 geographically isolated populations29 and Aboriginal 
and Torres Strait Islanders.30 The relationship between socio-economic status and 
diabetes has been examined in a number of the studies.31, 32 As diabetes 
complications occur more often in socio-economically disadvantaged populations,32 
it is important to understand the role of diabetes management in respect of this 
group. In addition, the relationship between geographic isolation and health has also 
been identified, with rural and isolated populations tending to have worse health 
status than those who live in metropolitan areas.33  
 
Aboriginal and Torres Strait Islanders suffer a disproportionate burden of diabetes 
and also have poor access to health care services.30 But as there is doubt about the 
identification of Aboriginal and Torres Strait Islanders in the Medicare database, a 
specific research question concerning this group was not able to be examined. 
However, the Northern Territory study in Chapter 5 was conducted in a jurisdiction 
with a relatively high population of Aboriginal and Torres Strait Islanders.30 Hence 
this study may provide an indication of the relationship between health care 
utilisation and diabetes complications for Aboriginal and Torres Strait Islanders 
across the Australian population.  
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In population-based studies it has been found that only about 50% of people with 
diabetes have been diagnosed with the condition.34 Diabetes complications, 
including vision-threatening retinopathy, have been shown to take many years to 
develop35, 24 and during much of this time patients are often unaware that they are 
suffering from diabetes or hyperglycaemia.24 In the pre-diagnosis period, people 
with diabetes do not attend practitioners for diabetes care, do not have access to 
hypoglycaemic medications and do not practise diabetes self-management. In 
hyperglycaemic patients, these circumstances may lead to poor metabolic control 
and the accelerated development of diabetes complications.36 Hence the timing of 
diagnosis is a critical factor in determining the risk of developing advanced diabetes 
complications, such as vision-threatening retinopathy.  
 
The significance of the timing of diagnosis is examined in two studies. In Chapter 6, 
a research question is examined to determine whether the timing of diagnosis or the 
pattern of care, is the more critical factor in the development of advanced 
complications. Differences in the patterns of care in an early-diagnosed group are 
used to establish which of the two is the most significant risk factor for the 
development of complications. In addition, in Chapter 7 whether patterns of care 
prior to the diagnosis of diabetes is a risk factor for advanced complications, using 
similar analyses is investigated. By using these studies the thesis is able to weigh up 
the relative merits of early diagnosis versus diabetes management as alternative 
population-based strategies for the prevention of complications.    
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There is also substantial evidence that the nature of GP treatment is a major factor 
that can determine the risk of complications.37 It has been found that practitioners 
who take a long-term perspective in the management of diabetes achieve better 
diabetes outcomes than those that focus on remedying its symptoms.38 Whilst much 
of the way in which GPs’ practice is determined by systemic factors such as the 
relationships between various sectors of health care,39, 40 some practices come down 
to practitioner attitudes, skills and knowledge. 41 In Chapter 10 the relationship 
between some of these personal attributes of practitioners and the development of 
advanced complications is examined.  
 
The issues examined in the studies represent some of the major challenges 
associated with the management of diabetes in Australia.42 Their findings have 
important implications for policy direction as they address issues such as whether 
diabetes management is adequate, whether the health care system should focus on 
the management of diabetes or on screening, whether efforts should be concentrated 
on primary or tertiary care, whether programs should be introduced to promote 
equity in how diabetes is addressed, and whether medical practitioners need to be 
better skilled in diabetes care. These are important issues to resolve if the 
management of diabetes is to be effective and equitable across the population in 
Australia.       
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Research questions  
 
1. To determine whether patterns of primary and secondary health care 
utilisation are risk factors for the development of diabetes complications in 
the population with diabetes in Australia.  
 
2. To determine whether state and territory health care systems play a role in 
the effectiveness of diabetes management in Australia. 
 
3. To determine whether patterns of care or delayed diagnosis is the greater risk 
factor for the development of diabetes complications in the population with 
diabetes in Australia. 
 
4. To determine whether health care utilisation prior to the diagnosis of diabetes 
is a risk factor for the development of diabetes complications in Australia.    
 
5. To determine whether socio-economic status is a risk factor for diabetes 
complications in Australia.  
 
6. To determine whether geographic isolation is a risk factor for diabetes 
complications in Australia.  
 
7. To determine whether the characteristics of GPs are associated with the risk 
of diabetes complications in Australia. 
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Chapter 2 
 
Literature review 
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The structure of the literature review  
 
The literature review is in five parts and establishes the need for the research 
questions to be resolved.  The review begins by identifying the major health issue 
that will be addressed in the thesis by providing an epidemiological and clinical 
overview of diabetes in Section 1. This is followed in Section 2 by a discussion of 
the health care system and the major interventions that can prevent the development 
of advanced diabetes complications. The focus then shifts to implementation, where 
Section 3 discusses the capacity of the health care system to support diabetes 
management. The issue of equity and its role in diabetes and its influence on health 
care utilisation is then considered in Section 4. Section 5 concludes the review by 
firstly summarising the major arguments in the review and then identifying the 
knowledge gaps that are addressed in the body of the thesis.     
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Section 1: Epidemiological and clinical overview of diabetes 
 
This section provides an epidemiological and clinical overview of diabetes. It 
describes the major diabetes types, their distribution in the population and the 
contemporary trend of increasing diabetes prevalence.7 Following the overview, a 
detailed clinical picture of diabetes is presented. This documents the clinical 
characteristics of diabetes, its major complications, most common treatments, and 
outlines the risk of each complication for people with diabetes in general and for 
particular risk groups.  
 
This descriptive section establishes a basic understanding of the epidemiological and 
clinical features of diabetes and sets the scene for Section 2, which discusses the 
clinical guidelines for the management of diabetes through which many of these 
complications can be controlled or prevented.   
 
Whilst diabetes imposes a large burden of disease globally,7 this section argues that 
there is much in the way of prevention that can be used to address the condition. 
Indeed, in many ways because these interventions have been developed, the large 
burden of disease from diabetes is not something that we must resign ourselves to, 
but is something that can be addressed. This is a major theme of the literature review 
and a primary message of the thesis.   
 
 24
EPIDEMIOLOGICAL OVERVIEW 
 
Diabetes is a chronic condition characterised by hyperglycaemia or high blood 
glucose.43 In adults, diabetes is diagnosed when fasting plasma glucose ≥ 7.0 mmol 
and/or when 2-h plasma glucose is ≥ 11.1 mmol/la and there are also symptoms of 
hyperglycaemia.44 Diabetes is the seventh leading cause of death in Australia and 
contributes significantly to morbidity, disability and poor quality of life.1 Its major 
impact is through complications, which include cardiovascular disease, retinopathy, 
renal disease and peripheral vascular disease (see Table 2.1 below).15  
 
The prevalence of diabetes is increasing worldwide, with most of this increase 
accounted for by type 2.b, 7 The International Diabetes Institute and the World Health 
Organisation estimate that by 2010 there will be approximately 221 million people 
with diabetes globally, which represents an almost doubling in the population 
affected from 124 million in 1997.7 Trends such as the ageing of the population, the 
growth of sedentary lifestyles and increasing rates of obesity account for much of 
the increase in diabetes across the globe.7 By contrast, in developed countries, whilst 
these trends have existed for years, they have increased steadily over the past 50 or 
so years. However, in developing countries they are a relatively recent phenomenon 
and are associated with the introduction of Western consumerism and sedentary 
                                                 
a Fasting Plasma Glucose (FPG): Blood glucose levels after overnight fasting. 
2-h blood glucose: Blood glucose levels during a 2-hour 75-gram oral glucose tolerance test.  
(World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. WHO: 1985). 
 
b The most common forms of diabetes are types 1 and 2 diabetes. Type 1 diabetes has an early onset 
and is related to an immunological disorder that impairs the functioning of the pancreas. Type 2 
diabetes develops later and is associated with insulin resistance related to lifestyle and diet. Types 1 
and 2 diabetes are discussed in detail below.  
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lifestyles.30 In addition, the increase in diabetes in developing countries has been 
explosive, reaching 20-30% in some populations.45  
 
Whilst the exact prevalence of diabetes in Australia is not known, when findings 
from health and diabetes surveys are extrapolated it is estimated that there may be up 
to one million people with the disorder.30 However, because the vast majority of 
diabetes is type 2, it is estimated that only about half of this population has been 
diagnosed with diabetes.34 This reflects the incipient nature of type 2 diabetes.46  
 
Indigenous Australians and some ethnic populations suffer a disproportionate burden 
of diabetes (these are discussed in detail below).30 This reflects the greater 
prevalence of behavioural risk factors,27 poorer living conditions and in some cases 
genetic predisposition among these groups.30 These etiological differences may 
explain some of the patterns of diabetes that have been observed among these 
populations, where type 2 develops at younger ages,27 complications are more 
advanced when identified47 and patients have poorer prognoses than populations of 
Anglo-European descent.30 In a study of diabetes in the indigenous population of 
North Queensland, McCulloch et al. found the prevalence of diabetes to be 12.6%,48 
which is approximately 4 times greater than in the general Australian population.48 
 
Diabetes care comprises a large and increasing component of the Australian health 
care budget. In 2003, Colagiuri et al. found that the annual cost of diabetes was 
approximately $3 billion per annum,49 which represents a significant share of health 
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care resources. Thus, there are sound economic reasons, as well as health ones, to 
address diabetes.  
 
CLINICAL CHARACTERISTICS 
 
The most significant pathology in diabetes is a disturbance in the mechanisms of 
glucose transport, which results in hyperglycaemia.50 The acute symptoms of 
hyperglycaemia such as ketoacidosis result from dysfunctional barrier and exchange 
mechanisms in the inter- and intra-cellular matrices that regulate the absorption of 
glucose.51 The chronic complications of diabetes result from the persistence of 
hyperglycaemia and associated metabolic disorders that degrade cells, tissues and 
organs.3, 5 The severity and persistence of hyperglycaemia, hypertension and 
dyslipidaemia determine the character and extent of this damage.52 
 
There is strong evidence that hyperglycaemia and hypertension are the principal 
causes of diabetes complications.3 In 1993, the Diabetes Complications and Control 
Trial (DCCT) published its seminal paper showing that intensive insulin therapy, 
with the aim of achieving near normoglycaemia, could significantly reduce the risk 
of advanced diabetes complications.3 This study found that for people with diabetes 
who maintained levels of HbA1c at or below 7.2%, the risk of developing diabetic 
retinopathy was diminished by 50%. Similar findings were also made in respect of 
other complications such as nephropathy and neuropathy, pointing to the need for 
the widespread adoption of HbA1c <7.2 as a therapeutic target.53  
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Although the incidence of macrovascular complications such as cardiovascular 
disease was lower in the experimental group in the DCCT, it was found not to be 
statistically significant.3 This confirmed that although related, microvascular and 
macrovascular complications were somewhat dissimilar and pointed to the 
importance of other factors such as hypertension54 and dyslipidaemia55 in the 
management of these conditions in diabetes.   
 
Whilst the DCCT established the importance of aggressive glycaemic control for the 
prevention of complications, it only included people with type 1 diabetes in the 
study.3 As there are a number of significant etiological and pathological differences 
in the two major diabetes types (see below), there was some doubt as to whether 
these findings, which related to type 1, would be relevant to type 2 when the study 
was first reported.56 This was supported by the epidemiological evidence at that 
time, where studies of the relationship between hyperglycaemia and complications 
in type 2 had been somewhat equivocal.56 It was not until the findings of the United 
Kingdom Prospective Diabetes Study (UKPDS) were published that the significance 
of glycaemic control in type 2 was firmly established, where it was found to have a 
similar role in type 2 to its role in type 1.57    
 
The UKPDS examined the role of hyperglycaemia and hypertension in the 
development of diabetes complications among people with type 2. In a number of 
important ways, the intervention examined in this study was similar to that of the 
DCCT in that it involved groups of newly diagnosed individuals who were given 
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intensive therapy with the aim of achieving low blood glucose targets. The study 
used metformin (an oral diabetes medication), blood pressure medication, and 
insulin as its major treatment modalities.5 In addition, by addressing hypertension, a 
greatly reduced risk of cardiovascular disease was found.5  
 
These studies were both well constructed and executed randomised controlled trials 
with large sample sizes, which provided findings with a high level of validity. They 
provided very strong evidence of the need to control hyperglycaemia in the 
management of diabetes.  
 
Classification of diabetes 
Type 1 diabetes 
Type 1 diabetes accounts for about 10-15% of diabetes in Australia. In this condition  
there is a total lack of, or a significant reduction in, the body’s capacity to 
manufacture  insulin because of the total or near total destruction (over 90%) of 
beta-cells in the pancreas.58 It occurs as a result of an immunological disorder.59  
 
Patients with type 1 diabetes usually present with symptomatic hyperglycaemia or 
diabetic ketoacidosis. Polyuria followed by polydipsia and weight loss occur when 
elevated plasma glucose levels lead to dehydration. In this condition, if insulin levels 
are not restored insulin deficiency can be fatal.59 The average age of diagnosis is 15 
years, although there is increasing evidence that the condition can develop at any 
age.59   
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The major therapy for type 1 diabetes involves the restoration of insulin levels.59 As 
the pancreas can no longer produce insulin, this hormone (insulin) is supplied by 
artificial means such as by regular injections or insulin pump.58 When insulin is well 
managed, people with type 1 diabetes can live a relatively normal life even though 
they have a potentially fatal condition.59     
 
Type 2 diabetes 
Type 2 diabetes accounts for about 85-90% of diabetes in Australia.60 In this 
condition insulin deficiency is not absolute but relative.61 Here, insulin deficiency 
results from insulin resistance (where insulin becomes less effective) and in the latter 
stages from  beta-cell exhaustion. As a result of metabolic dysfunctions, glucose 
absorbing tissues become resistant to insulin and higher concentrations in the blood 
are required for glucose metabolism.50 
 
Elevated blood glucose and insulin can have major pathological effects. Whilst 
hyperglycaemia causes diabetes complications, hyperinsulemia is associated with 
cardiovascular disease.62 If insulin resistance persists, beta-cells become exhausted, 
leading to a condition similar to the non-functioning of beta cells that occurs in type 
1, although absolute insulin deficiency does not eventuate.63   
 
Whilst the foundation of the management of type 2 diabetes rests on lifestyle 
changes such as increased physical activity and carbohydrate modified diets,64, 65 
remedial therapy can take either of three approaches: insulin resistance can be 
 30
reduced by oral medications (insulin sensitising agents); insulin can be increased by 
injection or both types of therapy can be used.66 Currently about one-third of type 2 
patients receive insulin, with the majority of the remainder using oral medications.66 
The average age of diagnosis of type 2 is 50, but since it has become more prevalent 
in the population it is being diagnosed at earlier ages.7  
 
There are three main risk factors for type 2 diabetes.67 These are older age,67 a 
family history of the condition,68 and obesity,61 which in turn is related to 
behavioural risk factors such as sedentary lifestyles69 and inappropriate nutrition.64 
However, these risk factors rarely cause the condition independently as they are 
strongly correlated in people with diabetes.70 Hence, it is common to find that people 
with type 2 possess a cluster of risk factors and require a range of treatments such as 
for hypertension,71 dyslipidaemia72 or hyperglycaemia during their diabetic 
lifetime.73 
 
Whilst the aetiology and phenotypic characteristics of types 1 and 2 diabetes differ 
markedly, the dysfunction that underlies diabetes, hyperglycaemia, is very similar in 
both conditions.61 Hence, many of the same treatment and management interventions 
are used for both.74  
  
Pre-diabetes and other related conditions 
Amongst the broad class of insulin deficiency syndromes of which types 1 and 2 
diabetes are a part, there is a range of other clinical types including impaired glucose 
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tolerance (pre-diabetes) and gestational diabetes mellitus that are also significant 
causes of diabetes-related morbidity.61  
 
Impaired glucose tolerance (IGT) is a condition of elevated blood glucose similar to 
that of type 2, but blood glucose is at levels below that which define diabetes (2-h 
blood glucose ≥ 7.8, but < 11.1).50 It is a common condition in overweight and obese 
individuals,7 a major risk factor for type 2 diabetes, and is associated with an 
increased risk of cardiovascular disease.75  
 
Gestational diabetes mellitus is the elevation of blood glucose that occurs during 
pregnancy in otherwise non-diabetic women.50 The condition can cause major 
obstetric and neonatal complications and hence is a major concern for pregnant 
women.76 In non-diabetic women gestational diabetes mellitus resolves after 
pregnancy and does not generally result in advanced complications.77 However, it 
can initiate symptoms of diabetes in people with impaired glucose tolerance and is 
often an indicator of incipient type 2.78 
 
Diabetes complications  
Table 2.1 below lists the most common forms of insulin deficiency syndromes 
(including diabetes) and their complications, which are discussed in the following 
pages. The greatest impact of diabetes results from its complications, which are 
primarily associated with damage to vascular systems.51 Although the body’s 
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vasculature is usually referred to as one system, the plural ‘systems’ is used here in 
order to differentiate the effects of diabetes on large and microscopic blood vessels.   
  
Table 2.1: Common insulin deficiency syndromes and  
diabetes complications 
 
 
Most common insulin deficiency syndromes 
• Type 1 diabetes 
• Type 2 diabetes 
• Impaired glucose tolerance (pre-diabetes) 
• Gestational diabetes 
 
Complications 
Microvascular 
• Diabetic retinopathy 
• Nephropathy 
• Neuropathy 
 
Macrovascular 
• Coronary heart disease 
• Stroke 
• Peripheral vascular disease 
 
Combined microvascular and macrovascular 
complications 
• Diabetic foot disease 
 
 
Whilst the precise mechanisms by which hyperglycaemia causes diabetes 
complications have not been fully described, there appears to be at least two distinct 
processes:  in microscopic vessels such as those which supply the kidneys and eyes, 
disturbances in the barrier and exchange mechanisms at the microcellular level 
degrade cell walls (angiopathy), eventually resulting in microvascular complications 
such as diabetic retinopathy.79  
 
In large (macrovascular) vessels such as the coronary and tibial arteries, damage to 
vessel walls result from the build up of atherosclerosis, that is thickening of the 
arterial walls by lipid deposits that obstruct and reduce blood flow, which in turn 
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stresses the cardiovascular system.80 There are a number of factors that lead to 
atherosclerosis in diabetes: these include hypertension81 and dyslipidaemia,82 which 
often precede hyperglycaemia. While atherosclerosis is a common condition in the 
broad population, it is more aggressive in people with diabetes.80 Hence the 
condition needs to be addressed assertively.  
 
At the microcellular level, the pathological consequences of the exposure of tissues 
to hyperglycaemia include acute, insulin-reversible and chronic non-reversible 
abnormalities in cell functioning.83 Amongst those abnormalities that are reversible 
are increased polyol pathway and protein kinase C activity, elevated hydrostatic 
pressure in microcirculation and the greater formation of early glycosylation 
products of matrix, cellular and plasma proteins.84, 85, 86 These abnormalities are 
associated with increases in the vascular permeability and protein leakage that 
characterise early diabetes. The irreversible abnormalities, however, primarily 
involve changes to long-lived molecules such as extracellular matrix components 
and chromosomal DNA.83 The cumulative effect of these pathologic processes is the 
narrowing of diabetic vascular lumina with inadequate perfusion in vulnerable 
organs that results in the vascular damage that characterises diabetes.  
 
Microvascular complications 
The most common microvascular complications of diabetes, as presented in Table 
2.1 above, include retinopathy, nephropathy and neuropathy.15 In addition, there are 
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also less well defined microvascular effects on the heart muscle, gastro-intestinal 
tract and erectile tissue,15 which are also important but not discussed here. 
 
Diabetic retinopathy 
Diabetic retinopathy is the most common cause of blindness in people aged 30 – 
69.24 It has an estimated prevalence of 15.4% among people with diabetes in 
Australia.60 The condition results from angiopathy of the retina, which can cause 
visual impairment and has the potential to lead to blindness.24  
 
Although type 2 diabetics comprise the largest number of people who develop 
retinopathy, type 1 patients are at higher risk.87, 88 This is because retinopathy is 
related to the length of exposure to hyperglycaemia and patients with type 1 
generally suffer from diabetes for longer. The causes of blindness from diabetic 
retinopathy are retinal ischaemia and structural changes to the macula (maculopathy) 
that result from the reversible and non-reversible pathological mechanisms described 
above, when they affect the eye.24  
 
In clinical studies diabetic retinopathy is classified into two broad types: non-
proliferative retinopathy and proliferative retinopathy, with the latter following from 
and more severe than the first.24 Non-proliferative retinopathy is characterised by the 
development of ischaemia and oedema on the retina.89 Whilst proliferative 
retinopathy has many of the same symptoms as non-proliferative retinopathy, it is 
differentiated by the development of new vessels on the macula, which poses a 
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greater threat of visual impairment.90 For most of its course diabetic retinopathy 
does not cause symptoms that patients are aware of as it is only when the retina has 
suffered significant damage that perceptible symptoms occur.24  
 
After 3 to 4 years following the diagnosis of diabetes, about 19% of people with type 
1 diabetes will have evidence of the condition.60 In addition, retinopathy starts early 
in the progression of type 2. After 20 years nearly all type 1s and about 60% of type 
2s will have retinopathy lesions. Further, after 20 years about 50% of type 1s and 
10% of type 2s will have developed proliferative retinopathy, representing a large 
burden of visual impairment.60   
 
The prevention and treatment of retinopathy is based on glycaemic control, 
ophthalmological screening and laser photocoagulation therapy (the outcome 
measure used in this study).24 It is estimated that up to 90% of diabetic blindness 
might be prevented through existing screening, control and treatment modalities if 
they were appropriately applied and utilised.91  
 
Diabetic nephropathy 
Diabetic nephropathy is the major cause of end-stage renal disease (ESRD), a life-
threatening condition that results in kidney failure.15 The clinical definition of 
nephropathy is the presence of proteinuria (more than 0.5g per 24 hours) in a 
diabetic patient without cardiac insufficiency, urinary tract infection or other renal 
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disease.15 It is estimated that 11.2% of people with diabetes have suffered or been 
treated for this condition in Australia.60  
 
The development of ESRD is related to proteinuria, which is defined as abnormal 
concentrations of protein in the urine. Proteinuria is an indicator of the health of the 
kidney, specifically of damage to glomerular filtration.92 In patients where 
proteinuria has been detected, 25% will go on to develop ESRD after about 6 years 
and 75% will develop the condition after 15 years, making it a very serious aspect of 
diabetes.93   
 
Particular ethnic groups appear to be especially prone to developing nephropathy, 
pointing to the influence of behavioural, lifestyle and/or genetic factors in the 
aetiology of the condition.94 For example, Indigenous Australians (see Section 4 
below),30 African Americans,95 and Pima Indians all have higher rates of 
nephropathy than people of Anglo-European background with diabetes.96 Proteinuria 
occurs in 15-40% of patients with type 197, 98 and between 5 to 20% of patients with 
type 2.99, 100  
 
The prevention and control of nephropathy relies on glycaemic and blood pressure 
control, which is similar to other diabetes complications.101, 102 This is achieved 
through dietary changes,103, 104 insulin and oral diabetic102 and blood pressure 
medications.105 The need to treat nephropathy by controlling hypertension accounts 
for the high proportion of people with diabetes using blood pressure medications.106 
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There is also strong evidence of a link between nephropathy and retinopathy.107 
Most people have retinopathy when they are diagnosed with nephropathy and there 
are common pathological mechanisms involving hyperglycaemia and hypertension 
in both conditions.108, 109  
 
Diabetic neuropathy 
Diabetes is the most common cause of neuropathy (nerve damage) in developed 
countries, with 9.8% of people with diabetes in Australia reported to suffer from this 
condition.60  Whilst the exact mechanism by which hyperglycaemia affects the 
nervous system is not well understood, it appears to result from damage to the 
vascular system at the micro-cellular level, as described above.110 
  
Diabetic neuropathy encompasses a range of abnormalities affecting both the 
peripheral and autonomic nervous systems.111 These include abnormalities in 
sensory tests and electrophysiology which may be accompanied by sensations of 
burning, numbness, tingling, fatigue, cramping and aching in the limbs.111 
 
Nerve damage is generally symmetric and starts from distal nerves in the lower 
extremities such as toes and feet and progresses towards the upper extremities.112 In 
its most severe manifestations, neuropathy can lead to ulceration, foot deformities 
and lower limb amputation.113 
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Diabetic neuropathy occurs at similar rates in both types 1 and 2 diabetes.114, 115 In a 
population-based study, the Rochester Diabetic Neuropathy Study, it was estimated 
that 66% of type 1 diabetics have the condition, along with up to 59% of patients 
with type 2 diabetes, making it possibly the most common of all diabetes 
complications.114  
 
Neuropathy can be prevented and managed by glycaemic control,3 while sensory 
tests and foot inspections can identify foot pathologies.116 Neuropathic pain can be 
treated by non-steroidal anti-inflammatory drugs (NSAIDS)117 and anti-
depressants.118 Depending on symptoms, treatments may include infection care and 
in rare cases, lower limb amputation.119  
 
Macrovascular complications 
The second classification of complications identified in Table 2.1 is macrovascular 
complications, which occur at three sites in the vascular system: the coronary, 
cerebral and peripheral arteries.120 These complications include cardiovascular 
disease and peripheral vascular disease.15 
  
Cardiovascular disease 
Cardiovascular disease is the main cause of death in people with diabetes, with an 
estimated 80% of diabetics dying from these conditions.121 In Australia, people with 
diabetes are about four times more likely to suffer a heart attack and five times more 
likely to suffer a stroke than the general population.60  
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The most common form of cardiovascular disease is coronary heart disease,122 which 
is caused by blockages from lipid deposits in the coronary arteries (atherosclerosis) 
that can lead to myocardial infarction (heart attack) or thrombosis.123 Stroke results 
from a similar pathogenic mechanism but is due to blockages in the blood supply to 
the brain and can result in paralysis or death.124, 125 In people with diabetes, 
cardiovascular disease can be addressed by lipid, 126 and blood pressure control,127 
which are facilitated by lifestyle changes such as improved diet, increased physical 
activity128 and appropriate medications.127, 126 There is some debate as to whether 
glycemic control is effective in this regard.3, 102, 129  
 
There are a number of common treatments for cardiovascular disease in people with 
diabetes. These include biguanide metformin,102 a medication primarily targeting 
hepatic tissue, which is involved in the regulation of blood glucose through glucose 
metabolism and storage. The UKPDS found that metformin reduced the incidence of 
fatal myocardial infarction by 50%, of stroke by 41% and of all cause mortality by 
36%.130 Metformin has become one of the mainstays of therapy in diabetes.  
 
In addition, statins, which reduce LDL cholesterol, are also used. These medications 
have been shown to reduce the risk of a first and recurrent cardiovascular event in 
people with type 2 diabetes. The Cholesterol and Recurrent Events (CARE) trial 
investigated pravastatin (40mg daily) in 586 subjects with impaired fasting glucose 
who were at high-risk of developing diabetes. It was found that those who took the 
medication had a 25% lower risk of recurrent coronary events.131 In addition, in a 
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combined analysis of the CARE trial and the Long-term Interventions with 
pravastatin in the Ischaemic Disease (LIPID) study (which was conducted in 
Australia), pravastatin (40 mg daily) reduced the cumulative risk of coronary events 
by 44%, which points to this agent being very effective in preventing acute 
cardiovascular conditions.132  
 
As well, the Diabetes Atherosclerosis Intervention Study (DAIS) investigated the 
effects of fenofibrate (200 mg/day), a treatment for dyslipidaemia in people with 
diabetes. It was found that after three years of taking this medication, the 
progression of localised coronary stenosis was reduced, resulting in fewer 
cardiovascular events.133  
 
With regard to hypercholesterolemia, the Scandinavian Simvastatin Survival Study 
(4-S) investigated whether another statin drug, simvastatin, was effective in reducing 
this aspect of dyslipidaemia. It was found that simvastatin reduced 
hypercholesterolemia in men who had had a previous myocardial infarction or 
coronary heart disease and significantly reduced the risk of a subsequent 
cardiovascular event.134  
 
Studies have also been conducted into hypertension therapy in diabetes. In the Heart 
Outcomes Prevention Evaluation study (HOPE), 3577 normotensive diabetes 
patients were given ramipril (10mg daily) and they experienced a 37% reduction in 
cardiovascular mortality.135  
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Studies have also shown that thiazolidinediones (troglitazone and rosiglitazone), 
which are used to treat insulin resistance, favourably alter fat distribution and 
dyslipidaemia in people with diabetes.136,137 In addition, among patients who are at 
an imminent risk of cardiovascular events heart or vessel surgery, such as coronary 
angioplasty may be appropriate interventions.138  
 
Peripheral vascular disease 
Peripheral vascular disease reduces the circulation of blood in the lower limbs, 
which can lead to a disease process that results in the need for amputation.116  The 
National Health Survey conducted in 2001 by the Australian Bureau of Statistics 
found that 2.1% of people with diabetes reported having had an amputation. This 
amounts to a four times greater risk than in the general population.60 
 
Peripheral vascular disease results from blockages in the tibial and peroneal arteries 
that serve the legs and feet by lipid deposits that can be detected by weakened pulse 
in these arteries.139 Although peripheral vascular disease is an infrequent cause of 
ulcers (which are more commonly associated with neuropathy),140 it plays a major 
role in wound healing and gangrene and is a common contributing factor to 
amputations.141 
  
Peripheral vascular disease can be prevented by glycaemic control,3 identified 
through foot screening.116 Topical wound and infection care may be required for 
treatment.141 However, normalising lipids or reducing blood pressure has not been 
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shown to improve the condition.116 In many cases, neuropathy and peripheral artery 
disease co-exist, resulting in legs or feet that have nerve damage as well as depleted 
circulation.141 This condition is termed diabetic foot disease and is discussed 
below.116   
 
Combined microvascular and macrovascular complications  
In addition to complications due to discrete microvascular or macrovascular 
pathologies, there are also complications that result from both of these pathological 
processes combined.116 The major complication of this type is diabetic foot disease.  
 
Diabetic foot disease 
Diabetic foot ulcers and lower-extremity amputations are common and can affect up 
to 15% of people with diabetes.116 They have a profound effect on the functionality 
and integrity of the foot.141 Ulcers, which are breaks in the skin that allow infections 
to penetrate, are the primary lesions of diabetic foot disease.141  If ulcers or 
infections develop, necrosis can occur leading to a need for foot or lower limb 
amputation.142 In addition, there are other effects on the structure of the foot leading 
to deformities.  These are termed Charcot foot.142  
 
There are two types of diabetes-related foot pathologies. These are neuropathic 
feet,143 in which nerve damage predominates and neuro-ischaemic feet, where both 
nerve damage and peripheral vascular disease occurs.144 In a review of the evidence, 
Gavin estimated that 60% of ulcers were due to a neurological cause and the 
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remaining 40% to peripheral vascular disease or both mechanisms combined.145 The 
neuro-ischaemic complication is the more severe of the two. 
 
Conclusion 
Section 1 of the literature review has provided an overview of the epidemiology and 
clinical characteristics of diabetes. It has shown that diabetes affects a broad range of 
tissues, organs and systems and makes a significant contribution to the overall 
burden of disease. However, there is a large body of evidence showing that with 
appropriate lifestyle changes and medical care, diabetes complications can be 
prevented,3, 5, 67, 146 as discussed in Section 2 below. This is because of the central 
role that hyperglycaemia, hypertension and dyslipidaemia play in complications.15 In 
most cases these metabolic conditions can be managed,3, 5 which is the principal 
concern of the research questions investigated in this thesis.   
 
As most interventions used to prevent complications can be readily provided through 
primary and secondary care,74 it has become possible in recent decades for the health 
care system to focus on the prevention of complications rather than on their 
remediation (see Section 2 below).147 Nevertheless, the epidemiological evidence 
suggests that the prevalence of advanced diabetes complications is high and may 
actually be increasing.7 This is the case even for complications that are well 
understood and easily prevented, such as diabetic retinopathy.146 This suggests that 
many health care systems have continued to focus on remediating the symptoms of 
diabetes rather than on preventing them. Thus non-clinical factors such as access to 
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primary health care on an ongoing basis may be one of the most significant factors 
determining morbidity from diabetes.147  
 
The section that follows reviews the preventive interventions as represented by 
clinical management guidelines for diabetes and explores the evidence concerning 
utilisation of the guidelines in Australia. The descriptive information in respect of 
the guidelines is provided in order to establish an understanding of codified 
standards of care aimed at preventing diabetes complications, the use of which is 
examined in the body of this thesis. The thesis uses indicators of health care 
utilisation that can approximate the use of the guidelines. The evidence in respect of 
the use of the guidelines, which is generally found to be inadequate, sets the scene 
for the subsequent section on a more effective model of chronic disease care.  
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Section 2: Clinical management guidelines for the prevention of 
diabetes complications.  
 
Having described the epidemiology and clinical features of diabetes in the previous 
section, this next section presents a discussion of the clinical management guidelines 
for diabetes. The clinical management guidelines are significant in that they embody 
evidence-based interventions for the prevention of complications and as such are 
intended to form the basis of a health care system that can systematically address 
diabetes.12  
 
The clinical and public health evidence suggests that the combination of effective 
self-management, matched with regular monitoring and screening of complications 
can significantly reduce the risk of diabetes complications.148, 149 The disposition of 
diabetes to be controlled is determined by its maturity,150 the proficiency of patients 
in self-management and their ability to obtain regular medical care.151, 152 The 
evidence shows that even patients with established diabetes and advanced 
complications benefit when their condition is managed in such a way as to achieve 
appropriate blood glucose targets.150 
 
After discussing the role of self-management in diabetes care, this section explores 
the importance of the structure and organisation of care for reducing the prevalence 
of complications. The major modalities of diabetes care are outlined and their 
functions discussed. The second half of the section focuses on clinical management 
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guidelines as a vehicle through which care can be organised. It summarises an 
example of such guidelines and then reports the evidence concerning aspects of 
management reflected in them. The broad finding that evidence-based clinical 
management guidelines are not well complied with is taken up in Section 3, which 
explores the potential to improve diabetes outcomes by reorganising the health care 
system towards the greater provision of appropriate chronic disease care.  
 
SELF-MANAGEMENT 
 
There is strong evidence that increasing the participation of patients in their own 
medical care by encouraging self-management, leads to better clinical outcomes.151, 
152 This has been found for diabetes153 and other chronic diseases such as asthma.154 
With regard to diabetes, the major self-management tasks in diabetes include: (1) 
engaging in activities that promote health and build physiological reserve such as 
exercise, proper nutrition, social activities and sleep; (2) utilising health care 
providers and systems and adhering to recommended treatment protocols; (3) 
monitoring physical and emotional status and making appropriate management 
decisions on the basis of symptoms and signs; and (4) managing the impact of 
diabetes on one’s ability to function in important roles, on emotions and self-esteem 
and on relations with others.155  
 
However, from the practitioner’s perspective, getting patients to effectively manage 
their diabetes can be a difficult undertaking.156, 157 This is not only because the 
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competencies required of the patient are numerous and demanding, but also because 
each competency needs to be tackled individually. It appears that competencies do 
not reinforce one another, such that patients can be very competent in some aspects 
of self-management but may fail to perform well in others.154 For example, it is 
common to find that patients who take their medication diligently are not sufficiently 
physically active.148 
 
The factors found to be related to competency in self-management include the 
personal characteristics of the patient such as self-efficacy,158 the strength of their 
motivation to protect their health and their understanding of the illness.159 In 
addition, social circumstances play a role, with patients who have adequate social 
support faring better.160  
 
Perhaps surprisingly, studies have found that there is no relationship between socio-
demographic characteristics and competence in self-management.149 This is despite 
the strong relationship between these characteristics and other aspects of diabetes 
such as the development of vision-threatening retinopathy161 and obesity. 162  
 
Studies have also found no consistent relationship between competence in self-
management and gender, 163, education, income,164 intelligence, general health 
knowledge, personality type or level of compliance to medical regimens, 149, 165 
despite all of these factors being related to health behaviour in other conditions.149 
Thus competence in diabetes self-management appears not to be determined by 
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factors that are generally related to self-care practices but rather seems to be 
problematic for most people with diabetes regardless of their social or psychological 
status.154  
 
THE ORGANISATION OF CARE 
 
When individuals are considered, the major determinants of the risk of 
complications include health status,150 lifestyle,166, 167 competence in self-
management,149 the appropriateness of the treatments they receive,168 whether they 
have a regular source of medical care169 and the competence and approach of their 
practitioners.170 By contrast, when populations are considered, a major determinant 
of the risk of complications is the organisation of the health care system. 171 This is 
because at the macro level, the health care system influences the individual 
determinants identified above, governs access to medical care and determines the 
nature of the care that is provided.172 
 
In Australia, health care is the responsibility of both the Commonwealth and state 
and territory governments.173 Whilst the Commonwealth government funds general 
practice and some specialist care through the Medicare system, the states administer 
public hospitals.173 Because people with diabetes generally suffer from both acute 
and long-term conditions,15 they are generally users of both the Medicare and 
hospital systems.147 The influence of state and territory health care systems on the 
risk of complications is examined in Chapter 5 of the thesis.  
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The significance of the funding source stems from the administrative arrangements 
that underpin it, as different funding sources point to federal and state bureaucracies 
being responsible for specific parts of the health care system.174 However, it also 
points to the potential for the fragmentation of care as patients move between levels 
of care.175, 176  
 
Reflecting the broad range of health care received by people with diabetes, there are 
a number of modalities of care involved in the treatment of this condition.175 The 
modalities generally address different aspects of diabetes and have a varying 
capacity for involvement in day-to-day management of the disease. The major 
modalities of care include that provided by GPs, medical specialists, specialist 
outreach programs, ambulatory care (or diabetes centres), acute care hospitals and 
shared care.42 An overview of these modalities is provided here to illustrate the 
nature of health care systems that are involved in diabetes.  
 
Modalities of care 
Care by GP alone 
Between 80 and 90% of people with type 2 diabetes may be managed by their GP 
alone, and this care is primarily funded by Medicare.177 This common arrangement 
equates to a conventional doctor-patient relationship and is the most accessible form 
of health care for the population.178 In this modality, a GP provides generalist care 
and co-ordinates care from all sources. When specialist or allied health services are 
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required, patients are referred to them, but the GP retains overall responsibility for 
the patient’s care.179 
 
Ideally, patients will have only one GP. However, in Australia there is no 
mechanism by which attendance at GPs can be restricted,178 as occurs through 
patient registration in the National Health Service in the United Kingdom180 and in 
Norway and Denmark.181 In the absence of such a mechanism, patients are free to 
move between doctors.178 Whilst this may enable greater freedom of choice on the 
patient’s behalf, it can also result in the fragmentation of care if the patient has 
frequent changes of GP. Because of the danger of patients receiving incompatible 
treatments, frequent changes can have serious consequences for the effectiveness of 
the management of diabetes.169 Similarly, a patient without strong ties to one 
practice is less able to engage in ongoing, high quality diabetes care.169  
 
As diabetes management is primarily provided by GPs,177 it is likely that the 
majority of care represented in the Australian epidemiological evidence reported 
below refers to this modality. The role of GPs in the management of diabetes is 
examined in Chapters 4 to 10 of this thesis. 
 
Care by medical specialists and consultant physicians 
It is uncommon for medical specialists or consultant physicians, such as 
endocrinologists, to be the principal providers of care for people with diabetes.182 
However, they play a significant role in the management of diabetes. Indeed, 
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Overland estimated that during the 1990s up to 38.5% of diabetes patients in 
Australia were treated at some stage by consultant physicians.183 Generally, medical 
specialists focus on applying their specialist knowledge and skills in their medical 
practice and tend to see patients on a sessional basis.175  
 
When they do take a principal role in the management of diabetes, this may be an 
indication of a greater need for intensive therapy as a result of a more symptomatic 
condition.177 As this care is provided in the community and in public hospitals, it is 
funded by both Commonwealth and state and territory health care systems.173 The 
role that medical specialists and consultant physicians play in the management of 
diabetes is investigated in Chapters 4 to 9 of this thesis.  
 
Specialist outreach services 
In communities where medical specialists and GPs are scarce, specialist outreach 
services have been established.42 These services often include ophthalmology, 
endocrinology, cardiovascular specialists and diabetes nurse educators, enabling 
geographically isolated populations access to diabetes care. Such services often 
represent the only access remote and regional populations have to these types of 
treatment.33 This care is funded by both Medicare and state and territory health care 
systems.173 
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Ambulatory care 
In Australia, diabetes centres are the principal providers of ambulatory care (or out-
patient hospital care) for people with diabetes.184, These centres offer a broad range 
of diabetes health care services, including complications monitoring and screening, 
as well as diabetes education and social support.184  
 
Patients often attend these centres for screening, to remedy crises, or when the 
treatment required is beyond the capacity of their regular GP (for example, 
retinopathy screening).184 Diabetes centres are usually based in or strongly linked to 
public hospitals, which provide them with a steady stream of newly diagnosed 
patients as well as patients whose diabetes is advanced and difficult to manage.42, 184  
 
In order to meet demand for the type of care that diabetes centres provide, some 
centres ration their services by avoiding taking formal clinical responsibility for 
patients (the co-ordination of care role). They do this by restricting the length of 
time over which most patients can attend centres, thus coercing patients to return to 
their GP for the long-term management of diabetes.185 As most diabetes centres are 
based in public hospitals, they are primarily funded by state and territory health care 
systems, although Medicare funds some of the services depending on how particular 
practitioners are reimbursed.173 The role of ambulatory care in the management of 
diabetes could not be specifically examined in the thesis. 
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Diabetes care in public hospitals (acute care) 
Even though public hospitals operate separately from general practice in Australia, 
they provide a large range of medical care to people with diabetes.186 This mainly 
relates to tertiary, acute and emergency care and hospitals are rarely involved in the 
day-to-day management of diabetes. This care is primarily funded by states and 
territory health care systems.173 Whilst public hospitals could not be directly 
examined in this thesis, their influence can be inferred from the state and territory 
study (Chapter 5), as how hospitals are organised is the primary difference between 
the states and territory health care systems.173  
 
Shared care arrangements 
The most effective modality of diabetes care is shared care, which refers to co-
operative arrangements between GPs, medical specialists and allied health 
practitioners such as diabetes educators.42 Studies have shown that when diabetes 
management is provided in a comprehensive and co-operative manner, diabetes 
outcomes improve significantly.38   
 
The National Diabetes Strategy summarised the aims of shared care as:  
 
to provide the person with diabetes integrated and better quality care by: (1) 
improving communication between primary and specialist services; (2) 
improving co-ordination in the planning and delivery of diabetes care; (3) 
increasing the involvement and skills of GPs in caring for people with 
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diabetes; (4) promoting consistent standards of care; (5) avoiding duplication 
of services.42  
 
Each of these aims has been shown to improve the quality of diabetes care (see 
section 3 below).38  
 
Despite the evidence in support of shared care, most people with diabetes do not 
receive this type of management, as it requires a significant profession and skills 
base that is rare, as well as formal agreements between practitioners.187 This care is 
funded by both Medicare and state and territory health care systems.173 Similar to the 
modalities of care above, the role of shared care in the management of diabetes 
could not be examined in the thesis.  
 
Adequacy of modalities for chronic disease management 
In general, the effectiveness of modalities of care in managing diabetes is 
determined by their ability to provide ongoing and appropriate diabetes care.38 For 
some modalities such as GP care, this is more able to be achieved than for others, 
such as public hospitals.179 However, in many cases, people with diabetes are 
required to rely on modalities of care that are not appropriate to provide diabetes 
management. This may lead to poor management and a higher risk of complications 
even though practitioners may be highly skilled in treating diabetes.175  
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Even in modalities that are appropriate for ongoing chronic disease management, 
other factors may lead to poor quality care, particularly where treatment involves a 
short-term focus and where medical care is disease rather than patient focused.188 
Hence, it is not just important that patients gain access to the appropriate modality, 
they must also be provided with care that is of an appropriate nature and standard.189  
 
The preceding overview has shown that there are a number of institutions and 
modalities involved in the care of people with diabetes. Whilst there is a range of 
systems and practitioners involved in diabetes care, GPs provide the majority of care 
for diabetes in Australia. This reflects the nature of the medical care required by 
people with diabetes, as well as the structure of the health care system through 
which this care is provided.179  
 
Recently, however, it has been recognised that GPs, both in Australia and 
internationally, have not been very proficient in managing diabetes.190, 191 This is 
evident in the rate of risk factors among regular GP attendees,192 in addition to the 
often inadequate level of screening and monitoring reported in epidemiological 
studies (see Chapter 4 below).190, 193  
 
In some countries this has led to a shift back to acute care hospitals as the major 
providers of diabetes management,38 although this has not occurred in Australia.42 
At the same time, a large number of policy makers and practitioners have also 
recognised the importance of keeping diabetes care largely in the primary health care 
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system.194, 195, 196 This is because of the need to make diabetes care widely accessible 
and community-based, rather than reverting to a more specialised and intensive 
mode of treatment.196, 197, 198 These authors have argued for a greater orientation of 
the primary health care system towards chronic diseases.6, 194  
 
Before exploring how the health care system could be oriented to more effectively 
manage chronic disease, the literature review sets out the evidence-based clinical 
guidelines for the management of diabetes. The guidelines can serve as a vehicle 
through which diabetes care is organised and which has the potential to significantly 
improve the quality of management.199 The section then reports on the findings from 
a number of studies that have examined the extent to which the guidelines have been 
implemented in Australia. Together these findings point to delivery of sub-optimal 
care by the primary care sector to people with diabetes during the 1990s. This 
evidence sets the scene for the analyses of current care models comprising Chapters 
4 to 10 of this thesis.  
 
CLINICAL GUIDELINES FOR THE MANAGEMENT OF DIABETES  
 
Much like other individuals, diabetes patients seek medical care for a wide range of 
purposes and in addition, obtain a large amount of care in respect of their diabetes.193 
In Australia, most care for diabetes is provided by GPs, supplemented by occasional 
visits to acute care hospitals, diabetes centres, medical specialists and allied health 
professionals,42 as discussed above.  
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Reflecting the major role played by GPs in diabetes care, in the past few decades 
there has been a concentrated effort to improve the capacity of GPs to manage 
diabetes.42, 74, 200 This has been driven by factors such as the development of 
inexpensive and effective prevention interventions,74 the prohibitive cost of hospital 
care, and the need to make care for diabetes more widely available.194   
 
Australian health departments have sought to consolidate GPs as the major providers 
of diabetes care by codifying primary care-based screening and monitoring 
interventions into clinical management guidelines as the basis for the management 
of diabetes (see Table 2.2 below).74, 200 The guidelines are based on both established 
and contemporary clinical evidence which shows that by following the prescribed 
interventions, most diabetes patients should minimise the risk of developing 
advanced complications.12  
 
The guidelines recommend complications screening and monitoring at identified 
intervals that should be achievable in primary care. From the perspective of 
facilitating diabetes management, the guidelines can be used in two ways: either as a 
method of planning clinical practice, or for evaluating the quality of care.199 Health 
care utilisation that approximates the level of adherence to the guidelines, forms the 
basis of the main research question testing chapters in the thesis (Chapters 4 to 9). 
 
The guidelines published by the New South Wales Department of Health in 1996, 
replicated in Table 2.2 below, are typical of those developed in other states and 
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territories of Australia. They also reflect contemporary international standards of 
diabetes care.201  
 
Table 2.2: The Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus 
 (The New South Wales Department of Health, 1996) 
 
 
(1) Assess diabetes control by measuring HbA1c  
 
Every 6 months for insulin treated patients. 
Every 6 to 12 months for non-insulin treated patients. 
 
(2) Ensure that a comprehensive ophthalmological examination is carried out 
 
At diagnosis and then every 1 to 2 years for patients whose diabetes onset was at age 30 years or more. 
 
Within five years of diagnosis and then every 1 to 2 years for patients whose diabetes onset was at age 
less than 30 years. 
 
(3) Measure weight and height and calculate BMI 
 
On initial visit, then measuring weight every 3 months. 
Measure weight more frequently if the patient is on a weight reduction program. 
 
(4) Measure blood pressure 
 
(5) Examine feet 
Every six months or at every visit if high-risk foot or active foot problem. 
Refer to specialist experienced in the care of the diabetic foot if infection or ulceration is present. 
 
Ensure that patients with high-risk foot or active foot problem receive appropriate care from specialists 
and podiatrists expert in the treatment of diabetic foot problems. 
 
(6) Measure total cholesterol, triglycerides and HDL cholesterol 
 
Every 1 to 2 years (if normal). 
Every 3 to 6 months (if abnormal or on treatment). 
 
(7) Test for microalbuminuria 
 
At diagnosis and then every 12 months for patients with type 2 diabetes. 
5 years post diagnosis and then every 12 months for patients with type 1 diabetes. 
 
(8) Encourage healthy lifestyle 
 
Healthy food choices. 
Appropriate physical activity.  
No smoking. 
 
 59
The purpose of the guidelines 
Both Australian and international studies show that the quality of diabetes care 
varies significantly between practitioners and across jurisdictions.202, 203, 204 This 
often means that some patients receive high quality care, whilst others are treated 
very inadequately. Thus an important goal of health care policy has been to 
standardise the quality of diabetes care,199 and this is promoted through the use of 
clinical management guidelines such as those presented above.   
 
The interventions that are recommended are those required by patients from the time 
of diagnosis and throughout their diabetic lifetime in order to achieve diabetes 
control.12 Whilst the medical care individuals obtain will vary due to differences in 
the character of diabetes (for example, some patients may need to focus on specific 
co-morbidities such as hypertension), the guidelines represent a minimum inventory 
of care that is required by all patients for the management of diabetes.12  
 
In Australia, the guidelines have been introduced with education and skills-based 
programs for GPs and medical specialists,200 and in recent times they have been 
formalised by being incorporated into the funding schedules of Medicare.205   
 
Structure of the guidelines 
The guidelines are comprehensive in their scope and address two levels of risk 
relevant to diabetes. These are proximal risk factors (Guidelines 1,2,4,5,6 and 7 in 
Table 2.2) and underlying risk factors (Guidelines 3 and 8), where the hierarchy 
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represents the closeness of the risk factor to the principal pathology implicated in the 
complication. 
 
Proximal risk factors can be distinguished as those that are monitored using 
pathology, diagnostic and sensory tests for hyperglycaemia, hypertension and 
dyslipidaemia, or that represent actual morbidities such as foot disease and 
retinopathy. By contrast, underlying risk factors are states or behaviours that 
attenuate proximal risk factors, for example obesity, smoking, physical inactivity 
and poor diet and are not specific to diabetes.  
 
At the time that many of the studies reported in this section were conducted, the 
clinical management guidelines were promoted through state and Commonwealth 
based education and training programs for GPs and medical specialists,200 but 
specific Medicare funding for diabetes management had not yet been introduced 
(this was not established until 1999). However, the pathology tests prescribed in the 
guidelines were able to be claimed as individual items (such as HbA1c tests) from 
the time of the establishment of the Medicare system in February 1984 and all 
medical attendances were funded.206    
 
What the guidelines measure  
Assess diabetes control by measuring HbA1c (Glycosylated haemoglobin) every 6-12 months  
Glycosylated haemoglobin (HbA1c) is a measure of glycaemic control.207 The 
advantage of HbA1c over other indicators is that it is not affected by short-term 
 61
fluctuations in blood glucose, which commonly occur, as its value depends on the 
concentration of glucose in the blood over a 120 day period.207 As has been 
established in Section 1, glycaemic control is essential for the management of 
diabetes.208 The use of HbA1c testing in the management of diabetes in Australia is 
examined in Chapters 4 to 9 of this thesis. 
 
Ensure that a comprehensive ophthalmological examination is carried out every 1 to 2 years  
Annual or biannual ophthalmological examinations are recommended for the 
prevention of diabetic blindness. During examinations, the condition of the retina is 
observed in order to identify retinopathy.144, 209 
 
There are two methods of examination used in Australia: ophthalmological 
examination using ophthalmoscope or retinal photography.210 In both methods, 
practitioners look for the signs of retinopathy, which include haemorrhages, 
distinctive textures and spots, the density and characteristics of which can be graded 
and related to the risk of blindness.211, 212 The use of ophthalmological screening can 
be inferred from the specialist and optometrist data in the studies in Chapters 4 to 9. 
In addition, these studies include a retinal photography indicator.  
 
Measure weight and height and calculate body mass index (BMI) every 3 months 
Body Mass Index is an important indicator of overweight and obesity (BMI ≥ 25), 
which as noted in Section 1 above, is a major risk factor for coronary heart disease 
and stroke in people with diabetes.213  
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Measure blood pressure 
High blood pressure is a symptom of cardiovascular disease and nephropathy. 
Whilst it has many of the same consequences in both diabetic and non-diabetic 
individuals, in diabetes, morbidity occurs at blood pressures below that of the non-
diabetic population. Thus there is a need for aggressive treatment for this 
condition.214  
 
Examine feet every 6 months  
Foot examinations include a range of checks including visual inspection for skin 
discolouration, oedema, ulcer, callus and deformities. In addition, foot temperature, 
vibration perception and tactile sensation are tested. 215 To assess the vascular status 
of feet, vascular claudication, rest pain and pedal pulses are also examined by 
practitioners.140  
 
Measure total cholesterol, triglycerides and HDL cholesterol every 1 to 2 years 
Hyperglycaemia results in a particular type of dyslipidaemia, where people with 
diabetes tend to have high levels of LDL-cholesterol and triglycerides and low levels 
of HDL-cholesterol. There are also changes in the nature of LDL-cholesterol, such 
that the cholesterol particles become more dense, which may increase the deposition 
of atherosclerosis on vessel walls.216 The role of HDL-cholesterol testing in the 
management of diabetes is examined in Chapters 4 to 9 of this thesis.  
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Test for microalbuminuria every 12 months 
Elevated microalbuminuria is the earliest reliable and clinically detectable sign of 
nephropathy and is an indicator of the integrity of glomerular filtration.101 Changes 
in the structure and function of the kidney in diabetes can lead to ESRD.15 Only 
limited data on the role of microalbumin testing and the management of diabetes 
were available for the present study (1998-99 only). This is presented in the 
multivariate models in Chapters 4 to 9 of this thesis.   
 
Encourage a healthy lifestyle 
As was discussed above, the largest component of diabetes is provided by diabetes 
patients themselves through self-management.149 Reducing the risk of complications 
requires that patients obtain sufficient physical activity, eat healthy diets, participate 
in social activities and get enough sleep.155 The principal means by which self-
management is promoted in the medical setting is by diabetes education.217 
Compliance with this aspect of the clinical management guidelines was not 
examined in the thesis, although it can be inferred as being a component of the 
medical attendances in the studies reviewed below, as well as the GP data used in 
Chapters 4 to 9.   
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EVIDENCE ON THE EXTENT OF SCREENING AND MONITORING DIABETES 
COMPLICATIONS IN AUSTRALIA 
 
A number of Australian studies have reported on aspects of diabetes management 
reflected in the clinical management guidelines. These studies are reviewed in order 
to provide a picture of diabetes care in recent times in Australia.    
 
Methodology for selecting studies 
The aim of the following review is to represent diabetes management practices in 
Australia for the general diabetic population as they occurred in the 1990s, 
according to the best epidemiological evidence. To achieve this, the literature 
included in this review was selected according to three criteria. Firstly, the findings 
included information on the use of interventions identified in the clinical 
management guidelines. Secondly, the studies were population-based so that the 
findings were generalisable to the broader population. This resulted in the exclusion 
of studies solely concerned with type 1,182, 218  as well as those utilising diabetes 
register populations.219 Finally, the studies were required to be relevant to 
contemporary diabetes care, such that studies that used data collected before 1990 
were excluded.186 From the application of these criteria to the Australian diabetes 
literature, six studies emerged.  
 
Each of the studies was ranked according to these criteria, with the ranks then 
summed to give an overall score of validity and relevance. The studies are reported 
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for each of the guidelines with the highest ranked study first, followed by studies 
that were ranked successively lower. The studies show widely varying estimates of 
diabetes screening and monitoring, reflecting different practices, populations and 
methods of data collection. The studies provide robust estimates of the levels of 
adherence to some of the guidelines (such as ophthalmological screening) but for 
others, the data are much less reliable (for example, weight measuring). In addition, 
there is an absence of longitudinal studies, as most are cross-sectional. 
 
HbA1c testing  
Two studies reported on levels of HbA1c testing in Australia, using data from New 
South Wales190 and Western Australia.193 In a study of the Medicare records of the 
diabetes patients of GPs in South Western Sydney, Harris et al.190 found that 12.7% 
of 3828 diabetes patients had been tested for HbA1c between January and June 
1996. This rose slightly to 13.6% of 5481 diabetes patients in July and December 
1998 in the same locality. Kamien et al. conducted an audit of the diabetes care 
received by 467 type 2 diabetes patients selected from the patients of a random 
sample of 204 GPs in Perth, Western Australia in 1991 to 1992.193 They found that 
52% of patients in this sample had received an HbA1c test within 12 months. The 
overall impression is that the level of HbA1c testing was well below the 
recommendation in the clinical management guidelines that patients obtain this test 
every 6 to 12 months.12   
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Ophthalmological examinations 
Using the AusDiab study, a population-based study of 11,067 diabetes patients 
across Australia conducted in 1999 to 2000, Tapp et al. reported that 77% of 
diabetes patients had received an eye examination in the 2 years prior to the study 
being conducted.203 The New South Wales Health Survey, which was at that time, a 
biannual survey of the health of the population of New South Wales,204 suggested 
higher levels of screening, with 54.7% of 726 people identified with diabetes having 
received an eye check within the 12 months prior to the survey. Additionally, the 
study by Kamien et al. of general practice patients found that 50.1% of diabetes 
patients had received an eye examination or been referred to an ophthalmologist 
over a 12 month period,193 which is close to the findings of the New South Wales 
Health Survey.  
 
When compared, the studies show varying levels of ophthalmological screening and 
visits to eye care specialists. Whilst the most robust study, AusDiab, suggests that 
about 35% of people with diabetes obtained screening in the 1990s, this was well 
below the findings in New South Wales.204 This suggests that either the level of 
ophthalmological screening was higher in New South Wales than in the other states 
and territories, or that studies measured screening differently. Despite the major 
differences between the studies, the overall impression is that the level of 
ophthalmological screening in Australia during the 1990s was well below the 
clinical management guideline that patients obtain an ophthalmological examination 
every 1 to 2 years.12      
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Weight and height measuring (to calculate BMI) 
Only one study reported on weight measurement. However, because it may be an 
unremarkable aspect of a medical consultation there may be significant under-
reporting against this guideline. In the only study that reported it, Kamien et al.,193 
found that 55.9% of diabetes patients had been weighed by their GP over a 12 month 
period. Whilst it is not possible to generalise this finding to the Australian diabetes 
population, it suggests that a significant proportion of patients may not have had 
their weight monitored according to the clinical management guideline, which 
recommends that patients be weighed every 3 months.12  
 
Blood pressure checking 
The New South Wales Health Survey of 1997 found that 86.8% of diabetes patients 
had their blood pressure checked in the previous 3 months.204 Kamien et al. found 
that 94% of patients had received a blood pressure check in 12 months.193 These 
findings suggest that the level of blood pressure testing was high during the 1990s.  
 
Foot examinations 
Tapp et al. found that 50% of diabetes patients in Australia were examined for foot 
pathologies in a year.203 However, the New South Wales Health Survey found that 
foot examinations may have been about half this level (25.6%).204 This may reflect 
differences between the Australian and New South Wales populations, or indicate 
that alternative methods of measuring of foot examinations were used.220 However, 
overall the findings suggest that the level of foot examination was well below the 
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clinical management guideline that patients obtain foot examinations every six 
months.    
 
Cholesterol and triglyceride testing 
The New South Wales Health Survey of 1997, found that 80% of diabetes patients 
had their cholesterol checked in the previous 12 months.204 However, Harris et al. 
found very low levels of lipid testing with 3.9% of diabetes patients being tested in 
the six months between January to June 1996, which increased to 4.6% in July to 
December 1998.190 In addition, Kamien et al. found that 56.1% of diabetes patients 
had received a cholesterol test and 48.8% a triglyceride test over a three-year 
period.193 The large variation in the level of cholesterol, triglyceride and lipid testing 
between the studies suggests that there may be major differences in testing or that 
this testing was measured differently in each study. If the New South Wales Health 
Survey data is most representative, the level of testing in Australia may be close to 
the level recommended in the clinical management guideline. However, if Harris et 
al. or Kamien et al.’s studies are most representative, there were significant deficits 
in the levels of testing during the 1990s, which is recommended to occur every 1 to 
2 years.12     
 
Microalbumin tests 
The guidelines recommend that patients be tested for microalbumin every 12 
months. Harris et al. found that the level of microalbumin testing was very low, with 
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6.9% of diabetes patients tested between January and June 1996, which increased to 
10.2% in July to December 1998.190 
   
Encourage healthy lifestyle (diabetes education) 
In their general practice study, Kamien et al.193 found that 66.2% of patients had 
been given dietary advice, 35.8% advice on exercise and 36.2% advice on smoking. 
In a 1996 population-based survey of 191 people with type 2 diabetes in South 
Australia, Phillips et al. found that most patients had received some education or 
advice about diabetes from their GP, but the nature of the advice was not 
comprehensive.191 While 90% of patients had received advice on blood pressure and 
84% on cholesterol control, only 38% had been advised on physical activity and 
40% on body weight. In addition, only 60% of smokers had been advised to quit. 
The studies suggest that diabetes education is commonly provided during general 
practice consultations but that doctors are more likely to provide information that is 
disease rather than lifestyle oriented, making it difficult for patients to take 
responsibility for their diabetes.221 Diabetes education is seen as an ongoing 
responsibility for doctors and appears to be a common component of GP 
consultations.       
 
Conclusion 
This section has documented evidence relating to the prevention of complications 
and the utilisation of prevention interventions in Australia in the 1990s. By 
comparing actual rates to the standards set by the clinical management guidelines a 
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number of conclusions about the potential of screening and monitoring practices in 
Australia to prevent diabetes complications in recent times can be drawn.  
 
First, the studies suggest that the practice of diabetes care did not match what was 
recommended in 1990s. This is despite the introduction of significant programs to 
promote the guidelines during that decade.74, 183  
 
Looking across the studies, compliance with recommended guidelines was low in 
relation to every guideline except blood pressure testing, which almost certainly 
would have taken place as a routine part of any medical attendance and may not 
reflect diabetes-specific care.222 Compliance was particularly poor for HbA1c 
testing, weight monitoring, foot testing and microalbumin testing. In addition, 
ophthalmological examination was moderately low.  
 
Whilst the levels of diabetes education appeared to be high,191 the effectiveness of 
this education must be questioned. This is signalled by Phillips et al.’s study which 
found that whilst many patients recalled receiving diabetes education from their 
GPs, the nature of this education was limited. In particular, GPs provided many 
patients with information about diseases and their medical control, such as 
hypertension and related medications, but little information about aspects of diabetes 
over which patients themselves could exercise control, such as physical activity.191 
This suggests that despite the high level of diabetes education reported above, 
patients may have been poorly advised about how to manage their diabetes.   
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The medical care examined in this review occurred at a time when the health care 
system in Australia was relatively stable,173 and it is unlikely to represent a 
temporary state of affairs in a system that was otherwise well functioning and 
effective in its approach to diabetes management: Medicare had been introduced at 
least seven years prior to the earliest data reported in the studies and the 
organisational infrastructure supporting the system was well established.173  
 
The difference between the general diabetes population (as documented above), 
insulin-users and other diabetes register patients, may provide an indication as to 
how the health care system needed to improve with regard to diabetes care in the 
1990s. Studies by McCarty D et al.218 and Sale et al.182 of insulin using patients on 
the Tasmanian Diabetes Register during the 1990s, along with Bonney et al.’s study 
of the National Divisions of General Practice Diabetes Project,219 showed higher 
levels of screening and monitoring, as well as of GP, specialist and allied health 
attendances, than did the studies of Tapp et al.,203 the New South Wales Health 
Survey,204 Harris et al.,190 McCarty DJ et al.223 and Kamien et al.,193 which 
concerned the general diabetes population. For example, Sale found that in 2000, 
69% of patients on the Tasmania Diabetes Register had obtained an 
ophthalmological examination, 93.5% had their blood pressure checked and 47.3% 
had their feet examined.182 In addition, Bonney et al., who examined patients 
enrolled on diabetes registers, found that between 1999-2000, 48% of patients had 
received an HbA1c test, 43% had been weighed, 56% had their blood pressure 
checked and 35% had their feet checked over a six-month period. Also, 60% of these 
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patients had received a lipid test and 36% a microalbumin test in a 12 month period, 
while 51% had received an ophthalmological examination within two years.219 This 
indicates somewhat higher quality of diabetes care among register patients than in 
the general diabetes population (although there was still considerable room for 
improvement in the latter).197 
 
In addition to diabetes registers, the epidemiological evidence provides other 
pointers towards improving diabetes care. Some of the interventions that have been 
found to be effective in this regard include improving the skills of GPs in diabetes 
management,224  and increasing the role of diabetes nurses in the provision of 
diabetes care. 225, 226 Whilst there is no data on the effectiveness of these 
interventions in the Australian context, many of the improvements in diabetes care 
internationally have been traced to these interventions.227, 228 
 
In sum, Section 2 has presented the clinical management guidelines for diabetes and 
has examined the evidence concerning the utilisation of the guidelines in Australia. 
The clinical evidence upon which the guidelines are based would suggest that the 
levels of utilisation documented here would result in a significant burden of diabetes 
complications.12 However, because the relationship between the level of utilisation 
of the guidelines and the incidence of diabetes complications has not been evaluated 
in Australia, it is not known whether these two factors are related. This is despite the 
strong clinical evidence for most of the interventions included in the guidelines.12  
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In light of this knowledge gap, this thesis sets out to explore the relationship 
between diabetes management and the development of diabetes complications in 
Australia through a series of population-based case-control studies. This 
investigation will enable a determination of whether the poor levels of diabetes 
management documented here may have resulted in the greater prevalence of 
diabetes complications during the 1990s and the contemporary period.   
 
Before proceeding to examine this issue in a series of studies (see Chapters 4 to 10), 
the nature of the health care system through which diabetes management is provided 
needs to be considered. It is possible that the primary reason that advanced 
complications occur at the present time is that the health care system does not 
provide the organisational support for effective diabetes management,16 as this 
would result in low levels of screening and monitoring. Without an understanding of 
the health care system and how it manages chronic diseases, it will not be possible to 
determine whether the guidelines are ineffective because they are based on limited 
clinical evidence and may not be appropriate for a population-based approach to the 
management of diabetes, or whether their ineffectiveness stems from not being 
implemented well in population health settings. 
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Section 3: Enhancing diabetes management through the primary health 
care system  
 
As has been shown, diabetes results in a significant health burden as a consequence 
of a range of potentially disabling complications.15 However, the previous section 
showed that improving self-management practices and increasing compliance with 
clinical management guidelines could avoid much of this morbidity.12 Nevertheless, 
it has been shown that the standard of care in Australia was poor during the 1990s, 
and this could have led to a significant burden of complications.   
 
This section explores why the standard of care was poor in this period. In particular, 
the nature of the health care system is examined, as it is the major institution 
involved in the provision of health care.6 The section presents a best practice model 
of chronic disease care: the Chronic Care Model developed by Wagner et al.38 and 
reports the findings of studies of the utilisation of the health care system by people 
with diabetes in Australia, in order to build a picture of the system of Australian 
diabetes care. In this regard, a number of conclusions about the capacity of the 
system to manage diabetes are drawn. This discussion sets the scene for Section 4 of 
the literature review, which focuses on other factors that can have a major influence 
on the capacity of the system to manage diabetes, in particular structural factors such 
as the socio-economic status of patients and their relative geographic isolation.  
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HEALTH CARE SYSTEM MODEL BASED ON CHRONIC DISEASE CARE 
 
Both Australian and international evidence suggest that the level of screening, 
monitoring and diabetes education that occurs in a population is a function of the 
structure of the health care system.38 Where systems have a greater focus on chronic 
disease, such as by providing a diabetes register, recall and reminder systems,197 the 
standard of diabetes management is much improved (as measured by the 
interventions discussed in Section 2).23 By contrast, in health care systems where a 
chronic disease focus does not prevail, the standard of care is low.176 For example, in 
disadvantaged populations in the United States, where patients have poor access to 
health care, screening for retinopathy, as well as foot screening and HbA1c testing is 
very low.229 Key studies point to the need for the health care system to be 
purposefully designed for the management of chronic diseases.194  
 
In recent times, the need to establish systems for the long-term management of 
diabetes has been widely recognised.230 At the same time, as the clinical and 
pathological characteristics of diabetes has become better understood, it has become 
possible to manage most diabetes by relatively simple interventions delivered 
through primary care (as exemplified by the clinical management guidelines 
discussed above in Section 2).12  
 
Whilst by the 1990s GPs played the major role in the management of diabetes 
internationally, it became clear that they were not performing well in this regard and 
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that improvements in the standard of care were required.23 The inadequate level of 
screening and monitoring such as HbA1c testing, lipid testing and retinopathy 
screening in Australia reported above was typical of the standard of diabetes 
management at that time.193, 203 
 
In response, there was recognition that if diabetes care were to be improved major 
reforms to general practice would be required.197 For example, in 1989 the St 
Vincent Declaration on Diabetes Care in the 1990s,231 identified the need to improve 
the standard of diabetes management in primary care and in 1999 in Australia, the 
Commonwealth Department of Health in Australia established incentives for GPs to 
manage chronic disease through its Enhanced Primary Care Initiative in 1999, which 
particularly focused on diabetes.205 This indicated a tacit recognition of the need to 
improve the standard of care. 
 
In the process of designing a health care system that could respond effectively to 
chronic disease, important lessons have been learned from the practices of hospital 
diabetes clinics.232, 233 Studies had shown, for example, that when high quality 
diabetes care was provided, this was not just due to the superior competence that is 
part of a hospital clinic’s expertise, but was also because of the way in which clinics 
arranged care for their patients.6 Features that were found to be most important in 
this regard included the ability to focus on a narrow range of pathologies and the 
provision of a more planned and structured approach to medical care.232, 234  
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Since this realisation, there have been major efforts to incorporate these features into 
general practice by establishing diabetes clinics in primary care,235, 23 as well as 
registers and recall and reminder systems.6 However, despite the sound evidence of 
the effectiveness of these features with regard to improving the standard of diabetes 
management, their incorporation into general practice has proven to be problematic 
in Australia as such infrastructure and clinics have remained relatively rare.219, 236  
 
Many of the problems associated with the implementation of these interventions 
stem from how general practice has developed historically, in particular that it 
evolved when infectious diseases were the major concern for population health.237 
This led to the development of a system that was focused on the cure of diseases 
rather than their management, where medical care involved short term and episodic 
engagements between doctors and patients which were modelled on the sick role.238 
However, both the Australian and international experiences have shown that this 
approach to medical care is inappropriate for diabetes, as it leaves many of the most 
important aspects of chronic disease management unaddressed.193, 237 The evidence 
for this contention is very strong. For example, in a meta-analysis of randomised 
controlled trials concerning the management of diabetes, Griffin found that the 
evidence supported a need for highly structured and long-term medical care in order 
to address diabetes.197 
 
In response to evidence such as that described above, a large literature on the 
structural and organisational requirements of chronic disease management has 
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developed. Wagner et al. from the United States published the most influential 
model of chronic disease management in 1996, and this is captured in Figure 2.1 
below.38  
 
Following a thorough review of literature concerning the management of chronic 
disease, the authors developed a model consisting of elements of care for which 
there was clinical or public health evidence of efficacy. In a statement of principle, 
Wagner et al. argued that the best outcomes had resulted from health care systems 
that were patient-centred, proactive and anticipatory, with assessments, health 
education and follow up delivered at pre-determined intervals, and with the active 
support of patients taking responsibility for the management of their diabetes.38 This 
represents a major contrast with the conventional model of health care that expects 
patient passivity, employs a narrow therapeutic focus, encourages limited 
engagement with the health care system and whose purpose is for a doctor to cure a 
disease.239 
 
Chronic Care Model    
Wagner et al.’s Chronic Care Model seeks to improve the quality of care by re-
orienting the health care system so that it is more in tune with the management of 
chronic disease. Wagner et al. proposed that the effectiveness of such a system 
would be demonstrated by greater participation in preventive health care, as 
represented by high levels of adherence to clinical management guidelines and 
improved self-management, in addition to better health outcomes.38
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Figure 2.1: Chronic Care Model for improving outcomes in chronic illness 
 
From: Wagner E, Austin T, Von Korff M. Organizing Care for Patients with Chronic Illness, Milbank 
Quarterly 1996, p. 519 38  
 
 
The model has four strata that represent a hierarchy of influence over the quality of 
chronic disease management. At the uppermost stratum (Level 4) are clinical 
guidelines which ensure that the health care provided is evidence based and hence of 
proven clinical effectiveness. The guidelines provide an explicit statement of what 
needs to be done, at what intervals and by whom.199  
 
Below this level, the philosophy of the system is defined. This is termed evidence-
based planned care (Level 3) and is founded on the need to reorganise the health 
care system to facilitate effective chronic disease management. In the 
implementation of evidence-based planned care (Level 2), Wagner et al. argue there 
are at least four major elements for achieving this objective: practice redesign; a 
focus on patient education; the establishment of health care infrastructure, such as 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Appointments 
• Roles 
• Follow - up 
• Self management 
• Behavioural change 
• Psychological support 
• Patient participation 
• Provider education 
• Decision support 
• Consultation 
• Reminders 
• Outcomes 
• Feedback 
• Care planning 
GUIDELINES 
EVIDENCE-BASED, PLANNED CARE 
PRACTICE 
REDESIGN 
PATIENT 
EDUCATION
EXPERT 
SYSTEM
INFORMATION
 80
expert systems for increasing the knowledge and skills of GPs; and the easy flow of 
information between practitioners and patients.38 The elements are described below.  
 
Practice redesign 
The authors argue that the introduction of systems of care that anticipate patient 
needs and follow them up through regular medical appointments are required in the 
management of chronic disease, as without such systems chronic disease patients are 
likely to miss out on significant amounts of medical care and are thus at risk of 
developing advanced complications.240   
 
In addition, Wagner et al. argue for a shift in the nature of the doctor-patient 
relationship. The authors believe that some of the functions of this relationship need 
to be transferred from an individual doctor to a multidisciplinary team dedicated to 
managing diabetes.241, 242 The ideal team, they suggest, would consist of a GP, a 
diabetes nurse, medical specialists and allied health practitioners who would be 
jointly responsible for a patient’s management.38 Advantages of the team approach 
are that it increases the accessibility of specialist expertise, provides a vehicle for the 
co-ordination of care and facilitates shared responsibility for the patient.242  
 
As optimal diabetes care involves a range of health practitioners and the active 
participation of patients, the co-ordination of care is centrally important. When care 
is well co-ordinated, patients receive a broad range of management interventions at 
appropriate intervals in keeping with the optimum standard of care.243 This leads to 
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more effective treatment, less duplication and better compliance with clinical 
management guidelines.243 Because diabetes management is demanding, the authors 
argue for a dedicated professional such as a nurse to co-ordinate care for diabetes 
caseloads in general practice. The co-ordinator of care would facilitate optimal 
access to practitioners, as well as provide diabetes education and counselling.243    
   
Patient education to improve self-management and behavioural change 
The second organisational element of evidence-based planned care in Wagner et 
al.’s model is patient education.38 This has the important goals of improving and 
supporting self-management and promoting positive behaviour change in patients. In 
diabetes care, health education is not just an adjunct to medical care, but is the major 
mode of intervention.151, 152 
 
With regard to effective diabetes education, two types of intervention have been 
shown to be efficacious: cognitive behavioural therapy and greater involvement by 
patients in decision making about their medical care. Interventions that use these 
methodologies have been found to improve knowledge about diabetes, dietary habits 
and physical activity.244, 245, 246  
 
Currently GPs are the major providers of diabetes education in Australia.191 
However, evidence suggests that they may not be the most appropriate practitioners 
for providing diabetes advice. For example, Phillips et al. showed that although most 
GPs provided information about diabetes to their patients, it was often of a highly 
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selective nature which left many patients ill-informed about important aspects of 
diabetes.191 To address this problem Wagner et al. suggest that a diabetes educator 
be a major provider of education to people with diabetes.38    
 
Expert systems 
Identifying a third element of evidence-based planned care, Wagner et al. argue that 
the management of chronic disease requires the establishment of systems to facilitate 
access to expert advice.247 The authors argue that the typical approach of referring 
patients to specialists has the disadvantage of potentially leading to the 
fragmentation of care. Some of the interventions that have been proposed to address 
this problem generally involve greater collaboration between primary health care 
practitioners and specialist or other practitioners.224  
 
Wagner et al. point out that the dissemination of information technology (IT) has 
significantly improved the nature and availability of specialist expertise, through 
computerised decision support systems.248 For example, IT is the basis of most 
diabetes register, recall and reminder systems.197 In the past two decades, IT has 
facilitated changes that have the potential to significantly increase the capacity of the 
health care system as well as make it more efficient.249  
 
Information 
Wagner et al.’s fourth major organisational element concerns information and 
communication, and is closely linked to the previous element. The Chronic Care 
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Model is built upon the ready flow of information within diabetes teams and from 
teams to patients.249 This is most effective when communications systems are 
attached to diabetes registers where patients can be prompted to attend for screening 
monitoring and checkups.250 The implementation of diabetes registers has been 
shown to significantly improve the standard of care.   
 
At a basic level, communication between doctors and patients can be conducted via 
telephone, which can be a cost-effective method of communicating with patients. 251 
At a more sophisticated level, automated diabetes register, recall and reminder 
systems can be used as the basis of communication in diabetes care.249  
 
The fragmentation of care 
In their review, Wagner et al. acknowledged the potential for fragmentation of care 
to occur with the introduction of the Chronic Care Model.38 This danger arises when 
the specific requirements of diabetes separate diabetes care from the rest of the 
health care system, such that patients use one health care system for the management 
of diabetes and the primary health care system for other health care needs. Whilst 
the evidence points to the need for chronic disease focused care systems, Wagner et 
al. warn of the implications of such specialisation on the need for primary care.38   
 
How the Chronic Care Model is implemented in health care systems will show 
considerable variation. For example, in some health care systems the role of a team 
approach to the management of diabetes has been well legitimated,242 while in others 
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it does not fit well with current financial or organisational arrangements.252 Hence, 
whilst the epidemiological evidence provides support for the Chronic Care Model, 
there is no one recipe for its implementation. 
 
THE PRIMARY HEALTH CARE SYSTEM AND DIABETES IN AUSTRALIA 
 
Having outlined the ‘ideal’ model of a health care system for addressing chronic 
disease this section reviews the structure of the primary health care system in 
Australia and compares it to this ideal. Whilst an earlier section examined the 
utilisation of clinical management guidelines in Australia, this section evaluates the 
capacity of the Australian health care system to manage chronic diseases. It 
examines the structure of the diabetes care system by investigating the patterns of 
attendance at primary and secondary care, as documented by studies that have 
sought to examine the utilisation of health care by people with diabetes. In this 
review, the structure of the health care system is roughly defined by the health care 
utilisation of people with diabetes.   
 
Methodology for the selection of studies  
The aim of the review below is to analyse the structural characteristics of the health 
care system through which diabetes care was provided in the 1990s, according to the 
best epidemiological evidence available. To achieve this, the literature used was 
selected according to three criteria.  The first criterion was that the findings of the 
studies included information on the use of the primary and secondary health care 
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systems, which form the basis of diabetes care. The elements considered to be 
relevant included general practice care, specialist care, allied health care and chronic 
disease management infrastructure (based on the Chronic Care Model presented in 
Figure 2.1 above). The second criterion was that the studies needed to be population-
based so that they could be generalised to the broader population. Thirdly, the 
studies needed to report recent findings in order to make the analysis relevant to the 
contemporary health care system.  On the basis of these criteria, six studies emerged.  
 
Each of the studies was ranked according to the three criteria with the ranks then 
summed to give an overall score of validity and relevance. The studies are reported 
for each of the aspects of health care, with the highest ranked study first and the 
others in subsequent rank order. Overall, the studies show widely varying estimates 
of health care utilisation, which reflect different populations and methods of data 
collection, as well as differences in study instruments. While the studies provide 
robust estimates on some aspects of health care utilisation such as the number of 
patients who visited ophthalmologists (McCarty CA. et al.),253 for other aspects of 
health care utilisation the data are much less reliable (for example, shared care). 
Notwithstanding their limitations, these studies offer the best evidence for evaluating 
the role of the health care system in the management of diabetes. Most studies 
included in this section were utilised in the review of compliance with clinical 
management guidelines provided in Section 2.  
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General practice care 
As diabetes care is centred in primary care, facilitating access to GPs is perhaps the 
single most important function of the health care system. The Australian evidence 
shows that people with diabetes generally have good access to GPs and confirms 
that the primary health care system provides a large component of care to these 
patients. In a study using Medicare data, Harris et al. found that the proportion of 
diabetes patients from South Western Sydney who attended a GP in the six months 
of January to June 1996 was 74%, which increased to 87% between July to 
December 1998.190 This high level of utilisation was reflected in the study of 
Kamien et al., who found that diabetes patients attended a GP 12.3 times in a 12-
month period, of which 7.1 visits were specifically for diabetes.193 This compares to 
6.5 times on average for the Australian population during 1997-1998, suggesting 
that people with diabetes were high users of GP services.254 The role of GP care in 
the management of diabetes is evaluated in chapters 4 to 10 of the thesis.  
 
Specialist care 
Whilst the locus of diabetes care has shifted to general practice in recent decades, 
medical specialists still play an important role in the management of diabetes, such 
as in diabetic retinopathy screening. Some of the specialists involved in diabetes 
care include endocrinologists, ophthalmologists and paediatricians. The New South 
Wales Health Survey of 1997 found that of 726 people who had been diagnosed with 
diabetes, 58.2% had consulted an eye care specialist in the previous year.204 Lower 
levels of eye screening were suggested in the Melbourne Visual Impairment Project, 
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a study of eye disease in a representative sample of the Melbourne population aged 
40 years and older conducted between 1996 and 1997. Of the 162 people with 
diabetes identified in this study, 52.6% had visited an ophthalmologist in the two 
years prior to the survey.253 Overall, people with diabetes were intensive users of 
medical specialists and secondary care. The role of specialists in diabetes 
management is evaluated in chapters 4 to 9 of the thesis.  
 
Allied health practitioners 
The third type of practitioner involved in the management of diabetes was allied 
health practitioners, which included diabetes educators, nurses, optometrists, 
opticians, podiatrists and psychologists. Their involvement in diabetes care is similar 
in many ways to the role of medical specialists, in that they operate primarily on a 
sessional basis and do not take overall control of diabetes care. In the New South 
Wales Health Survey 1997, 34.5% of diabetes patients had consulted a diabetes 
educator in the previous 12 months. In addition, 30.9% had consulted a dietician and 
25.3% a podiatrist over a 12-month period.204 In their general practice study, 
Kamien et al. found that people with diabetes were very high users of allied health 
practitioners, with 95% having attended at least one of these practitioners over 
twelve months. These authors found the most frequented allied health practitioners 
were opticians, whom 33% of patients reported having attended, followed by 
podiatrists, who had been attended by 21%. A further 16% had attended a dietician. 
In addition, Kamien et al. found that 15% of patients had attended a diabetes nurse, 
perhaps reflecting the significant role nurses play in diabetes education and the co-
 88
ordination of care.193 Of the 162 people with diabetes identified across the 
Melbourne metropolitan area, 49.4% had visited an optometrist in the two years 
prior to the survey. 253 These findings suggest that people with diabetes are high 
users of allied health care. However, the only allied health practitioners included in 
the data collection of the present study were optometrists. Their role in the 
management of diabetes is examined in Chapters 4 to 9 of this thesis.  
 
Practice systems   
Turning to the extent to which elements of Wagner et al.’s Chronic Care Model had 
been built into the Australian diabetes care system, the literature indicates that in 
Australia, diabetes registers, recall and reminder systems were not widely available 
in general practice during the 1990s. Kamien et al. found that only 9% of general 
practices had a diabetes register, while 6% had reminder and recall systems.193 
Beilby et al. found similarly low levels of diabetes infrastructure, with only 8% of 
surgeries having at risk recall and reminder systems.255 
 
In addition, Beilby et al.’s findings indicated an apparent reluctance on the part of 
GPs to prompt their patients to attend for diabetes care, with only 37% reporting that 
they sometimes contacted their patients about medical care - which may have 
significantly limited the potential of diabetes recall and reminder systems to work 
effectively. With regard to the use of clinical management guidelines, Beilby et al. 
found 24% of GPs reported that they used written prompts (flow sheets 
operationalising the guidelines that are designed to trigger recommended aspects of 
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care) when they managed diabetes, indicating a low level of acceptance of tools, 
despite the major focus that Australian health authorities have placed on guidelines 
for improving diabetes care.255 
 
Summary 
In summary, the epidemiological evidence suggests that the system of diabetes care 
in Australia is comprised primarily of community based GPs, medical specialists and 
allied health practitioners. The literature suggests that there has been a poor level of 
implementation of diabetes management infrastructure as many of the systems that 
are used internationally were not evident in Australia during the period of the studies 
cited here. While diabetes patients were intensive users of health care during the 
1990s,193 the apparent lack of chronic disease infrastructure suggests that most 
diabetes patients relied on conventional systems of care for the management of 
diabetes. This may explain the low level of screening and monitoring reported in 
Section 2.255 The coinciding of conventional systems of care with low levels of 
compliance with recommended diabetes management guidelines suggests a strong 
relationship between the organisation of care and the standard of diabetes 
management during this period.  
 
Whilst the studies did not report on the use of diabetes team based management, the 
New South Wales Health Survey 1997 indicated that over a third of diabetes patients 
had consulted a diabetes educator in a 12 month period.204 These educators are often 
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involved in diabetes team-based care.241 However, whether this was part of an 
ongoing or co-operative arrangement could not be determined.  
 
There were no reliable data available on the use of expert systems in diabetes 
management. There were also few studies reporting on the utilisation of 
communication systems in the management of diabetes. However, as noted above, 
Beilby et al. found a general reluctance on the part of GPs to contact their patients 
with regard to their medical care, which indicates that there may be substantial 
barriers to the implementations of diabetes registers reminder and recall systems.236 
On the other hand, it also points to the potential gains that more formal, automated 
systems offer GPs by circumventing the need for them to rely on their own initiative 
when managing patients.6  
 
Conclusion 
This section has argued that the structure of the health care system is a major factor 
determining the quality of diabetes care at the population level. The studies cited 
here provide only limited evidence on the organisation of diabetes care across the 
population, both because the implementation of the Chronic Care Model was not 
specifically evaluated and because the nature of the organisation of care was 
sketched from limited information on the utilisation of health care practitioners and 
diabetes care infrastructure. Nevertheless, the evidence suggests that few of the 
elements of Wagner et al.’s Chronic Care Model were present in the Australian 
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health care system over the period of the studies cited, and thus that it was ill-
equipped to provide high quality diabetes care.   
 
However, since the studies reported in this section were conducted, some important 
aspects of the Chronic Care Model have been introduced into the Australian health 
care system, perhaps indicating a recognition that the standard of care needed to be 
improved. These include new Medicare schedules that directly pay GPs to manage 
chronic diseases,205 and the introduction of Medicare payments for nurse 
practitioners who can co-ordinate care and provide diabetes education.20   
 
Whilst it appears that the new Medicare schedules have been well accepted amongst 
GPs,256 it is too early to determine whether they have had a significant impact on the 
standards of care. Nevertheless the clinical evidence points to their potential to 
improve diabetes management as it is now directly funded.257 Similarly, the role of 
nurse practitioners in improving the standards of care has not been evaluated, but if 
the international experience is repeated in Australia, the greater use of nurses should 
lead to more comprehensive diabetes education and improved co-ordination of 
care.6, 243   
 
Still many important aspects of the Chronic Care Model are yet to be implemented 
in Australia. For example a strong movement towards diabetes team-based care has 
not emerged, with many GPs still reluctant to become involved in formal co-
operative arrangements for patient care.252 Also, where diabetes registers do exist 
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they tend to be for insulin users, and do not generally serve most people with type 
2.182, 190, 236   
 
It appears that we are currently in a transition phase with regard to the management 
of diabetes and many of the elements identified in the Chronic Care Model such as 
population wide diabetes registers may yet be introduced into Australia.  However, 
there may be significant limitations to the extent of changes achievable in the 
Australian health care system given the nature of how it is structured and run.  
 
Whilst no particular aspect of the Chronic Care Model appears to be antagonistic to 
the Australian health care system, the scope of the reform it implies may be a major 
barrier. One of the key goals of the Chronic Care Model is to raise the standard of 
diabetes care across the population. However, this will require the implementation of 
the Model by all or most GPs. Whilst many GPs may welcome this as an opportunity 
to improve care for patients with chronic disease, others GPs may resist, seeing it as 
an extension of government demands and control.258  
 
Historically, the private health care sector in Australia, which includes the majority 
of GPs and specialists, has resisted the imposition of government regulation over 
health care even though most practitioners are dependent on government finance.258 
This has meant that programs have often been limited in their ability to engage 
doctors in systemic changes to medical care. Typically in Australia, changes to the 
health care system are achieved by providing financial incentives to doctors rather 
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than through structural reforms.205 Thus the basic structure of the health care system, 
from which many of the problems with medical care flow, is rarely altered.   
Section 2 of the literature review noted that the relationship between diabetes 
management and the development of complications had not been evaluated in a 
population-based study in Australia. As diabetes management is provided by the 
health care system, this can also be said of the health care system. However, the 
population-based case-control studies that evaluate the effectiveness of diabetes 
management in this thesis can, by extension, also be considered to be an evaluation 
of the effectiveness of the health care system in managing diabetes.   
  
Before this evaluation is conducted, it is important to consider factors other than the 
structure of the health care system that also impact upon the nature of diabetes care 
as well including the risk of complications. While understanding the effectiveness of 
the health care system in managing diabetes is an essential step in improving 
diabetes management, so too is understanding the nature of inequalities in respect of 
diabetes. This is significant as inequalities in health and access to services determine 
to an important degree the management of diabetes across the population.164 There is 
a danger that if diabetes management programs are introduced without equity being 
considered, they will not address a significant burden of the disease and may 
actually attenuate existing health inequalities. The nature of equity and diabetes is 
discussed in the section that follows (Section 4). 
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Section 4: Equity and the management of diabetes   
 
Having described the epidemiology and clinical characteristics of diabetes in Section 
1, discussed the clinical management guidelines in Section 2 and examined the role 
of the health care system in Section 3, the literature review now turns to the issue of 
equity in diabetes. Equity is significant because diabetes, its complications and risk 
factors are unequally distributed across the population and because more broadly, 
social inequalities influence health care utilisation. There is evidence that if a health 
care system is to deal with diabetes effectively it must not only provide adequate 
standards of diabetes management, it must also address social inequalities.32, 33, 164  
 
This section begins by reporting key international evidence on the impact of socio-
economic status on diabetes. Most of the literature cited is from Europe, in particular 
the United Kingdom, where there have been a number of population-based studies 
examining the relationship between socio-economic status and diabetes, which offer 
reliable population estimates of diabetes, complications, risk factors and health care 
utilisation for socio-economic groups.32 Following this discussion, evidence on 
socio-economic status and geographic isolation in respect of diabetes is presented, 
with an examination of how these inequalities are associated with diabetes and 
health care utilisation in the Australian context. The literature concerning the 
relationship between geographic isolation and diabetes is then reported. Next, the 
evidence concerning diabetes and the Aboriginal and Torres Strait Islander 
population is examined, showing that this group is very badly affected by diabetes, 
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while also experiencing socio-economic and geographic inequalities.30 Finally, 
evidence from the Australian and international literature is presented which 
examines how health care systems address health inequalities and the factors that 
need to be considered when improving the management of diabetes.259 In this 
discussion a number of implications of health inequalities for the Chronic Care 
Model are identified: these include the need to provide greater diabetes 
infrastructure in disadvantaged populations. This section sets the scene for the final 
section of the review (Section 5 below) which identifies the major gaps in 
knowledge in the operation of the health care system in the management of diabetes 
in Australia. These are further addressed in the epidemiological studies in the thesis 
(Chapter 4 to 10).    
 
SOCIO-ECONOMIC INEQUALITIES AND DIABETES 
 
Socio-economic status is an indicator of an individual’s, a community’s, or a 
population’s material resources, and is determined by factors such as level of 
income, occupation or workforce status.260 There is a large body of evidence 
showing that socio-economic disadvantage has a major influence on health, 
including in relation to diabetes.261 Socio-economic inequalities are instrumental to 
our understanding of diabetes management and prevention as they can have a major 
impact in determining the risk and severity of complications.32   
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A detailed overview of the international literature on the relationship between socio-
economic status and diabetes is presented below, including in relation to the 
prevalence of diabetes, mortality rates, the incidence of complications and the 
utilisation of health care services among people with diabetes. Next, the Australian 
evidence on the association between diabetes and socio-economic status is 
summarised using similar themes. By highlighting different levels of health needs 
among different population groups, as well as poorer access to health care services 
by certain groups, this section points to the need for a focus on equity in the health 
care system that addresses diabetes.  
 
International evidence on the relationship between socio-economic status and diabetes 
The prevalence of diabetes and socio-economic status 
There is strong evidence that low socio-economic status significantly increases the 
risk of type 2 diabetes, but not type 1.262 This has been reported from developed 
countries including Australia,263 the United Kingdom, 262, 264 the United States, 265, 266 
and Canada.267, 268 For example, in an analysis of a diabetes register with coverage of 
all patients with known diabetes in the South Tees Region of the United Kingdom in 
1994, Connolly et al. found that the prevalence of type 2 diabetes was 1.4 times 
greater in the lowest socio-economic areas, as compared to the highest.269 In 
addition, in the US, Everson reported that in the baseline survey of the Alameda 
County Study, which began in 1965, low socio-economic status respondents were 
2.8 times more likely to report that they suffered from type 2 diabetes than their high 
status counterparts.266 Finally, in an analysis of the 1996-1997 Canadian National 
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Population Health Survey, Tang et al. found that low income respondents were 2.16 
times more likely to report that they suffered from type 2 diabetes than those who 
had high incomes. This points to a need for preventive health care systems to focus 
on low socio-economic groups.268 
 
Mortality and socio-economic status in people with diabetes  
Secondly, as well as being at greater risk of diabetes, there is sound evidence that 
people of low socio-economic status are at a greater risk of premature death than the 
more affluent. For example, in an analysis of the diabetes register mentioned above, 
Roper et al. found that in the South Tees Region of the United Kingdom, diabetes 
patients from the most deprived areas had a 1.8 times greater standardised mortality 
rate (death from all causes) than those from the most affluent areas. 270 Similarly, in 
a report from the Whitehall II study of British civil servants in 1995, Chaturvedi et 
al. found that of 218 civil servants with diabetes, those from the lowest occupational 
groups were 1.7 times more likely to have died since the study began than those 
employed in professional or executive occupations.32 The authors also analysed data 
from the London component of the 1995 WHO multinational study of vascular 
disease in diabetes. In this study of 300 people with diabetes, the probability of 
dying was 2.1 times greater in the lowest social class when compared to the highest 
(when assigned by occupation).32  
 
Interestingly, a study from Finland conducted by Koshkinen et al. found no 
difference in mortality by socio-economic status in people with diabetes. This study 
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investigated 11,215 deaths of people who were registered as suffering from diabetes 
between 1981 and 1985 and followed up in 1990. The authors reported that in 
contrast to the studies citied above, people with diabetes of lower social class in 
Finland did not have a higher all cause mortality rate than those of higher social 
class.271 They suggested that the difference between their findings and other studies 
was that health inequalities may have been ameliorated through the Finnish health 
care system which has a great concern for equity.271  
 
Diabetes complications and socio-economic status  
In relation to the need for screening and prevention interventions, a third dimension 
of the relationship between socio-economic status and diabetes is that the incidence 
of complications is higher among those who are socially disadvantaged. With regard 
to macrovascular complications, Chaturvedi et al. reported that among people with 
diabetes in the Whitehall study, low status civil servants were twice as likely to 
suffer from ischaemic heart disease than were high status civil servants.32 Similarly, 
in the WHO multinational study of vascular disease in diabetes, Chaturvedi et al. 
reported that people with diabetes of lower social class were 2.27 times more likely 
to die from cardiovascular disease than those of higher social class.32  
 
With regard to microvascular complications, Chaturvedi et al. also found that people 
with diabetes of lower social class were 1.8 times more likely to suffer from 
proteinuria (an indicator of kidney disease) than those of higher social class.32 In 
addition, the same study found that people with diabetes of lower social class might 
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have been at higher risk of developing retinopathy than those of higher social class, 
although this relationship was not statistically significant.32 
 
Finally, Klein et al. reported on a number of findings concerning socio-economic 
status and risk of eye disease in a population-based study of 2990 people with 
diabetes in Wisconsin in the United States. The sample was stratified into younger 
onset diabetes patients (aged less than 30) and older onset diabetes patients (aged 30 
or older) to provide an approximate division of types 1 and 2 diabetes. The authors 
found that in the younger onset group, doubling of the visual angle, an indicator of 
visual impairment, was 1.6 times less likely to develop in employed men compared 
to those who were unemployed. In addition, the risk of proliferative retinopathy was 
found to be related to educational status among women (an indicator of socio-
economic status), where for every five or more years of formal education, the risk of 
this complication decreased significantly.161 Further, for older onset subjects, men 
with less education or of lower socio-economic status were more likely to have a 
doubling of the visual angle than those with more education or of higher socio-
economic status. A similar relationship was also found between level of education 
and clinically significant macular oedema, common symptoms of diabetic 
retinopathy.161 The differential rates of diabetes complications point to more 
persistent and severe diabetes in lower socio-economic groups and accord with the 
findings on metabolic risk factors below. 
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Risk factors for diabetes and its complications and socio-economic status 
In relation to the development of new cases of diabetes, the literature indicates that 
the greater prevalence of diabetes, higher mortality rates and greater risk of 
complications among people of lower socio-economic status documented above is 
reflected in the higher prevalence of risk factors among this group. For example, 
with regard to metabolic risk factors for diabetes, Chaturvedi et al. found that 
systolic blood pressure and blood glucose may have been higher in lower status civil 
servants compared to higher status employees, although these relationships were not 
statistically significant.32 Similarly, in a case control study of 192 matched diabetes 
patients enrolled on a population diabetes register in the district of Kristianstad, 
Sweden, Larsson et al. found that those with poorly controlled diabetes had lower 
education levels that those with good metabolic control.272 Finally, in study of 1549 
subjects in Newcastle-upon-Tyne in the United Kingdom, Bhopal et al. investigated 
both socio-economic and ethnic differences in risk of cardiovascular disease and 
diabetes. The study compared 840 European subjects with 709 subjects of South 
Asian background who were resident in the same area between 1993 and 1997. 
Differences in metabolic risk factors were found mainly in the European subjects, 
and men of lower socio-economic status were found to have higher levels of 2-h 
glucose and systolic blood pressure than those of higher socio-economic status. In 
addition, higher levels of 2-h glucose were found in low socio-economic status 
women.262  
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In relation to obesity, in the WHO study noted above, Chaturvedi et al. reported that 
in people with diabetes, body mass index (BMI) was 1.8 points higher for those of 
lower social class, than those of higher social class.32 In addition, in an analysis of 
the 6266 people enrolled on a diabetes register in the district of Tayside in Scotland, 
of whom 792 had type 1 and 5474 type 2 diabetes, Evans et al. found a strong 
relationship between obesity and socio-economic status, although this was only 
evident in type 2 patients.262     
 
In an extensive review of the evidence from 144 published studies of the relationship 
between socio-economic status and obesity, Sobel and Stunkard found a strong 
inverse relationship in developing countries. However, in developed countries, a 
consistent inverse relationship was only found among women.162 
 
In addition to biological risk factors for diabetes, there is strong evidence of a higher 
prevalence of behavioural risk factors such as sedentary lifestyles and poor nutrition 
among diabetes patients of lower socio-economic status. For example, in an analysis 
of 770 people with diabetes recruited from 40 GPs in Avon and Somerset in the 
United Kingdom, Bachman et al. found that those of low socio-economic status were 
10.8 times more likely not to obtain sufficient physical activity than high status 
patients.273 Further, in an analysis of the 1989-1984 baseline survey of a random 
sample of 2682 men who participated in the Kuopio Ischaemic Heart Disease Risk 
Factor Study, Lynch et al. found that less educated men were more than twice as 
likely to lead sedentary lifestyles than those with higher levels of education. Similar 
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patterns were also found according to income and employment status and physical 
activity.164 Finally, in an analysis of 6980 subjects who took part in the Whitehall II 
Study, Brunner et al. reported that lower social class civil servants with diabetes 
were 1.4 times more likely to be physically inactive than those of higher social 
class.274  
 
Reporting on diet and nutrition in the Kuopio Ischaemic Heart Disease Risk Factor 
Study, Lynch et al. found that people with diabetes with less education consumed 
poorer diets.164 Bartley et al. made this same finding with regard to the wives of 
British civil servants.275   
 
In addition to obesity related risk factors, smoking is a major risk factor for 
cardiovascular disease which is also related to socio-economic status.  In the WHO 
study Chaturvedi et al. found that people with diabetes of lower social class were 1.8 
times more likely to be smokers than those of higher social class. Whilst this same 
relationship was evident in the Whitehall II study, the differences between the civil 
servants were not statistically significant.32 However, in the Kuopio Ischaemic Heart 
Disease Risk Factor Study, Lynch et al. reported that subjects with poor education 
were 1.4 times less likely to be non-smokers and were also found to have smoked for 
an average of 1.8 times longer than those with higher education.164 Both the 
prevalence of diabetes and complications are strongly related to the risk factors 
discussed above. The higher rate of these risk factors in low socio-economic groups 
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points to the need for targeted interventions to address these causes of diabetes and 
complications.  
 
The utilisation of health care and socio-economic status of people with diabetes  
However, despite the greater burden of disease and potential for new cases of 
diabetes among socio-economically disadvantaged groups, there is evidence that the 
same groups have poorer access to diabetes care. For example, in a study of 620 
diabetes patients registered with seven randomly selected general practices in 
Leicestershire in the United Kingdom diagnosed prior to 1990, Goyder et al. found 
major socio-economic differences in access to diabetes care, as reflected in patterns 
of health care utilisation between 1990 and 1995.276 Patients with access to a car (an 
indicator of greater economic resources) were 1.35 times more likely to have 
attended a hospital diabetes clinic (an indicator of greater structure in diabetes care) 
over the study period than patients without; patients who owned their own home 
were 1.36 times more likely to have attended a hospital diabetes clinic than patients 
who did not; and patients employed in non-manual occupations were 1.32 times 
more likely to have attended a hospital diabetes clinic than those who worked in 
manual occupations. In addition, the authors found that patients of low socio-
economic status, as measured by the Townsend score (a measure of relative 
disadvantage often used in the United Kingdom), were less likely to have attended a 
general practice for a diabetes review over the study period.276 Further, in a study of 
patients on a diabetes register in the Salford district in the United Kingdom between 
1993/94 and 2000/01 (where 4034 patients were included on the register in 1993 and 
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5671 in 2001), Edwards et al. reported that diabetes patients from more deprived 
areas were 1.27 times less likely to have shared care arrangements for their 
diabetes.277 As this is the most effective arrangement for the management of 
diabetes, this may be an indicator of unequal access to high quality care.  
 
The study by Bachman et al. noted above also examined the relationship between 
socio-economic inequalities and the utilisation of health care among people with 
diabetes. The authors reported that in the Avon and Somerset regions of the United 
Kingdom, diabetes patients with lower levels of education were less likely to attend 
hospital diabetes clinics than those with higher educational status. Low socio-
economic groups appear to be specifically disadvantaged with regard to the 
utilisation of health care. This may help to explain the lower levels of diabetes 
complications screening and monitoring that are often found in lower socio-
economic groups.273 
 
Discussion 
The international evidence of a link between diabetes and socio-economic status is 
compelling and shows a greater risk of diabetes, its complications and of premature 
death among socio-economically disadvantaged groups. This appears to be 
associated with higher levels of metabolic risk factors such as obesity and with 
behavioural risk factors such as smoking.  
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However, the evidence concerning the relationship between socio-economic 
differences and the utilisation of health care is more equivocal.277 Whilst the level of 
diabetes care appears to be poorer in socio-economically disadvantaged populations 
in some localities,276 this is not the case for all.277 The literature indicates that the 
relationship between health care utilisation and social class is complex. Typically, 
attendance at GPs is higher among lower socio-economic groups, perhaps as a result 
of poorer health status. However, socio-economic inequalities are often found in the 
quality of the health care that is provided, such that disadvantaged groups are less 
likely to attend specialists or to obtain structured care or shared care for their 
diabetes.273  
 
The chain of causation in the relationship between low socio-economic status and 
health inequalities has been explored by a number of authors.261 In general, these 
studies have shown that health inequalities result from poor living standards 
associated with fewer material resources. The relationship between low socio-
economic status and health care utilisation has been shown to derive from both the 
greater burden of ill health in low socio-economic groups and from institutional 
discrimination in the functioning of health care systems, where poorer people obtain 
higher levels of general practice care, but receive lower levels of prevention, 
specialist care and diabetes education.276 As these factors are instrumental in the 
management of diabetes they may explain the greater prevalence of diabetes and 
complications in disadvantaged populations. 
  
 106
In relation to addressing socio-economic disadvantage and health, the evidence 
supports a broader public policy approach aimed at improving living standards and 
not just the introduction of medical interventions to reduce the burden of disease. 
This is not to discount the importance of improving access to appropriate medical 
care, which has also been shown to lead to better health, as demonstrated by 
evidence from Finland271 and Salford in the United Kingdom.277 However, as the 
genesis of most diabetes lies in poorer social conditions, these must be addressed if 
the disorder is to be properly prevented.  
 
Having presented key international studies on the association between socio-
economic status and diabetes, Australian evidence regarding this relationship will 
now be presented. Where there is an absence of studies specifically examining 
diabetes, reference is made to diabetes-related morbidity, mortality and risk factors 
such as cardiovascular disease, from which inferences about diabetes can be made. 
These findings paint a picture of a similar relationship between socio-economic 
status and diabetes as that evident in the international literature.  
 
Socio-economic status and diabetes in Australia 
The prevalence of diabetes, mortality, complications and socio-economic status in Australia 
The socio-economic inequalities in diabetes documented in the international 
literature are to a large extent reflected in Australia. Firstly, the prevalence of 
diabetes is about twice as high among low socio-economic groups as it is among 
more affluent populations.278 In addition, similar to the picture in the United 
 107
Kingdom, all cause mortality rates from diabetes are higher among disadvantaged 
groups, with poor women with diabetes about twice as likely to die than their better 
off counterparts.60  
 
Whilst Australian data on the relationship between socio-economic status and 
diabetes complications are limited, there is evidence of a relationship between socio-
economic status and cardiovascular disease that may reflect morbidity from diabetes. 
For example, in a study of the association between coronary heart disease and socio-
economic status in New South Wales which used hospital in-patient data, Taylor et 
al. found that when adjusted for age, country of birth and region, the lowest socio-
economic groups were 1.4 times more likely to suffer from an acute myocardial 
infarction than the more affluent.279 In addition, in a study of the relationship 
between socio-economic status and causes of death in Australia using mortality 
records, Turrell and Mathers found that in 1995-1997 people of low socio-economic 
status were 1.94 times more likely to die of a disease of the circulatory system 
(including coronary heart disease and stroke) than the population on average,263 
again a similar relationship to that found overseas. 
 
Risk factors for diabetes, complications and socio-economic status in Australia  
Reflecting the international picture above, Australian studies have found socio-
economic inequalities in relation to metabolic risk factors. For example, in an 
analysis of the 1989 National Heart Foundation Risk Factor Prevalence Survey, 
Bennett found that men of low educational status were 1.65 times more likely to 
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suffer from hypertension than those with higher levels of education.280 Women of 
low educational status were 3.3 times more likely to have high systolic blood 
pressure and 1.8 times more likely to suffer from hypertension than their high status 
counterparts.280  
 
As in the international evidence, associations between socio-economic status and 
risk factors for diabetes and its complications have been documented in Australia. In 
the 1999-2000 AusDiab study, a population-based cross-sectional survey of people 
with diabetes aged over 25, it was found that of 4996 men, those with lowest 
education status were 2.4 times more likely to be obese than those with high 
education status.31 A similar differential was found among 6071 women subjects, 
where those of low educational status were 2.1 times more likely to be obese than 
those with higher levels of education.31  
 
Also, in a recent analysis of the National Health Foundation Risk Factor Prevalence 
Survey 1989, Salmon et al. found that of 9309 subjects, those from low status 
occupational groups were 1.4 times less likely to participate in any leisure time 
physical activity and 1.8 times more likely to smoke.281 These risk factors may be 
particularly important with regard to preventing morbidity from diabetes.  
  
The utilisation of health care and socio-economic status for people with diabetes in Australia 
Again, the Australian patterns of socio-economic inequalities and utilisation of 
health care among people with diabetes have similarities to the international 
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findings. In a study of the relationship between medical attendances and socio-
economic status for 177,280 people with diabetes in New South Wales, Overland et 
al. found that those of lowest socio-economic status were 2.5 times less likely to be 
under the care of a GP than those of highest socio-economic status. In addition, 
people with diabetes of lowest socio-economic status were 2 times less likely to 
have attended consultant physicians and 1.4 times less likely to have attended 
medical specialists than those of high socio-economic status, and this points to major 
inequalities in care.22  
 
Discussion  
The Australian evidence on the relationship between diabetes and socio-economic 
status reported here points to a greater risk of diabetes and its complications for 
socio-economically disadvantaged groups, similar to that found in international 
studies. This relationship appears to be associated with higher levels of metabolic 
risk factors such as obesity and with behavioural risk factors such as diet and 
physical activity, each of which are more prevalent among low socio-economic 
groups.  
 
A noteworthy point of departure from the weight of international research is 
Overland et al.’s finding that suggests that people with diabetes of low socio-
economic status use GPs less in Australia.22 This is at odds with the usual evidence 
with regard to socio-economic status and GPs and perhaps points to differences 
associated with people with diabetes and perhaps other chronic diseases, when 
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compared to the general population. The finding may explain the overall lower level 
of health care utilisation among low socio-economic groups, which might result in 
under testing and under-referral for diabetes care. The relationship between socio-
economic status, health care utilisation and diabetes complications is investigated in 
Chapters 6 to 8 of the thesis.  
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GEOGRAPHIC ISOLATION AND DIABETES 
 
In addition to socio-economic status, there are also significant geographic 
inequalities in respect of diabetes (see Chapter 9). While there have only been 
limited investigations of the relationship between geographic isolation and health in 
developed countries, there is growing recognition that geographical isolation is a 
major source of health inequality. It is especially significant in Australia, in that just 
over a third of the population live outside of metropolitan areas.33  
 
There are methodological issues affecting research into geographic isolation and 
health. Whilst many populations at high risk of diabetes and its complications are 
often geographically isolated, such as indigenous groups, they also tend to have 
lower living standards than metropolitan populations. Thus, it is often difficult to 
separate out the effects of relative poverty from geographic isolation.  Nevertheless, 
there is strong evidence that relatively isolated populations, both in Australia and 
internationally, have higher levels of diabetes complications and risk factors than the 
urban populations, even when income level or other measures of socio-economic 
status are controlled.282 
 
With regard to the international evidence, in a 1998 Canadian study of 9,042 patients 
of 241 randomly selected primary care physicians, Leiter et al. found that the 
prevalence of impaired glucose tolerance was 1.6 times greater among those from 
rural as compared to urban populations.29 In addition, in an analysis of 16 
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jurisdictions in the United States as part of the National Health Interview Survey 
conducted in 1991, which compared 4391 women of rural, urban and suburban 
residence aged between 40 and 64, Ramsay et al. reported that rural women were 1.3 
times more likely to be obese than their urban counterparts, which increased their 
risk of diabetes.283  
 
Further, in the pooled results of two population-wide health surveys in Finland 
conducted in 1991 and 1998, which together included 26,014 adults, Laaksonen et 
al. found that respondents who lived in rural areas were 1.02 times more likely to be 
physically inactive than those who lived in cities and 1.4 times more likely to eat an 
unhealthy diet.284 
 
There is also some evidence concerning geographical isolation and mortality among 
people with diabetes. Using the National Mortality Database compiled from Births, 
Deaths and Marriages registered in Australia, the Australian Institute of Health and 
Welfare (AIHW) estimated death rates from diabetes for metropolitan, rural and 
remote populations and found that between 1992 and 1996, people who lived in 
remote locations were almost 2.5 times more likely to die from diabetes than those 
who lived in cities.33 When this is compared to the data on socio-economic status, it 
appears that geographically isolated individuals may be at a higher risk of dying 
from diabetes than those who are socio-economically disadvantaged. 
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In a study using the National Hospital Morbidity Database compiled from hospital 
separations in most Australian states and territories, the AIHW found that between 
1995 and 1996, people who lived in remote areas were hospitalised for diabetes 
more than twice as often as metropolitan residents. 33 In addition, the population in 
remote localities who lived outside of remote centres were 1.6 times more likely to 
be hospitalised for stroke than those who lived in cities.33 However, in an analysis of 
death rates no difference between metropolitan, rural or remote locations was 
found.33  
 
Analysing coronary heart disease and geographic isolation between 1995 and 1996, 
the AIHW found that populations who lived in small regional centres were 1.1 times 
more likely to be hospitalised for this condition than metropolitan residents.33 
Further, between 1992 and 1996, populations from large rural centres were 1.13 
times more likely to die from coronary heart disease than those who lived in 
metropolitan centres.33    
 
However, caution must be exercised when interpreting levels of hospitalisation in 
isolated settings in Australia. In many geographically isolated areas, acute care 
hospitals play a greater role in the provision of general practice care as a result of the 
scarcity of private medical practitioners. In these settings, levels of hospitalisation 
are likely to be indicators of the availability of health services as well as of 
morbidity.    
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There is some evidence concerning the relationship between geographical isolation 
and the risk factors of overweight and obesity, again from Australia. The ABS 
National Health Survey 1995 reported that the prevalence of these conditions was 
1.15 times higher in rural women that in women from metropolitan areas. However, 
no similar differential was found in men.285 In addition, people who lived outside of 
remote population centres were found to be 1.2 times less likely to walk for exercise 
and 1.2 times more likely to smoke.285 This is a similar excess in smoking to that 
found in lower socio-economic groups in the Kuopio study.164   
 
There are a number of factors that may explain the relationship between geographic 
remoteness and disease. These relate to the nature of remote populations, which tend 
to be poorer and less healthy than those who live in urban areas.33 In addition, many 
rural populations are older, which increases the risk of chronic disease. In addition, 
there is a shortage of GPs and specialists in rural areas in Australia which affects 
access to health care,286 and which may mean that people with diabetes in these 
areas are less likely to be diagnosed or appropriately treated.  
 
In conclusion, there is evidence of a relationship between geographical isolation and 
diabetes.33 Many of the factors that make diabetes a more common and severe 
disease in low socio-economic groups also occur in geographically isolated 
populations. This commonality potentially points to similar influences on health in 
isolated localities as occur in socio-economically disadvantaged populations. This 
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may mean that many of the interventions aimed at improving diabetes management 
in low socio-economic groups could also benefit isolated populations.  
 
Ensuring equity of access to health care for the management of chronic disease in 
isolated communities poses a particular challenge. There are very few models of 
care that have been shown to provide adequate levels of care for chronic diseases in 
rural and remote settings (the role of outreach care for people with diabetes was 
discussed in Section 2). In these areas access to services appears to be a particularly 
difficult problem to solve as isolated populations suffer from a lack of medical 
practitioners and there are diseconomies of scale that preclude the introduction of 
specialist or tertiary health care services.286 This means that many patients are 
required to travel to population centres in order to receive the medical care they 
require. These factors may seriously confound efforts to improve the management of 
chronic disease. The association between relative isolation, health care utilisation 
and the risk of diabetes complications is explored in Chapter 9 of this thesis.   
 
DIABETES AND THE INDIGENOUS POPULATION 
 
Having examined the influence of socio-economic status and geographic isolation on 
diabetes more generally, the impact of diabetes on the indigenous population is now 
considered. As noted above, the disproportionate prevalence of diabetes and its 
complications among indigenous people gives this population special purchase in a 
study evaluating the effectiveness of the health care system in managing diabetes.30  
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The evidence regarding diabetes in the indigenous population shows that they are at 
a greater risk of diabetes than the rest of the population and appear to suffer 
disproportionately from mortality and complications.30 However, our knowledge is 
limited with regard to risk factors and the impact of specific complications. This is 
partly the result of the quality of indigenous health data and the problem of correctly 
identifying Aboriginal and Torres Strait Islanders.287  
 
With regard to identifying the indigenous population in health and other data sets, 
the Australian Bureau of Statistics has identified four factors that significantly 
impact on the quality of information on indigenous health. These include the 
problem of implementing standard methods and procedures for identifying 
indigenous people, which vary between locality and setting; the completeness by 
which indigenous data are recorded in health surveys and administrative databases, 
which also applies to the Medicare database; and the validity and reliability of self-
report data also affects knowledge of health status in the general population.287 
 
These impediments mean that there is generally limited information on diabetes and 
health status in the indigenous population. However, a number of studies have been 
conducted which estimate factors associated with diabetes in Aboriginal and Torres 
Strait Islander populations and these can be used to build a picture of diabetes. Some 
of the findings are discussed below. 
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Prevalence estimates for diabetes have found high and increasing rates of type 2 
diabetes in the indigenous population. When early studies are compared with more 
recent investigations, it has been found that Aboriginal and Torres Strait Islanders 
originally had very low (or non-existent) levels of diabetes, while in recent times 
they have recorded some of the highest rates in the world.30  
 
The contrast between the early and late studies is thought to partly reflect the impact 
of social change and epidemiological transition on the Aboriginal and Torres Strait 
Islander population. With regard to recent estimates, a North Queensland study 
conducted in 2003 found that 12.6% of Aboriginal and Torres Strait Islander adults 
had been diagnosed with diabetes,48 which was approximately four times greater 
than in the Australian population in general.288  
 
With regard to mortality, the evidence suggests that diabetes may account for a 
larger proportion of mortality among indigenous groups than among the non-
indigenous population. For example in the Northern Territory, it has been estimated 
that diabetes contributed 3% to 5% of excess deaths in the indigenous population.289 
 
As has been noted, Aboriginal people have a much greater incidence (4 times) of 
end-stage renal disease.290  For example, in the Northern Territory it was found that 
the age-adjusted risk of ESRD in the indigenous population was 17.4 times greater 
than for the rest of the Australian population.291 Phillips et al. found that renal 
disease was the most common cause of death in Central Australia.292 It is estimated 
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that between 20 and 30% of ESRD in Aboriginal and Torres Strait Islander 
communities is attributable to diabetes.291, 293 
 
Whilst there are some data available on renal disease, there is little information on 
other microvascular complications. However, it is believed that sensory neuropathy 
may be more common among Aboriginal and Torres Strait Islanders, although they 
may suffer from similar levels of retinopathy to the rest of the population.294, 295 
There is no information on the prevalence of diabetic foot disease among indigenous 
people.30 
 
One of the major reasons that diabetes is a major concern for indigenous health is 
that it is related to cardiovascular disease, which is among the major causes of death 
in Aboriginal and Torres Strait Islanders.296 For example, in a study from the 
Kimberley, the prevalence of “Probable and suspect coronary heart disease” was 
found to be 1.5 times greater among Aboriginal and Torres Strait Islander men 
compared to non-Aboriginal men. For women, this difference was 2.4 times 
greater.297 In addition, it is estimated that Aboriginal people suffer 2-3 times more 
from ischaemic heart disease298 and 6.9 times more from stroke299 than the general 
Australian population. 
   
The higher level of diabetes and its complications in the Aboriginal population could 
be explained by the greater prevalence of risk factors such as obesity. For example, 
The National Aboriginal and Torres Strait Islander Health Survey in 1994 found that 
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57% of Aboriginal women and 60% of Aboriginal men were overweight or obese, 
compared to 38% of the general population.287 In addition, the Kimberley study 
mentioned above found that Aboriginal women might experience twice the risk of 
hypertension than among non-Aboriginal women.297 
 
Reflecting the higher risk of renal disease, a Northern Territory study found that the 
frequency of proteinuria was 6 times greater in the Aboriginal and Torres Strait 
Islander population.300 Moreover, they may also have a high risk of 
macroalbuminuria. Rowley et al., in a survey of Aborigines of Northern Australia, 
found that 22.2% of men and 26.9% of women suffered from this condition.301  
  
Whilst there is an established epidemiological relationship between diet and 
diabetes, the evidence regarding these risk factors in the Aboriginal and Torres Strait 
Islander population is equivocal. A number of studies have found higher levels of fat 
and refined sugar in Aboriginal and Torres Strait Islander diets, however, others 
have found no such relationship.302, 303, 304 In addition, there is also scant evidence 
about physical activity. However, in a study of risk factors for diabetes in Northern 
Queensland, McCulloch found that Aborigines in this area had inadequate levels of 
physical activity.48 
  
Indigenous populations in Australia not only have much worse health status; they are 
also disadvantaged with regard to the utilisation of health care services.292 Whilst 
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this is partly a function of geographical remoteness, there are also factors related to 
social exclusion that impact on the accessibility of medical care.305  
 
Conclusion 
The Australian evidence on diabetes in the Aboriginal and Torres Strait Islander 
population is roughly in accord with the evidence on indigenous populations 
internationally, which shows comparatively high levels of diabetes and 
complications.306, 307, 308 This greater prevalence appears to be related to the recent 
erosion of traditional lifestyles through dispossession, and with the poverty 
associated with this.309 The high level of diabetes, risk factors and complications 
appear to be associated with the transition from traditional lifestyles to modern 
Western ones.310 In addition, the trends that initiated the epidemic of diabetes in 
indigenous populations appear to be far from ending.  
 
However, in comparison to other similar groups, Aboriginal and Torres Strait 
Islanders appear to be particularly disadvantaged. Whilst in many indigenous 
populations, living standards and health status have improved in recent decades, 
these improvements have largely bypassed Aboriginal and Torres Strait Islanders.287 
This has occurred as a result of the continuation of poverty, low social status and 
poor living conditions that typify this population.  
 
However, the fact that the health and socio-economic status of indigenous groups in 
other countries have improved, points to the potential of a similar improvement in 
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Aboriginal and Torres Strait Islanders.311, 312 In countries that have achieved the 
greatest gains, this has come about by major social changes where indigenous 
populations have been able to assert their identity and improve their socio-economic 
status.313 This suggests that were such changes to occur in Australia similar 
improvements in health would be forthcoming.  
 
ACHIEVING EQUITY IN HEALTH CARE 
  
The previous discussion documented the Australian and international literature on 
the relationship between socio-economic status, geographic isolation and diabetes.  
A discussion on diabetes in the indigenous population ensued as arguably this group 
has the most to gain from the development of a health care system that can 
effectively manage diabetes.   
 
The proven association between equity and health, as discussed above, has been a 
strong motivator for the development of health care policy, both in Australia and 
overseas. For example, health care systems such as the National Health Service in 
the United Kingdom have been introduced with the aim of raising the health status 
of the poorest groups by providing them with access to health care.314 Similarly, 
Australia’s Medicare was introduced with an explicit goal of ensuring access to 
health care for all members of the community.315  
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In both countries however, the goal of equal access to health care has not been 
achieved22 nor has that of eliminating socio-economic or geographic differentials in 
health.33, 277 This is evidenced by continuing socio-economic differentials in access 
to medical care, especially access to medical specialists, and also by hospital 
separation rates which exhibit significant inequalities in relation to diabetes care.22 
Not only have health inequalities persisted despite the introduction of these systems; 
in some cases they have widened as a result of the increasingly wider socio-
economic inequalities over the last 20 years or so. 316 This is particularly true for the 
Aboriginal and Torres Strait Islander population.287   
  
Some researchers and policy makers have argued that the reason for the limited 
success of these health care systems in addressing inequalities has been that causes 
of disease lie in broader social conditions and it is the failure to address these factors 
that socio-economic inequalities persist.316 According to this argument, government 
responses to health inequalities that have relied solely on the health care system to 
deliver better health outcomes have been of limited success as they do not address 
the root causes of poverty and inequality.316 The authors point to the historical 
record, which has shown that when health improvements occurred, this has most 
often been the result of factors such as the remediation of over-crowding and poor 
sanitation which represent improvements in social conditions.316    
 
When confronted by the fact that health care systems can only have a limited 
influence on health status, policy makers have had to be very cautious in how they 
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approach health inequalities. Typically they have adopted an approach that seeks to 
improve equity in how the health care system operates rather than focusing on health 
outcomes. Mooney, for example, argues that the only rational objective for policy 
makers in this context is equal access to health care for people of equal need. This, 
the author argues, is an appropriate objective as access to health care is more able to 
be achieved by health policy changes and is also to the broader population’s 
benefit.259 The principle forms the basis of Medicare in Australia315 and the National 
Health Service in the United Kingdom.180    
 
There are a number of ways in which the principle of equal access for equal need 
can be promoted. However, they all share a common methodology: that of 
uncoupling a person’s capacity to pay from their access to health care.259 In some 
cases medical care is provided free as of a right to all attendees, such as in public 
hospitals in Australia,258 and in respect of general practice in the United Kingdom.180 
In other systems, individuals are provided with taxpayer funded health insurance, as 
occurs in Medicare.258  
 
Conclusion 
 
The section has drawn on a range of evidence that shows diabetes to be a greater 
burden on disadvantaged groups than on more advantaged populations. This burden 
includes greater rates of diabetes, higher morbidity and mortality, and poorer levels 
of metabolic control. In addition, socially disadvantaged groups tend to perform 
comparatively poorly in obtaining preventive care, notwithstanding the findings of 
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the literature review in Section 2 above, which suggested that diabetes self-
management may be problematic for all people with diabetes. Similarly, there is 
evidence that geographically isolated individuals are disadvantaged in access to 
health care in a number of significant ways. Further, the section has reported on the 
evidence concerning the profound disadvantage experienced by indigenous 
Australians in respect of diabetes.  
 
The breadth of the impact of social disadvantage, both internationally and in 
Australia, strongly suggests that there is a need for greater equity in diabetes care 
and that care needs to be organised with the goal of equity in mind. Whilst the 
overall level of access to care among disadvantaged groups, apart from Aboriginal 
and Torres Strait Islanders, appears to be good in Australia, as reflected in high rates 
of utilisation of GPs,286 there is evidence that once people acquire a chronic disease, 
major socio-economic inequalities develop. This is suggested by Overland et al., 
who found lower levels of general practice and secondary care utilisation among 
socio-economically disadvantaged groups with diabetes.22 In addition, in the 
international literature there was evidence of significant inequalities in diabetes 
clinic attendances, shared care and specialist and consultant physician attendances as 
found by Goyder et al.,276 Edwards et al.277 and Bachman et al.273 from the United 
Kingdom. This evidence suggests that the quality of diabetes management is 
significantly poorer among disadvantaged populations.  
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However, when equal access to the Chronic Care Model, which has the potential to 
remediate many of the problems with diabetes care is considered, the Model may 
pose its own problems with regard to inequalities. For example, the emphasis on 
prevention may be problematic because of the lower propensity of disadvantaged 
populations to participate in preventive care interventions.317, 318, 319 As well, poor 
patients are less likely to play an active role in their treatment and are more likely to 
rely on a traditional doctor-patient arrangement for their medical care.305, 319  
 
In addition, other aspects of the model raise the issue of medical practitioner supply 
which may be a particularly acute problem in socio-economically disadvantaged or 
isolated regions. For example, the practice redesign element of the Chronic Care 
Model requires medical care to be arranged by a multidisciplinary diabetes team. 
However, in many places the personnel that are required to staff these teams might 
not be available.320 Whilst this is most likely to relate to medical specialists and 
allied health practitioners, in some areas there are also chronic shortages of GPs.320  
 
However, there is less evidence of socio-economic inequalities in self-management, 
as was discussed in Section 2, which appears to be similarly poor in advantaged and  
disadvantaged populations,154 although it may differ in qualitative terms. This is the 
case even though it includes actions and interventions that have traditionally been 
found to be problematic for disadvantaged groups in other contexts.321  
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Whilst the equity-related problems discussed above may be difficult to rectify, there 
could be considerable scope for the broad implementation of diabetes registers to 
improve the management of diabetes across socio-economic groups.6 Diabetes 
registers could be used to prompt GPs and patients to make the best use of the 
medical care that is available, even though this may be below that which could be 
achieved in well-served affluent metropolitan areas.  
 
Another practitioner supply issue which is perhaps able to address supply-based 
inequalities relates to the third element of the Chronic Care Model, expert systems. 
There has been a vast dissemination of information technology through the health 
care system in recent decades and these technologies have reached many 
disadvantaged and remote communities.322, 323 This has allowed the expertise and 
support they offer to penetrate into hard to reach disadvantaged and isolated areas. 
Hence, IT may serve to address some aspects of health inequality and counter some 
of the impediments to the management of chronic disease.  
 
Thus while some elements of the Chronic Care Model may fit into the current 
arrangements for medical care in disadvantaged populations, there are other barriers 
that need to be addressed if the management of chronic disease is to be improved 
across the population. There is a danger that unless the barriers are addressed, the 
promises of the model will not be shared by disadvantaged populations.  
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Whilst there appears to be good sense in the introduction of the Chronic Care Model 
within disadvantaged populations, as was the case in Sections 2 and 3 above, we do 
not know whether it is the quality of care offered in disadvantaged populations in 
Australia that increases the risk of complications. This is because to date there have 
been no population-based studies examining health care utilisation and its 
relationship to the risk of diabetes outcomes in disadvantaged populations. It is 
important that this relationship be investigated as a large proportion of the burden of 
diabetes lies in these populations and this needs to be better understood if 
complications are to be prevented. This challenge is taken up by this thesis in 
Chapters 6, 7, 8, 9 and 10, which investigate whether health care utilisation 
associated with socio-economic status and geographic isolation is related to the 
development of diabetes complications.  
 
In conclusion, whilst the Australian health care system provides a solid foundation 
for pursuing equal access to health care for equal need through the Medicare system 
and free hospital care,173, 258, 286 it appears that chronic diseases present their own 
problems for service delivery. Perhaps it is because chronic diseases rely so much on 
the competence and capacity of patients, as well as preventive care and the long-
term commitment of practitioners, both of which are supported by a complex system 
of health care arrangements, that achieving equity in diabetes poses particular 
challenges for the health care system. However, before going on to evaluate the role 
of social disadvantage in the health care system, which is explored in Chapters 8 and 
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9, Section 5 below presents a summary of the arguments covered in the review and 
documents the evidence gaps that will be addressed in the thesis.     
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Section 5: Summary of the literature review and the evidence gaps 
addressed in the thesis 
 
The key argument informing the literature review is that whilst a lot is known about 
diabetes, there are key knowledge gaps that hold back the development of health 
care systems to prevent complications. These relate primarily to the effectiveness of 
current care models for the management of diabetes. This was established by firstly 
describing the epidemiological and clinical characteristics of diabetes, which were 
presented in Section 1. This section argued that diabetes was a major public health 
problem because of its complications and its increasing prevalence across the globe. 
It was also noted that it is of particular concern for high-risk groups such as 
Aboriginal and Torres Strait Islanders, where there was urgency for diabetes to be 
addressed.  
 
Following this description a clinical overview of diabetes was presented, which 
considered the major pathologies, aetiologies and risk factors for types 1 and 2 
diabetes. A detailed description of microvascular and macrovascular complications 
then followed. For each complication, its clinical manifestations, risk factors, 
distribution in the population, and most common interventions were presented. 
Section 1 concluded by arguing that despite the clinical complexity of diabetes, the 
burden of diabetes could be addressed as there were many prevention and 
management interventions available.  
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Having described the health impact of diabetes, Section 2 sought to explore the 
nature of diabetes management. The section began by exploring self-management, 
and argued that this was the most important component of diabetes management as 
the development of complications is largely dependent on the capacity of people 
with diabetes to manage their own condition.  
 
This was followed by a wide-ranging discussion on the nature of diabetes 
management, which included consideration of the major modalities involved in 
providing diabetes care. Each modality was evaluated in terms of its capacity to 
manage diabetes. The Clinical Management Guidelines for Diabetes in Adults74 
were then presented as a means by which diabetes could be effectively managed 
across the population. A description of each guideline and its usefulness was then 
presented. This was followed by a review of the evidence regarding the use of the 
guidelines in Australia during the 1990s. Section 2 concluded by arguing that the 
epidemiological evidence suggested that the use of the guidelines was poor in 
Australia. However, it was argued that it was not known whether this had led to a 
greater burden of diabetes.  
 
Having established that diabetes management was inadequate during the 1990s, 
Section 3 sought to explore why this could have occurred. It was noted in this 
section, that the evidence, both from Australia and internationally, pointed to the 
importance of the structure of the health care system in determining the quality of 
diabetes management. It was argued that major problems existed in conventional 
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health care systems with regard to the management of chronic disease and these 
related to the purpose of medical care, which was of curing disease; to the method of 
care, which was largely practitioner driven; and to the nature of engagement, that 
relied on short-term and intermittent contact to deliver medical care. The review 
observed that these characteristics pervaded the Australian health care system and 
may have been responsible for the poor standard of diabetes care that was observed 
in Section 2.  
 
Following these observations, Wagner et al.’s Chronic Care Model38 was presented 
as a means by which diabetes management could be improved. The model represents 
the ideal design of a health care system that could provide optimum care for 
diabetes. To illustrate the deficiencies of the Australian health care system, it was 
compared to Wagner et al.’s model in regard to the major elements used in the 
management of diabetes. In this analysis, the health care system was found to lack 
significant infrastructure such as diabetes registers, reminder and recall systems and 
that it appeared to promote conventional models of care. It was hypothesised that the 
inadequate level of screening and monitoring was a direct result of its lack of 
capability to manage chronic disease.  
 
Having argued in Section 3 that there was a need for the Australian health care 
system to develop greater capabilities in the management of chronic disease, Section 
4 identified equity as another major concern with regard to diabetes. Studies had 
found that major inequalities existed with regard to the risk of type 2 diabetes, 
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diabetes related  mortality, morbidity and risk factors in addition to access to health 
care. Of particular concern was low socio-economic status, geographic isolation and 
indigenous status, which were all investigated in relation to diabetes.   
 
Having identified major equity issues, the section proceeded to explore health care 
systems and how many of them had developed in order to address social inequalities. 
Of particular note was Medicare and the state and territory public hospital systems in 
Australia, which both provided free or inexpensive access to health care.  
 
A discussion then ensued regarding the challenge of introducing the Chronic Care 
Model into disadvantaged populations. It was found that there were a number of 
significant impediments that could compromise the quality of care. It was 
concluded, that although desirable, the improvements in chronic disease 
management in disadvantaged groups may be harder to achieve than for the rest of 
the population.   
 
Throughout the literature review it has been argued that despite the nature of 
diabetes and its management in Australia being reasonably well understood, it is not 
known whether the diabetes management practices that have prevailed have resulted 
in a greater burden of complications. Thus because there have been no longitudinal 
population based evaluations of the health care system which have focused on the 
management of diabetes, this has left a number of very significant evidence gaps 
regarding diabetes management and the health care system that need to be 
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addressed. The studies that follow address a number of these gaps using population-
based longitudinal studies. 
 
EVIDENCE GAPS ADDRESSED IN THE THESIS 
 
The evidence gaps identified in this section form the basis of the research questions 
in Chapter 1. In the previous discussion it has been argued that there was a need to 
evaluate the Australian health care system and its capacity to manage diabetes if 
diabetes management was to be improved. Whilst there have been a number of 
population-based studies of diabetes management, most studies have used a process 
of care, such as the frequency of retinopathy screening or metabolic risk factor, such 
as HbA1c value as a measure of its effectiveness.277, 324 However, these study 
outcomes represent risk factors for complications rather than complications 
themselves, hence doubt has remained as to whether the interventions have been 
truly tested as to their capacity to manage diabetes.  
 
Whilst a diabetes complication could not be used as the study outcome in the thesis, 
a process of care that is highly correlated with an advanced diabetes complication 
was used as the outcome in these studies.24 This has meant that the health care 
system was measured against the risk of developing an advanced complication, in 
particular vision-threatening retinopathy, in these studies. This provides a more 
direct link between health care utilisation and the development of complications than 
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most other studies. This is a characteristic of all of the current studies (Chapters 4 to 
10).     
 
Much of the discussion in Sections 2 and 3 of the literature review concerned the 
effectiveness of different models of care. This related to the observation that the 
current Australian health care system was not well designed for chronic disease.187 
However, a study that was able to compare actual health care systems was not 
identified. In this thesis the capacity of eight (albeit related) health care systems 
could be compared. These were the state and territory samples. By comparing the 
patterns of care and the development of diabetes complications for each state and 
territory, this evaluated the effectiveness of individual health care systems and their 
capacity to manage diabetes. This is reported in Chapter 5 of the thesis. 
 
With the increasing prevalence of diabetes and complications across the globe there 
is an urgency to the development of public health strategies that can address the 
condition. From the perspective of health care policy makers there are a number of 
alternative strategies that could be used.325 However, these strategies are difficult to 
compare. With regard to preventing complications there is dispute as to whether 
public health agencies should put their efforts into achieving the early diagnosis of 
diabetes,326 or whether they should focus on managing patients who have already 
been diagnosed.12 These strategies are weighed up in Chapter 6 of the thesis.  
 
 135
Whilst evidence for the clinical effectiveness of the clinical management guidelines 
is strong, few studies have investigated risk factors related to health care during the 
pre-diagnosis period. This period is significant because during the pre-diagnosis 
period, people with diabetes do not attend practitioners for diabetes care, they do not 
have access to hypoglycaemic medications, nor do they practise diabetes self-
management. In hyperglycaemic patients these circumstances could lead to poor 
metabolic control and the accelerated development of diabetes complications.12 This 
is investigated in Chapter 7 of the thesis.  
 
Whilst the relationship between socio-economic status and diabetes complications 
has been explored both internationally and in Australia  - where a higher risk of 
complications has been found in low socio-economic groups - it is not known 
whether this is related to health care utilisation. This is explored in Chapters 6 to 8 
of the thesis.  
 
Similarly, the relationship between geographic isolation and complications has also 
been investigated in international and Australian studies. Again it is not known 
whether this is related to health care utilisation. This is explored in Chapter 9 of the 
thesis.  
 
The literature on chronic disease management stresses the significance of the role of 
practitioners in determining the standard of care. In this literature this is often related 
to the cultural and attitudinal characteristics of practitioners.41 However, in these 
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studies quality of care is most often measured by process outcomes, such as the 
provision of diabetes education or pathology testing.327 Yet, these are intermediate 
outcomes in the development of advanced diabetes complications and may be 
tenuously related. Hence the relationship between practitioner factors and health 
status is not well understood. This is explored in Chapter 10 of the thesis.  
 
With the prevalence of diabetes growing and risk factors increasing,7 and in the 
context of social trends that are accentuating the risk of diabetes and its 
complications, it is vital to understand the capacity of the major institution involved 
in providing health care to manage diabetes. By exploring the relationship between 
health care utilisation and the development of advanced complications at the 
national level as well as within states, at critical periods and for high risk groups, the 
thesis should provide a comprehensive assessment of the capacity of the Australian 
health care system to manage diabetes.  
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Chapter 3 
 
Methods  
 138
Introduction 
 
The literature review has documented the clinical and epidemiological 
characteristics of diabetes and its complications, described the management of 
diabetes, the nature of the health care system as well as the most significant equity 
issues with regard to diabetes. However, having identified these issues as highly 
important with regard to the development of diabetes complications, it has also been 
argued that the effectiveness of diabetes management and the equity of health 
service provision in this regard, has not been well evaluated in Australia. These 
observations formed the basis of the research questions presented in Chapter 1.  
 
The research questions were tested in a series of seven population-based case control 
studies. In the first study, documented in Chapter 4, health care utilisation over 
seven years was compared between case and control groups to determine if there 
was a relationship between patterns of care and the development of diabetes 
complications. In the second study, set out in Chapter 5, this same relationship was 
explored within states and territories to determine whether local health care systems 
influenced the development of advanced complications. In the third study, 
documented in Chapter 6, the relationship between patterns of care and 
complications was investigated in subjects whose diabetes was diagnosed 
comparatively early. The fourth study in Chapter 7, examined whether patterns of 
care prior to the diagnosis of diabetes determined the development of advanced 
diabetes complications. In Chapter 8, the fifth study investigated the relationship 
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between socio-economic status and the development of complications in Australia. 
In Chapter 9 the sixth study investigated the relationship between geographic 
isolation and the development of advanced complications, which is another source of 
health inequality. The final study, set out in Chapter 10, extended the analysis by 
investigating the relationship between the characteristics of GPs and the 
development of complications. Chapter 3 describes the methods used in these 
studies.     
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Section 2: Characteristics of studies 
 
STUDY POPULATION 
 
The population with which the studies in the thesis are concerned is estimated to 
number approximately 500,000 individuals, that is approximately 0.25% of the 
Australian population.60 This includes all people who have been diagnosed with 
diabetes in Australia, which is estimated to be about of 50% total diabetes 
population.1 Whilst it would have been desirable to have investigated subjects with 
types 1 and 2 diabetes separately, the database did not allow them to be 
disaggregated. 
  
DATA COLLECTION 
 
To examine the relationship between the quality of care and the development of 
diabetes complications, extracts from an administrative database were used. This 
database has substantial coverage of the Australian population, enabling the 
examination of the research questions from a national perspective.328 
 
Administrative databases are commonly used in research as they often contain 
information that is useful for examining epidemiological questions. They may 
include large and definable populations, which is a consequence of often expansive 
administrative systems and the need to narrowly define eligibility for payment or 
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accountability purposes.329 In addition, as a by-product of the management of health 
care systems the data they contain are often closely aligned to the operation of that 
system,330 thus they can provide a good measure of how diseases are managed.   
 
The present studies utilised the Medicare database, which is the national archive of 
the compulsory and universal health insurance system that funds health care 
provided by privately practising GPs, specialists, consultant physicians and some 
optometrists throughout Australia.173 The database has been recognised as the only 
systematic national collection of health care data relevant to GPs and specialists in 
Australia.190  
 
The Medicare system was established in February 1984 and contains records of 
health care utilisation from that time to the present.206 It is an important resource for 
the study of diabetes with the Health Insurance Commission, which administers the 
system, estimating that 494,611 patients utilised Medicare between 1999 and 2000 
for diabetes care.60   
 
The record of fees charged to Medicare (identified as item numbers in the Medicare 
Benefits Schedule, MBS) creates a comprehensive record of health care utilisation 
for each individual patient.254 For each item of service the Health Insurance 
Commission receives information on the patient, the provider, the items of health 
care supplied as well as the location and time of the consultation.33 
 
 142
Whilst Medicare has substantial coverage of the Australian health care system not all  
care is funded by it. The most notable gap concerns care provided to public patients 
in public hospitals which is funded by states and territories. 173  It is estimated that 
Medicare funds 75% of health care in Australia.258 
 
While the Medicare database provides an accurate record of the processes of care, it 
does not include records of health outcomes.183 Nevertheless, in some cases it is 
possible to study disease outcomes using these processes of care. This occurs when a 
process of care is used exclusively to treat a particular condition and thus can be 
taken as a direct marker of the outcome.91 As laser photocoagulation therapy is used 
exclusively for the treatment of vision-threatening retinopathy, the item number for 
this process of care was able to be used in the studies comprising the thesis, as a 
proxy indicator of that diabetes outcome.91  
 
In addition, a long-standing funding condition in the MBS made it possible to select 
out diabetes patients from the rest of the database using a straightforward and 
reliable indicator: the HbA1c test. Not only is this the most commonly used 
pathology test in the management of diabetes, it only attracts a Medicare rebate 
when it can be shown that it was used on patients with an existing diagnosis of 
diabetes.206 Hence selecting the sample on the basis of this test creates an exclusive 
sample of people diagnosed with diabetes.183    
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STUDY DESIGNS 
 
Population based case-control studies were used in each of the studies comprising 
the thesis.331 Case-control studies compare a group of individuals who have 
experienced an outcome (cases) to a group who have not (controls).13 The aim of the 
analysis is to determine if the patterns of exposure to risk factors differ between the 
groups, and hence help to explain the development of the outcome.331 In this regard, 
the first six studies (the results of which are documented in Chapters 4 to 9) 
compared the medical care obtained by people with diabetes who developed vision-
threatening retinopathy (cases) to similar patients who did not develop the 
complication (controls) over a seven-year period. In the final study (set out in 
Chapter 10) the characteristics of cases’ GPs were compared to those of controls to 
determine whether there were any systematic differences between the groups that 
could be related to the development of complications. 
 
DATABASES USED IN THE STUDY 
 
Patient database (Chapters 4-9) 
The patient database consisted of the Medicare records of 9264 people with diabetes 
over the period 1993 to 2000. The database was divided into equal numbers of cases 
and controls (4632 in each group). Cases were diabetes patients who had received 
laser photocoagulation therapy in 2000, while controls were patients of a similar age 
and diabetes status that had not received this treatment.  
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Figure 3.1: Patient database  
 
Figure 3.1 presents the steps involved in assembling the database. The process of 
data retrieval involved the creation of a series of matched population-based case-
control studies from Medicare records. 
 
The first step involved retrieving the study population by selecting all people who 
had diabetes between 1994 and 2000 from the Medicare database. This was 
accomplished by identifying all people on the Medicare database with an HbA1c test 
in these years.  
 
Once this group had been selected, the case group was assembled, as represented on 
the left hand side of Figure 3.1. This process involved selecting all patients who had 
evidence of laser therapy between 1993 and 2000. In a second step all of those who 
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had laser between 1993 and 1999 were discarded. This left a sample of 4632 patients 
who were new laser therapy patients in 2000. These became the cases.   
 
The control selection followed from the identification of the cases, as documented 
on the right side of Figure 3.1. Controls were selected from the database from which 
all laser therapy patients had been removed. To be eligible to become a control, 
patients needed to have a Medicare claim between 1993 and 2000, and to not have 
received laser treatment in any of those years. As the next step, patients who had no 
Medicare claim in 2000 were removed from the database, which left a large sample 
of patients who had not received laser but had a Medicare claim in 2000. It was from 
this group that controls were selected.c  
 
Once the case and control databases had been created, the age and state 
characteristics of individual cases were used to define a sampling frame from which 
controls were to be selected. Once this sampling frame had been established, 
subjects eligible to become controls were assembled and the control selection 
procedure was conducted. One subject  was selected from the sampling frame on a 
random basis and became the control. This procedure was repeated for each control 
selected.  
 
                                                 
c In the original data request controls needed to have a Medicare record in 2000 to be considered for 
inclusion in the study. However, this specification was not met for a small number of controls (186) 
and there was a concern that this could have led to bias in the studies. For an examination of the 
impact of the inclusion of these controls in the study see the methods of Chapter 6 below.      
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Once the case and control groups had been assembled they were disaggregated by 
state and territory to create eight individual population-based case-control studies. 
The final step involved the aggregation of studies to create one national study which 
was used in the majority of analyses comprising the thesis.     
 
Provider database  (Chapter 10) 
The provider database consisted of the Medicare records for the year 1999 of all 
12,283 GPs involved in the treatment of subjects comprising the patient database. 
The database is made up of three more or less equal groups: GPs who treated cases; 
GPs who treated controls; and those who treated both. Only one year of data was 
available at the time that the data were extracted as the previous years had been 
placed in Commonwealth Health Department archives. Whilst the year 2000 was 
available to be used in the studies, it was unsuitable as it would have included 
records of practitioners that related to both the development and treatment of vision-
threatening retinopathy.  
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Figure 3.2: Provider database 
 
 
 
Figure 3.2 presents the steps involved in the composition of the provider database 
used in Chapter 10. Whilst provider data were used for the analysis, the subjects 
were identified from information included in the patient database (Figure 3.1). The 
first step involved identifying all medical care providers in Australia that had 
claimed for a GP service in the Medicare database in 1999. This was achieved by 
selecting all GPs who had claimed an A1 or A2 item in that year. 
 
The second step involved retrieving the Medicare provider numbers of practitioners 
who had treated study subjects in 1999 from the patient database. Medicare provider 
numbers identify whether the practitioner is able to claim from Medicare, and is 
widely regarded as essential for the practice of medicine in Australia.332 Providers 
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are readily identifiable in the database as each Medicare claim includes details of 
both the patient and provider.  
 
Once this group had been selected, data on the number of cases and controls seen by 
each provider in 1999, along with the practitioner variables (see below), were 
retrieved. This resulted in a population-based case-control study331 that could 
compare the characteristics of cases’ GPs to those of controls with regard to a 
number of important risk factors relevant to the management of diabetes.   
 
MEASUREMENT 
 
Measurement in Chapters 4-9 
The variables used in the first six of the seven studies, the results of which are 
presented in Chapters 4 to 9, were a standard set of diabetes related Medicare items 
used by the Health Insurance Commission to investigate diabetes, and which roughly 
correspond to the clinical management guidelines described in Chapter 2. 
Unfortunately to date there has been no validation of the items in terms of their 
relationship to the management of diabetes. However, as most diabetes care would 
have been captured by this database, the data are likely to bear a strong resemblance 
to diabetes management that was actually provided.    
 
The MBS items for primary care (general practitioner attendance, HbAlc testing and 
HDL-cholesterol testing) and those for secondary care (specialist and optometry 
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attendances) comprise the independent variables, while laser photocoagulation 
therapy is the study outcome.  
 
Whilst the pathology tests, retinal photography and laser therapy can each be 
explicitly linked to diabetes,12, 330 the generic nature of the attendance items mean 
that diabetes related utilisation cannot be isolated. Therefore all attendances which 
might have involved diabetes care were included in the analyses. Table 3.1 sets out 
the Medicare items used in the first six studies comprising the thesis  
 
 
Table 3.1: Medicare items used in patterns of care studies (Chapters 4 to 9) 
 
Medicare items Medicare item 
numbers 
  
Retinal photocoagulation 42809 
Retinal photography 11218 
HDL- c 66536 
HbA1c± 66551 
Microalbumin 66560 
GP attendances A1 and A2 
Specialist and consultant 
physician attendances 
A3 and A4 
Optometrist attendances A10 
Age  
Sex  
State  
SEIFA  
RRMA  
 ±  Haemoglobin A1c tests   
 
Age 
In the original database, that is the Medicare database from 1993 to 2000, age was 
provided as a series of 20 categorical variables. However, there were two scales, one 
for large states and another for small states and territories whose categories 
overlapped when they were combined in the one (national) database. In order to 
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create an indicator that could be used across the whole sample, a continuous variable 
was created using a smoothing function across all age categories.  
 
Gender 
In the original database gender was not supplied for subjects from Tasmania, the 
Northern Territory and the Australian Capital Territory (hereafter ACT) because of 
the possibility that this variable could enable the identification of individuals in these 
small samples. Therefore, in these jurisdictions gender was imputed according to the 
distribution of the sexes in the national sample.      
 
State or territory of residence 
For cases, state and territory were assigned according to the state in which laser 
therapy had occurred. However, for controls it was assigned according to the state 
and territory of the earliest HbA1c test. That state and territory were assigned 
differently was a result of the computer program involved in the data retrieval, 
which would not allow the allocation of state and territory on the same basis for the 
two groups. Although using different methods was not ideal there was no evidence 
that there was bias in sampling.    
  
Socio-Economic Index for Areas Index of Social Deprivation (SEIFA) 
The SEIFA Index of Social Deprivation is a measure of socio-economic status 
derived from the Australian Bureau of Statistics (ABS) Australian Census of 
Population and Housing, which is an aggregate measure derived from up to 50 
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variables related to socio-economic status. 260 The index used in the thesis was that 
derived from the 2001 census.   
 
The Index is based on two levels of variables related to social disadvantage: level 1 
includes education, income and occupation, while level 2 measures the effects of 
disadvantage such as the number of bedrooms in a house, whether a house is owned 
or rented and whether it has access to the Internet. 260 In the present studies SEIFA 
was assigned to individuals by their postcode.260 
 
There were 70 subjects (0.3%) who had non-residential post-codes, such that SEIFA 
was not supplied. These subjects were distributed more or less evenly between cases 
and controls. SEIFA values were imputed for these subjects. This was based on the 
proportion of the sample in each state and territory and the median value of SEIFA 
quintiles in these jurisdictions. 
 
Rurality and Remoteness Index of Areas  (RRMA) 
RRMA is a measure of geographic remoteness derived from the ABS Australian 
Standard Geographical Classification (ASGC) Remoteness Areas Classification, 
which allocates a category of remoteness to areas based on an average of the road 
distance to the closest population centre.333 RRMA areas are classified as either 
major cities, inner regional or outer regional, or remote and very remote. In this 
study the distinction between inner rural and outer rural was not applied. There were 
70 subjects (0.3%) with non-residential post-codes for which RRMA was not 
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supplied. For these subjects, RRMA values were imputed according to each state or 
territory and based on the proportion of subjects within RRMA categories within 
each jurisdiction.  
 
General practitioner attendances (1993 – 2000) 
For the Australian population most clinical care for diabetes occurs through GPs.193 
Thus the level of attendance at GPs is an important indicator of diabetes 
management. The GP variable included all attendances at vocationally registered 
GPs (according to the A1 schedule) and other medical practitioners who had 
provided GP services.334 The latter are termed Other Medical Practitioners (OMPs) 
and use Medicare schedule A2. In the present studies A1 and A2 were combined to 
give one indicator of GP services.   
 
Specialist and consultant physician attendances (1993 – 2000) 
Whilst diabetes patients attend specialists and consultant physicians for a range of 
reasons the most routine need for attendance is to be screened for diabetic 
retinopathy.223 In the Medicare Schedule there are two classifications of medical 
specialists: A3 includes practitioners identified as medical specialists, while A4 
includes consultant physicians. Whilst these two types of practitioner provide similar 
services, consultant physicians are the more senior of the two and receive a higher 
level of reimbursement.328 In the analysis these two indicators were combined to 
give one indicator of specialist attendances.  
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Optometrist attendances (1993 – 2000) 
During the studies optometrists were the only non-medical practitioners that could 
be reimbursed by Medicare, and were denoted by A10 Schedule.328 In the 
management of diabetes optometrists are involved in screening for retinopathy.336 
 
HbA1c tests (1993 – 2000) 
HbA1c is an important pathology test used to measure blood glucose in the 
management of diabetes.207 The test has its own Medicare item numbers: 66551 and 
66557. The latter item identifies whether the test has been ordered for a pregnant 
woman, while the former test is for the remainder of the diabetes population.  As 
there were very few claims for 66557 in the database, these item numbers were 
combined to give one indicator of HbA1c testing.  
 
HDL-c tests (1993 – 2000) 
HDL-cholesterol is an important pathology test in the management of dyslipidaemia 
in people with diabetes.12 The item number for this test is 66560. The need to 
monitor HDL-cholesterol, as opposed to total cholesterol and LDL-cholesterol is not 
commonly understood by medical practitioners. Hence HDL- cholesterol testing can 
be an indicator of how knowledgeable practitioners are about the management of 
diabetes.335  
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Microalbumin tests (1998-2000) 
Microalbumin testing is used to monitor microalbuminuria, which is an indication of 
diabetic kidney damage.92 The test has its own item number (66536), and is 
commonly used for people with diabetes.  
 
Retinal photography (1993 – 2000) 
Retinal photography is a method of screening for diabetic retinopathy.336 The 
procedure has its own item numbers that are often found in the Medicare histories of 
people with diabetes. 11215 refers to photography of one eye and 11218 to both 
eyes. In the present studies these items were combined to give one indicator of 
retinal photography.   
 
Laser photocoagulation therapy (2000) 
Vision-threatening retinopathy was identified in the database by the occurrence of 
laser photocoagulation therapy, marked by the Medicare item number 42809. Laser 
photocoagulation therapy is a reliable indicator of vision-threatening retinopathy as 
it is the major and almost singular treatment for this condition.91 It has been 
estimated that appropriately timed treatment for vision-threatening retinopathy can 
prevent up to 98% of severe vision loss associated with diabetic retinopathy.91 
 
Matching337 
Controls were matched to cases on age (within one year) because of the strong 
association between vision-threatening retinopathy and the duration of diabetes.25 It 
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was thought that had they not been matched, cases would have been on average 
older than controls and may have had diabetes for longer. Thus matching on age 
controlled for confounding by the duration of diabetes.  
 
Matching by state or territory was conducted in order to facilitate within and 
between jurisdiction comparisons of the patterns of care. It was thought that without 
matching, state and territory differences in health care systems could have resulted 
in administrative related differences in patterns of care between cases and controls 
that might have mistakenly been attributed as risk factors for complications. Thus 
matching by state and territory controlled for confounding by different methods of 
data collection.329   
 
Measurement in Chapter 10 
The measures used in the final study of the thesis, the results of which are presented 
in Chapter 10, refer to the characteristics of GPs that were available in the data from 
1999. There are three types of measures used in the study: these concern the nature 
of the case load (variables 1 and 2), the characteristics of GPs themselves (variables 
3 to 7), and the characteristics of the GP’s practice (variables 8 and 9). The three 
types of variables were selected in order to provide a multidimensional picture of 
GPs.  
 
However, as the nature of GP data in the Medicare database is very limited, there is 
a range of potentially important factors that were not able to be included in the study 
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such as whether the practitioner had a special interest in diabetes.328 Nevertheless, 
these limitations had to be accommodated to enable any examination of the 
relationship between the characteristics of GPs and the study outcome.  
 
 
Table 3.2: GP characteristics used in Chapter 10  
 
 Variables Unit of measurement Level of measurement 
    
1 No cases seen in 1999 Individual Continuous 
2 No controls seen in 1999 Individual Continuous 
3 Gender of GP Individual Dichotomous 
4 Vocational registration in 1999 Individual Dichotomous 
5 Years of practice in 1999 Individual Continuous 
6 Age in 1999 Individual Continuous 
7 Overseas trained Individual Dichotomous 
8 SEIFA of major practice Aggregate Quintiles 
9 RRMA of major practice Aggregate Quartiles  
 
Age in 1999 
The age of practitioners can be an important indicator of the nature of medical care. 
Older GPs tend to have longer consultation times,338 which perhaps gives them more 
opportunity to provide more effective chronic disease management. Age was 
provided as a continuous variable for the sample of GPs. 
 
Gender of GP 
Gender is a potentially important variable as it has been shown that women GPs 
provide different kinds of services to men.339 Gender was provided as a binary 
variable.   
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Overseas training 
Whilst overseas trained doctors need to demonstrate their proficiency in medical 
care in order to work in Australia, they often have different methods of practice, 
which may impact on the management of diabetes. They are also more likely to 
provide services to their own ethnic group, which may be at a higher risk of 
developing diabetes.340 Overseas training was provided as a binary variable, where 0 
equalled Australian trained and 1 was overseas trained. The source of the training 
could not be identified.  
 
No of cases seen in 1999 
This indicator enumerated the number of cases seen by a GP in 1999 and together 
with the indicator below was the basis by which GP status was ascribed in the study. 
This variable was provided as a continuous variable with a minimum of 1.    
 
No of controls seen in 1999 
This indicator enumerated the number of controls seen by a GP in 1999. Similar to 
the variable above, this was the basis upon which GPs were allocated to the study 
groups. This variable was provided as a continuous variable with a minimum of 1.   
  
Years of practice in 1999 
Years in medical practice has been shown to be an important indicator of the 
patterns of care, with differences associated with the nature of medical training as 
 158
well as clinical experience.338 There is some evidence that younger doctors are more 
likely to perform more up to date (and perhaps more evidence based) practices. This 
variable was supplied as a continuous variable denoting years in practice in the 
relevant year.  
 
Vocational registration in 1999 
Vocational registration is an accreditation scheme conducted by the Royal 
Australian College of General Practitioners.334 To attain accreditation doctors need 
to demonstrate certain proficiencies in general practice and provide particular 
services (such as after hours medical care), some of which are related to the 
management of chronic disease.254 This variable was supplied as a binary variable 
where 0 was equal to no registration and 1 indicated that the practitioner was 
registered.  
 
Socio-Economic Index for Areas of major practice (SEIFA)(1999) 
As discussed in the literature review, socio-economic status is an important indicator 
of the risk of complications and access to medical care. If a GP principally works in 
a deprived area this is likely to be reflected in a greater caseload of diabetes. The 
SEIFA variable used in respect of the geographic area in which the GPs practised 
was the same as that used in the patient database.260 However, instead of referring to 
the post-code of the patient, this indicator refers to the post-code of the major 
practice of the GP. SEIFA was provided as a continuous variable, which was 
transformed into quintiles for use in the analyses.   
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Rurality and Remoteness Index of Areas of major practice (RRMA)(1999) 
For similar reasons to those associated with SEIFA, remoteness and rurality, as 
denoted by RRMA can be an important indicator of health need and access to care. 
The RRMA variable used was the same as that used in the patient database. 
However, instead of referring to the post-code of the patient, this indicator refers to 
the post-code of the major practice of the GP.341 RRMA was provided as a 
categorical variable with four categories indicating whether the main practice of the 
GP was in a metropolitan or outer-metropolitan area, or a rural or remote locality.  
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Section 3: Methods used in individual studies 
 
Chapters 4 to 9 used samples derived from Table 3.3 below. Whilst Chapters 4,5,8 
and 9 used the entire sample, Chapter 6 used 1993 and 1994 only, and Chapter 7 the 
sample from 2000.      
Table 3.3: Year of earliest HbA1c± test, n (%) 
±  Haemoglobin A1c tests  *Five subjects tested using item code for HbA1c during pregnancy. 
 
 
Chapter 4  
The patterns of care as a risk factor for the development of vision-threatening 
diabetic retinopathy: a population-based matched case-control study using 
insurance claims (Medicare) data 
 
The aim of this study was to test the first research question: To determine whether 
patterns of primary and secondary care is a risk factor for the development of 
diabetes complications in the population with diabetes in Australia. This was 
achieved by comparing the medical care received by cases to that of controls over a 
period of seven years. This study used the total sample in Table 3.3. The level of 
medical care was measured by attendances at general practitioners and medical 
Year Case  Controls Total P of diff 
     
1993 345 (7.4) 917 (19.8) 1262 (13.6) <0.0001 
1994 320 (6.9) 566 (12.2) 886 (9.6) <0.0001 
1995 345 (7.4) 543 (11.7) 888 (9.6) <0.0001 
1996 269 (5.8) 460 (9.9) 729 (7.9) <0.0001 
1997 269 (5.8) 466 (10.0) 729 (7.9) <0.0001 
1998 255 (5.5) 536 (11.6) 761 (8.2) <0.0001 
1999 291(6.3) 538 (11.6) 829 (8.9) <0.0001 
2000 2538 (54.8) 606* (13.1) 3144(33.9) <0.0001 
Total 4632  4632  9264  
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specialists, as well as diabetes related pathology tests such as HbA1c and HDL-
cholesterol testing.  
 
The statistical analyses consisted of between groups comparisons of independent 
variable histories. Differences in proportions were calculated using χ2 tests; 
frequencies were compared using independent samples t-tests; weighted logistic 
regression was used to measure trends in proportions;342 and weighted multiple 
linear regression was used to measure trends in frequencies (means). Multivariate 
conditional logistic regression was used to identify risk factors for the development 
of vision-threatening retinopathy (Table 4.5). 342 The analyses used a stepwise 
process with the backwards conditional method of variable selection, and all 
statistical analyses were performed using SPSS for Windows 11.5.343   
 
Chapter 5 
To determine whether state and territory health care systems play a role in the 
effectiveness of diabetes management in Australia. 
 
Having examined the relationship between medical care and the risk of vision-
threatening retinopathy at the national level, Chapter 5 presents the investigation of 
this relationship for all states and territories. This was to test the second research 
question: To determine whether state based health care systems helped to determine 
the risk of diabetes complications in Australia. This was achieved by repeating the 
study reported in Chapter 4, but disaggregating the national data by the state and 
territory variable so that each of the 8 states and territories could be compared and 
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examined individually. There were equal numbers of cases and controls within each 
state and territory sample and the study used the whole sample in Table 3.3. 
  
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. When risk 
factors were compared between states and territories, for proportions, χ2 tests for 
trend were used, and analysis of variance was used for frequencies (the Bonferroni 
adjustment was used to account for type 2 error).342 For each risk factor, and within 
cases and controls in each state and territory, trends over time were calculated. For 
proportions, multivariate logistic regression of weighted proportions was used, and 
for frequencies, multiple linear regression of weighted means. The multivariate 
analyses were conducted using conditional logistic regression, where the paired 
study design could be taken into account (Tables 5.9 to 5.16), and conventional 
logistic regression where a matched variable was included as a risk factor (state and 
territory in Table 5.8).342 The regression analyses used a stepwise process with the 
backwards conditional method of variable selection, and all statistical analyses were 
performed using SPSS for Windows 11.5.343   
 
Chapter 6 
What goal should a health system have: delayed diagnosis or improved diabetes 
management? 
 
Chapter 6 represents a sub-study of Chapter 4 and developed out of the finding that 
cases had on average received their earliest HbA1c test (an indicator of diagnosis) 
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much later than controls.344 This suggested that delayed diagnosis, and perhaps not 
the pattern of care was responsible for the development of vision-threatening 
retinopathy. This study sought to test the third research question: To determine 
whether patterns of care or delayed diagnosis is the greater risk factor for the 
development of diabetes complications in the population with diabetes in Australia. 
    
This research question was tested using a population-based case-control study,331 
which compared the demographic characteristics and patterns of care of case and 
control groups. Subjects were selected based on having their earliest HbA1c test in 
1993 or 1994, as shown in Table 3.3.  
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests, and frequencies by independent samples t-tests. For each 
risk factor, and within cases and controls, trends over time were calculated. For 
proportions, multivariate logistic regression of weighted proportions was used, and 
for frequencies, multiple linear regression of weighted means.342 The regression 
analyses used a stepwise process with the backwards conditional method of variable 
selection.342 Socio-economic status was entered as four dummy variables in Table 
6.4 (for a broader analysis of socio-economic status see Chapter 8), and all statistical 
analyses were performed using SPSS for Windows 11.5.343 
 
Following further analysis, it was found that 186 (12.5%) subjects of the control 
group in this study did not have a Medicare item in 2000, suggesting that they may 
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have died or emigrated. As it would have been impossible to relate their records of 
health care utilisation to the study outcome they were excluded from the study.  
 
To assess how the exclusion of these controls affected the findings, excluded 
controls were compared to those who were included on major risk factors (Table 
6.1). In this analysis it was found that had excluded controls been included, the 
control group would have been slightly older, the proportion of males would have 
been greater and there would have been some minor differences in health care 
utilisation. In particular, in the early years, differences between cases and controls 
would have become more extreme, but in the latter years the control group would 
have become more like cases. All of the subjects that had missing data were in the 
1993 to 1994 sample. Whilst this methodological flaw is not corrected in Chapters 
4,5, 8 and 9, because of the small numbers affected it was thought that it would have 
had little influence on studies that used the whole sample in Table 3.3  
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Table 3.4: The demographic and health utilisation characteristics of controls excluded from Chapter 6, 
compared to controls that were included in the study   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Included Excluded P 
N 1297 186 1483 
    
Age, mean (sd) 62.9 (13.7) 72.6 (11.5) <0.0001 
Gender (% male) 681(52.5) 128 (68.8) <0.0001 
    
GP attendances, mean (sd)    
1993 11.3(10.8) 14.9 (13.0) <0.0001 
1994 11.6(9.1) 14.6 (18.6) <0.0001 
1995 11.4(9.6) 12.0 (20.9) 0.48 
1996 11.4(9.9) 7.9 (14.8) <0.0001 
1997 12.0(10.3) 5.5 (11.2) <0.0001 
1998 11.9(10.4) 2.07 (5.9) <0.0001 
1999 12.0(11.2) 0.03 (0.44) <0.0001 
    
S&CP, mean (sd)    
1993 2.5 (3.9) 4.4 (6.4) <0.0001 
1994 2.6 (3.7) 4.9(8.9) <0.0001 
1995 2.7(4.3) 3.2(7.9) 0.21 
1996 2.7(4.4) 3.0 (10.3) 0.49 
1997 2.6(3.9) 1.8 (4.9) 0.10 
1998 2.6(3.9) 0.6 (2.7) <0.0001 
1999 3.1(7.0) 0.0 (0.0) <0.0001 
    
HbA1c testing, mean (sd)    
1993 0.89(0.93) 0.92(0.80) 0.71 
1994 1.14(0.96) 0.92(0.91) 0.003 
1995 0.86(1.03) 0.51(0.93) <0.0001 
1996 0.84(1.07) 0.39(0.81) <0.0001 
1997 0.88(1.07) 0.25(0.70) <0.0001 
1998 0.89(1.05) 0.07 (0.38) <0.0001 
1999 0.95(1.12) 0.005 (0.07) <0.0001 
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Chapter 7 
Do the patterns of care prior to the diagnosis of diabetes determine the risk of 
advanced diabetes complications? 
 
Having explored delayed diagnosis as a risk factor for the development of vision-
threatening retinopathy in Chapter 6, the investigation in Chapter 7 sought to 
answer the fourth research question: To determine whether the patterns of care 
prior to the diagnosis of diabetes are a risk factor for the development of 
advanced diabetes complications. The study examined whether patient 
demographic characteristics, GP, specialist and optometry attendances were risk 
factors for diabetes complications by comparing cases to controls. The study 
used the 2000 sample in Table 3.3.  
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. For each 
risk factor, and within cases and controls, trends over time were calculated. For 
proportions, multivariate logistic regression of weighted proportions was used, 
and for frequencies, multiple linear regression of weighted means.342 The 
regression analyses used a stepwise process with the backwards conditional 
method of variable selection.342 Socio-economic status was entered as four 
dummy variables in Table 7.4 (for a broader analysis of socio-economic status 
see Chapter 8), and all statistical analyses were performed using SPSS for 
Windows 11.5.343  
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Chapter 8 
Does socio-economic status determine the risk of complications in people with 
diabetes? 
 
Chapter 8 reports the test of the fifth research question, which related to equity: 
To determine whether socio-economic status is a risk factor for diabetes 
complications in the population with diabetes in Australia. A population-based 
case-control study similar to those in Chapters 4 and 5 was used.331 The study 
examined patient demographic characteristics, the utilisation of primary and 
secondary care, diabetes related pathology tests and the risk of complications 
between cases and controls across socio-economic groups, using the entire 
sample in Table 3.3.  
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. When 
risk factors were compared between socio-economic groups, for proportions, χ2 
tests for trend were used, and for frequencies analysis of variance was used (the 
Bonferroni adjustment was used to account for type 2 error).342 For each risk 
factor, and within cases and controls in each socio-economic group, trends over 
time were calculated. For proportions, multivariate logistic regression of 
weighted proportions was used, and for frequencies, multiple linear regression of 
weighted means. The multivariate analyses were conducted using conditional 
logistic regression, which could take into account the paired study design (Tables 
8.8 to 8.13).342 The regression analyses used a stepwise process with the 
backwards conditional method of variable selection (Tables 8.8 to 8.13). Socio-
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economic status was entered as four dummy variables in Table 8.8, and all 
statistical analyses were performed using SPSS for Windows 11.5.343 
 
Chapter 9 
Are geographically isolated patients at greater risk of complications because of 
poor access to health care? 
 
In Chapter 9 the sixth research question is tested: To determine whether 
geographic isolation is a risk factor for the diabetes complications in the 
population with diabetes in Australia. A population-based case-control study, 
similar to those in Chapters 4, 5 and 8 was used.331  The study examined patient 
demographic characteristics, the utilisation of primary and secondary care, 
diabetes related pathology tests and predicted complications across remoteness 
groups, and used the whole sample in Table 3.3.  
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. When 
risk factors were compared between remoteness groups, for proportions, χ2 tests 
for trend were used, and for frequencies analysis of variance was used (the 
Bonferroni adjustment was used to account for type 2 error).342 For each risk 
factor, and within cases and controls in each remoteness group, trends over time 
were calculated. For proportions multivariate logistic regression of weighted 
proportions was used, and for frequencies, multiple linear regression of weighted 
means. The multivariate analyses were conducted using conditional logistic 
regression to take account of the paired study design, and the regression analyses 
used a stepwise process with the backwards conditional method for variable 
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selection. (Tables 9.8 to 9.12). Geographic isolation was entered as three dummy 
variables in Table 8.9, and all statistical analyses were performed using SPSS for 
Windows 11.5.343 
 
Chapter 10 
Do the characteristics of GPs determine the risk of complications? 
 
Table 3.5: GPs in the provider database 
 
 
 
Studies reported in Chapters 4 to 9 used patient data to investigate the research 
questions, Chapter 10, on the other hand, used practitioner data, which was also 
collected in Medicare. This study tested the seventh research question: To 
determine whether the characteristics of GPs are associated with the development 
of complications in the population with diabetes in Australia. The study was a 
population-based case-control study 331 of all GPs who had been attended by 
cases or controls in 1999. In the analysis case GPs were compared to control GPs 
to determine whether there were any systematic differences between them.    
 
The study population consisted of GPs who had made a Medicare claim for a 
general practice service in 1999 (schedules A1 and A2).328 Once these 
practitioners had been identified GPs who had been attended by a subject 
included in Table 3.3 were selected to be included in the study. The linkage of 
GPs to patients was conducted through patient records as each Medicare claim 
includes information on both the patient and the provider.328 Once the GP sample 
Group Case GPs Control GPs Both Total 
     
n (%) 4258(34.7) 4499(36.6) 3526(28.7) 12283 (100) 
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had been chosen the demographic characteristics, accreditation status and the 
location of their principal practice were collected from the Medicare database. 
The data items used in the study are presented in Table 3.2.  
 
In the univariate analyses, which compared case to control practitioners, as well 
as to those who treated both, proportions were compared using χ2 tests and 
frequencies by analysis of variance (the Bonferroni adjustment was used to 
account for type 2 error).342 The multivariate analysis in Table 10.2 was 
conducted using logistic regression, which used a stepwise process with 
backwards conditional as the variable selection criteria.342 Socio-economic status 
was entered as four dummy variables and RRMA as three dummy variables in 
Table 10.2. The regression analyses used a stepwise process with the backwards 
conditional method of variable selection, and all statistical analyses were 
performed using SPSS for Windows 11.5.343 
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Section 4: Limitations of the thesis 
 
Limitations of case control studies 
While the studies in the thesis suggest that the pattern of care causes advanced 
diabetes complications to develop, case-control studies cannot establish 
causation.331 This is because subjects in these studies are not randomly selected, 
and the way in which the subjects were selected may be responsible for the 
relationships between variables that are found.331 Given this limitation, case-
control studies can only show that study factors and outcomes are associated with 
each other.    
 
Where patients had not received HbA1c test 
Diabetes patients who had not received an HbA1c test between 1994 and 2000 
would not be included in the thesis. This would exclude people with diabetes 
who had not been diagnosed during these years, and those who had a diagnosis 
but had not been tested. This could lead to selection bias which would favour 
patients who were more likely to be tested. Such patients could include those 
with easier access to health care or from less deprived areas.277   
 
Inability to differentiate between type 1 and type 2 diabetes.  
Types 1 and 2 diabetes are separate clinical entities with different aetiologies and  
populations at risk.1 This is reflected in, amongst other things, different levels of 
risk of advanced diabetes complications.12 As they require different types of 
medical management, it would have been useful to examine them separately. 
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However, it was not possible to differentiate the types in the Medicare database. 
As type 2 diabetes is much more prevalent, the studies are likely to reflect the 
relationship between patterns of care and the development of complications for 
this condition. The findings may be less applicable to type 1.   
 
Use of procedure as outcome 
The use of laser therapy as an indicator of vision-threatening retinopathy as the 
outcome may have resulted in selection bias in cases. This would occur as 
patients with poorer access to laser therapy would have been less likely to be 
included in the case group. If access to laser therapy is determined by similar 
factors to those that determine access to specialists, which provide the procedure, 
the use of laser therapy as the outcome could result in fewer patients of low 
socio-economic status,22 Aboriginal and Torres Strait Islander30 and other 
populations in cases. As these groups typically suffer more from diabetes 
complications,273, 299 their exclusion could bias the case sample towards patients 
with fewer diabetes symptoms.        
 
Where patients had received care outside of the Medicare system  
The measurement of health care utilisation was limited to that which had been 
funded by Medicare. As the Medicare database does not cover all health care in 
Australia, patients may have obtained more treatment than that which was 
investigated in the studies.183 When comparing cases and controls, under-
enumeration is problematic only when it differs between groups,331 whether or 
how it differs could not be determined by the studies in the thesis.    
 173
Earliest HbA1c test as an indicator of diagnosis  
The study used the earliest HbA1c test as an indicator of the timing of diagnosis, 
however, this indicator may not be accurate. As patients need to have been 
diagnosed with diabetes to receive a Medicare funded HbA1c test, thus it can 
precisely identify diabetes. However, patients may have been diagnosed well 
before the earliest HbA1c test indicates. This may mean that the findings in the 
thesis that concern the timing of diagnosis do not relate to diagnosis, but to the 
ease of access to HbA1c testing. This may mean that patients who have poorer 
access to HbA1c testing are more likely to be counted as late diagnosed.22 
However, as this limitation applies to all subjects the discrepancy is likely to be 
similar among both groups, thus it may have little bearing on the findings.   
 
Limitations of the variables 
Whilst HbA1c, HDL cholesterol and microalbumin testing can be specifically 
linked to diabetes12 the attendance items were generic, meaning that whether an 
attendance was diabetes related could not be determined. Thus some of the 
medical care studied in the thesis may not concern diabetes. However, the studies 
included all GP, specialist and optometrist attendances that could have concerned 
diabetes over the period of the study. However, as this limitation applies to all 
subjects the discrepancy is likely to be similar among both groups, thus it may 
have little bearing on the findings.   
 
Limitations in the range of variables 
It would have been desirable to include additional diabetes management 
variables, such as blood pressure tests 72 and foot testing,116 however, these tests 
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do not have their own Medicare item numbers. Other key parameters that were 
not captured include measures for weight and height.  
 
The GP data available in the Medicare database are very limited and there is a 
range of potentially important factors that could not be included in the study in 
Chapter 10. Of greatest significance was that there was no indicator that could 
measure the level of involvement a GP had in the care of diabetes patients. Thus 
the contribution of individual practitioners to the management of diabetes 
patients could not be determined.172 Thus the study only allows limited 
inferences about the role of GP characteristics in the development of diabetes 
outcomes. 
 
Chapter 10 – one years worth of data may not be representative of involvement in 
diabetes care    
 
GPs were only chosen from the 1999 records of patients. However, medical care 
provided over one year may be insufficient to present an accurate picture of GP 
involvement in diabetes care.  This may mean that case and control GPs are less 
distinct, as study subjects would have had the opportunity to attend a greater 
range of practitioners, including practitioners who treated either group in 1999.   
 
Clustering of GPs not able to be taken into account 
GP studies conventionally use clustered study designs in order to adjust for the 
lower level of variation in characteristics between practitioners who work in the 
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same practices.342 However, this requires a variable through which clusters can 
be defined. Unfortunately at the time of the data collection, there was not a 
suitable variable that could be used in this manner. Therefore in this study, a 
more conventional analytical approach was taken that treated each GP as an 
independent practitioner. By not adjusting for clustering, however, the 
confidence intervals may not accurately reflect the true level of variation in GP 
characteristics across the sample.342 
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Conclusion 
 
A number of significant knowledge gaps have been identified in the literature 
review regarding the current level of evidence related to the capacity of the 
Australian health care system to manage diabetes. The methods chapter 
described a series of case-control studies that were aimed at addressing these 
gaps and thus providing information about the capacity of the Australian health 
care system to manage diabetes.  
 
The studies described were concerned with investigating the nature of the 
relationship between health care utilisation and the development of 
complications. They represent an improvement over previous studies that have 
had similar aims in that they are population-based, longitudinal in design and use 
a process of care that is highly correlated with an advanced diabetes complication 
as the outcome of the studies.  
 
The seven chapters that follow represent the main body of the thesis in that they 
report on the evaluation of the research questions. The studies represent a 
thorough evaluation of the capacity of the Australian health care system to 
manage diabetes.  
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Chapter 4 
 
The patterns of care as a risk factor for the development of 
vision-threatening diabetic retinopathy: a population-based 
matched case-control study using insurance claims (Medicare) 
data 
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Abstract 
 
 
OBJECTIVES: To evaluate systematically the effectiveness of the primary health care system in 
Australia in preventing the development of advanced diabetes complications.  
 
METHODS: 4632 diabetes patients who had received their first laser photocoagulation treatment 
in 2000 were compared to a random sample of diabetes patients who had never received this 
treatment (n = 4632). Patterns of health care utilisation were compared over a seven-year period 
(1993-1999) using the Australian Medicare database.  
 
RESULTS:  There were significant differences in levels of health care utilisation between cases 
and controls: a lesser proportion of cases attended GPs, from 69.6% in 1993 to 85.2% in 1999, 
compared to 93.5% and 91.0% in these same years in controls (P<0.0001 in all years). In 
addition, fewer cases attended specialist and consultant physicians, from 21.5% in 1993 to 36.6% 
in 1999,  compared to 49.3% and 56.2% in these same years for controls (P<0.0001 in all years). 
Moreover, fewer cases were tested for HbA1c, from 7.4% in 1993 to 17.1% in 1999, compared to 
19.8% and 44.1% in these same years for controls. Finally, fewer cases were tested for HDL-
cholesterol with 0.5% in all years,  compared to 11.4% in 1993 and 19.5% in 1999 for controls. 
The multivariate analysis emphasised timely diagnosis, HDL-cholesterol testing and optometry 
attendances in the prevention of advanced diabetes complications.  
 
CONCLUSIONS:  The study supports the contention that health care utilisation may be as 
important a determinant of health outcomes as clinical risk factors such as blood glucose control. 
This highlights the importance of early diagnosis and the need to address systemic barriers to 
increase primary care utilisation for people at risk of advanced diabetes complications. 
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Introduction 
 
One million people in Australia are estimated to have diabetes,288 where this 
disease is ranked eighth in frequency of disorders managed in general practice.345 
With the prevalence of diabetes set to double within 20 years 346 the prevention 
of diabetes and its complications is a major public health priority.1  
 
Whilst diabetes takes a heavy toll on individual and population health, there are 
evidence-based clinical and health service interventions that delay the 
development of diabetes complications.74 For example, the Diabetes Control and 
Complications Trial3 and the United Kingdom Prospective Diabetes Study57 
established the efficacy of blood glucose and blood pressure control for 
preventing microvascular complications, while Griffin demonstrated the 
effectiveness of computerised central recall systems for improving the quality of 
care.197  
 
However, evidence for these interventions has largely been derived from clinical 
studies focused on individual risk factors, using highly motivated and 
homogenous groups of selected individuals. Whilst this is entirely appropriate for 
determining the efficacy of clinical interventions, it often means that we do not 
know if they will work in routine settings of care.11 Moreover, interventional 
studies do not usually take into account factors such as access, poverty, 
knowledge or competency on the part of the patient or provider that may impact 
on the nature of care delivered.  These types of factors are hypothesised to be key 
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upstream determinants of the quality of care which if not addressed will lead to a 
higher than expected incidence of complications in at risk groups. 
 
In Australia, the adoption of diabetes as a national health priority in 1996 forged 
a cross-government commitment for tackling the disorder and reaffirmed primary 
care as the key modality of care linked to specialist care settings.1 Various 
strategies to improve awareness, knowledge and the capacity to detect diabetes 
complications have been introduced.74, 200 However, the reach or success of these 
strategies as evidenced by outcomes such as delay in the development of diabetes 
complications has not been determined as to date there has been no systematic 
evaluation of the effectiveness of current care models. 
 
In this study the evaluation of current care models was conducted by testing the 
relationship between patterns of health care utilisation over a seven year period 
among a representative sample of Australian diabetes patients174 and the 
development of a quantifiable advanced diabetes complication, vision-
threatening retinopathy.24 
 
This corresponds to the first research question of the thesis: whether patterns of 
primary health care utilisation are a risk factor for the development of diabetes 
complications in the population with diabetes in Australia. Whilst case-control 
studies can only provide evidence of epidemiological association, when 
conducted robustly the evidence they provide is highly suggestive of 
causation.331 
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The use of vision-threatening retinopathy as the outcome of the study is highly 
significant as it is one of the most common advanced complications of diabetes, 
with 2-3% of patients estimated to suffer from the condition in Australia. 218, 347 
More broadly, vision-threatening retinopathy is the most common cause of 
blindness among people of working age.35 Vision-threatening retinopathy also 
has profound clinical significance as its development can be slowed by 
glycaemic control3, 57 facilitated by blood glucose testing207 and retinopathy 
screening.24 It is also highly treatable by laser photocoagulation therapy,91 with 
early detection readily able to prevent further morbidity.  
 
In this study we aimed to test the research question of whether the pattern of care 
delivered to an individual with diabetes is a risk factor for diabetes 
complications, in other words, whether appropriate quality of care (as defined by 
clinical management guidelines) would facilitate better health outcomes. 
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Methods 
 
This research question was tested using a population-based case-control study,331 
which compared the demographic characteristics and health care utilisation of 
cases and controls. Subjects’ characteristics are set out in Table 4.1 below. Cases 
comprised a national sample of 4632 patients who had received their first laser 
photocoagulation therapy in 2000, while controls were a sample of 4632 people 
with diabetes who had not received this treatment (this included the total sample 
in Table 4.2). Controls were matched to cases on age (within one year) and state 
of residence at the time of their earliest HbA1c test.   
 
The statistical analyses consisted of between groups comparisons of independent 
variable histories. Differences in proportions were calculated using χ2 tests; 
frequencies were compared using independent samples t-tests; weighted logistic 
regression was used to measure trends in proportions;342 and weighted multiple 
linear regression was used to measure trends in frequencies.342 Multivariate 
conditional logistic regression was used to identify risk factors for the 
development of vision-threatening retinopathy (Table 4.5).342 The variable 
selection algorithm was backwards conditional and all statistical analyses were 
performed using SPSS for Windows 11.5.343 
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Results 
 
CHARACTERISTICS OF THE SAMPLE 
 
The age of subjects ranged from 12 to 97 years, with the mean age being 62.4 
years (sd = 13.1 years). Table 4.1 shows that when stratified by tertiles, the 
sample was concentrated in the age group 59 years and over, with one third of 
subjects aged 59 to 69.  
 
Table 4.1: Characteristics of study subjects 
 
 
 
Table 4.1 shows that 54.3% of subjects were male and 45.7% female, reflecting 
the gender distribution of diabetes in Australia.288 When case and control groups 
were compared, the gender distributions were found to be very similar in each 
group (χ2 = 1.11, 1df, p = 0.3), suggesting that whilst the risk of diabetes was 
higher in men, the risk of developing vision-threatening retinopathy was not 
determined by gender.   
  Cases (%) Controls(%) Total, n(%) 
     
Age 12 – 58 1544 (33.3) 1544(33.3) 3088(33.3) 
 59 – 69 1544(33.3) 1544(33.3) 3088(33.3) 
 70 -  97 1544(33.3) 1544(33.3) 3088(33.3) 
     
Gender M 2488 (53.7) 2539 (54.8) 5027(54.3) 
 F 2144 (46.3) 2093 (45.2) 4237(45.7) 
     
Total  4632 4632 9264(99.7) 
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EARLIEST HBA1C TEST  
 
The year in which patients’ earliest HbA1c test occurred was used as an 
approximate indicator of the timing of diabetes diagnosis.183 It was assumed that 
patients with an earliest HbA1c test in 1993 or 1994 had a diagnosis of diabetes 
in these years or before, but that those with an earliest test between 1995 and 
2000 had been diagnosed during the period covered by the study. Table 4.2 sets 
out the year of the earliest HbA1c test for cases and controls.   
 
 
Table 4.2: Year of earliest HbA1c± test, n (%) 
 
Year Case  Controls Total P of diff 
     
1993 345 (7.4) 917 (19.8) 1262 (13.6) <0.0001 
1994 320 (6.9) 566 (12.2) 886 (9.6) <0.0001 
1995 345 (7.4) 543 (11.7) 888 (9.6) <0.0001 
1996 269 (5.8) 460 (9.9) 729 (7.9) <0.0001 
1997 269 (5.8) 466 (10.0) 729 (7.9) <0.0001 
1998 255 (5.5) 536 (11.6) 761 (8.2) <0.0001 
1999 291(6.3) 538 (11.6) 829 (8.9) <0.0001 
2000 2538 (54.8) 606* (13.1) 3144(33.9) <0.0001 
Total 4632  4632  9264  
±  Haemoglobin A1c tests  *Five subjects tested using item code for HbA1c during pregnancy. 
 
 
The table shows cases and controls exhibited significant differences in the timing 
of their earliest HbA1c test, with cases on average receiving their earliest test 
much later than controls. Indeed, at least 50% of cases received their earliest 
HbA1c test in the same year as they received their first laser therapy (2000), 
suggesting that they were diagnosed with diabetes in the same year that they 
were treated for the complication. In comparison, only 13% of controls received 
their earliest HbA1c test in 2000. This difference was highly statistically 
significant (p<0.0001).  
 
 185
GP ATTENDANCES  
 
Table 4.3 shows that in each year a significantly lower proportion of cases than 
controls attended GPs. Whilst there were significant differences in all years, they 
were particularly marked in 1993 and 1996. For example, in 1993 30% of cases 
did not see a GP at all for any reason as compared to 6.5% of controls. Overall, 
the level of attendance among controls was near to the Australian average in all 
years (90% of the population attend a GP in a year).254 Although the level of 
attendance at GPs for cases increased over the study period, the proportion of 
attendees did not reach that of controls and remained significantly below the 
Australian average.   
 
The frequency of GP attendances was also lower among cases, as shown in Table 
4.4. For example, cases attended an average of 4.3 times in 1993, increasing to 
an average of 6.9 times in 1999. By contrast, controls attended an average of 9.5 
times in 1993, which increased to an average of 10.5 times in 1999. In all years 
these differences were highly statistically significant (p<0.0001).  
  
SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES 
 
Specialist and consultant physician attendances include visits to all medical 
specialists including ophthalmologists and endocrinologists. Table 4.3 shows that 
a smaller proportion of cases attended specialists and consultant physicians as 
compared to controls. For example, in 1993, 21.5% of cases attended a specialist 
or consultant physician, while almost 50% of controls attended these 
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practitioners. Similarly, in 1999 approximately 37% of cases attended a specialist 
or consultant physician compared to 56% of controls. These differences were 
highly statistically significant (p<0.0001). 
 
The differences in the proportion of cases and controls attending a specialist or 
consultant physician each year were reflected in the frequency of attendances, as 
is presented in Table 4.4. In 1993 cases attended a specialist or consultant 
physician an average of 0.64 times compared to 1.9 times for controls. Whilst in 
1999 the level of attendance in both groups increased, however, the differential 
remained with cases attending specialists and consultant physicians an average of 
1.4 times, compared to 2.5 times for controls. Again these differences were 
highly statistically significant.  
 
OPTOMETRIST ATTENDANCES 
 
A similar pattern was found with optometrist attendances, as presented in Table 
4.3, where only 1.6% of cases attended an optometrist in 1993, compared to 
22.7% of controls. In 1999 3.0% of cases attended an optometrist, compared to 
24.7% of controls.  
 
Again the differences in the proportions were reflected in the frequency of 
attendances, as presented in Table 4.4. In 1993 cases attended optometrists 0.02 
times on average compared to 0.27 times on average for controls. In 1999 cases 
attended optometrists 0.03 times on average, compared to 0.31 times for controls. 
These differences were highly statistically significant (p<0.0001). 
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Table 4.3: Health care utilisation between 1993 and 1999 for cases and controls, n (%) 
 
     Year 
 
     
Cases  1993 1994 1995 1996 1997 1998 1999 Annual  
trend (OR) 
P 
 GP   3325(69.6) 3368(72.7) 3462(74.7) 3549(76.6) 3622(78.2) 3760(81.2) 3944(85.2) 1.15∗ <0.0001 
 HbA1c ±          345(7.4) 458(9.9) 583(12.6) 552(11.9) 639(13.8) 698(15.1) 791(17.1) 1.14# <0.0001 
 HDL-c†            23(0.5) 16(0.2) 24(0.5) 23(0.5) 23(0.5) 23 (0.5) 23(0.5) 1.02# <0.0001 
 S&CP‡             996(21.5) 103922.4) 1117(24.1) 1151(24.8) 1253(27.1) 1379(29.8) 1697(36.6) 1.17∗ <0.0001 
 Optometrist     74(1.6) 74(1.6) 99(2.1) 98(2.1) 116(2.5) 126(2.7) 137(3.0) 1.11∗ <0.0001 
           
Controls           
 GP                   4332(93.5) 4343(93.8) 4361(94.1) 4347(93.8) 4307(93.0) 4277(92.3) 4217(91.0) 0.93∗ <0.0001 
 HbA1c±           917(19.8) 1089(23.5) 1264(27.3) 1333(28.8) 1558(33.6) 1828(39.5) 2043(44.1) 1.21# <0.0001 
 HDL-c †           528(11.4) 628(13.6) 759(16.4) 729(15.7) 809(17.5) 887(19.1) 905(19.5) 1.10# <0.0001 
 S&CP‡             2283(49.3) 2416(52.2) 2438(52.6) 2543(54.9) 2539(54.8) 2575(55.6) 2602(56.2) 1.04∗ <0.0001 
 Optometrist     1126(22.7) 1035(22.3) 1162(25.1) 1146(24.7) 1178(25.4) 1167(25.2) 1146(24.7) 1.02∗ <0.0001 
The differences in the proportion of attending or testing for each year for cases vs controls was significant at p<0.0001.∗ Reference group = not attended, # reference group = not tested 
 ±Haemoglobin A1c tests, † HDL cholesterol tests and ‡ Specialist and consultant physician attendances 
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Table 4.4: Health care utilisation between 1993 and 1999 for cases and controls, mean (sd) 
 
 
 
The differences in all annual means for each variable for cases vs controls were significant at p<0.0001. ±Haemoglobin A1c tests,† HDL cholesterol tests,‡ Specialist and consultant 
physician attendances 
 
     Year 
 
     
 Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
GP Case 4.31(7.13) 4.78 (7.92) 5.05 (7.92) 5.55 (8.60) 5.76 (8.61) 6.28 (8.96) 6.86 (9.16) 0.99 <0.0001 
 Control 9.46 (10.30) 9.77 (10.08) 10.27(10.60) 10.3 (10.07) 10.5 (9.91) 10.52(10.04) 10.45(9.86) 0.89 <0.0001 
           
S&CP‡ Case 0.64(2.17) 0.66 (2.24) 0.78 (3.04) 0.79 (3.49) 0.90 (3.13) 1.05 (3.91) 1.36 (5.60) 0.93 <0.0001 
 Control 1.92(3.53) 2.0 (3.74) 2.21(4.76) 2.32 (4.50) 2.31(4.03) 2.31 (4.12) 2.51 (5.43) 0.94 <0.0001 
           
Optom Case 0.019(0.18) 0.017 (0.13) 0.024 (0.17) 0.026 (0.22) 0.028 (0.18) 0.03 (0.19) 0.03 (0.21) 0.94 <0.0001 
 Control 0.27 (0.54) 0.26 (0.53) 0.29(0.57) 0.30 (0.60) 0.30 (0.58) 0.31 (0.62) 0.31 (0.64) 0.91 <0.0001 
           
HbA1c± Case 0.10 (0.40) 0.13 (0.43) 0.16 (0.48) 0.15 (0.48) 0.19 (0.53) 0.20 (0.53) 0.23 (0.57) 0.97 <0.0001 
 Control 0.28 (0.66) 0.36 (0.75) 0.41 (0.78) 0.44 (0.82) 0.53 (0.88) 0.62 (0.92) 0.70 (0.97) 0.99 <0.0001 
           
HDL-c† Case 0.006 (0.09) 0.005 (0.09) 0.005 (0.07) 0.005 (0.07) 0.005 (0.07) 0.006 (0.9) 0.005(0.08) 0.0 1.0 
 Control 0.14 (0.43) 0.17 (0.49) 0.22 (0.56) 0.21 (0.54) 0.24 (0.59) 0.25 (0.61) 0.26 (0.60) 0.95 <0.0001 
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HbA1C AND HDL-CHOLESTEROL TESTS 
 
Table 4.3 shows in all years, the proportion of cases tested for HbA1c was less 
than half that of controls. Whilst the trend was for increased testing in both 
groups, the increase was greatest in controls (OR = 1.14 for cases and 1.21 for 
controls).  
 
The differences between the groups in respect of the proportion of patients tested 
were reflected in the frequency of tests (Table 4.4). In 1993, cases received an 
average of 0.1 HbA1c tests per year compared to almost three times as many 
tests for controls (an average of 0.28). In 1999, although the level of testing had 
significantly increased, cases still only received an average of 0.23 tests per year 
and the three-fold differential remained. In all years the differences between the 
groups were highly significant (p<0.0001). 
 
 
Table 4.3 also shows the proportions of subjects who were tested for HDL-
cholesterol each year, again indicating very large differentials between the 
groups. Whilst testing was inadequate in both groups, it was very rare in cases, 
with only 0.5% being tested within a year. This is despite the HDL-cholesterol 
testing being included in clinical management guidelines for diabetes during this 
period.74 In addition, there was little evidence of the level of testing substantially 
increasing over the study period for these patients.  
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PATIENT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS 
 
The study also investigated whether patient characteristics and seven-year health 
care utilisation predicted laser photocoagulation therapy. This was tested using a 
conditional logistic regression analysis captured in Table 4.5 below. The utility 
of this model lies in its capacity to predict the occurrence of laser therapy from 
patient demographic characteristics and health care utilisation over a period of 
seven years.342  
 
The model showed that the most consistent predictors of laser therapy in 2000 
were whether patients had attended an optometrist or received an HDL 
cholesterol test in the preceding years. In addition, cases were much more likely 
to have received retinal photography. 
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Table 4.5: Conditional logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Gender* 0.75 0.60 – 0.94 0.01 
Dx before 2000Г 0.14 0.10 – 0.20 <0.0001 
    
1993    
GP 0.96 0.94 – 0.98 <0.0001 
S&CP‡ 0.95 0.90 – 0.99 0.02 
Optometry 0.25 0.17 – 0.37 <0.0001 
HDL-c† 0.27 0.12 – 0.33 0.002 
Retinal Ph§ 1.93 0.63 – 5.93  0.25 
    
1994    
S&CP 0.92 0.88 – 0.96 <0.0001 
Optometry 0.12 0.07 – 0.21 <0.0001 
HDL-c 0.17 0.07 – 0.39 <0.0001 
Retinal Ph 3.46 0.83 – 14.5 0.09 
    
1995    
GP 0.98 0.96 – 1.004 0.11 
S&CP 0.95 0.91 – 0.98 0.003 
Optometry 0.20 0.12 – 0.30 <0.0001 
HDL-c 0.07 0.02 – 0.17 <0.0001 
Retinal Ph 2.41 0.86 – 6.78 0.09 
    
1996    
Optometry 0.37 0.26 – 0.54 <0.0001 
HDL-c 0.11 0.04 – 0.27 <0.0001 
Retinal Ph 5.68 1.22 – 26.3 0.03 
    
1997    
Optometry 0.20 0.14 – 0.34 <0.0001 
HDL-c 0.11 0.03 – 0.20 <0.0001 
Retinal Ph 2.85 0.99 – 8.15 0.05 
    
1998    
Optometry 0.20 0.13 – 0.3 <0.0001 
HDL-c 0.13 0.05 – 0.24 <0.0001 
Retinal Ph 2.59 0.97 – 6.91 0.06 
    
1999    
GP 1.02 1.003 – 1.03 0.02 
Optometry 0.21 0.14 – 0.33 <0.0001 
HbA1c†± 0.74 0.61 – 0.89 0.001 
HDL-c 0.02 0.008 – 0.07 <0.0001 
Retinal Ph 26.8 8.64 – 83.2 <0.0001 
Microalbumin 2.57 1.90 – 3.50 <0.0001 
Reference group = controls,*reference group = females,  
Гreference group = not diagnosed.  
Model overall χ2 = 3103.6, 31 df, p <0.0001. 
±Haemoglobin A1c tests, 
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances. 
§ Retinal photography  
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Discussion 
 
The study showed that diabetes patients who developed vision-threatening 
retinopathy had significantly lower levels of diabetes-related health care 
utilisation across almost all aspects of primary and secondary care examined. 
Overall, those who developed vision-threatening retinopathy had a pattern of 
care that included delayed diagnosis, lower levels of medical care attendances, 
under-testing and under-referral over a seven-year period when compared to 
controls. This population level finding strongly supports the contention that 
patterns of primary care utilisation may be as important a determinant of diabetes 
outcomes as clinical risk factors such as blood glucose control and 
hypertension.55, 57 
 
Perhaps the most notable observation concerned the timing of diagnosis. 
Alarmingly, over half of the cases obtained their earliest HbA1c test in the same 
year as they were treated for laser photocoagulation therapy, suggesting a 
relationship between delayed diagnosis and vision-threatening retinopathy. The 
evidence suggests that the deprivation of medical care resulting from the delayed 
diagnosis of diabetes could itself have led to the development of complications,12 
as people with diabetes who have not been diagnosed would not have received 
appropriate treatment. The issue of timing of diagnosis is examined in detail in 
Chapters 6 and 7 below. 
 
A second major finding was the under-utilisation of GPs among those who 
developed vision-threatening retinopathy, and the study suggests both 
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quantitative and qualitative dimensions to this risk factor. On the quantitative 
dimension, the number of attendances at GPs may have been critical in 
determining the quality of care and thereby the progress of diabetes, as GP 
attendance enables access to most aspects of diabetes management.39  
 
Qualitative differences in care are suggested by the major disparities in testing 
for HDL-cholesterol between cases and controls. The significance of this test lies 
in its specificity to glucose metabolism conditions and its rare use for other 
disorders.348 However, HDL- cholesterol is not the most common test ordered by 
practitioners for detecting dyslipidaemia in people with diabetes, which is 
usually total or LDL-cholesterol.22 Therefore, its use can be regarded as a marker 
of a greater understanding of diabetes among practitioners. These findings 
suggest that there were deficiencies in provider behaviour perhaps explained by a 
lack of time or even poor competency,349 which may have contributed to the 
development of vision-threatening retinopathy.    
 
Looking beyond utilisation to risk groups, the multivariate analysis indicated an 
increased risk of vision-threatening retinopathy among women. While two 
hypotheses emerge from this finding, the data do not allow a conclusive 
explanation to be made. It may be that women are at an apparent higher risk of 
vision-threatening retinopathy because of a health status predisposition or, 
alternatively, the higher risk may reflect easier access to laser photocoagulation 
therapy. However, as is examined in a later chapter, the gender difference was 
only apparent in Victoria (Table 5.10), SEIFA 1 (Table 8.9) and RRMA 3 (Table 
9.11). As the increased risk in women was confined to these particular sub-
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populations it is unlikely to reflect differentials in the predisposition to vision-
threatening retinopathy between the sexes.   
 
In conclusion, the findings highlight the need for timely diagnosis, improved 
access to medical care and greater quality of care if diabetes complications such 
as vision-threatening retinopathy are to be prevented. Together, these imperatives 
demand an intensification of effort, at both the primary care and policy levels, to 
truly reflect the status of diabetes as a national health priority.  
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Chapter 5 
 
Diabetes management across Australian states and territories:         
Do different models of tertiary care impact on the nature and 
effectiveness of diabetes management?   
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Abstract 
 
OBJECTIVES: To evaluate the role of state and territory health care systems in the management of 
diabetes and the prevention of complications.  
 
METHODS:  Diabetes patients (n = 4632) who received their first laser photocoagulation 
treatment in 2000 were compared with a random sample of diabetes patients from the same states 
and territories who had never received this treatment (n = 4632). Patterns of health care 
utilisation were compared over a seven-year period (1993-1999) within state and territories using 
the Australian Medicare database.  
 
RESULTS:  Similar differences between cases and controls to those reported in Chapter 4 were 
evident in all jurisdictions. Cases were diagnosed earliest in Victoria and latest in South 
Australia, whilst controls were diagnosed earliest in New South Wales and latest in South 
Australia. For GP attendances, among cases, these were highest in South Australia (7 year 
average 80.7%), and lowest in the Northern Territory (7 year average = 60.4%), P<0.0001. 
Among  controls, the highest proportion that attended GPs was in Queensland (7 year average = 
94.6%), and the lowest was in Western Australia (7 year average = 90.1%), P<0.0001. With 
regard to specialist and consultant physician attendances: for cases the highest proportion of 
attendances was in New South Wales (7 year average = 29.2%), whilst the lowest was in the 
Northern Territory (7 year average = 14.3%), P<0.0001. For HbA1c testing, among cases the 
highest proportion tested was in South Australia (7 year average = 29.3%), and the lowest in the 
Northern Territory (7 year average = 14.3%), P<0.0001. For controls, the highest proportion 
tested was in Victoria (7 year average = 32.7%) and the lowest was in the Northern Territory (7 
year average = 24.6%), P<0.0001. State and territory was tested as a risk factor in a logistic 
regression analysis, with the finding that the highest risk of vision-threatening retinopathy was in 
Queensland and Tasmania and the lowest was in the Australian Capital Territory, (P<0.0001 for 
model). The major risk factors for vision-threatening retinopathy were delayed diagnosis, 
optometry attendances, HDL cholesterol testing and retinal photography (which was higher in 
cases), with P<0.0001 for all models.   
 
CONCLUSIONS:  The findings show that levels of practitioner attendances and pathology testing 
differed between jurisdictions, however, these were often difficult to relate to the risk of vision-
threatening retinopathy. State and territory health care systems appeared to play little role in the 
management of diabetes, and as a result, suggest that the health care system at the national level 
is more important in determining the risk of complications.  
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Introduction 
 
The study reported in the previous chapter found that patients who developed 
vision-threatening retinopathy (cases) had significantly lower levels of general 
practice, specialist, and optometrist attendances, as well as poorer rates of HbA1c 
and HDL-cholesterol testing during the seven years prior to the development of 
complications than controls. This relationship was strong, multifaceted and 
consistent. However, having made these findings at the national level, we were 
interested to investigate whether different patterns emerged in individual states 
and territories. This corresponds to testing the second research question of the 
thesis: whether state and territory health care systems influence the risk of 
diabetes complications in Australia. 
 
As was discussed in the literature review, the federal system of government in 
Australia is such that some aspects of health care, most significantly primary care 
are the domain of national policy, while other aspects of care are state and 
territory responsibilities, most importantly tertiary care.173 Therefore each state 
and territory has its own unique health care system that provides some important 
aspects of diabetes care, particularly as it relates to public hospitals.173 Whilst 
medical care provided by states and territories is primarily delivered through 
hospitals, there are also state-based diabetes prevention programs such as clinical 
management guidelines targeted at GPs and specialists that can also influence the 
management of diabetes.74  
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Whilst differences in hospital care are frequently found between jurisdictions,350 
differences in care provided through the Medicare system are also evident.286 
These relate to how Medicare operates within each state and territory286 and 
perhaps also to differences in hospital care which can also influence how 
Medicare is utilised.   
 
As primary, secondary and tertiary care are closely related,173 how one part of the 
system operates affects the operation of other parts, in some cases resulting in 
clinically significant differences in health outcomes.350 Thus even though state 
and territory health systems have only a limited role in the provision of primary 
care, they can influence Medicare through the operation of their hospital and 
broader health care systems.173 Therefore, understanding the use of Medicare 
within states and territories is important for understanding the relationship 
between health care and diabetes complications across Australia.  
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Methods 
 
To investigate the relationship between health care utilisation and diabetes 
outcomes across Australian states and territories, a population-based case-control 
study similar to that presented in Chapter 4 was used.331 The study examined 
patient demographic characteristics, utilisation of primary and secondary care 
and use of diabetes related pathology tests, over a period of seven years, as risk 
factors for the development of complications across all eight Australian states 
and territories.  
 
Cases comprised a national sample of 4632 patients who had received their first 
laser photocoagulation therapy in 2000, and controls were a random sample of 
4632 people with diabetes who had not received this treatment (the total sample 
in Table 4.2). Controls were matched to cases on age (within one year) in 2000, 
and state of residence at the time of their earliest HbA1c test. There were equal 
numbers of cases and controls within each state and territory sample. 
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests, and frequencies by independent samples t-tests. When 
risk factors were compared between states and territories, for proportions, χ2 tests 
for trend were used, and for frequencies analysis of variance was used (the 
Bonferroni adjustment was used to account for type 2 error).342 For each risk 
factor and for cases and controls in each state and territory, trends over time were 
calculated. For proportions, multivariate logistic regression of weighted 
proportions was used, and for frequencies, multiple linear regression of weighted 
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means.342 The multivariate analyses were conducted using conditional logistic 
regression, where the paired study design could be taken into account (Tables 5.9 
to 5.16), and conventional logistic regression where a matched variable was 
included as a risk factor (state and territory in Table 5.8).342 The regression 
analyses used a stepwise process with backwards conditional as the variable 
selection criteria. All statistical analyses were performed using SPSS for 
Windows 11.5.343   
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Results  
 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF SUBJECTS BY STATE AND 
TERRITORY 
 
Table 5.1 shows the distribution of subjects by state and territory, where the 
highest incidence of vision-threatening retinopathy was in the Northern Territory 
(37 per 100,000 population in 2000) and South Australia (31 per 100,000 
population in 2000), and the lowest was in the Australian Capital Territory (16 
per 100,000 population in 2000) and Queensland (20 per 100,000 population in 
2000). The remaining states were near to the national average, showing that the 
incidence of laser therapy patients was roughly proportional to the size of the 
state or territory population.351 
 
Table 5.1 shows that the mean age of subjects ranged from 56.3 years (sd = 11.9) 
in the Northern Territory to 63.5 years (sd = 14.1) in the Australian Capital 
Territory  (Analysis of variance (ANOVA), was not significant (ns) for all states 
and territories except the Northern Territory). The age differences between states 
and territories were all non-significant, with the exception of the Northern 
Territory, where subjects were younger (ANOVA, p<0.05 New South Wales, 
Victoria, Queensland, Western Australia, South Australia, Tasmania, Australian 
Capital Territory).351  
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Whilst there were more men than women in both case and control groups, this 
occurred in all states and territories (ANOVA, ns for all states and territories). 
Thus the gender distribution was similar in all localities.  
 
In Chapter 4 delayed diagnosis was identified as a risk factor for diabetes 
complications (see Table 4.5 above). When this risk factor was examined, it was 
found to be important in all states and territories. Whilst overall, cases had been 
diagnosed later than controls, there were some important differences: in Victoria 
the diagnosis of diabetes occurred earlier in cases than it did in other localities, 
whilst the timing of diagnosis for controls was about the same across 
jurisdictions (ANOVA, p<0.05, New South Wales, Queensland, Western 
Australia, South Australia). However, in South Australia, diagnosis occurred 
later among both groups (ANOVA, p<0.05 for New South Wales, Victoria, 
Queensland, Western Australia, Tasmania), which may have been reflected in the 
higher proportion of vision-threatening retinopathy in this state in the univariate 
analysis.  
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Table 5.1: Characteristics of study subjects by state and territory 
*ANOVA testing differences in age distribution in states: F 7, 9256 df, = 5.81, p<0.0001,** χ2  test for differences in gender distribution between states: 3.19, 7df, p = 0.87.  
#
 Population distribution from 1998 Australian Census of Population and Housing.± per 100,000 population in 2000. 
  NSW Victoria Qld WA SA Tas NT ACT Total 
           
Cases, n (%)    1590 (34.3) 1164 (25.1) 684 (14.7) 493 (10.6) 460 (9.9) 123 (2.6) 70 (1.5) 48 (1.0) 4632 
Pop, n (%)
#
  6,432,000 
(33.8) 
4,661,000 
(24.8) 
3,456,000 
(18.4) 
1,831,000 
(9.8) 
1,487,000 
(7.9) 
472,000 
(2.5) 
190,000 
(1.0) 
308,000 
(1.6) 
18,751,000 
Difference (%)  0.5 0.3 -3.7 0.8 2.0 0.1 0.5 -0.6 0.012 
P of difference  0.47 0.67 <0.0001 0.043 <0.0001 0.55 0.0007 0.001  
           
Incidence±(95%CI)  25(23 to 26) 25(23 to 26) 20(18 to 21) 27(24 to 29) 31(28 to 37) 26(21 to31) 37(28 to 45) 16(11 to 20) 25(24 to 25) 
           
Age, mean (sd)*  62.6 (12.6) 62.3 (13.0) 62.1 (14.0) 62.6 (13.2) 63.4 (12.8) 61.2 (13.8) 56.3 (11.9) 63.5 (14.1) 62.4 (13.1) 
           
Gender** Male,n(%) 54.0 (1717) 54.5 (1268) 52.7 (721) 54.9 (541) 56.3 (518) 54.1(133) 55.0 (77) 54.2 (52) 54.5 
 Female,n(%) 46.0 (1463) 45.5 (1060) 47.3 (647) 45.1 (445) 43.7 (402) 45.9 (113) 45.0 (63) 45.8 (44) 45.5 
           
Dx before 2000 Cases, n(%) 661 (41.6) 642 (55.2) 281 (41.1) 234 (47.5)  158 (34.3) 66(53.7) 31 (44.3) 21 (43.8) 45.2 
 Controls,n(%) 1405(88.4) 1022 (87.8) 594 (86.8) 430 (87.2) 367(79.8) 108 (87.8) 61 (87.1) 39 (81.3) 85.2 
           
N  3180 2328 1368 986 920 246 140 96 9264 
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GP ATTENDANCES BY STATE AND TERRITORY 
 
Tables 5.2 and 5.3 show that there were noteworthy differences in the proportion 
and frequency of general practice attendances. Firstly, the difference between 
cases and controls evident in Chapter 4, was found to exist in all states and 
territories. Secondly, when states and territories were compared, GP attendances 
were highest in Queensland and lowest in the Northern Territory. This may 
reflect different methods of management, access to care or diabetes severity in 
these populations.  
 
With regard to trends in GP attendances, Table 5.2 shows that the proportion of 
cases that attended GPs increased in all states and territories over the study 
period, however, attendance by controls declined. However, the frequency of 
attendances increased in both groups. This suggests that whilst the proportion of 
controls that attended GPs declined over time, if the frequency of attendances 
can be interpreted as an indicator of the quality of care, this may have improved 
in most states and territories over the study. 
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Table 5.2: GP attendances between 1993 and 1999 by state and territory, n (%) 
 
Differences between cases and controls: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001
     Year      
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 NSW 1135(71.4)*** 1160(73.0)*** 1197(75.3)*** 1224(77.0)*** 1254(78.9)*** 1309(82.3)*** 1369(86.1)*** 1.16 <0.0001 
 Victoria 806 (69.2)*** 840 (72.2)*** 869 (74.7)*** 895 (76.9)*** 893 (76.7)*** 939 (80.7)*** 1003(86.2)** 1.15 <0.0001 
 Queensland 468 (68.4)*** 494(72.2)*** 504 (73.7)*** 527 (77.0)*** 542 (79.2)*** 537 (78.5)*** 567 (82.9)*** 1.13 <0.0001 
 WA 339 (68.8)*** 352 (71.4)*** 359 (72.8)*** 362 (73.4)*** 383 (77.7)*** 402 (81.5)*** 403 (81.7)** 1.13 <0.0001 
 SA 329 (71.5)*** 361 (78.5)*** 361 (78.5)*** 370 (80.4)*** 372 (80.9)*** 394 (85.7)*** 412 (89.6) φ 1.18 <0.0001 
 Tasmania 82 (66.7) *** 87 (70.7) *** 92 (74.8) *** 95 (77.2) *** 96 (78.0) *** 98 (79.7) ** 100 (81.3)** 1.13 0.002 
 NT 31 (44.3) *** 38 (54.3) ** 44 (62.9) *** 43 (61.4) ** 47 (67.1) ** 46 (65.7) ** 47 (67.1)** 1.16 0.002 
 ACT 35 (72.9) * 36 (75.0) ** 36 (75.0) ** 33(68.8) *** 35 (72.9) * 35 (72.9) ** 43 (89.6) φ 1.09 0.18 
           
 P of diff 0.001 0.004 0.017 0.015 0.18 0.001 <0.0001   
           
Controls           
 NSW 1511 (92.2) 1523(95.8) 1518 (95.5) 1501 (94.4) 1489 (93.6) 1474 (92.7) 1447 (91.0) 0.84 <0.0001 
 Victoria 1073 (92.2) 1076 (92.4) 1087 (93.4) 1093 (93.9) 1079 (92.7) 1065 (91.5) 1057 (90.8) 0.97 0.10 
 Queensland 656 (95.9) 644 (94.2) 654 (95.6) 650 (95.0) 646 (94.4) 642 (93.9) 638 (93.3) 0.93 0.03 
 WA 442 (89.7) 443 (89.9) 450 (91.3) 447 (90.7) 444 (90.1) 445 (90.3) 438 (88.8) 0.99 0.69 
 SA 427 (92.8) 428 (93.0) 424 (92.2) 432 (93.9) 429 (93.1) 428 (93.0) 420 (91.3) 0.98 0.59 
 Tasmania 114 (92.7) 114 (92.7) 117 (95.1) 116 (94.3) 113 (91.9) 115 (93.5) 114 (92.7) 0.99 0.89 
 NT 65 (92.9) 69 (98.6) 66 (94.3) 61 (87.1) 63 (90.0) 63 (90.0) 62 (88.6) 0.85 0.051 
 ACT 44(91.7) 46(95.8) 45 (93.8) 47(97.9) 44(91.7) 45(93.8) 41(85.4) 0.87 0.21 
           
 P of diff <0.0001 <0.0001 0.006 0.012 0.13 0.34 0.19   
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Table 5.3: GP attendances between 1993 and 1999 by state and territory, mean (sd) 
 
Differences between cases and controls: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001 
Test for homogeneity of means (Oneway ANOVA): Cases: Statistically significant differences between states in all years except 1994 (p=0.11) and 1996 (p=0.10).  
Controls: Statistically significant difference between states in all years. 
     Year     
 
 
State Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
NSW Case 4.6(6.9) *** 5.0(7.2) *** 5.4(7.3) *** 5.6(7.7) *** 5.9(7.3) *** 6.4(8.2) *** 7.1(8.7) *** 0.99 <0.0001 
 Control 9.9 (9.8) 10.3(10.2) 10.6(11.1) 10.6(11.1) 10.7 (9.2) 10.5 (9.3) 10.6 (9.6) 0.73 <0.0001 
           
Victoria Case 4.3(6.6) *** 4.7(6.6) *** 4.9(6.4) *** 5.5(7.4)***  5.7(8.1)***  6.2(7.8) *** 6.6(7.7) *** 0.99 <0.0001 
 Control 9.1 (9.8) 9.4 (9.6) 10.2(10.1) 10.0(10.1) 10.4(10.9) 10.2 (9.8) 10.4 (11.0) 0.86 <0.0001 
           
Queensland Case 4.2(10.2)*** 4.7(12.4)*** 5.1(12.7)*** 5.7(13.4)*** 5.9(13.6)*** 6.4(13.9)*** 7.4(14.1)*** 0.99 <0.0001 
 Control 10.1 (11.8) 10.7 (12.2) 11.0 (11.9) 10.9 (9.6) 11.0 (10.3) 11.4 (9.7) 11.3 (9.4) 0.90 <0.0001 
           
WA Case 3.5 (4.9) *** 4.1(5.7) *** 4.5 (6.1) *** 4.8 (6.3) *** 5.0 (6.3) *** 5.2 (6.1) *** 5.7 (7.0) *** 0.98 <0.0001 
 Control 9.1 (9.6) 9.5 (9.3) 9.7 (9.0) 9.8 (8.9) 10.3 (10.1) 10.2 (9.9) 10.1 (9.2) 0.91 <0.0001 
           
SA Case 4.6 (6.1) *** 5.2 (6.6) *** 4.9 (5.9) *** 6.1 (8.2) *** 6.0 (6.7) *** 7.0 (7.2) *** 7.2 (6.9) *** 0.95 <0.0001 
 Control 9.4 (12.7) 9.4 (9.6) 10.2 (11.2) 10.8 (11.9) 10.5 (9.4) 11.2 (12.9) 10.7 (9.9) 0.87 <0.0001 
           
Tasmania Case 4.8 (7.4) * 5.1 (7.7) * 5.6 (8.2) * 5.3 (7.0) ** 6.8 (9.1) * 7.2  (10.5)φ 7.3 (8.4) φ 0.94 <0.0001 
 Control 6.9 (6.1) 7.0 (6.3) 8.3 (6.8) 8.3 (6.8) 9.6 (8.4) 9.9 (12.3) 8.8 (7.7) 0.85 <0.0001 
           
NT Case 1.8 (2.8) *** 2.7 (4.3) *** 2.8 (4.2) *** 3.2  (4.1) *  3.3 (4.1) ** 4.0  (5.6) * 3.8 (4.8) * 0.95 <0.0001 
 Control 6.4 (6.3) 6.4 (6.3) 7.0 (6.7) 5.7 (6.2) 6.8 (7.7) 6.7 (6.4) 5.9 (4.9) -0.18 <0.0001 
           
ACT Case 3.4 (4.4) * 5.2  (6.2) φ 3.9 (5.4) *  5.3  (6.3) φ 5.3  (8.1) φ 5.8 (8.2) φ 7.4  (8.8) φ 0.87 <0.0001 
 Control 5.9 (4.7) 6.2 (4.5) 6.1 (4.2) 6.1 (3.9) 5.7 (5.4) 6.5 (5.9) 5.2 (4.3) -0.35 <0.0001 
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SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES BY STATE AND 
TERRITORY 
 
Tables 5.4 and 5.5 show that there were significant differences between cases 
and controls in the proportion and frequency of specialist and consultant 
practitioner attendances. Whilst Table 5.4 shows that the proportion of cases that 
attended was between a third and a half that of controls, there were also 
significant differences between jurisdictions. The highest proportions were in 
South Australia, followed by New South Wales and Victoria. The lowest 
proportions were in Western Australia and the Northern Territory. These 
differences perhaps point to differentials in access to specialist care or diabetes 
management practices between states and territories.  
 
For controls, the χ2 tests showed similar differences between states and territories 
in specialist attendances to those found in cases. The proportions of controls 
attending specialists were highest in New South Wales, Victoria and South 
Australia. The lowest proportions were in the Northern Territory and the 
Australian Capital Territory. That the highest and lowest proportions for controls 
occurred in similar jurisdictions to cases suggests that states and territories 
provide broadly comparable levels of access to these practitioners for the two 
patient groups.        
 
With regard to the frequency of specialist and consultant physician attendances, 
Table 5.5 shows that there were similar differences to those captured in Table 
5.4. Whilst the highest frequencies were in New South Wales and Victoria, the 
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lowest were in the Northern Territory, the Australian Capital Territory and 
Western Australia (ANOVA, p<0.05 in all years).  
 
The proportion and frequency of specialist and consultant physician attendances 
found in this study may be an indicator of the availability of these practitioners in 
individual states and territories. Several states and territories, especially those 
with sparse populations, have low numbers of medical practitioners and this 
results in poor access and low levels of utilisation.320 In other jurisdictions, levels 
of utilisation may be higher because specialists and consultant physicians are 
much more accessible.  
 
The data also suggest that there was a strong relationship between GP and 
specialist attendances. Where attendance at GPs was low, this tended to result in 
fewer specialist attendances, and where GP attendances were high, similarly high 
levels were found in specialists.  
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Table 5.4: Specialist and consultant physician attendances between 1993 and 1999 by state and territory, n (%) 
 
 
Differences between cases and controls: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001
     Year      
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
p 
 NSW 387(24.3)*** 396(24.9)*** 430(27.0)*** 426(26.8)*** 477(30.0)*** 515(32.4)*** 631(38.7)*** 1.12 <0.0001 
 Victoria 259(22.3)*** 284(24.4)*** 279(24.0)*** 308(26.5)*** 329(28.3)*** 378(32.5)*** 441(37.9)*** 1.13 <0.0001 
 Queensland 127(18.6)*** 123(18.0)*** 139(20.3)*** 156(22.8)*** 156(22.8)*** 157(23.0)*** 228(33.3)*** 1.12 <0.0001 
 WA 86 (17.4)*** 90 (18.3)*** 106(21.5)*** 95 (19.3)*** 99 (20.1)*** 118(23.9)*** 122(24.7)*** 1.07 0.001 
 SA 96(20.9) *** 109(23.7)*** 115(25.0)*** 121(26.3)*** 142(30.9)*** 155(33.7)*** 205(44.6)** 1.19 <0.0001 
 Tasmania 23(18.7) ** 18 (14.8) *** 28 (22.8) *** 28 (22.8) *** 31 (25.2) *** 37 (30.1) *** 38 (30.9) ** 1.15 0.001 
 NT 10(14.3)* 5 (7.1)*** 10 (14.3) φ 7 (10.0)** 10 (14.3) φ 10 (14.3)* 18 (25.7) φ 1.15 0.03 
 ACT 8(16.7)*** 14 (29.2) φ 10 (20.8)*** 10 (20.8)** 9 (18.8) * 9 (18.8)* 14 (29.2) φ 1.03 0.64 
           
 P of difference 0.006 <0.0001 0.008 0.001 <0.0001 <0.0001 <0.0001   
           
Controls           
 NSW 880(55.3) 931 (58.6) 894 (56.2) 957 (60.2) 964 (60.6) 981 (61.7) 974 (61.3) 1.04 <0.0001 
 Victoria 537 (46.1) 594 (51.0) 633 (54.4) 665 (57.1) 650 (55.8) 646 (55.5) 668 (57.4) 1.07 <0.0001 
 Queensland 331(48.4) 339 (49.6) 348 (50.9) 344 (50.3) 342 (50.0) 336 (49.1) 341 (49.9) 1.004 0.79 
 WA 219 (44.4) 236 (47.9) 236 (47.9) 232 (47.1) 237 (48.1) 249 (50.5) 256 (51.9) 1.04 0.02 
 SA 218 (47.4) 226 (49.1) 220 (47.8) 236 (51.3) 244 (53.0) 248 (53.9) 255 (55.4) 1.06 0.002 
 Tasmania 45(36.6) 44 (35.8) 64 (52.0) 61 (49.6) 65 (52.8) 68 (55.3) 62 (50.4) 1.12 0.001 
 NT 23 (32.9) 24 (34.3) 15 (21.4) 21 (30.0) 17(24.3)  24 (34.3) 23 (32.9) 1.005 0.92 
 ACT 30 (62.5)  22 (45.8) 28 (58.3) 27 (56.3) 20 (41.7) 23 (47.9) 23 (47.9) 0.92 0.14 
           
 P of difference <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001   
 210 
 
 
Table 5.5: Specialist and consultant physician attendances between 1993 and 1999 by state and territory, mean (sd) 
 
Differences between cases and controls: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. Test for homogeneity of 
means (Oneway ANOVA): Cases: Statistically significant differences between states in all years. Controls: Statistically significant difference between states in all years. 
 
     Year 
 
     
State Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
NSW Case 0.7(2.1)*** 0.7(1.9)*** 0.7(2.0)*** 0.7(1.9)*** 0.9(2.3)*** 1.0(3.3)*** 1.3(3.2)*** 0.87 <0.0001 
 Control 2.3 (3.9) 2.3 (3.7) 2.4 (4.6) 2.6 (3.8) 2.6 (3.8) 2.7 (4.2) 2.8 (4.8) 0.98 <0.0001 
           
Victoria Case 0.7(2.6)*** 0.7(2.6)*** 0.7(2.5)*** 0.7(2.2)*** 1.1(3.9)*** 1.2(3.9)*** 1.3(3.9)*** 0.90 <0.0001 
 Control 1.8 (3.2) 2.1 (4.1) 2.3 (4.5) 2.5 (5.6) 2.4 (4.1) 2.4 (4.4) 2.8 (6.7) 0.91 <0.0001 
           
Queensland Case 0.6(1.8)*** 0.6(2.9)*** 1.1(5.5)** 1.3(10.7)φ  0.9(4.0)*** 1.2 (5.3) *  1.9(12.0)φ 0.83 <0.0001 
 Control 1.7 (3.2) 1.7 (3.3) 2.1 (4.8) 2.0 (4.0) 1.9 (3.8) 1.9 (3.8) 2.3 (5.9) 0.72 <0.0001 
           
WA Case 0.5(1.6)*** 0.5(1.8)*** 0.6(2.2)*** 0.4(1.1)*** 0.5(1.5)*** 0.6(2.1)*** 0.7(2.0)*** 0.55 <0.0001 
 Control 1.5 (2.9) 1.6 (2.8) 1.9 (3.6) 1.7 (3.5) 1.7 (3.2) 1.8 (3.7) 1.7 (2.8) 0.48 <0.0001 
           
SA Case 0.7(2.4)*** 0.6(1.6)*** 0.6(1.5)*** 0.7(1.8)*** 1.0(3.5)*** 1.3 (4.8) * 1.7 (4.2)* 0.71 <0.0001 
 Control 1.9 (3.9) 2.1 (4.4) 1.8 (3.4) 2.2 (4.3) 2.3 (4.9) 2.3 (4.9) 2.5 (5.7) 0.85 <0.0001 
           
Tasmania Case 0.5* (1.8)* 0.3 (1.0) φ 1.3(5.5) * 0.5(1.7)*** 0.9 (2.9) φ  1.2 (3.9)** 0.8  (2.5)* 0.47 <0.0001 
 Control 1.5 (3.3) 1.1 (2.4) 2.7 (12.4) 2.8 (5.9) 2.3 (4.5) 1.8 (2.9) 1.8 (2.8) 0.23 <0.0001 
           
NT Case 0.3 (0.9) * 0.4 (2.6) φ 0.6 (2.7) φ 0.1 (0.5) * 0.2 (6.2) φ 0.4 (1.4) φ 0.7 (1.7) φ 0.29 <0.0001 
 Control 1.0 (2.8) 1.3 (4.4) 0.8 (2.9) 0.9 (2.8) 1.4 (6.3) 1.2 (3.8) 1.5 (4.6) 0.56 <0.0001 
           
ACT Case 0.5 (1.8) * 1.1 (3.0) φ 0.4(0.8)*** 0.4 (0.8)** 0.7 (2.2) φ 0.4 (0.9)** 0.7 (1.4) * -0.15 0.006 
 Control 1.3 (1.4) 1.7 (3.2)  1.6 (1.9) 1.3 (1.8) 1.3 (2.1) 2.3 (3.9) 1.8 (3.2) 0.50 <0.0001 
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HbA1C TESTS BY STATE AND TERRITORY 
 
Tables 5.6 and 5.7 show that there were major differences in the proportions and 
frequencies of HbA1c testing between cases and controls. Table 5.6 shows that 
the proportion of cases tested in each state and territories was between a third and 
a half that of controls. For cases, the highest proportions were in Victoria, whilst 
the lowest were in South Australia, the Northern Territory and the Australian 
Capital Territory. Among controls, the highest proportions tested were in 
Victoria also and the lowest in the Northern Territory and the Australian Capital 
Territory. Whilst states and territories showed similar trends of increased testing 
in cases, the greatest improvement was in controls.   
 
With regard to the frequency of HbA1c testing, for cases this was highest in 
Victoria and lowest in Queensland, South Australia and the Northern Territory 
(ANOVA, p <0.05 in all years). For controls, the frequencies were highest in 
Victoria and lowest in the Australian Capital Territory, showing that the patterns 
in frequencies closely followed those of proportions. With regard to trends, there 
were positive odds-ratios for both groups in all states and territories, with the 
frequency of testing increasing over time. Nevertheless, in all jurisdictions both 
cases and controls remained below clinical management guidelines, which 
recommend that HbA1c testing be conducted annually (which would represent a 
frequency of 1 or more in a particular year).74 
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Table 5.6: HbA1c testing between 1993 and 1999 by state and territory, n (%) 
Differences between cases and controls: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level, χ2 = is significant at p<0.0001
     Year      
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 NSW 106(6.7)*** 141(8.9)*** 156(9.8)*** 163(10.3)*** 173(10.9)*** 224(14.1)*** 255(16.0)*** 1.16 <0.0001 
 Victoria 112(9.6)*** 164(14.1)** 217(18.6)*** 209(18.0)*** 236(20.3)*** 239(20.5)*** 282(24.2)*** 1.15 <0.0001 
 Queensland 47(6.9)*** 45(6.6)*** 64(9.4)*** 73(10.7)*** 78(11.4)*** 89(13.0)*** 89(13.0)*** 1.14 <0.0001 
 WA 35(7.1)*** 50(10.1)***  74(15.0)*** 55(11.2)*** 65(13.2)*** 68(13.8)*** 70(14.2)*** 1.09 0.001 
 SA 27(5.9)*** 33(7.2)*** 42(9.1) *** 30 (6.5) *** 47(10.2) *** 45(9.8) *** 54(11.7) *** 1.11 0.001 
 Tasmania 8(6.5) * 13 (10.6) φ 15(12.2) * 14(11.4) * 22 (17.9) * 24(19.5) ** 23(18.7) *** 1.20 <0.0001 
 NT 8(11.4) φ 8(11.4) φ 9(12.9) φ 6 (8.6) * 11(15.7) φ 7(10.0)** 8(11.4)* 1.0 1.0 
 ACT 2(4.2) φ 4(8.3) φ 6(12.5) φ 2(4.2) φ 7(14.6) φ 2(4.2)* 10(20.8) φ 1.19 0.06 
           
 P of difference 0.051 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001   
           
Controls           
 NSW 341 (21.4) 388 (24.4) 447(28.1) 477(30.0) 559 (35.2) 629(39.6) 720 (45.3) 1.20 <0.0001 
 Victoria 211 (18.1) 272 (23.4) 333 (28.6) 365(31.4) 434 (37.3) 499 (42.9) 556 (47.8) 1.26 <0.0001 
 Queensland 133 (19.4) 157 (23.0) 170 (24.9) 178(26.0) 208 (30.4) 275 (40.2) 290 (42.4) 1.21 <0.0001 
 WA 120 (24.3) 138 (28.0) 154 (31.2) 141(28.6) 158 (32.0) 187 (37.9) 195 (39.6) 1.12 <0.0001 
 SA 70(15.2) 84(18.3) 102 (22.2) 112(24.3) 136 (26.9) 156 (33.9) 188 (40.9) 1.24 <0.0001 
 Tasmania 21 (17.1) 24 (19.5) 28(22.8) 33 (26.8) 42 (34.1) 48(39.8) 56(45.5) 1.27 <0.0001 
 NT 12(17.1) 15(21.4) 18(25.7) 19(27.1) 9(12.9) 24(34.3) 24(34.3) 1.13 0.02 
 ACT 9(18.8) 11(22.9) 12(25.0) 8 (16.7) 12(25.0) 10 (20.8) 14(25.0) 1.06 0.39 
           
 P of difference 0.011 0.041 0.036 0.029 <0.0001 0.006 0.003   
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Table 5.7: HbA1c testing between 1993 and 1999 by state and territory, mean (sd) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differences between cases and controls: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. Test for homogeneity of 
means (Oneway ANOVA): Cases: Statistically significant differences between states in all years. Controls: Statistically significant difference between states in all years. 
     Year 
 
     
State Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 
NSW Case 0.09(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.2(0.5)*** 0.2(0.5)*** 0.82 <0.0001 
 Control 0.3 (0.7) 0.4 (0.8) 0.4 (0.8) 0.5 (0.8) 0.6 (0.9) 0.6 (0.9) 0.7 (0.9) 0.98 <0.0001 
           
Victoria Case 0.1 (0.5) *** 0.2(0.6)*** 0.3(0.7)*** 0.3(0.7)*** 0.3(0.7)*** 0.3(0.7)*** 0.4(0.8)*** 0.89 <0.0001 
 Control 0.3 (0.7) 0.3 (0.8) 0.4 (0.8) 0.5 (0.9) 0.6 (0.9) 0.7 (0.9) 0.8 (1.0) 0.99 <0.0001 
           
Queensland Case 0.07(0.3)*** 0.08(0.3)*** 0.1(0.3)*** 0.1(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.80 <0.0001 
 Control 0.3 (0.6) 0.3 (0.8) 0.4 (0.8) 0.4 (0.8) 0.5 (0.9) 0.6 (0.9) 0.7 (0.9) 0.97 <0.0001 
           
WA Case 0.09(0.4)*** 0.1(0.3) *** 0.2(0.5)*** 0.1(0.4)*** 0.1(0.4)*** 0.2(0.5)*** 0.2(0.4)*** 0.60 <0.0001 
 Control 0.3 (0.7) 0.4 (0.8) 0.4 (0.8) 0.4 (0.7) 0.5 (0.9) 0.6 (0.9) 0.6 (0.9) 0.95 <0.0001 
           
SA Case 0.07(0.3)*** 0.09(0.3)*** 0.1(0.4)*** 0.07(0.3)** 0.1(0.4)*** 0.1(0.4)*** 0.1(0.4)*** 0.60 <0.0001 
 Control 0.2 (0.6) 0.2 (0.6) 0.3 (0.6) 0.4 (0.8) 0.4 (0.8) 0.5 (0.9) 0.6 (0.9) 0.98 <0.0001 
           
Tasmania Case 0.06 (0.2) *   0.1 (0.4) φ 0.1 (0.3) * 0.1 (0.4) ** 0.2 (0.5)** 0.2(0.5)*** 0.2(0.6)*** 0.92 <0.0001 
 Control 0.2 (0.7) 0.2 (0.5) 0.3 (0.7) 0.4 (0.7) 0.5 (0.9) 0.6 (0.9) 0.7 (0.9) 0.99 <0.0001 
           
NT Case 0.1 (0.3) φ 0.1 (0.4) φ 0.2 (0.5) φ 0.1 (0.3) *  0.2 (0.5) φ 0.1(0.3)*** 0.1 (0.4) *  0.0 1.0 
 Control 0.2 (0.6) 0.3 (0.7) 0.3 (0.6) 0.3 (0.6) 0.1 (0.4) 0.5 (0.8) 0.5 (0.8) 0.58 <0.0001 
           
ACT Case 0.04 (0.2) * 0.08 (0.3) * 0.1 (0.3) φ 0.06(0.3) φ 0.1 (0.4) φ 0.06(0.3)* 0.2 (0.6) φ  0.64 <0.0001 
 Control 0.2 (0.5) 0.2 (0.5) 0.3 (0.6) 0.2 (0.7) 0.3 (0.6) 0.3 (0.8) 0.4 (0.8) 0.82 <0.0001 
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PATIENT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS BY STATE AND TERRITORY 
 
In Table 5.8 below, whether state and territory, patient characteristics and 
patterns of care predicted laser photocoagulation therapy was tested using a 
logistic regression analysis. In this analysis, state and territory was as added as a 
risk factor (as seven dummy variables) to the logistic regression model in Table 
4.6.   
 
This analysis revealed that patients in Victoria, Queensland and Tasmania were 
at higher risk of vision-threatening retinopathy than those in other states and 
territories. This points to the influence of local health care systems,173 and 
perhaps also to characteristics of local populations,351 in determining the risk of 
diabetes complications.  There were also similar risk factors for vision-
threatening retinopathy to those captured in Table 4.6: delayed diagnosis and low 
levels of optometry attendances, HDL-cholesterol testing, as well as retinal 
photography, and microalbumin testing. The findings suggest that these risk 
factors are important in determining the risk of complications at the national 
level.   
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Table 5.8: Logistic regression analysis predicting laser therapy in 2000 using state and territory  
characteristics, demographic characteristics, and health care utilisation between 1993 and 1999, 
Australia 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
NSW (ref) 1.0   
Victoria 1.27 1.05 – 1.52 0.01 
Queensland 1.36 1.09 – 1.70 0.007 
Western Australia 1.01 0.79 – 1.70 0.91 
South Australia 0.74 0.57 – 0.94 0.01 
Tasmania 1.36 0.85 – 2.20 0.20 
Northern Territory 0.69 0.39 – 1.20 0.19 
ACT 0.52 0.29 – 0.95 0.03 
    
Gender* 0.77 0.67 – 0.89 <0.0001 
Dx before 2000 Г  0.19 0.16 – 0.22 <0.0001 
    
1993    
GP 0.96 0.95 – 0.97 <0.0001 
S&CP‡ 0.92 0.89 – 0.95 <0.0001 
Optometry 0.22 0.17 – 0.30 <0.0001 
HDL-c† 0.29 0.28 – 0.46 <0.0001 
Retinal Ph§ 1.80 0.76 – 4.24 0.18 
    
1994    
GP 1.0 0.99 – 1.01 0.86 
S&CP 0.92 0.89 – 0.95 <0.0001 
Optometry 0.12 0.07 – 0.21 <0.0001 
HDL-c 0.22 0.13 – 0.37 <0.0001 
Retinal Ph 2.63 1.03 – 6.67 0.04 
    
1995    
GP 0.98 0.97 – 0.99 0.003 
S&CP 0.98 0.95 – 0.99 0.04 
Optometry 0.22 0.17 – 0.28 <0.0001 
HbA1c± 1.04 0.91 – 1.17 0.56 
HDL-c 0.14 0.08 – 0.23 <0.0001 
Retinal Ph 2.30 1.13 – 4.64 0.02 
    
1996    
S&CP 0.99 0.98 – 1.01 0.59 
HbA1c 0.92 0.81 – 1.04 0.19 
Optometry 0.26 0.20 – 0.34 <0.0001 
HDL-c 0.16 0.09 – 0.27 <0.0001 
Retinal Ph 5.82 2.16 – 15.7 <0.0001 
    
1997    
Optometry 0.22 0.17 – 0.29 <0.0001 
HDL-c 0.12 0.07 – 0.19 <0.0001 
Retinal Ph 5.40 2.5 – 11.7 <0.0001 
    
1998    
GP 1.004 0.99 – 1.02 0.54 
S&CP 0.99 0.97 – 1.01 0.50 
Optometry 0.20 0.16 – 0.26 <0.0001 
HbA1c 0.93 0.83 – 1.04 0.19 
HDL-c 0.15 0.09 – 0.23 <0.0001 
Retinal Ph 3.93 1.92 – 8.03 <0.0001 
Continued below    
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Table 5.8: Continued 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
1999    
GP 1.02 1.007 – 1.03 0.002 
Optometry 0.26 0.20 – 0.33 <0.0001 
HbA1c 0.75 0.67 – 0.84 <0.0001 
HDL-c 0.10 0.06 – 0.17 <0.0001 
Retinal Ph 41.9 18.5 – 94.7 <0.0001 
Microalbumin 2.40 1.96 – 2.89 <0.0001 
Reference group = controls, *reference group = female,  
Гreference group = not diagnosed.  
Model overall χ2 = 7733.6, 45 df, p <0.0001.  
± Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances 
§ Retinal photography.  
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PATIENT CHARACTERISTICS AND HEALTH CARE UTILISATION FOR CASES VS 
CONTROLS FOR INDIVIDUAL STATES AND TERRITORIES 
 
Tables 5.9 to 5.16 present the findings of logistic regression models for 
individual states and territories. In Table 5.9 the logistic regression model for 
New South Wales shows that the risk factors for vision-threatening retinopathy 
in that state were very similar to those identified through the national model 
(Table 4.5), with the only significant difference being the absence of gender.   
 
Table 5.10 presents the logistic regression model for Victoria. This analysis 
showed similar risk factors to the national model and to New South Wales. 
However, women were at higher risk of vision-threatening retinopathy. When 
this is considered in the light of Table 5.8, which showed that patients in Victoria 
as a whole were at a higher risk of diabetes complications, it is possible that this 
elevated risk is due to the excess in women in this state.  
 
Table 5.11 shows the risk factors for laser therapy in Queensland. Table 5.8 had 
shown that the risk of laser therapy in Queensland was greater than in most other 
states and territories. However, the results of logistic regression analysis for this 
state were very similar to those nationally and in New South Wales and Victoria, 
with no distinguishing characteristics evident. The apparent higher risk of vision-
threatening retinopathy in Queensland may be due to the influence of local health 
care systems,173 or perhaps also the characteristics of local populations in 
determining the risk of complications.351  
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Table 5.12 shows the logistic regression model for vision-threatening retinopathy 
in Western Australia. It indicates that the risk factors in this state were very 
similar to those in respect of the national model, along with New South Wales, 
Victoria and Queensland. With an average risk of vision-threatening retinopathy, 
there were no risk factors that distinguished this jurisdiction.   
 
Table 5.13 presents the logistic regression model for South Australia. In the 
crude analysis captured in Table 5.1, people with diabetes in South Australia 
appeared to be at higher risk of diabetes complications. However, this higher risk 
was not evident in the logistic regression analysis in Table 5.8. This suggests that 
the increased prevalence of vision-threatening retinopathy in South Australia was 
due to a correlated risk factor (such as delayed diagnosis) being greater in this 
state. The logistic regression model also showed similar risk factors in South 
Australia as were found nationally and in respect of New South Wales, Victoria, 
Queensland and Western Australia.  
  
The logistic regression model in Table 5.8 also showed that the risk of vision-
threatening retinopathy was higher in Tasmania than in most other states and 
territories. However, the logistic regression model captured in Table 5.14 
indicates that the risk factors in Tasmania were very similar to those in other 
localities. The apparent higher risk vision-threatening retinopathy in this state 
may be due to the influence of local health care systems, or perhaps to the 
characteristics of local populations, in determining the risk of complications.  
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Table 5.15 presents the analysis from the Northern Territory, which was 
distinguished in having the youngest population of all jurisdictions in this study. 
Although in some years there were no significant differences between cases and 
controls in the Northern Territory, where they did occur, they were similar to 
those found in other states and territories (for example those for optometry 
attendances). This suggests that the lower number of risk factors in this 
jurisdiction was not a reflection of a different relationship between patterns of 
care and vision-threatening retinopathy, but is likely to be a result of the smaller 
sample size used in the model.342  
 
Whilst the logistic regression analysis in Table 5.8 showed that people with 
diabetes from the Australian Capital Territory had the lowest risk of vision-
threatening retinopathy of all jurisdictions, Table 5.16 indicates that it shared 
some of the same risk factors as were found in other states and territories, such as 
delayed diagnosis. As with the Northern Territory, the lower number of risk 
factors may not be a reflection of a different relationship between patterns of care 
and diabetes complications, but is most likely a result of the small sample size 
used in the model for this jurisdiction.342     
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New South Wales  
Table 5.9: Conditional logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999, New South Wales 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before  
2000 Г  
0.09 0.047 – 0.17 <0.0001 
    
1993    
GP 0.96 0.93 – 0.99 0.02 
S&CP‡ 0.93 0.84 – 1.02 0.14 
Optometry 0.11 0.04 – 0.29 <0.0001 
HDL-c† 0.17 0.03 – 1.12 0.07 
Retinal Ph§ 1.33 0.21 – 8.49 0.76 
    
1994    
S&CP 0.87 0.78 – 0.97 0.01 
Optometry 0.13 0.03 – 0.47 0.002 
HDL-c 0.10 0.02 – 0.53 0.007 
Retinal Ph 6.17 0.26 – 145.7 0.26 
    
1995    
S&CP 0.89 0.80 – 0.99 0.03 
Optometry 0.17 0.07 – 0.41 <0.0001 
HDL-c 0.13 0.03 – 0.53 0.004 
Retinal Ph 21.2 2.3 – 193.7 0.007 
    
1996    
S&CP 1.05 0.95 – 1.16 0.36 
Optometry 0.13 0.05 – 0.35 <0.0001 
HbA1c± 0.60 0.34 – 0.95 0.03 
HDL-c 0.05 0.006 – 0.48 0.009 
Retinal Ph 15.8 0.50 – 498.9 0.12 
    
1997    
Optometry 0.026 0.007 – 0.10 <0.0001 
HDL-c 0.21 0.07 – 0.66 0.007 
    
1998    
Optometry 0.24 0.09 – 0.59 0.002 
HDL-c 0.43 0.012 – 0.15 <0.0001 
Retinal Ph 3.45 0.62 – 19.0 0.15 
    
1999    
Optometry 0.20 0.08 – 0.50 <0.0001 
HbA1c 0.58  0.39 – 0.85 0.005 
HDL-c 0.002 0.000 – 0.06 <0.0001 
Retinal Ph 15.0 2.05 – 109.3 0.008 
Microalbumin 5.4 2.7 – 10.9 <0.0001 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed.  
Model overall χ2 = 1111.1, 29 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography.  
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Victoria 
Table 5.10: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, Victoria 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Gender* 0.54 0.34 – 0.88 0.01 
Dx before  
2000 Г  
0.10 0.05 - 0.19 <0.0001 
    
1993    
GP 0.98 0.93 – 1.02 0.28 
S&CP‡ 0.97 0.90 – 1.04 0.39 
Optometry 0.39 0.18 – 0.82 0.01 
HDL-c† 0.48 0.05 – 4.13 0.50 
Retinal Ph§ 0.63 0.08 – 4.81 0.65 
    
1994    
S&CP 0.90 0.83 – 0.98 0.02 
Optometry 0.11 0.04 – 0.30 <0.0001 
HDL-c 0.02 0.002 – 0.18 0.001 
Retinal Ph 5.7 0.32 – 99.2 0.23 
    
1995    
GP 0.96 0.92 – 1.01 0.14 
S&CP 1.005 0.93 – 1.09 0.91 
Optometry 0.18 0.07 – 0.45 <0.0001 
HbA1c± 0.99 0.69 – 1.43 0.97 
HDL-c 0.03 0.003 – 0.29 0.002 
Retinal Ph 3.2 0.56 – 18.0 0.19 
    
1996    
S&CP 0.93 0.84 – 1.02 0.14 
Optometry 0.45 0.26 – 0.77 0.004 
HDL-c 0.17 0.04 – 0.72 0.02 
Retinal Ph 0.97 0.06 – 14.4 0.98 
    
1997    
GP 0.96 0.93 – 0.99 0.02 
Optometry 0.15 0.06 – 0.39 <0.0001 
HDL-c 0.02 0.002 – 0.26 0.003 
Retinal Ph 10.5 1.4 – 78.2 0.02 
    
1998    
Optometry 0.17 0.07 – 0.37 <0.0001 
HbA1c 1.5 1.07 – 2.01 0.02 
HDL-c 0.004 0.000 – 0.21 0.006 
Retinal Ph 19.1 2.1 – 171.2 0.008 
    
1999    
Optometry 0.16 0.07 – 0.38 <0.0001 
HDL-c 0.04 0.007 – 0.19 <0.0001 
Retinal Ph 19.7 3.58 – 108.6 0.001 
Microalbumin 2.5 1.50 – 4.30 0.001 
Reference group = controls, *reference group = female, 
Гreference group = not diagnosed.  
Model overall χ2 = 744.9, 33 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography.
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Queensland 
Table 5.11: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, Queensland  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 
2000Г 
0.10 0.04 – 0.29 <0.0001 
    
1993    
GP 0.91  0.84 – 0.97 0.007 
S&CP‡ 0.83 0.65 – 1.06 0.14 
Optometry 0.14 0.06 – 0.35 <0.0001 
    
1994    
S&CP 0.84 0.73 – 0.97 0.02 
Optometry 0.06 0.01 – 0.34 0.001 
HbA1c± 0.71 0.37 – 1.40 0.32 
    
1995    
Optometry 0.13 0.05 – 0.36 <0.001 
HbA1c 1.70 0.73 – 3.83 0.22 
HDL-c† 0.001 0.000 – 0.13 0.006 
    
1996    
Optometry 1.01 0.54 – 1.89 0.98 
HDL-c 0.04 0.002 – 0.78 0.04 
    
1997    
Optometry 0.96 0.44 – 2.12 0.92 
HDL-c 0.29 0.01 – 5.60 0.29 
Retinal Ph 156.7 0.001 – 41303808 0.43 
    
1998    
GP 1.03 0.98 – 1.08 0.23 
Optometry 0.37 0.12 – 1.15 0.09 
HbA1c 0.29 0.14 – 0.64 0.002 
HDL-c 0.016 0.000 – 4.29 0.15 
    
1999    
Optometry 0.06 0.01 – 0.26 <0.0001 
HbA1c 0.49 0.26 – 0.94 0.03 
HDL-c 0.05 0.003 – 0.76 0.03 
Retinal Ph 449.4 6.23 – 32438.0 0.005 
Microalbumin 4.9 1.26 – 18.8 0.02 
Reference group = controls, *reference group = female,  
Гreference group = not diagnosed.  
Model overall χ2 = 479.6, 24 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography. 
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Western Australia 
Table 5.12: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, Western Australia  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 
2000Г 
0.13 0.04 – 0.43  0.001 
    
1993    
GP 0.92 0.86 – 0.98 0.01 
Optometry 0.11 0.007 – 1.80 0.12 
    
1994    
S&CP 0.98 0.86 – 1.12 0.78 
Optometry 0.03 0.003 – 0.35 0.005 
HbA1c± 0.25 0.10 – 0.64 0.004 
    
1995    
Optometry 0.10 0.000 – 0.31 0.008 
    
1996    
Optometry 0.009 0.000 – 0.54 0.02 
HDL-c† 0.001 0.000 – 3.617 0.77 
    
1997    
Optometry 0.11 0.02 – 0.52 0.005 
HDL-c 0.000 0.000 – 
3.0114 
0.72 
    
1998    
Optometry 0.03 0.002 – 0.37 0.007 
    
1999    
Optometry 0.08 0.01 – 0.56 0.01 
HDL-c 0.02 0.001 – 0.36 0.008 
Microalbumin 2.62 0.77 – 8.90 0.12 
Reference group = controls, *reference group = female,  
Гreference group = not diagnosed. 
Model overall χ2 = 330.1, 15 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography. 
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South Australia 
Table 5.13: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, South Australia 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 
2000Г 
0.13 0.056 – 0.34 <0.0001 
    
1993    
GP 0.94 0.88 – 0.10 0.05 
S&CP‡ 0.81 0.69 – 0.96 0.02 
Optometry 0.24 0.04 – 1.37 0.11 
    
1994    
S&CP 0.98 0.79 – 1.21 0.84 
Optometry 0.03 0.003 – 0.34 0.004 
    
1995    
GP 0.99 0.93 – 1.06 0.87 
Optometry 0.14 0.03 – 0.76 0.02 
    
1996    
Optometry 0.45 0.003 – 0.66 0.02 
HbA1c± 0.88 0.43 – 1.8 0.73 
HDL-c† 0.07 0.007 – 0.76 0.03 
    
1997    
Optometry 0.06 0.008 – 0.48 0.008 
HbA1c 0.61 0.31 – 1.20 0.15 
    
1998    
Optometry 0.10 0.02 – 0.49 0.004 
    
1999    
Optometry 0.19 0.03 – 1.13 0.07 
HDL-c 0.06 0.008 – 0.48 0.008 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed. 
Model overall χ2 = 295.9, 16 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography.  
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Tasmania 
Table 5.14: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, Tasmania  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 
2000Г 
0.32 0.04 – 2.44 0.27 
    
1993    
HbA1c± 0.56 0.06 – 5.52 0.62 
    
1994    
S&CP 0.39 0.10 – 1.60 0.19 
Optometry 0.24 0.005 – 12.9 0.48 
    
1995    
Optometry 0.02 0.000 – 0.94 0.05 
    
1996    
GP 0.73 0.57 – 0.93 0.01 
Optometry 0.000 0.000 – 
9.8310 
0.59 
    
1997    
Optometry 0.000 0.000 – 3.528 0.38 
    
1998    
GP 1.06 0.98 – 1.15 0.11 
Optometry 0.05 0.001 – 3.90 0.18 
    
1999    
Optometry 0.02 0.001 – 0.76 0.03 
HDL-c† 0.04 0.001 – 2.53 0.13 
Reference group = controls, *reference group = female,  
Гreference group = not diagnosed. 
Model overall χ2 = 82.7, 12 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography.  
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Northern Territory 
Table 5.15: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999, Northern Territory  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.11 0.017 – 0.77 0.02 
    
1993    
GP 0.40 0.02 – 0.80 0.009 
    
1995    
Optometry 0.001 0.000 – 2.22 0.08 
    
1996    
Optometry 0.09 0.005 – 1.71 0.11 
    
1998    
GP 1.30 1.02 – 1.60 0.03 
HbA1c± 0.03 0.001 – 0.65 0.03 
Reference group = controls, *reference group = female,  
Гreference group = not diagnosed. 
Model overall χ2 = 47.05, 6 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography. 
 
 
Australian Capital Territory 
Table 5.16: Conditional logistic regression analysis predicting laser therapy in 2000 using 
demographic characteristics, and health care utilisation between 1993 and 1999,  
Australian Capital Territory  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.15 0.03 – 0.88 0.03 
    
1993    
S&CP‡ 0.76 0.46 – 1.3 0.30 
    
1995    
S&CP 0.34 0.13 – 0.88 0.03 
    
1999    
GP 1.15 0.99 – 1.33 0.06 
HbA1c± 0.19 0.04 – 0.88 0.03 
Microalbumin 100.2 1.43 – 7025.2 0.03 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed. 
Model overall χ2 = 26.9, 6 df, p <0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances  
§Retinal photography. 
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Discussion 
 
The study found significant differences between cases and controls with regard 
to the timing of diagnosis and the patterns of care which were consistent across 
all states and territories in Australia. This suggests that similar factors were 
involved in the development of diabetes complications in all jurisdictions. This is 
despite the likelihood that patients had obtained some of their care in state and 
territory health care systems, which may have different methods of managing 
diabetes.286  
 
Whilst there were a number of significant differences between states and 
territories in the timing of diagnosis, the proportion and frequency of 
attendances, and HbA1c testing, the analysis showed that these were difficult to 
relate to the risk of vision-threatening retinopathy. In states where specialists and 
consultant physicians played a greater role in patients’ care, such as New South 
Wales, this was also reflected in higher levels of GP utilisation. Where specialists 
played a lesser role, this was evident in the workload of GPs. This suggests that 
the greater utilisation of one type of medical practitioner tends to increase the use 
of others. Thus states that are well off in terms of their medical workforce tended 
to result in higher levels of health care utilisation.286 Similarly, in poorly-off 
jurisdictions such as the Northern Territory, the smaller workforce appears to 
limit the utilisation of all practitioners.286 This suggests that some aspects of 
diabetes care may be driven by the requirements of practitioners,259 rather than 
the health needs of patients, as higher levels of utilisation did not necessarily lead 
to better health outcomes. 
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The logistic regression analysis shown in Table 5.8 indicated that patients in 
Victoria and Queensland had a higher risk of developing diabetes complications 
than those in other jurisdictions. However, these findings are hard to reconcile 
with the other findings that patients in these states had average or above average 
levels of health care utilisation. In addition, they do not accord with the general 
finding that higher levels of health care utilisation reduce the risk of diabetes 
complications.  
 
This discrepancy between the univariate and multivariate analyses suggests that 
there may be some other factors operating in Victoria and Queensland that 
increased the risk of diabetes complications. This may relate to the use of a 
medical procedure as an indicator of a disease outcome, as is the case in this 
study. It could be that in Victoria and Queensland the risk of vision-threatening 
retinopathy was not elevated but that patients had better access to laser therapy 
and that this resulted in an apparent greater risk of complications identified by 
the logistic regression analysis in Table 5.8.    
 
In the logistic regression analyses in Tables 5.9 to 5.16, risk factors for the 
development of vision-threatening retinopathy were found to be similar for 
individual states and territories to those found in the national model in Table 4.5. 
These risk factors included delayed diagnosis, and lower levels of optometry 
attendances, of HDL-cholesterol testing, and of specialist and consultant 
physician attendances (in some states and territories), but higher levels of retinal 
photography and microalbumin testing. Whilst there were some minor 
differences in risk factors between jurisdictions, for example, a greater risk 
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associated with gender in Victoria, on the whole the risk factors for laser therapy 
appear to be very similar across states and territories. This suggests that the care 
provided for diabetes is broadly similar in each state and territory, and that the 
quality of diabetes management is primarily determined at the national level. 
Thus nationally driven systems such as Medicare appear to have a much greater 
impact on diabetes outcomes than do state-based systems of tertiary or other 
care. 
 
In addition to findings in relation to patterns of care, there were some important 
findings with regard to the risk groups emerging in different jurisdictions. 
Perhaps most significant was the younger age of people with diabetes in the 
Northern Territory captured in Table 5.1.351 This may reflect the high prevalence 
of diabetes in the indigenous population in Australia, as the Northern Territory 
contains the largest proportion of indigenous people in Australia, who are not 
only younger on average than other Australians, but who also are at a 
significantly greater risk of developing diabetes and complications.30 In addition, 
Table 5.6 shows that people with diabetes in the Northern Territory were at 
higher risk of developing complications, which would be consistent with the 
often more severe manifestations of diabetes that is found in the Aboriginal 
population.30    
 
Whilst the study shows that poor quality care leads to the development of 
complications, it also suggests that the quality of care may have improved over 
the study period. This is evident in the trends in specialist and consultant 
physician attendances, HbA1c testing and the frequency of GP attendances. The 
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broad uniformity of increased frequency across all states and territories suggests 
that improvements in the quality of care were driven by something at the national 
level.  
 
Some of the national changes that occurred during the study period included the 
introduction of Clinical Practice Guidelines for the Management and Prevention 
of Diabetic Retinopathy,200 as well as Clinical Management Guidelines for 
Diabetes in Adults that were developed in New South Wales 74 In addition, 
diabetes became a National Health Priority in 1996, which increased the profile 
of the condition within the national health care system.1 These initiatives may 
have contributed to the improvements in the quality of care that were observed 
uniformly across states and territories.  
 
In summary, the findings suggest that the factors that determine the risk of 
diabetes complications were similar for individual states and territories, and that 
local factors were not important in defining diabetes management. The study also 
showed that primary and secondary care is more important in determining 
diabetes outcomes than hospital care. This implies that the key to reducing 
complications lies in changes to the primary and secondary care, for example 
through Medicare, rather than through the introduction or extension of state or 
territory-based diabetes programs.  
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Chapter 6 
 
Across a national population, what is the most effective strategy 
for preventing diabetes complication: early diagnosis or 
improved diabetes management?  
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Abstract 
OBJECTIVES: In the previous studies (Chapters 4 and 5), it was found that the development of 
diabetes complications was associated with low levels of health care utilisation, HbA1c and 
HDL-c testing over a seven-year period. However, it was also found that patients who developed 
vision-threatening retinopathy had been diagnosed with diabetes later than those who remained 
free of this condition. These studies, however, could not determine whether the pattern of care, or 
delayed diagnosis, was the stronger predictor of diabetes complications. As this issue has 
significant implications for understanding how complications develop, the study sought to 
identify which of these risk factors had the stronger association with diabetes complications.  
 
METHODS:  Diabetes patients (n = 665) who were diagnosed with diabetes seven or more years 
prior to receiving laser photocoagulation therapy in 2000 were compared to a random sample of 
diabetes patients, diagnosed in these same years, who had never received this treatment (n=1297). 
Patterns of health care utilisation were compared over a period of seven years.  
 
RESULTS: Controls were slightly older than cases (cases = 61.5 years (sd = 13.0) and controls = 
62.8 years (sd = 13.7), P<0.05). There was a greater proportion of men in both case and control 
groups (cases = 51.7% and controls = 52.5%, P=ns). There were significant differences in health 
care utilisation between cases and controls. With regard to GP utilisation: in 1993, 84.5% of 
cases attended, compared to 97.5% of controls, P<0.0001. In 1999, 89.4% of cases attended, 
compared to 97.6% of controls, P<0.0001. For medical specialist attendances: 34.6% of cases 
attended in 1993, compared to 60.3% of controls, P<0.0001. In 1999, 39.8% of cases attended, 
compared to 63.2% of controls, P<0.0001. For HbA1c testing: in 1993, 51.9% of cases were 
tested, which compared to 60.8% of controls, P<0.0001. In 1999, 29.6% of cases were tested, 
which compared to 52.6% of controls, P<0.0001. Similar differences were found in other years 
and in respect of other risk factors. Annual trends showed that cases were more likely to utilise 
health services as they approached their first episode of laser therapy, although their levels of 
utilisation at no time reached that of controls. In a logistic regression model, the strongest 
predictors of vision-threatening retinopathy were optometry attendances, HDL-cholesterol testing 
and retinal photography (which was higher in cases), over a seven-year period.  
 
CONCLUSIONS: We found that lower levels of diabetes management related health care 
utilisation was a stronger predictor of vision-threatening retinopathy than delayed diagnosis. 
Whilst timely diagnosis is important, the study highlights the provision of adequate medical 
management as more significant for the prevention of complications across a national population.  
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Introduction 
 
In Chapters 4 and 5 it was found that patients who developed vision-threatening 
retinopathy had significantly lower levels of general practice and specialist and 
consultant physician attendances, as well as of HbA1c and HDL-cholesterol 
testing than the controls, and that these patterns of care may have been related to 
the development of complications. However, the preceding studies also found 
that patients who developed complications may have been diagnosed with 
diabetes later than those who were unaffected, as evidenced by their earliest 
HbA1c test  (see Table 4.5), which may in itself have led to the development of 
complications.12 Thus, it was not possible to determine whether complications 
were associated with the pattern of care or with delayed diagnosis. This 
combination of risk factors was evident in Australia (Chapter 4), as well as in all 
states and territories (Chapter 5). 
 
Patterns of care and delayed diagnosis suggest different pathways leading to the 
development of complications. On the one hand, patterns of care could be 
indicative of poor diabetes management, which may lead to a lack of control over 
hyperglycaemia or hypertension, thus increasing the risk of complications.3, 5 On 
the other hand, delayed diagnosis may mean that patients being deprived of 
appropriate care may also lead to the development of complications.12 In 
addition, whilst both of these risk factors might lead to the same outcome, they 
imply very different strategies for the prevention of complications.74, 326  
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In the two previous chapters the patterns of care could not be examined 
independently of delayed diagnosis because both early and later diagnosed 
patients had been included in the studies. In this study, however, these risk 
factors were examined independently. The study tested the third research 
question: whether patterns of care or early diagnosis is the greater risk factor for 
the development of diabetes complications in the population with diabetes in 
Australia. This was achieved by controlling for the timing of diagnosis by 
including only early-diagnosed patients. The subjects were a group who had 
evidence of having a diagnosis of diabetes in 1993, 1994 or earlier, as indicated 
by an HbA1c test in either or both of these years.  
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Methods 
 
The research question of whether low levels of diabetes management-related 
health care utilisation is a greater predictor of diabetes complications than 
delayed diagnosis was tested using a population-based case-control study,331 
which compared the demographic characteristics and patterns of care for case 
and control groups. Subjects were selected based on having their earliest HbA1c 
test in 1993 or 1994. From this group, cases were assembled from subjects who 
had a record of receiving laser photocoagulation therapy in 2000. In a second 
step, patients who had received laser therapy prior to 2000 were excluded from 
the study, which left a group of 665 subjects who received their first laser 
therapy in that year. This group became the cases. Controls were assembled by 
the random selection of subjects from the database from which laser therapy 
patients had been removed. The case and control groups were drawn from the 
1993 and 1994 samples shown in Table 4.2.  
 
Following further analysis, it was found that 186 (12.5%) subjects in the control 
group did not have a Medicare item in 2000, suggesting that they may have died 
or emigrated during the study. As it would have been impossible to relate their 
records of health care utilisation to the study outcome, they were excluded from 
the study (see Chapter 3 for a discussion on the implications of this exclusion). 
This left a sample of 665 cases and 1297 controls in the study.  
 
In the univariate analyses which compared cases to controls, proportions were 
compared using χ2 tests, and frequencies by independent samples t-tests. For each 
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risk factor, and within cases and controls, trends over time were calculated. For 
proportions, multivariate logistic regression of weighted proportions was used, 
and for frequencies, multiple linear regression of weighted means. The 
multivariate analysis was conducted using logistic regression, which used a 
stepwise process with backwards conditional as the variable selection criteria.342 
Socio-economic status was entered as four dummy variables in Table 6.4 (for a 
broader analysis of socio-economic status see Chapter 8), and all statistical 
analyses were performed using SPSS for Windows 11.5.343
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Results 
 
CHARACTERISTICS OF THE SAMPLE 
 
Table 6.1 shows that cases were aged on average 61.5 years (sd =13.0), 
compared to 62.8 years (sd = 13.7) for controls. Whilst there was an over-
representation of males among study subjects, this occurred in both groups and 
was consistent with the samples of the studies presented in Chapters 4, 5, 7, 8 
and 9, as well as with the gender distribution of diabetes in Australia.60  
 
Table 6.1: Characteristics of study subjects  
*Difference between ages significant at p<0.05 
 
 
GP ATTENDANCES  
 
Table 6.2 shows that around 85% of cases attended a GP on an annual basis, 
compared to approximately 100% of controls. The odds ratios for trends show 
that the proportion of cases that attended a GP increased slightly over the study. 
This compared with no increase in controls. 
 
With regard to the frequency of attendances, Table 6.3 shows that cases attended 
between about a half and third as often as controls. Whilst there was a trend of 
increasing frequency for cases, at no time did their attendance reach that of 
 Cases  Controls Total, n (%) 
    
Age, mean (sd) 61.5(13.0) 62.8 (13.7)*  
    
Gender   M,n(%) 344 (51.7) 681 (52.5) 1025(52.2) 
               F, n(%) 321 (48.3) 616 (47.5) 937 (47.8) 
Total,          n(%) 665  1297 1962 
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controls. These analyses indicate that when compared to controls, fewer cases 
attended GPs, and they attended on fewer occasions over the seven-year period. 
Because of the central role GPs play in diabetes care, this may explain the pattern 
of under-referral and under-testing, as described below.195 
 
SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES  
 
The proportions of cases who attended specialists and consultant physicians over 
the study period were between about half and two-thirds that of controls (Table 
6.2). In addition, cases attended between 1.9 and 2.7 fewer times per year than 
controls (Table 6.3). Thus there were major differences in specialist attendances 
and referrals between those who developed vision-threatening retinopathy and 
those who remained free of the condition.  
 
OPTOMETRIST ATTENDANCES 
 
The proportion of cases that attended optometrists was between 5% and 10% that 
of controls, as shown Table 6.2. The frequency of attendances was also 
significantly lower, with cases attending between 24 and 10.3 fewer times per 
year than controls (Table 6.3). As the role of optometrists in diabetes 
management is to screen for diabetic retinopathy, the higher levels of attendance 
among controls may reflect higher levels of screening.352 
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Table 6.2: Health care utilisation between 1993 and 1999 for cases and controls, n (%) 
 
     Year  
 
     
 
Cases  1993 1994 1995  1996 1997 1998 1999 Annual  
trend (OR) 
P 
 GP            562(84.5)*** 571(85.9)*** 558(83.9)*** 564(84.8)*** 564(84.8)*** 571(85.9)*** 594(89.4)*** 1.04 0.03 
 S&CP‡          230(34.6)*** 203(30.6)*** 204(30.7)*** 224(33.7)*** 215(32.3)*** 243(36.5)*** 265(39.8)*** 1.05 0.002 
 Optometrist   7(1.1) *** 12(1.8) *** 15(2.3) *** 11(1.7) *** 16(2.5) *** 14(2.1) *** 19(2.9)*** 1.12 0.03 
 HbA1c±         345(51.9)*** 458(68.9)** 238(35.8)*** 205(30.8)*** 199(29.9)*** 199(29.9)*** 197(29.6)*** 0.77 <0.0001 
 HDL-c†        9(1.4)*** 6(0.9)*** 6(0.9)*** 4(0.6)*** 8(1.2)*** 6(0.9)*** 4(0.6)*** 0.93 0.32 
           
Controls           
 GP            1265(97.5) 1269(97.8) 1259(97.1) 1270(97.9) 1267(97.7) 1267(97.7) 1266(97.6) 1.008 0.81 
 S&CP           782(60.3) 833(64.2) 803(61.9) 821(63.3) 799(61.6) 795(61.3) 820(63.2) 1.004 0.71 
 Optometrist   267(20.5) 275(21.2) 312(24.1) 284(21.9) 304(23.4) 316(24.4) 330(25.4) 1.04 0.001 
 HbA1c 789(60.8) 968(74.6) 664(51.2) 621(47.9) 655(50.5) 675(52.0) 682(52.6) 0.90 <0.0001 
 HDL-c          228(17.6) 287(22.1) 259(20.0) 216(16.7) 246 (19.0) 263(20.3) 24.5 (18.9) 0.99 0.89 
Differences between cases and controls: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
±Haemoglobin A1c tests, † HDL cholesterol tests, ‡ Specialist and consultant physician attendances 
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Table 6.3: Health care utilisation between 1993 and 1999 for cases and controls, mean (sd) 
 
 
Differences between cases and controls: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. 
±Haemoglobin A1c tests,† HDL cholesterol tests, ‡ Specialist and consultant physician attendances. 
     Year 
 
     
 Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
GP Case 6.09(11.0)*** 6.73(13.0)*** 6.54(12.9)*** 6.84(13.4)*** 7.27(14.1)*** 7.37(14.0)*** 7.96(13.4)*** 0.96 <0.0001 
 Control 11.31 (10.8) 11.61 (9.1) 11.42 (9.6) 11.42 (9.9) 12.02 (10.3) 11.99 (10.4) 12.02 (11.2) 0.85 <0.0001 
           
S&CP‡ Case 1.07(2.5) *** 1.03 (2.9) *** 1.15 (4.3) *** 1.01 (2.5) *** 1.28 (4.6) *** 1.40 (4.7) *** 1.32 (3.0) *** 0.81 <0.0001 
 Control 2.50 (3.9) 2.57 (3.7) 2.71 (4.3) 2.72 (4.4) 2.60 (3.9) 2.63 (3.9) 3.13 (7.0) 0.71 <0.0001 
           
Optometry Case 0.01 (0.1) *** 0.019(0.1)*** 0.025(0.2)*** 0.016(0.1)*** 0.024(0.1)*** 0.024(0.2)*** 0.034(0.2)*** 0.82 <0.0001 
 Control 0.24 (0.5) 0.25 (0.5) 0.29 (0.6) 0.27 (0.6) 0.29 (0.6) 0.31 (0.6) 0.31 (0.6) 0.92 <0.0001 
           
HbA1c± Case 0.71 (0.8) *** 0.90 (0.8) *** 0.53 (0.8) *** 0.46 (0.8) *** 0.47 (0.9) *** 0.46 (0.8) *** 0.46 (0.8) *** -0.76 <0.0001 
 Control 0.89(0.9)  1.14 (0.9) 0.86 (1.0) 0.84 (1.1) 0.88 (1.1) 0.89 (1.0) 0.95 (1.1) -0.23 <0.0001 
           
HDL-c† Case 0.015(0.1)*** 0.013(0.2)*** 0.009(0.09)*** 0.006(0.08)*** 0.013(0.1)*** 0.009(0.09)*** 0.006(0.08)*** -0.67 <0.0001 
 Control 0.22 (0.5) 0.28 (0.6) 0.26 (0.6) 0.21 (0.5) 0.26 (0.56) 0.26 (0.6) 0.25 (0.6) 0.16 <0.0001 
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HbA1C TESTS 
 
In addition, the proportion of cases tested for HbA1c was significantly lower 
than that of controls in all years, with this difference being particularly marked 
after 1994 (Table 6.2). The frequency of tests among cases was also lower, with 
cases receiving on average between 1.2 and 2.0 fewer tests per year than 
controls. As was noted in the literature review, HbA1c is an important indicator 
of metabolic control and low levels of testing may have significant implications 
for the management of diabetes.74   
 
HDL – CHOLESTEROL TESTS 
 
Table 6.2 shows dramatic differences in HDL-cholesterol testing between cases 
and controls.  During the study, less than 1.5% of cases were tested in any year, 
as compared to at least 16.7% of controls. Whilst the frequency of tests for both 
groups was not high, it was between 22 and 41.6 times greater among controls 
(Table 6.3). This may point to an increased risk of diabetes related 
dyslipidaemia348 and perhaps also to lower levels of knowledge and skill on the 
part of the health care providers of cases.353    
 
SUBJECT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS 
 
Whether patient characteristics and patterns of health care utilisation predicted 
laser photocoagulation therapy was tested using a logistic regression model, and 
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this is captured in Table 6.4. In this analysis, socio-economic status was also 
entered as an additional risk factor (as four dummy variables).  
 
The model revealed consistent differences between the case and control groups 
in levels of health care utilisation. The strongest predictors of vision-threatening 
retinopathy were low HDL-cholesterol testing and low optometry attendances. 
However, socio-economic status was eliminated in the regression procedure. 
That patterns of care retained their predictive power suggests that the quality of 
diabetes management following the diagnosis of diabetes is a stronger risk factor 
for the development of complications than delayed diagnosis. 
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Table 6.4: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 
 
Risk factor OR 95%CI P 
    
Age 1.01 1.001 – 1.02 0.03 
    
1993    
GP   0.96 0.93 – 0.98 0.001 
S&CP‡ 0.96 0.90 – 1.02 0.16 
Optometry 0.12 0.05 – 0.30 <0.0001 
HDL-c† 0.24 0.11 – 0.52 <0.0001 
    
1994    
S&CP  0.90 0.85 – 0.96 0.001 
Optometry 0.14 0.06 – 0.30 <0.0001 
HbA1c± 1.008 0.83 – 1.22 0.93 
HDL-c 0.17 0.08 – 0.37 <0.0001 
    
1995    
Optometry  0.23 0.12 – 0.43 <0.0001 
HDL-c 0.10 0.03 – 0.29 <0.0001 
Retinal Ph 2.64 0.89 – 7.80 0.08 
    
1996    
S&CP  0.91 0.86 – 0.97 0.003 
Optometry 0.20 0.09 – 0.42 <0.0001 
HbA1c 0.97 0.79 – 1.2 0.86 
HDL-c 0.18 0.06 – 0.55 0.001 
Retinal Ph 3.26 0.82 – 12.9 0.09 
    
1997    
Optometry 0.22 0.12 – 0.42 <0.0001 
HDL-c 0.29 0.12 – 0.66 0.003 
Retinal Ph 5.4 1.5 – 19.9 0.01 
    
1998    
Optometry 0.17 0.09 – 0.31 <0.0001 
HbA1c 0.74 0.79 – 1.17 0.07 
HDL-c 0.2 0.08 – 0.51 0.001 
Retinal Ph 3.3 0.86 – 12.4 0.08 
    
1999    
GP  1.02 0.99 – 1.04 0.06 
Optometry 0.28 0.17 – 0.47 <0.0001 
HbA1c 0.64 0.52 – 0.79 <0.0001 
HDL-c 0.09 0.03 – 0.29 <0.0001 
Microalbumin 2.10 1.50 – 2.92 <0.0001 
Retinal Ph 9.85 3.5 – 28.2 <0.0001 
Reference group is controls, †reference group = not tested and  
Гreference group = not diagnosed. 
Model overall χ2 =1355.1, 30df, p<0.0001.  
±Haemoglobin A1c tests 
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances 
 
 
Socio-economic status (SEIFA 1-5) was entered as a risk factor 
into this model, but was eliminated by the backwards conditional 
method of variable selection. 
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Discussion  
 
The study found that patients’ patterns of care predicted the development of 
advanced complications in an early-diagnosed group, suggesting that diabetes 
management after the diagnosis of diabetes is a stronger predictor of advanced 
diabetes complications than delayed diagnosis. With regard to public health 
interventions, the findings thus support the provision of diabetes management in 
already diagnosed patients,12 rather than screening for diabetes, as the most 
effective complications prevention strategy.  
 
The differences between the groups in respect of patterns of care, were similar to 
those found in Chapters 4 and 5 – although the level of health care utilisation was 
higher in the current study. This suggests that the diagnosis of diabetes leads to 
an increase in health care utilisation. However, for some patients this increase is 
not of a sufficient magnitude for complications to be prevented. This suggests 
that there is some factor that holds back cases from reaching appropriate levels of 
health care utilisation.354  
 
In an attempt to explain the differences between the case and control group, 
socio-economic status was entered as a risk factor into the logistic regression 
model in Table 6.4.261 The table shows that the stepwise variable selection 
method eliminated the risk factor from the model, indicating that socio-economic 
status was not a risk factor for advanced complications in early-diagnosed 
groups. 
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Some risk factors that may account for the higher risk among cases but which 
were not investigated in the study include poorer self-management,8 less 
competent practitioners 41, 353 and poorer access to health care,22 as these factors 
have all been found to contribute to poor diabetes management.   
 
Another important finding was the decline in the level of HbA1c testing over 
time. Significantly, this occurred at a time when levels of general practice and 
specialist attendance were high and increasing. The decline in testing under these 
conditions is most likely to reflect changes to practitioner, rather than patient 
behaviour, as pathology testing is largely initiated by the practitioners.355  
 
Factors that are known to influence practitioner behaviour in this way include the 
method and perceived adequacy of payment 356 and time pressure in 
consultations.338 However, it is not known whether these factors played a part in 
the decline in testing that was documented here.   
 
In conclusion, the study showed that poor diabetes management was a stronger 
predictor of diabetes complications than delayed diagnosis. Whilst timely 
diagnosis is desirable, it is only beneficial if it initiates appropriate diabetes 
management over time. Where this did not occur, patients remained at risk of 
developing advanced diabetes complications such as vision-threatening 
retinopathy. Thus whilst timely diagnosis is important, the study highlights the 
provision of adequate medical management over time as more significant for the 
prevention of complications across the population.12  
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Chapter 7 
 
Does delayed diagnosis increase the risk of complications                          
in Australia? 
 247
Abstract 
OBJECTIVES: In the previous chapter it was found that the key to preventing diabetes 
complications was timely diagnosis, followed by appropriate medical management. However, in 
Chapters 4 and 5, it had been found that over 50% of people who received laser therapy in 2000 
might have been diagnosed in that same year. This delayed diagnosis would have disallowed any 
clinical interventions from effectively preventing vision-threatening retinopathy. This suggested 
that the pre-diagnosis period had been critical in determining the outcome, and therefore that this 
period needed to be further explored. In this study, patient characteristics and patterns of health 
care utilisation during the pre-diagnosis period were examined in order to identify risk factors for 
vision-threatening retinopathy.  
 
METHODS:  Diabetes patients (n = 2538) who were diagnosed with diabetes in 2000 and received 
laser photocoagulation therapy in that same year were compared to a random sample of diabetes 
patients, diagnosed in the same year, who had never received this treatment (n=606). Patterns of 
health care utilisation were compared over a period of seven years.  
 
RESULTS: Cases were slightly older than controls (62.3 years (sd = 14.0) versus 60.7 years (sd = 
12.0), P=0.01). There was a greater proportion of men in each group (55.4% of cases and 54.4% 
of controls, P=ns). There were significant differences in health care utilisation between cases and 
controls. With regard to GP attendances, in 1993, 65% of cases attended, compared to 91.2% of 
controls, P<0.0001. In 1999, 82.3% of cases attended, compared to 95.7% of controls, P<0.0001. 
For specialist attendances, in 1993, 18.3% of cases attended, compared to 42.5% of controls, 
P<0.0001. In 1999, 32.4% of cases attended, compared to 50.7% of controls, P<0.0001. For 
optometrist attendances, in 1993, 1.7% of cases attended, compared to 21.2% of controls, 
P<0.0001. In 1999, 2.9% of cases attended, compared to 26.4% of controls, P<0.0001. Similar 
differences were found in other years. Annual trends showed that cases were more likely to 
utilise health services as they approached their first episode of laser therapy, although their levels 
of utilisation at no time reached that of controls. In a logistic regression model, the strongest 
predictors of the development of vision-threatening retinopathy were low socio-economic status, 
optometry attendances and specialist attendances over seven years.  
 
CONCLUSIONS: The findings point to a need for early diagnosis in people at high-risk of 
developing diabetes complications. This would best be facilitated by active case finding with a 
focus on low socio-economic groups. In addition, following diagnosis, appropriate diabetes 
management needs to be established so that prevention of complications can be optimised.   
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Introduction 
 
Having established that patterns of care are very important risk factors for 
diabetes complications in Chapter 4, that this relationship existed at the national 
level, as well as in all states and territories in Chapter 5, and that early diagnosis, 
coupled with appropriate diabetes management was the key to preventing 
diabetes complications in Chapter 6, the relationship between patterns of care 
prior to the diagnosis of diabetes and the development of vision-threatening 
retinopathy is investigated in this fourth study in the thesis.   
 
Diabetes complications, including vision-threatening retinopathy, have been 
shown to take many years to develop,35 and during much of this time patients are 
often unaware that they are suffering from diabetes or have hyperglycaemia.35 
During the pre-diagnosis period, people with diabetes do not attend practitioners 
for diabetes care, they do not have access to hypoglycaemic medications; nor do 
they practise diabetes self-management. In hyperglycaemic patients these 
circumstances may lead to poor metabolic control and the accelerated 
development of diabetes complications.12 Therefore, understanding the risk 
factors that exist in the pre-diagnosis period is very important for understanding 
the development of complications. Therefore the fifth research question was 
posed: whether later diagnosis of diabetes is a risk factor for the development of 
diabetes complications in the population with diabetes in Australia.    
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Methods  
 
To investigate whether patterns of care prior to diagnosis determine the risk of 
diabetes complications, a population-based case-control study was used.331 The 
study examined whether patient demographic characteristics, GP, specialist and 
optometry attendances, were risk factors for diabetes complications by 
comparing these factors in cases to controls.   
 
Subjects were selected on the basis of having received an earliest HbA1c test in 
2000. From this group, cases were assembled from subjects who had a record of 
laser photocoagulation therapy in that same year. In a second step, patients who 
had received laser therapy prior to 2000 were excluded, which left a group of 
subjects who had been diagnosed with diabetes and received their first laser in 
the same year. This group became the cases. Controls were assembled by the 
random selection of subjects from the database from which the laser therapy 
patients had been removed. This group was comprised of people with diabetes 
who had been diagnosed with diabetes in 2000, but who had never received laser 
therapy. 2538 cases and 606 controls were included in the study, representing the 
2000 sample in Table 4.2. 
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. For each 
risk factor, and within cases and controls, trends over time were calculated. For 
proportions, multivariate logistic regression of weighted proportions was used, 
and for frequencies, multiple linear regression of weighted means. The 
multivariate analysis was conducted using logistic regression, which used a 
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stepwise procedure with backwards conditional as the variable selection 
criteria.342 Socio-economic status was entered as four dummy variables, as 
shown in Table 7.4 (for a broader analysis of socio-economic status see Chapter 
8), and all statistical analyses were performed using SPSS for Windows 11.5.343 
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Results 
 
CHARACTERISTICS OF THE SAMPLE 
 
Cases were aged 62.3 years (sd = 14.0) on average, compared to 60.7 years (sd = 
12.0) for controls. Whilst there was an over-representation of males in the study, 
this was the same in both groups, is similar to the findings in the studies detailed 
in Chapters 4, 5 and 6, and reflects the gender distribution of diabetes in 
Australia.60 The age and gender characteristics of the subjects are presented in 
Table 7.1. 
Table 7.1: Characteristics of study subjects  
*Difference between ages significant: p=0.01 
 
 
GP ATTENDANCES  
Table 7.2 indicates that over 65% of cases attended a GP annually, with the 
proportion that attended increasing over the study period. By contrast, over 90% 
of controls attended in any year. Whilst case and controls attended GPs regularly, 
controls had higher frequencies of attendances, from almost twice as many visits 
in 1993 to 1.5 times more in 1999 (Table 7.3).  
  Cases  Controls  Total(n (%)) 
Age, mean (sd)  62.3 (14.0) 60.7(12.0)*  
     
Gender  n(%) M 1406 (55.4) 328(54.4) 1734 (55.2) 
              n(%) F 1132 (44.6) 278(45.8) 1410(44.8) 
Total  2538 606 3144 
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SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES  
 
Table 7.2 indicates that between 18.3% and 32% of cases attended specialists and 
consultant physicians per year during the study, compared to between 42.5% and 
50.7% of controls. In addition, cases attended specialists and consultant 
physicians on one-third to two-thirds fewer occasions each year than controls, as 
shown in Table 7.3.  
 
OPTOMETRIST ATTENDANCES 
 
For optometrist attendances, Table 7.2 shows that between 1.7% and 2.9% of 
cases attended optometrists each year during the study. This compared to 
between 21.2% and 26.4% of controls. Table 7.3 shows that the frequency of 
attendances reflects these differences in proportions, as cases attended between 
12.3 and 12.5 fewer times per year than controls.   
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Table 7.2: Health care utilisation between 1993 and 1999 for cases and controls, n(%) 
Differences between cases and controls: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
. ‡ Specialist and consultant physician attendance 
 
 
 
Table 7.3: Health care utilisation between 1993 and 1999 for cases and controls, mean (sd) 
 
Differences between cases and controls: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001 
. ‡ Specialist and consultant physician attendance 
     Year  
 
     
Cases  1993 1994 1995 1996 1997 1998 1999 Annual  
trend (OR) 
P 
 GP               1699(65)*** 1727(68)*** 1797(70.8)*** 1832(72.2)*** 1876(73.4)*** 960(77.2)*** 2088(82.3)*** 1.13 <0.0001 
 S&CP‡           464(18.3)*** 512(20.2)*** 537(21.2) *** 511(20.1) *** 576(22.7) *** 694(25.4)*** 822(32.4) *** 1.12 <0.0001 
 Optometrist    44 (1.7) *** 39 (1.5) *** 46(1.8) *** 54(2.1) *** 66(2.6) *** 64(2.5) *** 74(2.9) *** 1.11 <0.0001 
Controls           
 GP               553 (91.2) 560 (92.4) 551 (90.9) 560(92.4) 560(92.4) 582(96.0) 580(95.7) 1.13 <0.0001 
 S&CP             258 (42.5) 265 (43.6) 256 (42.5) 280(46.3) 280(46.3) 289(47.9) 306(50.7) 1.05 0.001 
 Optometrist    128 (21.2) 146 (24.2) 151(25.0) 161(26.7) 158(26.2) 188(31.2) 160(26.4) 1.06 0.001 
     Year      
 Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
GP Case 3.9(6.2)*** 4.2(6.4) *** 4.6(6.8) *** 5.0(7.5) *** 5.3(7.5) *** 5.7(7.7)*** 6.3(8.0)*** 0.99 <0.0001 
 Control 7.7(8.2) 7.6(7.4) 8.0(8.1) 8.1(7.6) 8.4(8.3) 9.0(8.9) 9.5 (8.7) 0.86 <0.0001 
           
S&CP‡ Case 0.5(1.9)*** 0.6(2.1) *** 0.6(2.8) *** 0.6(2.5) *** 0.7(2.4) ***  0.9(4.0)*** 1.2(6.2)*** 0.89 <0.0001 
 Control 1.5(3.1) 1.4(2.9) 1.5(4.1) 1.8(3.9) 1.7(3.1) 1.8(3.4) 1.9 (3.6) 0.89 <0.0001 
           
Optometrist Case 0.02(0.2)*** 0.01(0.1)*** 0.03(0.2)*** 0.02(0.2)*** 0.03(0.2)*** 0.03(0.2)*** 0.03(0.2)*** 0.67 <0.0001 
 Control 0.2(0.5) 0.3(0.5) 0.3(0.5) 0.3(0.5) 0.3(0.6) 0.4(0.6) 0.3 (0.6) 0.67 <0.0001 
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SUBJECT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS 
 
Whether patient characteristics and patterns of health care utilisation predicted 
laser photocoagulation therapy was tested using a logistic regression model and 
was captured in Table 7.4. In this analysis, socio-economic status was also 
entered as an additional risk factor into the model (as four dummy variables).  
 
The model showed consistent differences between the case and control groups in 
levels of health care utilisation. The strongest predictors of vision-threatening 
retinopathy were socio-economic status, low GP, and low specialists and 
optometry attendances. The model suggests that the late diagnosed group were 
socio-economically disadvantaged and that this may have led to lower levels of 
health care utilisation and the higher risk of diabetes complications. 
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Table 7.4: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 
 
Risk factor OR 95%CI p 
    
SEIFA 5 high (ref) 1.0   
SEIFA 4 1.34 0.92 – 1.96 0.12 
SEIFA 3 1.13 0.78 – 1.62 0.51 
SEIFA 2 1.43 0.98 – 2.01 0.06 
SEIFA 1 1.89 1.29 – 2.80 0.001 
    
Age 1.03 1.02 – 1.04 <0.0001 
    
1993    
GP 0.96 0.94 – 0.97 <0.0001 
S&CP‡ 0.91 0.87 – 0.96 0.001 
Optometry  0.36 0.24 – 0.55 <0.0001 
    
1994    
S&CP  0.97 0.93 – 1.03 0.33 
Optometry  0.10 0.06 – 0.16 <0.0001 
    
1995    
Optometry  0.18 0.12 – 0.27 <0.0001 
    
1996    
S&CP  0.95 0.91 – 0.99 0.02 
Optometrist  0.33 0.22 – 0.48 <0.0001 
    
1997    
S&CP  0.95 0.91 – 0.99 0.009 
Optometry  0.29 0.20 – 0.41 <0.0001 
    
1998    
GP 0.99 0.97 – 1.003 0.10 
Optometry  0.14 0.10 – 0.20 <0.0001 
    
1999    
Optometrist  0.29 0.21 – 0.42 <0.0001 
Reference group is controls. 
Model overall χ2 =1227.09, 18df, p<0.0001.  
‡ Specialist and consultant physician attendances 
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Discussion  
 
The findings indicate that the patterns of care predicted the development of 
complications in this late diagnosed group. This suggests that health care 
utilisation prior to the diagnosis of diabetes may have determined the 
development of advanced diabetes complications.  
 
The difference between the groups with regard to health care utilisation was 
similar to that found in Chapter 6. This suggests that similar factors may have 
been involved in determining health care utilisation in both early and late 
diagnosed groups.354 This points to the level of health care utilisation being a 
somewhat stable characteristic among people with diabetes.  
 
In an attempt to explain differences between case and control groups, the logistic 
regression model revealed that low socio-economic status was a risk factor for 
the development of advanced diabetes complications. This finding contrasts with 
the study in Chapter 6, where socio-economic status was found not to pose a risk.   
 
When the two studies are considered together, they suggest that there is a higher 
risk of advanced complications among low socio-economic groups when patients 
have not been diagnosed. However, and perhaps surprisingly, once diagnosis has 
occurred, the risk of complications in low socio-economic groups becomes equal 
to the rest of the population. This suggests that the way in which diabetes 
management was conducted in Australia during the 1990s was able to address a 
major inequality in diabetes.  
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With regard to the health policy implications of these findings, the greater 
occurrence of delayed diagnosis in low socio-economic groups, and the higher 
risk of advanced diabetes complications associated with this delay suggests a 
need to improve the timing of diagnosis in socio-economically disadvantaged 
populations.357 However, the lack of significance of socio-economic status in 
Chapter 6 points to the need for diabetes management interventions to be 
targeted at the whole population.  
 
When the course of a condition can be significantly altered by early diagnosis, 
population screening is often proposed as an appropriate prevention 
intervention.358 However, for population screening to be effective, very particular 
conditions are required that are rarely met by diseases 358 (including diabetes).357   
 
Perhaps a more appropriate prevention strategy is proactive case finding.359 This 
involves doctors actively seeking out diabetes in their patients.360 Whilst this 
strategy may miss cases that rarely attend doctors, this is unlikely to occur in this 
population. Cases were found to have attended GPs on an average five times per 
year, which should allow plenty of opportunity for the diagnosis of diabetes. 
Given that cases were such regular attendees at GPs, it would be difficult to 
justify population screening, as this would be unlikely to identify many people 
with diabetes who would not have otherwise have been diagnosed in a routine 
GP attendance.357 It is more likely that encouraging doctors to be more proactive 
in identifying diabetes would be the most effective strategy for achieving early 
diagnosis in this population.   
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An alternative to clinical interventions to reduce the risk of complications might 
involve establishing health promotion programs focusing on risk factors for 
diabetes complications in the non-diagnosed population. However, this would 
require targeting the whole population with prevention complication programs.361 
Whilst this may appear to be potentially wasteful and ineffective, it could 
potentially only entail the extension of current programs that target smoking and 
other cardiovascular risk factors, as they also benefit those with diabetes.362  
 
In conclusion, the study suggests that most people who develop diabetes 
complications are disadvantaged with regard to health care utilisation and that 
this pre-dates the diagnosis of diabetes. This points to the need for early 
diagnosis in this population, which would best be facilitated by active case 
finding with a focus on low socio-economic groups. Yet, even if early diagnosis 
is established this population still needs to receive appropriate diabetes 
management over time if prevention of complications is to be optimised.  
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Chapter 8 
  
Does socio-economic status determine the risk of complications  
in people with diabetes?  
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Abstract 
OBJECTIVES: In Chapter 7, socio-economic status was identified as a risk factor for diabetes 
complications in those at imminent risk of vision-threatening retinopathy. However, it was found 
not to be a risk factor once diabetes management had been established (Chapter 6). Whilst the 
significance of socio-economic status has been established in the populations included in these 
studies, it is not known whether socio-economic status is a risk factor for diabetes complications 
in the broader diabetes population. The study sought to examine this question.  
 
METHODS: 4632 diabetes patients who had received their first laser photocoagulation treatment 
in 2000 were compared to a random sample of diabetes patients who had never received this 
treatment (n = 4632). Patterns of health care utilisation were compared within and between socio-
economic groups over a seven-year period (1993-1999) using the Australian Medicare database.  
 
RESULTS:  Similar differences between cases and controls to those found in Chapter 4 were 
evident in all socio-economic groups. There was a greater proportion of cases in lower socio-
economic groups. SEIFA 1 (lowest) had 21% of cases, which compared to 18.7% of controls; 
SEIFA 2 had 20.4% of cases, which compared to 19.5% of controls; SEIFA 3 had 19.9% of 
cases, which compared to 20.1% of controls; SEIFA 4 had 19.6% of cases, as compared to 20.5% 
of controls; and SEIFA 5 (highest) had 18.7% of cases, compared to 21.3% of controls. These 
differences were highly significant (P=0.001).  With regard to health care utilisation, for GP 
attendances, in cases, the highest proportion attended was in SEIFA 1 (7 year average of 79.4%), 
whilst the lowest was in SEIFA 5 (7 year average of 74.7%), P<0.0001. For controls, the highest 
proportion attended was in SEIFA 3 (7 year average = 93.8%), whilst the lowest proportion was 
in SEIFA 5 (7 year average of 91.9%),  P<0.0001. For specialist attendances, in cases, the highest 
proportion of attendances was in SEIFA 5 (7 year average of 32.2%), whilst the lowest was in 
SEIFA 2 (7 year average of 23.6%), P<0.0001. For controls, the highest proportion of 
attendances was in SEIFA 5 (7 year average of 55.3%), whilst lowest was in SEIFA 2 (7 year 
average of 51.6%), P<0.0001. With regard to HbA1c testing, in cases, the highest proportion of 
testing was in SEIFA 5 (7 year average of 14.2%), whilst the lowest proportion was in SEIFA 1 
(7 year average of 11.9%), P<0.0001. For controls, the highest proportion tested was in SEIFA 4 
(7 year average = 33.5%), whilst the lowest was in SEIFA 5 (7 year average of 27.3%), 
P<0.0001. Socio-economic status was tested as a risk factor for vision-threatening retinopathy in 
a logistic regression model. Although it was found not to be statistically significant, there was 
evidence of a gradient from low risk in high socio-economic groups to high-risk in low socio-
economic groups. The major risk factors for vision-threatening retinopathy were delayed 
diagnosis, optometry attendances, HDL cholesterol testing and retinal photography (higher in 
cases), which was similar across all socio-economic groups, P<0.0001 for all models.   
 
CONCLUSIONS:  The findings suggest that socio-economically disadvantaged populations may be 
at higher risk of developing diabetes complications. However, in light of the findings in Chapters 
6 and 7, this disadvantage may be confined to late diagnosed groups. This suggests that strategies 
for early diagnosis should have a focus on disadvantaged populations, but that diabetes 
management interventions should target the broader diabetes population.  
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Introduction 
 
Having established in Chapter 4 that patterns of care are significant risk factors 
for diabetes complications; that this relationship occurs at the national level, as 
well as in all states and territories in Chapter 5; that early diagnosis, coupled with 
appropriate diabetes management is the key to preventing diabetes complications 
in Chapter 6; and that patterns of care prior to the diagnosis of diabetes are 
important predictors of complications in Chapter 7; this study investigates 
whether socio-economic status determines the risk of diabetes complications.  
 
In Chapter 7, socio-economic status was identified as a risk factor for diabetes 
complications in late diagnosed patients, concurring with the international and 
Australian epidemiological evidence cited in the literature review. This literature 
showed that diabetes, complications, risk factors and health care utilisation were 
all determined, at least partially, by socio-economic status.22, 262, 268, 269 In 
Chapter 6, however, socio-economic status was found not to be a risk factor for 
diabetes complications, which suggested that once diagnosis had occurred 
diabetes management was unaffected by socio-economic status. However, 
neither of these investigations was able to examine the role of socio-economic 
status across the entire population, and thus could not clarify whether early 
diagnosis or diabetes management interventions needed to be targeted at 
particular groups, or whether they would be better provided across the population 
for the greatest proportion of diabetes complications to be prevented. Hence the 
fifth research question of the thesis was tested:  whether socio-economic status is 
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a risk factor for diabetes complications in the population with diabetes in 
Australia.  
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Methods 
 
To investigate the relationship between socio-economic status and diabetes 
complications, a population-based case-control study similar to those in Chapters 
4 and 5 was used.331  The study examined patient demographic characteristics, 
the utilisation of primary and secondary care and of diabetes related pathology 
tests, and the risk of complications between cases and controls across socio-
economic groups.  
 
In this study, cases comprised a national sample of 4632 patients who had 
received their first laser photocoagulation therapy in 2000, and controls were a 
random sample of 4632 people with diabetes who had not received this treatment 
(the total sample in Table 4.2). Controls were matched to cases on age (within 
one year) in 2000 and state of residence at the time of their earliest HbA1c test.  
 
The measure of socio-economic status used was the Socio-Economic Index For 
Areas Index of Disadvantage (SEIFA),260 which is a measure of socio-economic 
status based on the aggregate of indicators of material resources that characterise 
localities (see Chapter 3 for a full description). In this study the Index is ascribed 
to an individual on the basis of their residential post-code.  
 
In the univariate analyses, which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. When 
risk factors were compared between socio-economic groups, for proportions, χ2 
tests for trend were used, and analysis of variance for frequencies (the Bonferroni 
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adjustment was used to account for type 2 error).342 For each risk factor, and 
within cases and controls in each socio-economic group, trends over time were 
calculated. For proportions, multivariate logistic regression of weighted 
proportions was used, and for frequencies, multiple linear regression of weighted 
means. The multivariate analyses were conducted using conditional logistic 
regression, which could take into account the paired study design (Tables 8.8 to 
8.13).342 The regression analyses used a stepwise process with backwards 
conditional as the variable selection criteria  (Tables 8.8 to 8.13). Socio-
economic status was entered as four dummy variables in Table 8.8, and all 
statistical analyses were performed using SPSS for Windows 11.5.343
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Results 
 
CHARACTERISTICS OF THE SAMPLE 
 
Cases comprised 4632 patients who had received their first laser 
photocoagulation therapy in 2000 and there was the same number of controls 
(see Table 8.1). The average age ranged from 62.1 years (sd = 12.9) to 62.5 years 
( sd = 13.8), which was similar across all five socio-economic groups (p = ns). 
There was a greater proportion of males in all socio-economic groups, although 
this distribution was the same for both cases and controls.   
 
Most notably, Table 8.1 shows that there was a greater proportion of cases in 
lower socio-economic groups than controls. Similarly, the proportion of controls 
was greater in higher status groups, which suggests that at this crude level, there 
was a relationship between socio-economic status and diabetes complications.  
 
With regard to the timing of diagnoses, cases from lower socio-economic groups 
had later diagnoses than those who were more affluent, which accords with the 
findings on socio-economic status and delayed diagnosis shown in Table 7.4. 
There was no evidence of a similar relationship in controls.   
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Table 8.1: Characteristics of study subjects by SEIFA 
 
* Age distribution, F = 0.71 4,9259 df , p = 0.58 
** Gender distribution, χ2= 4.53 4 df, p = 0.34 
*** SEIFA Difference between case and control groups, χ2 = 18.5, 4df, p = 0.001 
**** Dx before 2000:  Cases χ2 = 3.98, 4 df, p = 0.41 
   Controls χ2 = 2.8, 4 df , p = 0.59 
 
  SEIFA 1 SEIFA 2 SEIFA3 SEIFA 4 SEIFA 5 Total 
Age* Mean (sd) 62.8 (12.4) 62.1 (12.9) 62.4 (12.9) 62.3 (13.7) 62.5 (13.8) 62.4 (13.4) 
        
Gender** Male% 995 (53.7) 1018 (55.0) 970 (52.3) 1022 (55.0) 1022 (55.2) 5027 
 Female% 858 (46.3) 831 (45.0) 883 (47.7) 835 (45.0) 830 (44.8) 4237 
 Total% 1853 1849 1853 1857 1852 9264 
        
SEIFA by status*** Case n (%) 989 (21.4) 947 (20.4) 923(19.9) 908 (19.6) 865 (18.7) 4632 
 Control n (%) 864 (18.7) 902 (19.5) 930 (20.1) 949 (20.5) 987 (21.3) 4632 
 Total n (%) 1853 (20.0) 1859 (20.0) 1853 (20.0) 1857 (20.0) 1852 (20.0) 9264 
        
% Dx before 2000**** Cases% 424 (42.9) 424 (44.8) 424 (45.9) 413 (45.5) 409 (47.3) 2094 (45.2) 
 Controls% 760 (88.0) 784 (86.9) 800 (86.0) 833 (87.8) 849 (86.0) 4026 (86.9) 
 Total 1184 1208 1224 1246 1258 6120 
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GP ATTENDANCES 
 
Tables 8.2 and 8.3 show that there were significant differences in the proportions 
and frequencies of GP attendances between cases and controls, and also between 
socio-economic groups. Whilst the differences in the proportions of GP 
attendances for cases and controls were similar to those found in Chapters 4 and 
5, there were also major differences when socio-economic groups were 
compared. 
 
The highest proportions of attendances were among the lowest socio-economic 
group, and conversely, the lowest proportions of attendances were among the 
highest socio-economic group (Table 8.2). This accords with a number of studies 
that have investigated the use of GPs and socio-economic status in Australia 
which have found that disadvantaged individuals tend to be higher users of 
GPs.254 These findings were also reflected in the frequencies in Table 8.3.  
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Table 8.2: GP attendances between 1993 and 1999 for cases and controls by SEIFA, n (%) 
 
 
Differences between groups: φ χ2 = is not significant, *χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
 
     Year     
 
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 SEIFA1(low) 715(72.3)*** 752(76.0)*** 749(75.7)*** 776(78.5)*** 805(81.4)*** 843(85.3)*** 859(86.9) ** 1.16 <0.0001 
 SEIFA2 665(70.2)*** 692(73.1)*** 709(74.9)*** 736(77.7)*** 736(77.7)*** 748(79.0)*** 665(70.2)*** 1.03 0.05 
 SEIFA3 636(68.9)*** 655(71.0)*** 687(74.4)*** 690(74.8)*** 699(75.7)*** 751(81.4)*** 812(85.7)*** 1.17 <0.0001 
 SEIFA4 631(69.5)*** 658(72.5)*** 693(76.3)*** 697(76.8)*** 720(79.3)*** 738(81.3)*** 785(85.0)*** 1.16 <0.0001 
 SEIFA5 578(66.8)*** 611(70.6)*** 624(72.1)*** 651(75.3)*** 662(76.5)*** 680(78.6)*** 722(83.5)*** 1.14 <0.0001 
           
 P of diff 0.14 0.06 0.30 0.28 0.02 0.002 0.30   
           
Controls           
 SEIFA1(low) 822(95.1) 813(94.1) 812(94.0) 801(92.7) 799(92.5) 792(91.7) 782(90.5) 0.89 <0.0001 
 SEIFA2 845(93.7) 850 (94.2) 851(94.3) 838 (92.9) 837 (92.5) 834(92.5) 823(91.2) 0.93 0.006 
 SEIFA3 881(94.7) 878(94.4) 884(95.1) 883(94.9) 874 (94.0) 859(92.4) 853(91.7) 0.91 0.001 
 SEIFA4 878(92.5) 888 (93.6) 896 (94.4) 903(95.2) 898(94.6) 889(93.7) 872(91.9) 0.99 0.72 
 SEIFA5 906(91.8) 914(92.6) 918 (93.0) 922(93.4) 899(91.1) 903(91.5) 887(89.9) 0.95 0.03 
           
 P of diff 0.01 0.98 0.41 0.08 0.02 0.41 0.50   
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Table 8.3: GP attendances between 1993 and 1999 for cases and controls by SEIFA, mean (sd) 
 
     Year 
 
     
SES Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 
SEIFA1 Case 5.38(7.65)*** 5.84(7.92) *** 5.96(7.70) *** 6.50(8.50) *** 6.65(7.53)*** 7.38(8.80)*** 7.90(9.13) *** 0.98 <0.0001 
 Control 11.39(11.80) 11.35(10.7) 11.53(11.23) 11.73(10.5) 11.82(10.64) 12.20(10.32) 11.73(10.14) 0.80 <0.0001 
           
SEIFA2 Case 3.92(5.5) *** 4.37(5.75) *** 4.87(6.54) *** 5.25(7.05) *** 5.64(7.81)*** 5.84 (6.9) *** 6.54(7.47) *** 0.99 <0.0001 
 Control 9.1 (10.4) 9.67(9.19) 10.41(10.0) 10.28(10.06) 10.52(10.41) 10.36(10.56) 10.64(11.08) 0.85 <0.0001 
           
SEIFA3 Case 4.35(9.56)*** 5.06(11.56)*** 5.23(11.37)*** 5.87(12.25)*** 6.0(12.32)*** 6.6(12.8) *** 7.32(12.96)*** 0.99 <0.0001 
 Control 9.47(8.80) 9.61(9.07) 10.16(9.60) 10.02(8.84) 10.17(8.87) 10.08(8.82) 10.02(8.96) 0.72 <0.0001 
           
SEIFA4 Case 3.72(5.30)*** 4.15(5.67) *** 4.45(6.08) *** 5.0 (6.92) *** 5.29(6.8) *** 5.77(7.82)*** 6.24(7.1)*** 0.99 <0.0001 
 Control 8.97(9.75) 9.48(9.23) 10.28(10.17) 10.16(9.81) 10.77(10.24) 10.53(9.34) 10.75(9.80) 0.90 <0.0001 
           
SEIFA5 Case 4.09(6.61)*** 4.41(6.61)*** 4.65(6.63) *** 5.05(7.36) *** 5.15(7.24)*** 5.74(7.78)*** 6.22(7.70) *** 0.99 <0.0001 
 Control 8.58(10.36) 8.91(11.72) 9.15(11.69) 9.47 (10.86) 9.37(9.25) 9.57(10.85) 9.31(9.60) 0.83 <0.0001 
Differences between groups: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. Test for homogeneity of means 
(Oneway ANOVA): Cases: statistically significant differences (p<0.0001) between years in all socio-economic groups. Controls: statistically significant differences (p<0.0001)  
between years in all socio-economic groups. 
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SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES 
 
Tables 8.4 and 8.5 indicate that there were significant differences in the 
proportions and frequencies of specialist attendances between cases and controls, 
and between socio-economic groups. Whilst the differences in the proportions of 
attendances between cases and controls were similar to those found in Chapters 4 
and 5, there were major differences when socio-economic groups were 
compared.  
 
In a pattern that runs counter to that for GP attendances, the highest proportion of 
specialist attendances was in the high socio-economic group. Similarly, the 
lowest proportion was in the second lowest socio-economic group. These 
patterns were also evident in the frequencies captured in Table 8.5. This suggests 
that the lower level of GP attendances among higher socio-economic groups in 
Tables 8.2 and 8.3 may have been compensated for by the greater use of 
specialists by these groups.  
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Table 8.4: Specialist and consultant physician attendances between 1993 and 1999 for cases and controls by SEIFA, n (%) 
 
 
 
Differences between groups: φ χ2 = is not significant, * χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
 
     Year 
 
     
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 SEIFA1(low) 207(20.9)*** 223(22.5)*** 250(25.3)*** 244(24.7)*** 263(26.6)*** 286(28.9)*** 230(35.4)*** 1.04 0.004 
 SEIFA2 175(18.5)*** 181(19.1)*** 197(20.8)*** 212(22.4)*** 237(25.0)*** 236(24.9)*** 329(34.7)*** 1.14 <0.0001 
 SEIFA3 188(20.4)*** 202(21.9)*** 201(21.8)*** 227(24.6)*** 233(25.2)*** 256(27.7)*** 336(36.4)*** 1.13 <0.0001 
 SEIFA4 180(19.8)*** 195(21.5)*** 218(24.0)*** 236(26.0)*** 234(25.8)*** 268(29.5)*** 317(34.9)*** 1.13 <0.0001 
 SEIFA5 246(28.4)*** 238(27.5)*** 251(29.0)*** 232(26.8)*** 286(33.1)*** 333(38.5)*** 365(42.2)*** 1.12 <0.0001 
           
 P of diff <0.0001 0.001 <0.0001 0.23 <0.0001 <0.0001 0.005   
           
Controls           
 SEIFA1(low) 427(49.4) 474(54.9) 453(52.4) 473(54.7) 478 (55.3) 475(55.0) 466 (53.9) 1.02 0.06 
 SEIFA2 424 (47.0) 461(51.1) 459 (50.9) 473(52.4) 485(53.8) 479(53.1) 479(53.1) 1.04 0.004 
 SEIFA3 458(49.2) 472(50.8) 485(52.2) 504(54.2) 489(52.6) 497(53.4) 510(54.8) 1.03 0.009 
 SEIFA4 455(47.9) 502(52.9) 501(52.8) 525(55.3) 541(57.0) 558(58.8) 574(60.5) 1.08 <0.0001 
 SEIFA5 519(52.6) 507(51.4) 542(54.7) 568(57.5) 548(55.3) 566(57.3) 573(58.1) 1.04 0.001 
           
 P of diff 0.14 0.39 0.57 0.26 0.37 0.05 0.006   
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Table 8.5: Specialist and consultant physician attendances between 1993 and 1999 for cases and controls by SEIFA, mean (sd) 
Differences between groupsφ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. 
Test for homogeneity of means between socio-economic groups (Oneway ANOVA): Cases: Statistically significant differences in 1993, 1994, 1995, 1997, 1999 (other years ns).  
Controls: Statistically significant differences in all years. 
 
     Year 
 
     
SES Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend (OR) 
P 
 
SEIFA1 Case 0.70(2.50)*** 0.67(2.56)*** 0.77(2.64)*** 0.69(2.16)*** 0.76(2.27)*** 0.95(3.33)*** 1.05(2.89)*** 0.85 <0.0001 
 Control 1.82 (3.19) 2.10 (3.46) 2.17 (4.57) 2.21 (3.72) 2.46 (4.15) 2.43(4.27) 2.34 (4.43) 0.88 <0.0001 
           
SEIFA2 Case 0.51(1.73)*** 0.56(1.87)*** 0.55(2.18)*** 0.60(1.95)*** 0.71(2.57)*** 0.95(4.07)*** 1.20(2.90)*** 0.90 <0.0001 
 Control 1.78 (3.57) 1.99 (4.57) 2.02 (4.61) 2.18 (4.06) 2.15 (3.58) 1.98 (3.31) 2.21(4.99) 0.72 <0.0001 
           
SEIFA3 Case 0.59(1.91)*** 0.74(2.75)*** 0.69(2.51)*** 0.94(8.61)*** 0.83(3.02)*** 0.91(2.71)*** 1.37(4.06)*** 0.86 <0.0001 
 Control 1.99 (3.60) 1.94 (3.73) 2.20 (4.19) 2.15 (3.99) 2.07 (3.96) 2.17 (3.77) 2.28 (4.41) 0.77 <0.0001 
           
SEIFA4 Case 0.61(2.06)*** 0.51(1.51)*** 0.72(2.68)*** 0.78(2.33)*** 0.91(3.15)*** 1.18(4.62)*** 1.34(4.06)*** 0.95 <0.0001 
 Control 1.81 (3.21) 1.93 (3.32) 2.16 (3.69) 2.40 (5.94) 2.40 (4.24) 2.36 (4.27) 2.86 (7.11) 0.94 <0.0001 
           
SEIFA5 Case 0.83(2.51)*** 0.85(2.27)*** 1.19(4.61)*** 0.94(3.09)*** 1.36(4.37)*** 1.30(4.55)*** 1.91(9.69)*** 0.87 <0.0001 
 Control 2.21 (3.98) 2.06 (3.64) 2.48 (6.24) 2.66 (4.84) 2.46 (4.16) 2.60 (2.77) 2.79 (5.54) 0.85 <0.0001 
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 HbA1C TESTS 
 
Tables 8.6 and 8.7 show that there were significant differences in the proportions 
and frequencies of HbA1c testing between cases and controls, and also between 
socio-economic groups. Whilst the differences in the proportions of HbA1c 
testing for cases and controls were similar to those reported in Chapters 4 and 5, 
there were major differences when socio-economic groups were compared.  
 
The highest proportions of cases tested were in the highest socio-economic 
groups, and the lowest were in the lowest two socio-economic groups, although 
this difference was only statistically significant in 1996 and 1999. However, for 
controls, the highest socio-economic group had the lowest proportion tested, with 
testing higher in the second highest and lowest socio-economic groups. These 
same patterns were also evident in the frequencies captured in Table 8.7.   
 
These are difficult findings to explain as they suggest that the higher status group 
may have had poorer diabetes management. However, the lower prevalence of 
cases in this group, as well as the higher utilisation of medical specialists 
suggests that this is unlikely. The lower level of testing in high socio-economic 
groups might reflect a greater reliance on other measures of blood glucose, such 
as urine testing or self-management of blood glucose (SMBG),207 or that this 
group made greater use of medical care outside of the Medicare funded health 
care system (such as diabetes centres), which were not included in the data 
collection.  
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Table 8.6: HbA1c testing between 1993 and 1999 for cases and controls by SEIFA, n (%) 
 
Differences between groups: φ χ2 = is not significant, *χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
 
     Year 
 
     
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 SEIFA1 (low) 61(6.2) *** 100(10.1)*** 124(12.5)*** 112(11.3)*** 133(13.4)*** 155(15.7)*** 145(14.7)*** 1.14 <0.0001 
 SEIFA2 78(8.2) *** 95 (10.0) *** 115(12.1)*** 92(9.7) *** 116(12.2)*** 138(14.6)*** 150(15.8)*** 1.12 <0.0001 
 SEIFA3 70(7.6) *** 78(8.5) *** 104(11.3)*** 107(11.6)*** 129(14.0)*** 138(15.0)*** 161(17.4)*** 1.20 <0.0001 
 SEIFA4 62(6.8) *** 79(8.7) *** 113(12.4)*** 114(12.6)*** 134(14.8)*** 131(14.4)*** 170(18.7)*** 1.18 <0.0001 
 SEIFA5 74(8.6) *** 106(12.3)*** 127(14.7)*** 127(14.7)*** 127(14.7)*** 136(15.7)*** 165(19.1)*** 1.12 <0.0001 
           
 P of diff 0.26 0.06 0.28 0.02 0.51 0.90 0.05   
           
Controls           
 SEIFA1 (low) 166 (19.2) 201(23.3) 247(28.6) 259(30.0) 302 (35.0) 366(42.4) 389(45.0) 1.12 <0.0001 
 SEIFA2 180 (20.0) 226(25.1) 247 (27.4) 260 (28.8) 280 (31.0) 350(38.8) 403 (44.7) 1.20 <0.0001 
 SEIFA3 194 (20.9) 222(23.9) 236(25.4) 278 (29.9) 311(33.4) 360 (38.7) 402(43.2) 1.20 <0.0001 
 SEIFA4 198(20.9) 230 (24.2) 307(32.3) 295(31.1) 349(36.8) 407(42.9) 445 (46.9) 1.22 <0.0001 
 SEIFA5 179 (18.1) 210(17.1) 227 (23.0) 241(24.4) 316(32.9) 345(35.0) 404(40.9)  1.21 <0.0001 
           
 P of diff 0.52 0.37 <0.0001 0.01 0.07 0.002 0.10   
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Table 8.7: HbA1c testing between 1993 and 1999 for cases and controls by SEIFA, mean (sd) 
 
Differences between groups: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.001 level,*** t-test is significant at p<0.0001. 
Test for homogeneity of means between socio-economic groups (Oneway ANOVA): Cases: statistically significant differences in all years except 1998 (p=0.09). 
Controls: statistically significant differences in 1995 (p<0.0001), 1996 (p=0.02) and 1998 (p=0.002). 
 
     Year 
 
     
SES Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend (OR) 
P 
 
SEIFA1 Case 0.08(0.33)*** 0.12(0.42)*** 0.14(0.40)*** 0.14(0.41)*** 0.16(0.45)*** 0.19(0.51)*** 0.18(0.47)*** 0.95 <0.0001 
 Control 0.28(0.67) 0.38 (0.82) 0.44 (0.80) 0.47 (0.84) 0.55 (0.90) 0.67 (0.96) 0.72(0.96) 0.99 <0.0001 
           
SEIFA2 Case 0.12(0.46)*** 0.13(0.82)*** 0.16(0.47)*** 0.12(0.43)*** 0.15(0.45)*** 0.17(0.45)*** 0.20(0.50)*** 0.81 <0.0001 
 Control 0.28 (0.64) 0.38 (0.77) 0.41 (0.79) 0.43 (0.78) 0.49 (0.85) 0.62 (0.94) 0.72 (0.98) 0.97 <0.0001 
           
SEIFA3 Case 0.09(0.32)*** 0.10(0.35)*** 0.14(0.43)*** 0.15(0.44)*** 0.19(0.55)*** 0.19(0.53)*** 0.23(0.56)*** 0.98 <0.0001 
 Control 0.30(0.68) 0.34 (0.70) 0.36 (0.72) 0.46 (0.83) 0.52 (0.86) 0.59(0.88) 0.69 (0.95) 0.98 <0.0001 
           
SEIFA4 Case 0.08(0.35)*** 0.11(0.41)*** 0.16(0.49)*** 0.16(0.49)*** 0.20(0.54)*** 0.19(0.54)*** 0.26(0.62)*** 0.96 <0.0001 
 Control 0.32 (0.71) 0.37 (0.76) 0.49(0.83) 0.49(0.86) 0.58 (0.91) 0.68 (0.94) 0.77 (0.99) 0.99 <0.0001 
           
SEIFA5 Case 0.14(0.51)*** 0.18(0.54)*** 0.22(0.61)*** 0.22(0.60)*** 0.23(0.64)*** 0.24(0.63)*** 0.28(0.68)*** 0.95 <0.0001 
 Control 0.25 (0.62) 0.31 (0.70) 0.35 (0.74) 0.37 (0.78) 0.49 (0.86) 0.53 (0.86) 0.65 (0.93) 0.98 <0.0001 
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PATIENT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS 
 
Whether socio-economic status, patient characteristics and patterns of care 
predicted laser photocoagulation therapy was examined using a multivariate 
conditional logistic regression analysis and is captured in Table 8.8 below. In 
addition, Tables 8.9 to 8.13, indicate the relationship between patient 
characteristics, patterns of care and laser photocoagulation therapy within socio-
economic groups.   
 
Table 8.8 shows a socio-economic gradient in the level of risk of vision-
threatening retinopathy by socio-economic status, where lower socio-economic 
groups were at higher risk of developing the complications. However, this 
relationship was not statistically significant.  
 
Similar to the findings in Chapters 4 to 7, the strongest predictors of vision-
threatening retinopathy were delayed diagnosis, low HDL-cholesterol testing and 
low optometry attendances, which suggests that the introduction of socio-
economic status into the analysis did not appreciably alter the national picture 
(Table 4.5)   
 
When socio-economic groups were investigated individually, these same risk 
factors were significant but the frequency of GP and specialist and consultant 
practitioner attendances also became risk factors in some socio-economic groups, 
especially during the early years of the study. When the second lowest socio-
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economic group was investigated, a higher risk of vision-threatening retinopathy 
was found among women, which may be an indication of greater diabetes 
severity or better access to laser therapy. Whilst in the middle socio-economic 
group, age was also found to be significant, the adjusted odds ratio was 
diminutive and the confidence intervals narrow, indicating a small effect that 
may be of limited public health significance.   
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Table 8.8: Conditional logistic regression analysis predicting laser therapy in 2000 using socio-
economic status characteristics, demographic characteristics, and health care utilisation between 1993 
and 1999  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
SEIFA5 (ref) 1.0   
SEIFA4 1.13 0.77 – 1.64 0.53 
SEIFA3 1.27 0.87 – 1.9 0.21 
SEIFA2 1.29 0.88 – 1.89 0.20 
SEIFA1 1.39 0.96 – 2.01 0.08 
    
Gender* 0.75 0.59 – 0.95 0.015 
HbA1c before 
2000Г 
0.14 0.10 - 0.19 <0.0001 
    
1993    
GP 0.96 0.94 – 0.98 <0.0001 
S&CP‡ 0.95 0.90 – 0.99 0.02 
Optometry 0.25 0.16 – 0.37 <0.0001 
HDL-c† 0.28 0.12 – 0.65 0.003 
Retinal Ph§ 1.90 0.62 – 5.9 0.26 
    
1994    
S&CP 0.92 0.88 – 0.96 <0.0001 
Optometry 0.12 0.07 – 0.21  <0.0001 
HDL-c 0.17 0.07 – 0.39 <0.0001 
Retinal Ph 3.4 0.83 – 14.2 0.09 
    
1995    
GP 0.98 0.96 – 1.002 0.08 
S&CP 0.95 0.91 – 0.98 0.004 
Optometry 0.20 0.13 – 0.31 <0.0001 
HDL-c 0.06 0.02 – 0.17 <0.0001 
Retinal Ph 2.5 0.89 – 7.1 0.08 
    
1996    
Optometry 0.38 0.26 – 0.54 <0.0001 
HDL-c 0.11 0.04 – 0.27 <0.0001 
Retinal Ph 5.40 1.15 – 25.5 0.03 
    
1997    
Optometry 0.22 0.14 – 0.34 <0.0001 
HDL-c 0.07 0.03 – 0.19 <0.0001 
Retinal Ph 2.8 0.97 – 7.91 0.06 
    
1998    
Optometry 0.19 0.12 – 0.30 <0.0001 
HDL-c 0.12 0.05 – 0.25 <0.0001 
Retinal Ph 2.63 0.98 – 7.08 0.05 
    
1999    
GP 1.02 1.004 – 1.04 0.01 
S&CP 0.99 0.98 – 1.01 0.55 
Optometry 0.21 0.14 – 0.33 <0.0001 
HbA1c± 0.73 0.61 – 0.88 0.001 
HDL-c 0.02 0.008 – 0.07 <0.0001 
Retinal Ph 26.7 8.60 – 82.2 <0.0001 
Microalbumin† 2.6 1.89 – 3.5 <0.0001 
Reference group = controls, *reference group = female  
 Гreference group = not diagnosed.  
Model overall χ2 = 3107.3 35 df, p <0.0001. 
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§retinal photography. 
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Table 8.9: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (SEIFA 1) 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Gender* 0.61 0.43 – 0.85 0.004 
Dx before 2000Г 0.13 0.08 - 0.20  <0.0001 
    
1993    
GP 0.96 0.94 – 0.99 0.001 
S&CP‡ 0.99 0.93 – 1.07 0.94 
Optometry 0.21 0.11 – 0.39 <0.0001 
HDL-c† 0.35 0.12 – 1.06 0.06 
    
1994    
S&CP 0.89 0.83 – 0.94 <0.0001 
Optometry 0.14 0.07 – 0.29 <0.0001 
HDL-c 0.08 0.02 – 0.30 <0.0001 
Retinal Ph§ 1.21 0.18 – 8.2 0.84 
    
1995    
Optometry 0.34 0.20 – 0.59 <0.0001 
HDL-c 0.03 0.008 – 0.13 <0.0001 
Retinal Ph 7.33 0.30 – 179.0 0.22 
    
1996    
S&CP 0.97 0.90 – 1.05 0.47 
Optometry 0.21 0.11 – 0.38 <0.0001 
HDL-c 0.03 0.005 – 0.21 <0.0001 
Retinal Ph 8.9 1.35 – 58.9 0.02 
    
1997    
S&CP 0.93 0.87 – 0.99 0.02 
Optometry 0.29 0.16 – 0.52 <0.0001 
HDL-c 0.05 0.01 – 0.21 <0.0001 
Retinal Ph 5.82 0.98 – 34.6 0.05 
    
1998    
Optometry 0.14 0.08 – 0.25 <0.0001 
HDL-c 0.09 0.03 – 0.30 <0.0001 
Retinal Ph 11.9 2.08 – 67.7 0.005 
    
1999    
GP 1.03 1.01 – 1.05 0.002 
Optometry 0.34 0.19 – 0.60 <0.0001 
HbA1c± 0.67 0.52 – 0.86 0.002 
HDL-c 0.06 0.01 – 0.25 <0.0001 
Retinal Ph 9.28 2.46 – 34.9 0.001 
Microalbumin 4.15 2.32 – 7.41 <0.0001 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed. 
Model overall χ2 = 1625.8, 30 df, p <0.0001.  
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§Retinal photography. 
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Table 8.10: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (SEIFA 2) 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Age 1.03 1.02 – 1.04 <0.0001 
Dx before 2000Г 0.23 0.15 -  0.35 <0.0001 
    
1993    
GP 0.92 0.89 – 0.95 <0.0001 
S&CP‡ 0.93 0.86 – 0.99 0.03 
Optometry 0.20 0.10 – 0.39 <0.0001 
HbA1c± 1.02 0.76 – 1.37 0.89 
HDL-c† 0.22 0.06 – 0.74 0.01 
Retinal Ph§ 23.6 4.36 – 127.8 <0.0001 
    
1994    
GP 0.98 0.95 – 1.01 0.19 
S&CP 0.94 0.88 – 1.001 0.055 
Optometry 0.08 0.04 – 0.17 <0.0001 
HDL-c 0.24 0.05 – 1.04 0.06 
    
1995    
S&CP 0.93 0.87 – 0.99 0.03 
Optometry 0.21 0.12 – 0.36 <0.0001 
HDL-c 0.24 0.08 – 0.73 0.01 
    
1996    
S&CP 0.91 0.85 – 0.98 0.02 
Optometry 0.23 0.13 – 0.40 <0.0001 
HDL-c 0.10 0.03 – 0.37 0.001 
Retinal Ph 290.6 12.03 – 7023.0 <0.0001 
    
1997    
Optometry 0.31 0.16 – 0.57 <0.0001 
HDL-c 0.18 0.07 – 0.50 0.001 
Retinal Ph 3.96 0.61 – 25.6 0.15 
    
1998    
S&CP 1.05 0.99 – 1.10 0.06 
Optometry 0.25 0.15 – 0.39 <0.0001 
HbA1c 0.78 0.59 – 1.02 0.07 
HDL-c 0.09 0.03 – 0.29 <0.0001 
    
1999    
GP 1.03 1.003 – 1.05 0.03 
Optometry 0.25 0.14 – 0.46 <0.0001 
HbA1c 0.59 0.46 – 0.78 <0.0001 
HDL-c 0.25 0.08 – 0.75 0.01 
Retinal Ph 21.3 4.03 – 113.15 <0.0001 
Microalbumin 2.76 1.71 – 4.45 <0.0001 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed.  
Model overall χ2 = 1608.3, 32 df, p <0.0001.  
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances,  
§ retinal photography. 
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Table 8.11: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (SEIFA 3) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.29  0.19- 0.44  <0.0001 
    
1993    
GP 0.92 0.89 – 0.95 <0.0001 
S&CP‡ 0.90 0.84 – 0.97 0.006 
Optometry 0.12 0.06 – 0.23 <0.0001 
    
1994    
GP 1.01 0.98 – 1.04 0.39 
S&CP 0.98 0.92 – 1.04 0.57 
Optometry 0.07 0.03 – 0.15 <0.0001 
HbA1c± 0.69 0.49 – 0.97 0.03 
HDL-c† 0.03 0.003 – 0.31 0.003 
Retinal Ph§ 4.93 0.67 – 36.3 0.12 
    
1995    
S&CP 0.91 0.85 – 0.97 0.009 
Optometry 0.13 0.07 – 0.24 <0.0001 
HDL-c 0.15 0.04 – 0.49 0.002 
    
1996    
GP 1.02 0.99 – 1.06 0.11 
Optometry 0.38 0.24 – 0.61 <0.0001 
HbA1c 0.84 0.62 – 1.13 0.25 
HDL-c 0.12 0.04 – 0.38 <0.0001 
Retinal Ph 9.06 0.53 – 154.08 0.13 
    
1997    
Optometry 0.17 0.09 – 0.31 <0.0001 
HDL-c 0.04 0.01 – 0.21 <0.0001 
Retinal Ph 28.1 1.4 – 571.4 0.03 
    
1998    
GP 1.02 0.99 – 1.05 0.06 
S&CP 0.93 0.87 – 0.98 0.01 
Optometry 0.23 0.13 – 0.39 <0.0001 
HbA1c 0.76 0.57 – 1.0 0.05 
HDL-c 0.26 0.09 – 0.73 0.01 
Retinal Ph 23.6 2.50 – 218.9 0.005 
    
1999    
S&CP 1.06 1.02 – 1.11 0.007 
Optometry 0.21 0.12 – 0.37 <0.0001 
HbA1c 0.78 0.59 – 1.02 0.06 
HDL-c 0.16 0.06 – 0.41 <0.0001 
Retinal Ph 539.9 36.6 – 7964.3 <0.0001 
Microalbumin 1.79 1.21 – 2.67 0.004 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed.  
Model overall χ2 =1610.0, 34 df, p <0.0001. 
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§Retinal photography.  
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Table 8.12: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (SEIFA 4) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.14 0.09 – 0.22 <0.0001 
    
1993    
GP 0.97 0.94 – 1.0 0.048 
S&CP‡ 0.94 0.87 – 1.009 0.08 
Optometry 0.43 0.25 – 0.74 0.002 
HDL-c† 0.15 0.04 – 0.49 0.002 
Retinal Ph§ 1.64 0.37 – 7.2 0.51 
    
1994    
GP 0.96 0.93 – 0.99 0.04 
S&CP 0.88 0.81 – 0.95 0.001 
Optometry 0.16 0.08 – 0.32 <0.0001 
HDL-c 0.35 0.12 – 0.96 0.04 
    
1995    
GP 0.97 0.94 – 1.007 0.13 
Optometry 0.23 0.12 – 0.42 <0.0001 
HDL-c 0.16 0.06 – 0.48 0.001 
Retinal Ph 5.27 0.73 – 38.07 1.0 
    
1996    
S&CP 0.93 0.88 – 0.98 0.01 
Optometry 0.16 0.08 – 0.31 <0.0001 
HDL-c 0.12 0.04 – 0.37 <0.0001 
    
1997    
Optometry 0.23 0.13 – 0.39 <0.0001 
HDL-c 0.10 0.03 – 0.40 0.001 
Retinal Ph 27.8 2.4 – 318.9 0.008 
    
1998    
Optometry 0.12 0.07 – 0.23 <0.0001 
HDL-c 0.12 0.04 – 0.37 <0.0001 
Retinal Ph 3.93 0.76 – 20.17 0.10 
    
1999    
Optometry 0.10 0.05 – 0.19 <0.0001 
HbA1c± 0.81 0.64 – 1.03 0.09 
HDL-c 0.10 0.04 – 0.26 <0.0001 
Retinal Ph 321.1 25.6 – 4028.8 <0.0001 
Microalbumin 2.52 1.64 – 3.86 <0.0001 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed.  
Model overall χ2 = 1646, 28 df, p <0.0001.  
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§Retinal photography.  
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Table 8.13: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (SEIFA 5) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Age 1.03 1.02 – 1.05 <0.0001 
Dx before 2000Г 0.14 0.09 – 0.21 <0.0001 
    
1993    
GP 0.97 0.94 – 1.004 0.09 
S&CP‡ 0.88 0.82 – 0.94 <0.0001 
Optometry 0.23 0.10 – 0.51 <0.0001 
HbA1c± 0.94 0.68 – 1.3 0.72 
HDL-c† 0.51 0.20 – 1.3 0.15 
Retinal Ph§ 0.82 0.14 – 4.61 0.82 
    
1994    
GP 0.99 0.97 – 1.02 0.67 
S&CP 0.94 0.88 – 1.001 0.051 
Optometry 0.11 0.04 – 0.27 <0.0001 
HbA1c 1.08 0.79 – 1.47 0.64 
HDL-c 0.44 0.17 – 1.18 0.10 
Retinal Ph 3.6 0.42 – 29.9 0.24 
    
1995    
GP 0.98 0.95 – 1.02 0.29 
Optometry 0.13 0.07 – 0.25 <0.0001 
HbA1c 1.2 0.91 – 1.6 0.20 
HDL-c 0.09 0.03 – 0.32 <0.0001 
Retinal Ph 3.98 1.08 – 14.7 0.04 
    
1996    
S&CP 0.96 0.93 – 1.0 0.048 
Optometry 0.18 0.09 – 0.36 <0.001 
HDL-c 0.50 0.21 – 1.19 0.12 
Retinal Ph 2.15 0.43 – 10.8 0.35 
    
1997    
GP 0.98 0.96 – 1.01 0.31 
Optometry 0.17 0.09 – 0.32 <0.0001 
HDL-c 0.24 0.08 – 0.73 0.01 
    
1998    
Optometry 0.19 0.10 – 0.35 <0.0001 
HDL-c 0.17 0.06 – 0.46 0.001 
Retinal Ph 1.9 0.48 – 7.25 0.36 
    
1999    
Optometry 0.36 0.22 – 0.62 <0.0001 
HDL-c 0.04 0.01 – 0.15 <0.0001 
Retinal Ph 63.4 7.46 – 539.02 <0.0001 
Microalbumin 2.74 1.7 – 4.35 <0.0001 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed.  
Model overall χ2 = 1532.4, 33 df, p <0.0001.  
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§ Retinal photography.  
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Discussion 
 
The study showed that there was a greater risk of complications in lower as 
compared to higher socio-economic groups. This was evident in the univariate 
analysis (Table 8.1), as well as in the logistic regression model (Table 8.8), 
although in the latter socio-economic status was not significant. This accords 
with a large body of evidence concerning the relationship between socio-
economic status and diabetes. For example, Klein et al. found that the incidence 
of proliferative retinopathy was higher among lower status older men than in 
similar people with diabetes of higher status.161  
 
When the findings are considered in the light of those in Chapters 6 and 7, they 
might be explained by socio-economic status being influential in the late 
diagnosed group, but not in the early diagnosed population (Table 6.8). Thus, the 
strong relationship between socio-economic status and diabetes complications 
evident in Chapter 7 may have been diluted when the broader diabetes population 
was included in an analysis of the relationship between socio-economic status 
and vision-threatening retinopathy. This is apparent in the change in the value of 
the odds ratio for SEIFA 1 when Tables 7.4 and 8.8 are compared (OR = 1.89 
(1.29 ± 2.3) in Table 7.4, and OR = 1.39 (0.96 ± 2.01) in Table 8.8).  
 
With regard to the patterns of care, lower status patients made more use of GPs, 
attended specialist and consultant physicians less often and were tested for 
HbA1c more than their higher status counterparts. However, they were also at 
greater risk of developing diabetes complications. This suggests that the greater 
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use of medical specialists and lesser reliance on primary care which characterises 
the affluent group, might have reduced the risk of vision-threatening retinopathy.  
 
However, this finding runs counter to that in Chapter 5 that there was no 
advantage in greater specialist utilisation, when this was compared between 
states and territories. This suggests that the advantage in the higher socio-
economic group may be the result of some other factors such as fewer 
complications (less severe diabetes) and that this led to a lower risk of 
complications.273   
 
In Chapter 5 it was also found that states with higher levels of specialist 
attendances, also had higher levels of GP utilisation. However, this was not 
reflected in the current study, particularly in SEIFA 5, which also had high 
specialist attendances. This suggests that the synergistic relationship between GP 
and specialists attendances may be characteristic of particular states and territory 
health care systems and not of socio-economic groups.     
 
Tables 8.9 to 8.13 show that the risk factors for diabetes complications were 
remarkably consistent across socio-economic groups, indicating that patients 
who develop complications in all groups suffered from similar disadvantages 
with regard to diabetes management. This suggests that there may have been 
entrenched structural inadequacies in the health care system that affected all 
socio-economic groups.354 This may relate to the current system of primary 
health care in Australia or to the characteristics of people with diabetes.     
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In conclusion, socio-economic status was found to be a risk factor for the 
development of complications and this was evident in the univariate and 
multivariate analyses. However, when these findings are considered in the light 
of those in Chapters 6 and 7, it appears that low socio-economic status is a 
stronger risk factor in late diagnosed groups. The analysis of socio-economic 
status in these three studies provides support for the argument that early 
diagnosis interventions should be focused on low socio-economic groups but that 
interventions to improve diabetes management should target the diabetes 
population generally.      
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Chapter 9 
 
Are geographically isolated patients at greater risk of 
complications because of poor access to health care? 
 
 
 
 288
Abstract 
OBJECTIVES: In Chapters 7 and 8 socio-economic status was identified as a risk factor for 
diabetes complications. The effects of socio-economic status on health have often been explained 
to be a result of living conditions, behaviours and access to health care. One of the implications 
of Chapters 7 and 8 was that other populations that are similarly disadvantaged might also be at 
high risk of developing complications. One important group in Australia that also experiences 
poorer access to care is the rural and remote population. It was hypothesised that poor access to 
care, because of geographic isolation, would result in a higher risk of complications.  
 
METHODS: 4632 diabetes patients who had received their first laser photocoagulation treatment 
in 2000 were compared to a random sample of diabetes patients who had never received this 
treatment (n = 4632). Patterns of health care utilisation were compared within and between 
geographic remoteness groups over a seven-year period (1993-1999) using the Australian 
Medicare database.  
 
RESULTS:  There was a greater proportion of cases than controls in remote localities. RRMA 4 
(remote) contained 2.4% of cases, but only 1.3% of controls. RRMA 1 (metropolitan) contained 
49.2% of cases and 50.8% of controls, P<0.0001. People with diabetes in remote localities were 
younger than those in more populous regions: 57.8 years (sd = 12.9) in RRMA 4, compared to 
62.7 years (sd = 13.5) in RRMA 2, P<0.0001. In relation to GP attendances, for cases these were 
highest in RRMA 2 (7 year average = 78.7%) and lowest in RRMA 4 (7 year average = 64.5%), 
P<0.0001. For controls, the highest proportion of GP attendances was in RRMA 2 (7 year 
average = 93.7%), whilst the lowest was in RRMA 4 (7 year average = 90.0%). With regard to 
specialist attendances, for cases these were highest in RRMA 2 (7 year average = 30.9%), and 
lowest in RRMA 4 (7 year average = 12.1%), P<0.0001. For controls, specialist attendances were 
highest in RRMA 2 (7 year average = 56.3%) and lowest in RRMA 4 (7 year average = 38.3%), 
P<0.0001. For HbA1c testing, among cases, this was highest in RRMA 2 (7 year average = 
13.4%) and lowest in  RRMA 4 (7 year average = 8.6%), P<0.0001. For controls, HbA1c testing 
was highest in RRMA 1 (7 year average = 31.6) and lowest in RRMA 4 (7 year average = 
24.3%), P<0.0001. Geographic remoteness was also tested as a risk factor for vision-threatening 
retinopathy in a logistic regression model. Although it was found not to be statistically 
significant, there was evidence of a gradient in risk from low risk in metropolitan areas to high-
risk in remote localities. The major risk factors for vision-threatening retinopathy were delayed 
diagnosis, optometry attendances, HDL-cholesterol testing and retinal photography (which was 
higher in cases), which were similar across most groups regardless of remoteness.            
 
CONCLUSIONS: The findings indicated no consistent pattern of disadvantage in access to health 
care associated with geographic isolation. This suggests that access to health care is not a uniform 
problem for all isolated groups, but that other more general factors play a greater role in 
determining the quality and effectiveness of diabetes care.  
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Introduction 
 
Having established that patterns of care are very significant risk factors for 
diabetes complications in Chapter 4; that this relationship exists at the national 
level, as well as in all states and territories in Chapter 5; that early diagnosis, 
coupled with appropriate diabetes management is the key to preventing diabetes 
complications in Chapter 6; that the patterns of care prior to the diagnosis of 
diabetes are predictors of  complications in Chapter 7; and that socio-economic 
status was only a risk factor for diabetes complications in late-diagnosed groups 
in Chapter 8, this study investigates the role of geographic isolation as a risk 
factor for diabetes complications.   
 
The relationship between socio-economic status and diabetes complications in 
Chapters 7 and 8 implied that other populations which were similarly 
disadvantaged with regard to health status and access to health care may be at a 
similar high-risk of developing complications. One group of concern in this 
regard is the rural and remote population.363 In this study of the thesis, the 
research question was tested: whether geographic isolation was a risk factor for 
the diabetes complications in the population with diabetes in Australia.  
 
In national surveys rural and remote populations have been shown to have poorer 
metabolic control, less healthy lifestyles and poorer access to health care 
services.33, 283, 284 It was hypothesised that these factors - as measured by 
demographic characteristics, the timing of diagnosis and patterns of care - which 
had been shown to be risk factors for the development of advanced complications 
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in other populations, are also risk factors for advanced complications in rural and 
remote populations.
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Methods 
 
To investigate the relationship between geographic isolation and diabetes 
complications, a population-based case-control study similar to those in Chapters 
4, 5 and 8 was used.331 The study examined patient demographic characteristics, 
the utilisation of primary and secondary care, diabetes related pathology tests and 
predicted complications across groups categorised by remoteness.  
 
In this study, cases comprised a national sample of 4632 patients who had 
received their first laser photocoagulation therapy in 2000, and controls were a 
random sample of 4632 people with diabetes who had not received this treatment 
(the total sample in Table 4.2). Controls were matched to cases on age (within 
one year) in 2000, and state of residence at the time of their earliest HbA1c test.  
 
The measure of geographical isolation used in this study was the Regional and 
Remoteness for Areas (RRMA), a measure of geographic remoteness developed 
by the Australian Bureau of Statistics.341 The indicator measures the closeness of 
localities to major population centres when travelled by road. In this study, four 
classifications of geographic remoteness were used: RRMA 1 includes 
metropolitan areas; RRMA 2 outer metropolitan areas; RRMA 3 regional centres 
and country towns; and RRMA 4 remote locations. Subjects were ascribed an 
RRMA on the basis of their residential post-code.  
 
In the univariate analyses which compared cases to controls, proportions were 
compared using χ2 tests and frequencies by independent samples t-tests. When 
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risk factors were compared between remoteness groups, for proportions, χ2 tests 
for trend were used, and for frequencies analysis of variance was used (the 
Bonferroni adjustment was used to account for type 2 error).342 For each risk 
factor, and within cases and controls in each remoteness group, trends over time 
were calculated. For proportions, multivariate logistic regression of weighted 
proportions was used, and for frequencies, multiple linear regression of weighted 
means. The multivariate analyses were conducted using conditional logistic 
regression to take account of the paired study design, and the regression analyses 
used a stepwise process with backwards conditional as the variable selection 
criteria (Tables 9.8 to 9.12). Geographic isolation was entered as three dummy 
variables in the analysis reflected in Table 9.8, and all statistical analyses were 
performed using SPSS for Windows 11.5.343 
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Results 
 
CHARACTERISTICS OF THE SAMPLE 
 
Table 9.1 shows that 72% of cases lived in metropolitan or outer-metropolitan 
areas compared to 76% of controls (RRMA 1 and RRMA 2 combined). This 
suggests that there may be a slightly greater prevalence of diabetes in 
metropolitan and outer-metropolitan areas than in rural and remote localities.351 
However, the distribution of cases suggests that diabetes may be more severe in 
non-metropolitan areas.   
 
Whilst the average age of people with diabetes in metropolitan, outer-
metropolitan and regional areas was similar (62.1 to 62.6 years), subjects were 
significantly younger in remote locations (57.8). This may in part be an 
indication of the predominance of diabetes in indigenous groups in remote 
areas.30  
 
Whilst there were greater proportions of males in all areas, this occurred among 
both cases and controls (p = 0.45). Hence, vision-threatening retinopathy was not 
determined by gender. With regard to the timing of diagnosis, there were no 
significant differences between RRMA groups, suggesting that the timing of 
diagnosis of diabetes was not related to living in a rural or remote community. 
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Table 9.1: Characteristics of study subjects by RRMA 
 Differences in study groups: 28.7 3 df, p<0.0001  
**ANOVA for age differences:  F= 7.72 3,9260 df, p<0.0001 
*** Gender differences: χ2 = 2.63 3 df, p =  0.45. 
**** Differences in RRMA in Dx before 2000:  Cases: χ2 = 6.70 3 df, p = 0.08 
     Controls: χ2= 5.17 3 df, p = 0.16   
 
 
 
 RRMA 1 RRMA 2 RRMA 3 RRMA 4 Total 
      
Cases      n (%)* 2951(63.7) 397 (8.5) 1173(25.0) 111(2.4) 4632 
Controls n (%) 3045(65.7) 467(10.0) 1061(22.9) 59 (1.3) 4632 
Total n (%) 5996 (64.7) 864 (9.3) 2234 (24.0) 170 (1.8) 9264 
      
Age** (mean (sd)) 62.6 (12.9) 62.7(13.5) 62.1(13.3) 57.8(12.9) 62.4(13.1) 
      
Gender***      
Male      n (%) 3260(54.4) 457(52.9) 1226(54.9) 84(49.4) 5027 
Female  n (%) 2736 (45.6) 407(47.1) 1008(45.1) 86(50.6) 4237 
      
% Dx before 2000 ****      
Cases       n (%) 1353(45.8) 195(49.1) 498(42.5) 48(43.2) 2094(45.2) 
Controls  n (%) 2649(87.0) 419(89.7) 907(85.5) 51(86.4) 4026(86.9) 
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GP ATTENDANCES 
 
Tables 9.2 and 9.3 show that there were significant differences in the proportions 
and frequencies of GP attendances between cases and controls, and also between 
RRMA groups. Whilst the differences in the proportions of GP attendances for 
cases and controls were similar to those found in Chapters 4 and 5, there were 
major differences when RRMA groups were compared. 
 
Firstly, Table 9.2 shows that when cases are compared across RRMA groups, 
lesser proportions of remote patients attended GPs on an annual basis, and Table 
9.3 shows that this difference was reflected in the frequency of attendances. 
 
Table 9.2 also indicates that whilst the proportion of cases that attended GPs 
increased over the study, this did not occur amongst controls, as in metropolitan 
and outer-metropolitan areas the proportion that attended GPs declined. This 
suggests that access to GPs may have improved for cases in all localities, but for 
controls, such improvements occurred in remote localities only.  
 
Table 9.3 shows positive trends for both cases and control groups in the 
frequencies of attendances. This suggests that the quality of care may have 
improved across all RRMA groups over time, although the proportion of controls 
that received care from GPs declined.   
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Table 9.2: GP attendances between 1993 and 1999 for cases and controls by RRMA, n (%) 
 
 
 
Differences between groups: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
 
     Year 
 
     
Cases  1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 RRMA1 2085(70.7)*** 2191(74.2)*** 2228(75.5)*** 2308(78.2)*** 2356(79.8)*** 2435(82.5)*** 2551(86.4)*** 1.16 <0.0001 
 RRMA2 283(71.3) *** 291(73.3) *** 307(77.3) *** 308(77.6) *** 327(82.4) *** 335(83.4) ** 339(85.4) φ 1.16 <0.0001 
 RRMA3 794(67.7) *** 813(69.3) *** 860(73.3) *** 860(73.3) *** 865(73.7) *** 914(77.9) *** 979(83.5) *** 1.15 <0.0001 
 RRMA4 63(56.8) *** 73(65.8) * 67(60.4) ** 73(65.8) *** 74(66.7) *** 76(68.5) * 75(67.6) *** 1.07 0.07 
           
 P of diff 0.005 0.004 0.001 <0.0001 <0.0001 <0.0001 <0.0001   
           
Controls           
 RRMA1 2846(93.5) 2857(96.3) 2870(94.3) 2871(94.3) 2838(93.2) 2825(92.8) 2764(90.8) 0.94 <0.0001 
 RRMA2 444(95.1) 448(95.9) 450(96.4) 446(95.5) 435(93.1) 426(91.2) 417(89.3) 0.83 <0.0001 
 RRMA3 987(93.0) 987(93.0) 991(93.4) 977(92.1) 979(92.3) 973(91.7) 981(92.5) 0.97 0.2 
 RRMA4 55(93.2) 51(86.4) 50(84.7) 53(89.8) 55(93.2) 53(89.8) 55(93.2) 1.06 0.46 
           
 P of diff 0.51 0.02 0.002 0.01 0.78 0.43 0.17   
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Table 9.3: GP attendances between 1993 and 1999 for cases and controls by RRMA, mean (sd) 
 
     Year 
 
     
Geographic 
Isolation 
Group 1993 1994 1995 1996 1997 1998 1999 Annual  
trend (OR)  
P 
           
RRMA 1 Case 4.6(6.7)*** 5.1(7.0)*** 5.3(6.9)*** 5.9(7.7) *** 6.0(7.6) *** 6.6(7.9) *** 7.2(8.0) *** 0.99 <0.0001 
 Control 9.9(10.1) 10.2(10.3) 10.7(11.0) 10.8(10.7) 11.1(10.4) 11.1(10.7) 11.02(10.6) 0.91 <0.0001 
           
RRMA 2 Case 4.8(7.4)*** 5.3(7.7)*** 5.8(8.1)*** 6.4(9.9) *** 6.6(9.2) *** 7.1(10.1)*** 7.6(11.4)*** 0.99 <0.0001 
 Control 9.3(8.7) 10.1(10.8) 9.9(9.2) 10.1(8.5) 10.1(9.2) 9.8(8.5) 9.9(8.5) 0.99 <0.0001 
           
RRMA 3 Case 3.5(8.2)*** 3.9(9.7)*** 4.4(9.9)*** 4.5(10.2)*** 4.8(10.5)*** 5.3(10.9)*** 5.8(10.8)*** 0.99 <0.0001 
 Control 8.4(11.4) 8.59.0) 9.3(9.9) 8.9(8.5) 9.0(8.7) 9.2(8.7) 9.2(8.1) 0.76 <0.0001 
           
RRMA 4 Case 3.1(4.9)*** 4.2(6.7) * 3.6(5.9)*** 4.3(5.6) * 4.1(6.3) ** 4.5(5.7) ** 5.3(8.1) ** 0.86 <0.0001 
 Control 6.9(6.5) 6.4(5.8) 7.6(7.2) 6.3(6.1) 7.4(7.9) 7.7(6.8) 7.6(6.4) 0.58 <0.0001 
Differences between groups: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.01 level,*** t-test is significant at p<0.0001 
Test for homogeneity of means (Oneway ANOVA): Cases: Statistically significant differences between states in all years except 1994 (p=0.11) and 1996 (p=0.10). 
Controls: Statistically significant difference between states in all years. 
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SPECIALIST AND CONSULTANT PHYSICIAN ATTENDANCES 
 
Tables 9.4 and 9.5 show that there were significant differences in the proportions 
and frequencies of specialist attendances between cases and controls, and also 
between RRMA groups. Whilst the differences in the proportions of attendances 
between cases and controls were similar to those found in Chapters 4 and 5, there 
were major differences when RRMA groups were compared.  
 
Tables 9.4 and 9.5 show that when RRMA groups were compared, a similar 
difference to that found in respect of GPs attendances was also reflected in the 
proportion and frequency of attendance at specialists and consultant physicians. 
A smaller proportion of cases from remote localities attended specialists than 
cases from more populous regions, and this was also true when the frequency of 
attendances was compared. However, unlike with GPs, this same pattern was 
observed among controls, although the difference between geographic areas was 
not as great as it was with cases. This suggests that people with diabetes from 
remote localities have significantly poorer access to specialists and consultant 
physicians than less isolated patients.33  
 
Table 9.4 also shows that the proportion of subjects who attended specialist and 
consultant physicians increased in all RRMA groups over time, and this was also 
reflected in the frequencies in Table 9.5. This suggests that the level of access to 
specialist and consultant physicians improved over the study period.  
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When Tables 9.2 and 9.4 are compared, the findings suggest that there may have 
been a shift in participation in diabetes management from GPs to specialists and 
consultant physicians during the 1990s in some RRMA groups. This is indicated 
by the decline in the proportion of controls that attended GPs, and the 
simultaneous increase in the proportion that attended specialist and consultant 
physicians.  
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Table 9.4: Specialist and consultant physician attendances between 1993 and 1999 for cases and controls by RRMA, n (%)  
 
 
 
Differences between groups: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001 
 
 
 
     Year     
 
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual  
trend (OR) 
P 
 RRMA 1 674(22.8)*** 702(23.8)*** 769(26.1)*** 772(26.2)*** 873(29.6)*** 968(32.8)*** 1156(39.2)*** 1.13 <0.0001 
 RRMA 2 115(29.0)*** 106(26.7)*** 120(30.2)*** 119(30.0)*** 124(31.2)*** 115(29.0)*** 159(40.6) *** 1.07 0.002 
 RRMA 3 198(16.9)*** 222(18.9)*** 216(18.4)*** 247(21.1)*** 243(20.7)*** 280(23.9)*** 361(30.8)*** 1.12 <0.0001 
 RRMA 4 9(8.1) *** 9(8.1) *** 12(10.8) * 13(11.7) *** 13(11.7) *** 16(14.4) * 21(18.9) *** 1.17 0.005 
           
 P of diff <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001   
           
Controls           
 RRMA 1 1542(50.6) 1620(53.2) 1612(52.9) 1701(55.9) 1684(55.3) 1739(57.1) 1740(57.1) 1.04 <0.0001 
 RRMA 2 244(52.2) 273(58.5) 269(57.6) 273(58.5) 267(57.2) 255(54.6) 259(55.5) 1.002 0.90 
 RRMA 3 472(44.5) 504(47.5) 540(50.9) 548(51.6) 562(53.0) 560(52.8) 574(54.1) 1.06 <0.0001 
 RRMA 4 25(42.4) 19(32.2) 17(28.8) 21(35.6) 26(44.1) 21(35.6) 29(49.2) 1.07 0.21 
           
 P of diff 0.002 <0.0001 <0.0001 0.001 0.13 0.001 0.23   
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Table 9.5: Specialist and consultant physician attendances between 1993 and 1999 for cases and controls by RRMA, mean (sd) 
 
 
Differences between groups: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.01 level,*** t-test is significant at p<0.0001 
Test for homogeneity of means (Oneway ANOVA): Cases: Statistically significant differences between states in all years.  
Controls: Statistically significant difference between states in all years. 
 
     Year 
 
     
Geographic isolation Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 
           
RRMA 1 Case 0.69(2.2)*** 0.68(2.1)*** 0.84(3.1)*** 0.86(5.4)*** 1.0(3.4) *** 1.2(4.2)*** 1.5(6.6)*** 0.95 <0.0001 
 Control 2.1(3.7) 2.1(3.6) 2.3(4.9) 2.5(4.9) 2.4(4.2) 2.4(4.2) 2.6(5.4) 0.89 <0.0001 
           
RRMA 2 Case 0.93(2.9)*** 0.83(2.5)*** 1.3(4.8) ** 1.2(3.2) *** 1.2(3.5) *** 1.1(4.2)*** 1.5(4.2) ** 0.74 <0.0001 
 Control 1.9(3.3) 2.3(3.9) 2.2(3.3) 2.4(4.2) 2.5(4.5) 2.5(5.1) 2.5(5.4) 0.87 <0.0001 
           
RRMA 3 Case 0.46(1.6)*** 0.59(2.3)*** 0.45(1.5)*** 0.50(1.7)*** 0.59(2.4)*** 0.72(2.9)*** 0.92(2.6)*** 0.82 <0.0001 
 Control 1.53(2.9) 1.7(4.1) 1.9(4.8) 1.9(3.6) 1.9(3.3) 1.9(3.4) 2.3(5.5) 0.89 <0.0001 
           
RRMA 4 Case 0.29(1.5) * 0.28(2.1) φ 0.67(3.4) φ 0.38(1.5) φ  0.19(0.63)*** 0.63(3.1) φ 0.85(2.7) φ  0.59 <0.0001 
 Control 0.83(1.3) 0.75(1.8) 0.74(1.4) 0.76(1.2) 1.3(2.1) 1.0(1.8) 1.9(4.9) 0.77 <0.0001 
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HbA1C TESTING 
 
Tables 9.6 and 9.7 show that there were significant differences in the proportions 
and frequencies of HbA1c testing between cases and controls, and also between 
RRMA groups. Whilst the differences in the proportions of HbA1c testing for 
cases and controls were similar to those found in Chapters 4 and 5, there were 
major differences when remoteness groups were compared.  
 
Tables 9.6 and 9.7 reflect differences in RRMA groups that were found in GP 
and specialist and consultant physician attendances in Tables 9.2 to 9.5. They 
also show that the proportion and frequency of HbA1c testing increased in all 
RRMA groups, suggesting that the quality of diabetes management may have 
improved across all regions.   
 
Despite the lower level of access to GPs and other health care services in remote 
localities, the case group in the metropolitan areas had lower levels of testing 
than controls in remote localities. This indicates that diabetes complications were 
more strongly associated with the level of health care utilisation than with 
geographic isolation.  
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Table 9.6: HbA1c testing between 1993 and 1999 for cases and controls by RRMA, n (%)   
 
 
 
Differences between groups: φ χ2 = is not significant,*  χ2 = is significant at p=0.05 level,** χ2 = is significant at p=0.001 level,*** χ2 = is significant at p<0.0001
     Year     
 
 
Cases  1993 1994 1995 1996 1997 1998 1999 Annual  
trend(OR) 
P 
 RRMA 1 244(8.3)*** 327(11.1)*** 402(13.6)*** 368(12.5)*** 411(13.9)*** 441(14.9)*** 523(17.7)*** 1.12 <0.0001 
 RRMA 2 33(8.3) *** 35(8.8) *** 55(13.9) *** 41(10.3) *** 65(16.4) *** 71(17.9) *** 74(18.6) *** 1.17 <0.0001 
 RRMA 3 61(5.2) *** 90(7.7) *** 114(9.7) *** 132(11.3)*** 154(13.1)*** 172(14.7)*** 186(15.9)*** 1.20 <0.0001 
 RRMA 4 7(6.3)* 6(5.4) φ 12(10.8) φ 11(9.9)* 9(8.1)* 14(12.6)* 8(7.2)*** 1.07 0.31 
           
 P of diff 0.007 0.003 0.006 0.43 0.13 0.37 0.01   
           
Controls           
 RRMA 1 643(21.1) 745(24.5) 853(28.0) 891(29.3) 1053(34.6) 1194(39.2) 1348(44.2) 1.19 <0.0001 
 RRMA 2 93(19.9) 126(27.0) 129(27.6) 148(31.7) 150(32.1) 177(37.9) 201(43.0) 1.17 <0.0001 
 RRMA 3 171(16.1) 210(19.8) 272(25.6) 279(26.3) 341(32.1) 437(41.2) 470(44.3) 1.27 <0.0001 
 RRMA 4 10(16.9) 8(13.6) 10(16.9) 15(25.4) 14(23.7) 20(33.1) 24(40.7) 1.27 <0.0001 
           
 P of diff 0.005 0.001 0.14 0.12 0.15 0.45 0.91   
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Table 9.7: HbA1c testing between 1993 and 1999 for cases and controls by RRMA, mean (sd) 
 
 
 
Differences between groups: φ t-test is not significant,*  t-test is significant at p=0.05 level,** t-test is significant at p=0.01 level,*** t-test is significant at p<0.0001 
Test for homogeneity of means (Oneway ANOVA): Cases: Statistically significant differences between states in all years.  
Controls: Statistically significant difference between states in all years. 
 
     Year 
 
     
Geographic isolation  Group 1993 1994 1995 1996 1997 1998 1999 Annual 
trend(OR) 
P 
 
           
RRMA 1 Case 0.12(0.43)*** 0.15(0.46)*** 0.18(0.52)*** 0.16(0.50)*** 0.19(0.50)*** 0.20(0.55)*** 0.24(0.59)*** 0.94 <0.0001 
 Control 0.31(0.69) 0.37(0.77) 0.42(0.79) 0.46(0.83) 0.55(0.89) 0.62(0.92) 0.72(0.98) 0.99 <0.0001 
           
RRMA 2 Case 0.11(0.42)*** 0.11(0.39)*** 0.17(0.48)*** 0.13(0.44)*** 0.21(0.54)*** 0.22(0.53)*** 0.26(0.59)*** .0.93 <0.0001 
 Control 0.29(0.68) 0.39(0.76) 0.45(0.85) 0.52(0.89) 0.50(0.87) 0.59(0.90) 0.69(0.97) 0.97 <0.0001 
           
RRMA 3 Case 0.06(0.29)*** 0.09(0.37)*** 0.11(0.39)*** 0.14(0.44)*** 0.17(0.48)*** 0.18(0.50)*** 0.19(0.50)*** 0.99 <0.0001 
 Control 0.22(0.58) 0.30(0.71) 0.36(0.71) 0.39(0.76) 0.51(0.87) 0.68(0.91) 0.68(0.91) 0.98 <0.0001 
           
RRMA 4 Case 0.07(0.29) * 0.05(0.23)  * 0.14 (0.5) φ 0.11(0.37) * 0.10(0.38) * 0.14(0.40)*** 0.08(0.30)*** 0.38 <0.0001 
 Control 0.27(0.66) 0.15(0.41) 0.20(0.48) 0.25(0.44) 0.32(0.65) 0.56(0.93) 0.61(0.91) 0.85 <0.0001 
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PATIENT CHARACTERISTICS AND HEALTH CARE UTILISATION OVER SEVEN 
YEARS FOR CASES VS CONTROLS 
 
In Table 9.8 below, whether geographic isolation, patient characteristics and 
patterns of care predicted laser photocoagulation therapy was tested using a 
multivariate conditional logistic regression analysis. In addition, Tables 9.9 to 
9.12 capture the relationship between patient characteristics, patterns of care and 
laser photocoagulation therapy within RRMA groups.   
 
Table 9.8 shows a gradient in the risk of vision-threatening retinopathy by 
RRMA group, where the risk of complications increased as people with diabetes 
lived further away from metropolitan centres. The strongest predictors of vision-
threatening retinopathy in remoteness groups were delayed diagnosis, low HDL-
cholesterol testing and optometry attendances, which pointed to similar aspects 
of management of diabetes leading to the development of complications as was 
found in Tables 4.6 and others.   
 
When remoteness groups were considered individually, they had similar patterns 
of risk factors to those presented in Table 9.8. Perhaps the most significant 
difference was in RRMA 3, where gender was a risk factor. This may be 
indicating that in regional localities there is some aspect of femaleness that 
increases the risk of complications, such as access to care or the severity of 
diabetes. In addition, in some years there were no significant differences between 
cases and controls in RRMA 4. However, this is unlikely to be an indication of 
different relationships between the patterns of care and diabetes complications in 
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these localities, and is more likely to reflect the small sample size used in the 
analysis.342 
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Table 9.8: Conditional logistic regression analysis predicting laser therapy in 2000 using geographic 
isolation characteristics, demographic characteristics, and health care utilisation between  
1993 and 1999  
 
YEAR 
Risk factor 
OR 95% CI  P 
    
RRMA 4 (remote) (ref) 1.0   
RRMA 3  (rural/ regional) 0.47 0.19 – 1.16 0.1 
RRMA 2 (suburban) 0.51 0.19 – 1.34 0.17 
RRMA 1 (urban/metro) 0.55 0.23 – 1.3 0.2 
    
Gender* 0.76 0.60 – 0.95 0.02 
Dx before 2000Г 0.14 0.10 – 0.19 <0.0001 
    
1993    
GP 0.96 0.94 – 0.98 <0.0001 
S&CP‡ 0.94 0.90 – 0.99 0.01 
Optometry 0.25 0.17 – 0.38 <0.0001 
HDL-c† 0.25 0.11 – 0.58 0.001 
Retinal Ph§ 1.9 0.64 – 6.20 0.23 
    
1994    
S&CP 0.92 0.88 – 0.96 <0.0001 
Optometry 0.12 0.07 – 0.21 <0.0001 
HDL-c 0.16 0.07 – 0.38 <0.0001 
Retinal Ph 3.4 0.82 – 14.4 0.09 
    
1995    
GP 0.98 0.96 – 1.004 0.11 
S&CP 0.95 0.91 – 0.98 0.004 
Optometry 0.20 0.13 – 0.31 <0.0001 
HDL-c 0.07 0.03 – 0.19 <0.0001 
Retinal Ph 2.3 0.82 – 6.4 0.11 
    
1996    
Optometry 0.37 0.26 – 0.54 <0.0001 
HDL-c 0.11 0.04 – 0.27 <0.0001 
Retinal Ph 5.6 1.20 – 26.0 0.03 
    
1997    
Optometry 0.21 0.14 – 0.33 <0.0001 
HDL-c 0.08 0.03 – 0.21 <0.0001 
Retinal Ph 2.9 1.006 – 8.4 0.049 
    
1998    
Optometry 0.19 0.12 – 0.30 <0.0001 
HDL-c 0.11 0.05 – 0.23 <0.0001 
Retinal Ph 2.6 0.98 – 6.8 0.05 
    
1999    
GP 1.02 1.003 – 1.03 0.02 
Optometry 0.21 0.14 – 0.33 <0.0001 
HbA1c± 0.73 0.66 – 0.89 <0.0001 
HDL-c 0.02 0.008 – 0.07 <0.0001 
Retinal Ph 26.8 8.7 – 83.3 <0.0001 
Microalbumin 2.6 1.9 – 3.5 <0.0001 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed.  
Model overall χ2 = 3104.4, 34 df, p <0.0001. 
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§ Retinal photography.  
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Table 9.9 Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (RRMA 1) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.17 0.14 – 0.21 <0.0001 
    
1993    
GP 0.97 0.95 – 0.99 <0.0001 
S&CP‡ 0.91 0.88 – 0.94 <0.0001 
Optometry 0.18 0.12 – 0.27 <0.0001 
HDL-c† 0.39 0.22 – 0.68 0.001 
Retinal Ph§ 1.05 0.33 – 3.33 0.93 
    
1994    
GP 1.002 0.98 – 1.02 0.86 
S&CP 0.89 0.86 – 0.93 <0.0001 
Optometry 0.09 0.05 – 0.14 <0.0001 
HbA1c± 0.93 0.79 – 1.09 0.38 
HDL-c 0.21 0.11 – 0.38 <0.0001 
Retinal Ph 3.06 1.03 – 9.07 0.04 
    
1995    
GP 0.97 0.96 – 0.99 0.001 
Optometry 0.15 0.11 – 0.22 <0.0001 
HbA1c 1.07 0.92 – 1.25 0.37 
HDL-c 0.11 0.06 – 0.22 <0.0001 
Retinal Ph 2.32 0.97 – 5.59 0.06 
    
1996    
Optometry 0.26 0.18 – 0.36 <0.0001 
HDL-c 0.19 0.10 – 0.35 <0.0001 
Retinal Ph 4.47 1.55 – 12.9 0.006 
    
1997    
Optometry 0.19 0.13 – 0.26 <0.0001 
HDL-c 0.14 0.07 – 0.27 <0.0001 
Retinal Ph 3.64 1.43 – 9.27 0.007 
    
1998    
Optometry 0.16 0.11 – 0.22 <0.0001 
HDL-c 0.15 0.08 – 0.28 <0.0001 
Retinal Ph 5.65 2.22 – 14.3 <0.0001 
    
1999    
GP 1.01 1.003 – 1.03 0.01 
Optometry 0.30 0.22 – 0.41 <0.0001 
HbA1c 0.75 0.66 – 0.86 <0.0001 
HDL-c 0.08 0.04 – 0.16 <0.0001 
Retinal Ph 61.6 20.2 – 187.6 <0.0001 
Microalbumin 2.31 1.81 – 2.93 <0.0001 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed.  
Model overall χ2 = 5086.9, 32 df, p <0.0001.  
±Haemoglobin A1c tests,  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§ retinal photography.  
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Table 9.10: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (RRMA 2) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.20 0.11 – 0.37 <0.0001 
    
1993    
GP 0.96 0.93 – 0.99 0.04 
Optometry 0.081 0.02 – 0.33 <0.0001 
HDL-c† 0.12 0.02 – 0.84 0.03 
Retinal Ph§ 9.13 0.34 – 241.7 0.19 
    
1994    
S&CP 0.86 0.77 – 0.96 0.006 
Optometry 0.19 0.07 – 0.49 0.001 
HbA1c± 0.49 0.30 – 0.82 0.007 
HDL-c 0.47 0.09 – 2.54 0.38 
    
1995    
Optometry 0.17 0.06 – 0.45 <0.0001 
HDL-c 0.27 0.07 – 1.05 0.06 
Retinal Ph 718.3 0.000 – 1.316 0.67 
    
1996    
Optometry 0.15 0.05 – 0.41 <0.0001 
Retinal Ph 0.13 0.02 – 0.87 0.03 
    
1997    
Optometry 0.11 0.04 – 0.35 <0.0001 
HDL-c 0.10 0.02 – 0.53 0.007 
Retinal Ph 20.9 1.56 – 280.5 0.02 
    
1998    
Optometry 0.23 0.11 – 0.51 0.01 
HDL-c 0.12 0.02 – 0.62 0.01 
    
1999    
S&CP 1.09 1.02 – 1.16 0.01 
Optometry 0.29 0.14 – 0.60 0.001 
HbA1c 0.72 0.49 – 1.03 0.07 
HDL-c 0.21 0.07 – 0.59 0.003 
Retinal Ph 62.3 4.1 – 935.3 0.003 
Microalbumin 4.16 2.22 – 7.81 <0.0001 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed.  
Model overall χ2 = 742.7, 25 df, p <0.0001.  
±Haemoglobin A1c tests  
† HDL cholesterol tests, 
‡ Specialist and consultant physician attendances 
§ Retinal photography. 
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Table 9.11 Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (RRMA 3) 
 
YEAR 
Risk factor 
OR 95% CI  P 
    
Gender* 0.48 0.36 – 0.65 <0.0001 
Dx before 2000Г 0.22 0.15 – 0.31 <0.0001 
    
1993    
GP 0.92 0.90 – 0.95 <0.0001 
S&CP‡ 0.93 0.86 – 1.01 0.10 
Optometry 0.36 0.23 – 0.55 <0.0001 
HDL-c† 0.13 0.03 – 0.54 0.005 
Retinal Ph§ 3.65 0.88 – 15.1 0.07 
    
1994    
S&CP 0.96 0.92 – 1.01 0.15 
Optometry 0.19 0.11 – 0.33 <0.001 
HDL-c 0.32 0.09 – 1.10 0.07 
Retinal Ph 2.62 0.33 – 20.7 0.36 
    
1995    
S&CP 0.88 0.82 – 0.95 0.002 
Optometry 0.32 0.21 – 0.49 <0.0001 
HDL-c 0.12 0.04 – 0.37 <0.0001 
Retinal Ph 6.78 1.08 – 42.5 0.04 
    
1996    
S&CP 0.89 0.83 – 0.95 0.001 
Optometry 0.27 0.17 – 0.45 <0.0001 
HDL-c 0.09 0.03 – 0.31 <0.0001 
Retinal Ph 10.9 0.92 – 129.5 0.06 
    
1997    
Optometry 0.29 0.19 – 0.46 <0.0001 
HDL-c 0.09 0.04 – 0.26 <0.0001 
Retinal Ph 3.77 0.86 – 16.6  
    
1998    
GP 1.02 0.99 – 1.05 0.08 
S&CP 0.95 0.91 – 0.99 0.02 
Optometry 1.29 0.19 – 0.44 <0.0001 
HbA1c± 0.81 0.64 – 1.02 0.08 
HDL-c 0.21 0.09 – 0.49 <0.0001 
    
1999    
GP 1.03 1.001 – 1.05 0.04 
Optometry 0.19 0.12 – 0.31 <0.0001 
HbA1c 0.78 0.62 – 0.99 0.04 
HDL-c 0.05 0.01 – 0.19 <0.001 
Retinal Ph 24.8 4.72 – 130.6 <0.0001 
Microalbumin 1.94 1.27 – 2.97 0.002 
Reference group = controls, *reference group = female  
Гreference group = not diagnosed.  
Model overall χ2 = 1850.9, 33 df, p <0.0001.  
±Haemoglobin A1c tests  
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances 
§Retinal photography. 
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Table 9.12: Logistic regression analysis predicting laser therapy in 2000 using demographic 
characteristics, and health care utilisation between 1993 and 1999 (RRMA 4) 
YEAR 
Risk factor 
OR 95% CI  P 
    
Dx before 2000Г 0.16 0.01 – 1.7 0.12 
    
1993    
GP 0.94 0.78 – 0.13 0.94 
    
1995    
Optometry 0.006  0.99 
    
1996    
Optometry 1.1729  0.99 
HDL-c† 2.6810  0.99 
    
1998    
S&CP‡ 2.3514  0.97 
    
1999    
S&CP 115328.8  0.98 
Microalbumin 1.5730  0.98 
Reference group = controls, *reference group = female 
Гreference group = not diagnosed.  
Model overall χ2 = 191.9, 7 df, p <0.0001.  
±Haemoglobin A1c tests  
† HDL cholesterol tests 
‡ Specialist and consultant physician attendances 
§ Retinal photography.  
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Discussion 
 
There appear to be two distinct geographic populations in Australia with regard 
to diabetes: that is those who live in metropolitan areas and those who live in 
rural or remote localities. Whilst diabetes appears to be a greater problem in 
metropolitan areas it may be more severe in rural and remote localities. This 
could be a result of a greater concentration of people at high-risk of diabetes in 
urban populations along with poorer metabolic control and poorer access to 
health care services in non-metropolitan localities.33   
 
Access to health care, which has been identified as a major health issue in rural 
and remote populations, was a complex phenomenon in this study. Whilst 
geographic remoteness was found to be an important factor in determining the 
level of health care utilisation, many individuals appeared to be able to overcome 
remoteness as a barrier. This is evident in that the timing of diagnosis was 
comparable between RRMA groups, as was the proportion of controls that 
attended GPs. In addition, the proportion and frequency of GP and specialist 
attendances and HbA1c testing was lower among metropolitan cases than it was 
among controls from remote areas. This suggests the level of health care 
utilisation was not solely determined by proximity to health care services, but 
also by factors that are more general across the population such as patients’ self-
efficacy and the organisation of the health care system.151  
 
In addition to examining the factors that determine health care utilisation, the 
study also provided further insights into the changing nature of diabetes care. In 
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Chapter 4, it had been found that there had been a shift from GPs to specialists in 
the management of diabetes over the study period. However, the univariate 
analysis in the current study shows that this phenomenon may have been 
confined to metropolitan and outer metropolitan areas. This is evident in that in 
remote localities the utilisation of both GPs and specialists increased. Thus in 
metropolitan areas there may have been a greater specialisation of diabetes 
management, whilst in rural and remote localities both types of practitioners 
became more involved in diabetes.  
 
Whilst the lower risk of diabetes complications found in metropolitan and outer 
metropolitan areas may be indicating the benefits of specialisation, there may be 
other factors at play where the higher use of specialists did not result in a lower 
risk of diabetes complications shown in other chapters. Hence, the advantage in 
metropolitan areas may relate to some aspect of health status, lifestyle or health 
care that is protective of complications in more populous localities.279 
 
Table 9.8 reveals that the risk of complications increased as people with diabetes 
lived further away from metropolitan locations (although this relationship was 
not statistically significant). However, risk factors for diabetes complications did 
not appreciably change across RRMA groups (Tables 9.9 to 9.12). This suggests 
that the factors that increase the risk of diabetes complications in remote areas 
were similar to those that operated in metropolitan populations and that there 
may have been structural characteristics of the health care system that affected all 
groups.354     
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In conclusion, the study supports previous chapters findings that health care 
utilisation determined the risk of diabetes complications. However, in this study 
this relationship was found in all geographic locations. Thus despite the evidence 
concerning access to care in rural and remote localities, a consistent pattern of 
disadvantage associated with geographic isolation was not found. This suggests 
that access to health care is a problem that is uniform among rural and remote 
populations33 but that other factors, such as patients’ self- efficacy151 and the 
characteristics of health care systems,173 are stronger determinants of effective 
diabetes care than proximity to health care services.  
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Chapter 10 
 
Do the characteristics of GPs determine the                                  
risk of complications?  
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Abstract 
 
OBJECTIVES: There is substantial evidence that the characteristics and behaviour of GPs are 
important factors that determine the quality of care. However, few studies have been able to link 
these factors to the development of health outcomes such as diabetes complications. In this study, 
the relationship between provider characteristics and diabetes outcomes in patients is explored. 
The study aimed to determine whether the characteristics of GPs could explain the development 
of complications in their patients.    
 
METHODS: 4256 GPs who had exclusively treated cases in 1999 were compared to 4499 GPs 
who had exclusively treated controls, and 3526 GPs who had treated both groups, in this same 
year. The factors examined included the demographic characteristics and skills of GPs, as well as 
the location of their principal practice. The information was obtained from the Australian 
Medicare database.    
 
RESULTS: Close to 50% of Australian GPs were involved in the treatment of cases and controls. 
One-third exclusively treated cases, one-third exclusively treated controls and another third 
treated both groups. The average age of practitioners was 47.3 years (sd = 11.7), this did not 
differ by group, and the overwhelming majority were male. With regard to the location of 
principal practices, more GPs of cases served in lower socio-economic areas (19.1% of case GPs 
vs 17.7% of controls in SEIFA 1), however, the largest group was those who treated both cases 
and controls (24.1%), P<0.0001. In affluent areas (SEIFA 5), control practitioners dominated, 
with 22.4% vs 20.2% of case practitioners and 16.5% of those who treated both, P<0.0001. With 
regard to geographic isolation, case practitioners were more likely to serve in rural and remote 
localities (3.1% in RRMA 4 and 23.1% in RRMA 3), compared to controls (1.7% in RRMA 4 
and 22.9% in RRMA 3), and those who treated both (1.7% in RRMA 4 and 21.2% in RRMA 3), 
P<0.0001. With regard to the quality of care, the lowest proportion of vocationally registered GPs 
was in the case group (83.8%), which compared to 85% of control practitioners and 87.0% of 
those who treated both, P<0.0001. To identify the factors that differentiate case from controls 
GPs, a logistic regression analysis was conducted. The strongest risk factors were vocational 
registration (less in cases), serving high socio-economic areas (less in cases), and serving in 
remote locations (more in cases). This model was highly significant (P<0.0001).  
 
CONCLUSIONS: There were a number of factors that were found to differ between the GPs of 
cases and controls. In addition, these factors often reflected the risk factors for vision-threatening 
retinopathy in cases. However, data on the providers of diabetes care available in the Medicare 
system were limited. This meant that it was impossible to determine the significance of the 
provider characteristics for the development of diabetes complications.   
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Introduction 
 
In the previous chapters the relationship between patterns of care and the risk of 
advanced diabetes complications has been extensively explored. This included 
investigations at the national level, within states, for high-risk groups, by socio-
economic status and level of geographic isolation. In each of these studies it was 
found that people who developed diabetes complications had significantly lower 
levels of health care utilisation than those who remained free of the condition. 
They had also generally been diagnosed with diabetes later than unaffected 
controls.  
 
In the literature review (Chapter 2) the role of the health care system in 
governing the standard of diabetes management was discussed. Part of this 
discussion referred to the characteristics of practitioners as important factors in 
quality of diabetes management.41, 334, 338, 355 However, in the epidemiological 
evidence on which much of this argument was based, there has been a failure to 
link the characteristics of practitioners to the development of the health status of 
their patients. Thus little is known at present about the relationship between the 
characteristics of practitioners and the development of diabetes outcomes.     
 
In this study, the GPs of cases are compared to those of controls to examine the 
seventh and final research question in the thesis: whether there were any 
characteristics of GPs that could be related to the development of vision-
threatening retinopathy in patients.  
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Methods 
 
To examine the relationship between GP characteristics and the development of 
diabetes complications, a population-based case-control study was used.331 The 
study population consisted of GPs who had made a Medicare claim for a general 
practice service in 1999 (these were identified by whether practitioners had 
claimed for items in schedules A1 and A2 of the MBS).206 Once these 
practitioners had been identified, GPs who had been attended by a subject 
included in the sample captured in Table 4.2 were selected to be included in the 
study. The linkage of GPs to patients was conducted through patient records as 
each Medicare claim includes information on both the patient and the provider.206 
Once the GP sample had been chosen, the demographic characteristics, 
accreditation status and the location of their principal practice were collected 
from the Medicare database. The data items used in the study are presented in 
Table 3.2.  
 
In the univariate analyses, which compared case to control practitioners, as well 
as to those who treated both, proportions were compared using χ2 tests and 
frequencies by analysis of variance (the Bonferroni adjustment was used to 
account for type 2 error).342 The multivariate analysis in Table 10.2 was 
conducted using logistic regression, which used a stepwise process with 
backwards conditional as the variable selection method.342 Socio-economic status 
was entered as four dummy variables and RRMA as three dummy variables in 
Table 10.2. All statistical analyses were performed using SPSS for Windows 
11.5.343
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Results 
 
CHARACTERISTICS OF GPS AND THEIR PRACTICES 
 
Table 10.1 shows that there were 12,283 GPs involved in the care of cases and 
controls in 1999. In 1998-99, it was estimated that there were 24,176 providers of 
general practice care who billed Medicare in those years.d Thus the sample 
consisted of about 50% of the providers of general practice services in Australia 
at that time.254 
 
GPs were ascribed to one of three groups based on whether they had been 
attended by cases exclusively, controls exclusively or by both groups, with 
roughly one-third falling into each group (Table 10.1). When the groups were 
compared, case GPs were more likely to be male and to be overseas trained than 
control GPs, although, these factors were highest in GPs who had been attended 
by both cases and controls. However, case GPs were the least likely to have 
vocational registration.     
 
With regard to the principal medical practice, case GPs were more likely to work 
in low socio-economic areas than those of controls, although this was highest in 
GPs who had been attended by both cases and controls. However, case GPs were 
the most likely to work in geographically remote locations (RRMA 4).  
 
                                                 
d Providers of general practice services include vocationally registered GPs and other medical 
practitioners (OMPs).  OMPs include non-vocationally registered GPs as well as other medical 
practitioners who provide some general practice services (although they are not vocationally 
registered as GPs).  
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Table 10.1: Characteristics of GPs and their practices  
 
 
 
 
 Case  Control Both   P of differences 
     
Age,  mean (sd) 47.3(11.7) 46.9 (11.4) 47.1(11.0) 0.33  
Gender n (% male) 3103(72.9) 3110(69.1) 2849(80.8)  <0.0001 
Vocational registration, n (%) 3567 (83.8) 3850(85.6) 3067(87.0) <0.0001 
Overseas trained, n (%) 1192 (28.0) 1149(25.5) 1043(29.6) <0.0001 
     
SEIFA 1, n (%) 815 (19.1) 796(17.7) 850(24.1)  
SEIFA 2, n (%) 907(21.3) 863 (19.2) 682(19.3)  
SEIFA 3, n (%) 822(19.3) 892(19.8) 736(20.9)  
SEIFA 4, n (%) 853 (20.0) 939(20.9) 677(19.2)  
SEIFA 5, n (%) 861(20.2) 1009(22.4) 581(16.5) <0.0001 
     
RRMA 1, n (%) 2833 (66.5) 3019(67.1) 2375(67.4)  
RRMA 2, n (%) 310 (7.3) 360 (8.0) 345(9.8)  
RRMA 3, n (%) 983(23.1) 1030 (22.9) 747(21.2)  
RRMA 4, n (%) 132 (3.1) 90 (1.7) 59 (1.7) <0.0001 
     
Total, n (%) 4258(34.7) 4499(36.6) 3526(28.7) 12283 
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PREDICTING WHETHER GPS TREATED CASES OR CONTROLS  
 
The relationship between GP characteristics, vocational registration, the location 
of the principal medical practice and the development of diabetes complications 
was examined using a multivariate logistic regression model. This is captured in 
Table 10.2. As the factors that differentiate case GPs from control GPs was the 
primary focus of the study, GPs who had been attended by both groups were 
excluded from the analysis.  
 
In this model it was found that the strongest predictors of vision-threatening 
retinopathy were whether GPs were older, whether they had been vocationally 
registered, and whether their major medical practice was in a low socio-
economic or a non-metropolitan locality.   
 
 
Table 10.2: Logistic regression analysis comparing case to control GPs using demographic 
characteristics, vocational registration and characteristics of principal general practice (GPs who 
treated both groups excluded, n = 3184) 
 
RISK FACTOR OR 95% CI  P 
    
Age 1.004 1.0 – 1.008 0.04 
    
Vocational reg* 0.87 0.77 – 0.98 0.02 
    
SEIFA 1† 1.0  0.18 
SEIFA 2 1.08 0.94 – 1.24 0.27 
SEIFA 3 0.93 0.81 – 1.07 0.29 
SEIFA 4 0.92 0.80 – 1.06 0.26 
SEIFA 5 0.85 0.74 – 0.98 0.03 
    
RRMA 4 Remote‡ 1.0  0.02 
RRMA 3 0.67 0.50 – 0.89 0.009 
RRMA 2 0.61 0.44 – 0.83 0.002 
RRMA 1 Metropolitan 0.69 0.52 – 0.91 0.005 
Reference group = controls, *reference group = not registered,  
 † reference group = lowest SEIFA,  
‡ reference group = RRMA 4  
Model overall χ2 = 33.1, 9 df, p <0.0001.  
N = 8469 (case practitioners = 4114, Control practitioners = 4355) 
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Discussion  
 
The study examined the relationship between GP characteristics and the 
development of vision-threatening retinopathy using records contained in the 
Medicare database. A number of factors were found to differ between the GPs of 
cases and controls which may have been associated with the development of 
diabetes complications.  
 
Perhaps the most clinically significant finding concerned the lower proportion of 
vocational registration among the GPs of cases compared to control GPs and 
those who treated both groups. Vocational registration is an accreditation scheme 
for GPs that aims to ensure certain standards of care.254 These findings are 
consistent with studies that have compared register practitioners to non-register 
practitioners, and have found that registered practitioners provide higher quality 
care.334 
 
In addition, Table 10.2 shows that the strongest predictor of vision-threatening 
retinopathy was whether GPs practised in remote or rural locations. This accords 
with the Australian and international literature that has found diabetes 
complications to be more common in geographically isolated areas.33, 283 In 
addition, Table 10.2 shows that case GPs were also more likely to work in lower 
socio-economic areas. Again this is consistent with evidence linking social 
disadvantage with poorer health outcomes.22, 265, 279  
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When these findings are considered in the light of Chapters 4 to 9 there are a 
number of striking parallels between them, despite the very different methods 
used in the studies. When Table 10.2 is compared to 9.8 a similar differential in 
the risk of diabetes complications is apparent among isolated populations 
(although in Table 9.8, the relationship is non-significant). Similarly, when Table 
10.2 is compared to Table 8.8, a gradient in risk of complications is associated 
with socio-economic status (again not significant). This supports the patient data 
that also found these social and geographic factors to be risk factors for diabetes 
complications.  
 
With regard to vocational registration, which can be interpreted as a crude 
indicator of the knowledge and skills of GPs,334 the lower level of vocational 
registration among case GPs may be linked to the pattern of under-referral and 
under testing that is the hallmark of poorer quality care evident among cases.   
 
However, this study also contains a number of important limitations that must be 
considered when interpreting the findings. Firstly, the data did not identify the 
level of involvement of individual GPs in the care of patients: thus practitioners 
who were attended once were given equal weight to those attended multiple 
times. Whilst the care they provide may have ranged from a single episode to 
intense clinical involvement, the data did not allow this distinction to be made. 
Secondly, GPs were chosen only from 1999, whereas records from one year may 
be insufficient to represent how GPs provide diabetes care.  Finally, there was a 
very limited number of risk factors available for examination in the study, so a 
large number of potential determinants could not be included in the analysis.172 
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This meant that the study could only provide a very crude account of the 
association between GPs and the development of diabetes complications and 
further research is needed to validate these findings.    
 
In the context of these limitations, the findings indicate that the characteristics of 
practitioners may have played a role in the development of complications and 
this may relate to the nature of medical care provided to cases versus controls. 
However, because these data and methods were limited the significance of 
provider characteristics in the development of complications could not be 
determined. The major usefulness of the study to the thesis is that it confirms a 
number of findings in other chapters, namely the greater risk of advanced 
complications in lower socio-economic groups and in remote areas. In addition, 
the study also reinforces the contention of the importance of providing high 
quality of care in the management of diabetes.  
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Chapter 11 
 
Discussion 
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Structure of the discussion  
 
The studies in Chapters 4 to 10 represent a comprehensive examination of the 
capacity of the Australian health care system to manage diabetes, based on an 
analysis of the relationship between patients’ patterns of care and the health 
outcome of vision-threatening retinopathy. The discussion brings together these 
findings and identifies the key messages of the thesis. The first section 
summarises the major findings of each of the seven studies. In Section 2 these 
findings are integrated and the key findings identified. Section 3 discusses the 
major implications of the thesis for the health care system to enable it to  
effectively and equitably manage diabetes. 
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Section 1: Major findings of research questions 
 
RESEARCH QUESTION 1  
To determine whether patterns of primary health care utilisation are a risk factor 
for the development of diabetes complications in the population with diabetes in 
Australia.  
 
The first study in this thesis showed that diabetes patients who developed vision-
threatening retinopathy had significantly lower levels of diabetes related health 
care utilisation across almost all of the aspects of primary and secondary care 
that were examined. Overall, those who developed vision-threatening retinopathy 
had a pattern of care that included delayed diagnosis, lower levels of medical 
care attendances, under-testing for diabetes related pathology tests and under-
referral to specialists and optometrists over a seven-year period when compared 
to those who did not develop this complication.  
 
A second major finding was the under-utilisation of GPs among those who 
developed vision-threatening retinopathy, and the study suggests both 
quantitative and qualitative dimensions to this risk factor. On the quantitative 
dimension, the number of attendances at GPs may have been critical in 
determining the quality of care and the progress of diabetes, as GP attendance 
enables access to most aspects of diabetes management.39 
 
In addition, qualitative differences in care are suggested by the major disparities 
in testing for HDL cholesterol between cases and controls. The significance of 
this test lies in its specificity to glucose metabolism conditions and its rare use 
for other disorders.22 However, HDL-cholesterol is a less commonly used 
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pathology test for identifying dyslipidaemia in diabetes. The most common tests 
used for this purpose are LDL or total cholesterol.22 Therefore, its use can be 
regarded as a marker of a greater understanding of diabetes among the 
practitioners who use it. These findings suggest that there were deficiencies in 
provider behaviour perhaps explained by a lack of time or even poor 
competency, and that this may have contributed to the development of vision-
threatening retinopathy.    
 
RESEARCH QUESTION 2 
To determine whether state and territory health care systems determine the 
effectiveness of diabetes management. 
 
The second study found significant differences between cases and controls with 
regard to the timing of diagnosis and the patterns of care that were consistent 
across states and territories. This finding suggests that similar factors were 
involved in the development of advanced diabetes complications in all 
jurisdictions. This is despite the likelihood that patients had obtained some of 
their care in state and territory health care systems that may have had different 
methods for managing diabetes.173  
 
Where differences between states and territories were identified, these were often 
difficult to relate to the risk of vision-threatening retinopathy. For example, 
differences in specialist attendances between jurisdictions, as well as in HbA1c 
testing were not associated with a higher risk of retinopathy. Again this suggests 
that despite differences in health care systems, the medical care provided may 
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have been of a very similar nature across all jurisdictions, although it may have 
been delivered by different combinations of health care practitioners. 
 
Noteworthy differences in the combinations of health care practitioners were 
identified in the states and territories. For example, in states where specialists and 
consultant physicians played a greater role in patients’ care, this was matched 
with higher levels of GP utilisation. Conversely, in jurisdictions where specialists 
played a lesser role, GPs were also utilised less. This suggests that the greater 
utilisation of one type of practitioner tends to increase the use of others (Tables 
5.3 and 5.5). Nevertheless, higher levels of utilisation did not necessarily lead to 
fewer occurrences of vision-threatening retinopathy.  
 
When states and territories were compared using logistic regression analysis, 
some differences in the risk of diabetes complications between jurisdictions 
became apparent. People with diabetes in Victoria, Queensland and Tasmania 
were found to be at a higher risk of developing complications. However, when 
major risk factors for complications were compared between jurisdictions (GP, 
specialist attendances as well as HbA1c testing), no marked differences were 
evident. This suggests that risk factors for complications were very similar in 
each state and territory and that the factors that determined the effectiveness of 
diabetes management related to the health care system at the national level.173 
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RESEARCH QUESTION 3 
To determine whether patterns of care or delayed diagnosis is the more 
significant risk factor for the development of diabetes complications in the 
population with diabetes in Australia. 
 
Significant differences were found in the patterns of care for cases and controls 
in this third study. Selection of subjects on the basis of having been diagnosed 
with diabetes prior to 1995 allowed for an investigation of the impact of diabetes 
management in an early-diagnosed group. That patterns of care were found to be 
a risk factor for advanced complications points to the importance of the quality 
of diabetes management in preventing these conditions. The study showed that 
whilst early diagnosis was desirable, it was only beneficial if it initiated 
appropriate diabetes management over time. Where this did not occur, patients 
remained at risk of developing advanced complications such as vision-
threatening retinopathy.  
 
RESEARCH QUESTION 4 
To determine whether patterns of care prior to the diagnosis of diabetes is a risk 
factor for the development of diabetes complications in Australia.    
 
The fourth study showed that patterns of care predicted the development of 
complications in patients with a delayed diagnosis. This suggests that health care 
utilisation prior to the diagnosis of diabetes may have been a significant risk 
factor for the development of advanced diabetes complications.36  
 
The difference between cases and controls was similar to that found in the 
previous study. This suggests that similar factors may be involved in determining 
health care utilisation both preceding and following diagnosis. This points to the 
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utilisation of health care being a somewhat stable characteristic of patients, and  
not totally determined on the basis of need.354  
 
In an attempt to explain differences between case and control groups in this 
study, socio-economic status was entered as a risk factor into the logistic 
regression model in Table 7.4. These findings indicated that of people with 
diabetes who do not have a diagnosis, those who are of low socio-economic 
status are at higher risk of developing advanced complications.  
 
RESEARCH QUESTION 5 
To determine whether socio-economic status is a risk factor for diabetes 
complications in Australia 
 
The fifth study showed that there was a greater risk of complications in lower as 
compared to higher socio-economic groups. This was evident in the univariate 
analysis and the logistic regression model, although in the latter, socio-economic 
status was not significant. This accords with a large body of evidence concerning 
the association between socio-economic status and diabetes.270, 272, 273 
 
When the findings are considered in the light of the studies reported in Chapters 
6 and 7, they may be explained by socio-economic status being influential in the 
late diagnosed group, but not in the early diagnosed population. Thus in 
investigating the relationship between socio-economic status and advanced 
diabetes complications across the diabetes population, the strong relationship 
evident in Chapter 7 in the late diagnosed group was diluted as socio-economic 
status was not related to complications in other populations.   
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However, the nature of this greater risk in lower socio-economic groups is 
difficult to determine as low status patients made more use of GPs than higher 
status groups and were tested for HbA1c more often. The major difference 
between the groups concerned the higher use of specialists by higher status 
patients. This suggests that greater specialisation in diabetes care could lead to 
the reduced risk of advanced complications.349  
 
On the other hand, the benefits of specialisation were not borne out by the other 
studies that were able to investigate this aspect of care. For example, the greater 
use of specialists in particular states did not reduce the risk of complications in 
Chapter 5. This suggests that the lower risk of advanced complications in high 
socio-economic groups may be related to some other factor or factors that were 
not included in the study. For example, it may be that diabetes was less severe in 
high status groups or that they had a greater capacity to manage the condition. 
Whilst higher status groups could have had better self-management, this is not 
supported by the broader epidemiological literature.154 
 
RESEARCH QUESTION 6 
To determine whether geographic isolation is a risk factor for diabetes 
complications in Australia. 
 
There appear to be two distinct populations in Australia with regard to 
geographic isolation and diabetes: those who live in metropolitan areas and those 
who live in rural or remote localities, as these two groups face different levels of 
risk of developing diabetes complications.33 In this study a greater proportion of 
controls were found in more populous areas and more cases were found in 
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comparatively isolated localities. This suggests that diabetes may be more 
prevalent in metropolitan areas, but more severe in rural and remote localities. 
Hence, people with diabetes in more isolated localities may be at higher risk of 
developing advanced diabetes complications (although in the multivariate 
analysis the relationship was found not to be significant).33  
 
A principal concern with regard to geographic isolation relates to poor access to 
health care. Whilst geographic isolation was identified as a major risk factor in 
the study, its relationship to the development of advanced complications was 
complex. While rural and remote populations had lower levels of health care 
utilisation, this was not true for other risk factors included in the study. This 
suggests the level of health care utilisation was not solely determined by 
proximity to health care services, but also by factors that are more general across 
the diabetes population, such as low self-efficacy and poor self-management.151 It 
is probable that the factors that determine the development of advanced diabetes 
complications in rural and remote localities are very similar to those of the 
broader Australian population.  
 
Whilst the lower risk of diabetes complications found in metropolitan, outer 
metropolitan and rural areas may be indicating the benefits of specialist care, 
similar to the findings above, higher levels of such care do not automatically lead 
to a reduction in the risk of complications, as was discussed above. Hence, the 
advantage for people with diabetes who live in metropolitan areas may not just 
lie in having the greater utilisation of more knowledgeable practitioners, it may 
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also be explained by better overall health status, or perhaps some element of 
lifestyle that is protective of complications in more populous localities.279  
 
RESEARCH QUESTION 7 
To determine whether the characteristics of GPs are associated with the risk of 
complications in Australia.  
 
The study in Chapter 10 represents a substantial departure from the preceding six 
studies in that it used provider data to examine risk factors for the development 
of advanced diabetes complications. It sought to examine, whether, and if so 
which, GP characteristics determine the risk of developing vision-threatening 
retinopathy.  
 
The study found that there were many similarities between the GPs of cases and 
those of controls. Indeed in many cases, the greatest difference in GPs concerned 
practitioners who had treated both types of patient. Whilst the data used in this 
study were limited, a number of significant factors emerged in the statistical 
analyses that could be related to the development of advanced diabetes 
complications in patients. 
 
Perhaps the most significant factors related to the geographic location of the 
principal general practice: the GPs of cases were more likely to practise in low 
socio-economic and rural and remote localities than the GPs of controls. This 
accords with the patient findings in studies in Chapters 6 to 9, which found that 
people with diabetes of lower socio-economic status, as well as those who lived 
in rural areas, were at a higher risk of developing advanced complications.  
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Another notable characteristic that could be related to the development of 
advanced complications was vocational registration. As vocational registration is 
potentially an indicator of the level of skills and knowledge of GPs with regard to 
the provision of primary health care, the GPs of cases may have been less skilled 
or knowledgeable than those of controls.334 Whilst a more comprehensive 
indicator of the knowledge and skills of GPs would be needed to validate this 
finding, they accord with some of the findings in the patient studies, which also 
included a proxy indicator for the skills and knowledge of GPs, HDL-cholesterol 
testing as was discussed in Chapter 3. Together, these findings suggest that case 
GPs were less skilled and knowledgeable than control GPs and that this may 
have led to an increased risk of advanced diabetes complications.  
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Section 2: Key messages and implications 
 
Together the studies comprising this thesis represent an evaluation of the 
capacity of the Australian health care system to manage diabetes. Major 
differences between cases and controls were found in respect of this capacity. 
These related to patients’ patterns of care, the timing of diagnosis and equity. 
Key messages and implications in respect of the findings are explored below.    
 
PATTERNS OF CARE AND THE RISK OF ADVANCED DIABETES COMPLICATIONS 
 
The consistency of the relationship between patterns of care and diabetes 
complications found in the studies suggests that people who develop advanced 
complications are a distinctive group with long-term and sustained problems 
associated with diabetes management and health care utilisation. These 
difficulties transcend state and territory borders as well as socio-economic status 
and level of geographic isolation, and suggest the need for a national and 
consistent approach to the management of diabetes so that the system can be both 
equitable and effective.  
 
The differences in the patterns of care between those that developed an advanced 
complication and those that did not were reflected in cases’ under-utilisation of 
GPs, specialists and pathology tests over a seven-year period, and these 
differences were common across each of the studies comprising the thesis. As 
well as revealing stark quantitative differences in levels of care, the findings also 
point to qualitative differences in the nature of care as important. Qualitative 
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differences were suggested by the lower level of HDL-cholesterol testing among 
cases in Chapters 4 to 9, and the lower level of vocational registration among the 
practitioners of cases found in Chapter 10. The qualitative differences suggest 
that even where patients have adequate access to health care they may still be 
disadvantaged with regard to diabetes management.353 
 
When the logistic regression analyses are considered the most important aspects 
of diabetes care for the prevention of complications become apparent. In the 
majority of these analyses, the smallest odds ratios belong to optometry 
attendances and HDL-cholesterol attendances, indicating that these measures are 
most strongly associated with the prevention of advanced diabetes complications.  
 
The significance of optometry attendances is likely to be pointing to the 
importance of screening for retinopathy,79 and this was reinforced by the odds 
ratios for specialist attendances in the models, which were also higher in controls 
and include visits to ophthalmologists. Whilst the significance of HDL-
cholesterol testing may lie in its relative obscurity as an aspect of diabetes 
management, use of this test suggests a more sophisticated understanding and 
approach to diabetes management on the part of practitioners.353 As patients who 
received this test may also have been more likely to obtain other testing and 
monitoring included in the guidelines, it may be an indicator of overall better 
diabetes care.  
 
However, the clinical literature suggests that HbA1c testing is the most important 
test, as it is directly related to hyperglycaemia.207 But the differences in HbA1c 
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testing between cases and controls were not as great as between the two previous 
risk factors. This suggests that most doctors understand the significance of 
HbA1c, but fail to understand the importance of the other elements included in 
the clinical management guidelines such as HDL-cholesterol testing.  
 
Another important finding was captured in Tables 6.3 and 7.3, which presented 
the univariate analyses of health care utilisation of two different sub-groups. 
Table 6.3 presented results from the early-diagnosed group, and Table 7.3, 
results from patients whose diagnosis had been delayed. These studies could be 
considered to be comparing two different phases in the development of diabetes.  
 
These analyses showed that the differential in the frequency of GP attendances 
between cases and controls was of a similar magnitude in both the pre-diagnosis 
(Chapter 7) and post-diagnosis periods (Chapter 6), with cases attending between 
a half and a third less often than controls. In addition, there were consistent 
differences in specialist attendances.  
 
When the pre-and post-diagnosis periods are compared, the findings suggest that 
the disadvantage experienced by cases in respect of diabetes management may 
have its origins in the earlier period.25, 36 This suggests that cases may belong to a 
group that is generally disadvantaged with regard to the utilisation of health care 
and that the development of advanced diabetes complications is largely due to 
pre-diagnosis experiences.   
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Whilst it is difficult to determine the factors that separated cases from controls in 
respect of patterns of care, Pringle et al. have argued that the management of 
chronic disease is determined by a number of sets of factors: those related to 
practitioners, to patients and to the health care system. While there is some 
evidence that all three are at play in the findings of the studies comprising the 
thesis, in the literature review it was argued that the most significant factor that 
determined the standard of diabetes care across the population is the nature of the 
health care system.172 This is supported by the literature that formed the basis for 
Wagner et al.’s Chronic Care Model and which provided sound evidence that 
where the health care system has a greater focus on acute conditions, the standard 
of diabetes management is poor.196 However, where greater structure is provided, 
the standard of diabetes care is much improved.197  
 
Wagner et al.’s Chronic Care Model, detailed in the literature review, emphasises 
the need for infrastructure to support planned and systematic care.38 The 
infrastructure that has been found to be most effective in this regard are diabetes 
registers, reminder and recall systems. Whilst this type of infrastructure has only 
been introduced in a very limited way in Australia,190 other less tangible factors 
that are linked to the structure of the system may also play a role in the 
effectiveness of diabetes management. For example the value of continuity of 
care in the management of diabetes has been well demonstrated,364 and controls 
may have been more likely to have a regular diabetes doctor.  
 
The findings indicate the need for measures to improve health care utilisation in 
patients who are disadvantaged in this regard, as well as both the quantity and 
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quality of health care for people with diabetes. With regard to the former, factors 
that have been found to lead to lower levels of health care utilisation include 
socio-economic, gender and ethnicity characteristics, as well as the poor supply 
of GPs.354 The Australian and international literature demonstrates the 
importance of addressing these and other barriers to care.365  
 
Perhaps the primary contribution of this thesis is in illuminating the differences 
and consequences of the patterns of care. Whilst low levels of health care 
utilisation have been identified before in studies of diabetes,22, 183 few have been 
able to link actual health care utilisation to the development of an advanced 
complication. As cases were found to have significantly lower levels of health 
care utilisation and pathology testing, the thesis provides a strong argument for 
the development of strategies to increase their engagement with the health care 
system. 
 
Since the period selected for the present analysis, measures have been introduced 
to improve diabetes management in Australia. Use of the clinical management 
guidelines is now supported by their formal incorporation into Medicare 
schedules under the Practice Incentive Program and Service Improvement 
Programs,174 where GPs are now paid to manage diabetes on an annual basis. 
However, this initiative has not yet been evaluated in terms of its capacity to 
prevent diabetes complications. The studies comprising this thesis would provide 
a useful baseline for the evaluation of these measures.  
 
 341
DELAYED DIAGNOSIS AND THE RISK OF ADVANCED DIABETES COMPLICATIONS 
 
Over fifty-percent of patients in this thesis who developed vision-threatening 
retinopathy may not have been diagnosed with diabetes prior to the development 
of their advanced complication. This suggests that a significant proportion of 
people with diabetes received delayed diagnosis.  
 
The risk associated with delayed diagnosis stems from the nature of medical care 
in the period prior to diagnosis, as during this period patients would not have 
been having their diabetes managed. The association between delayed diagnosis 
and advanced complications observed in this thesis is consistent with the clinical 
evidence presented in the literature review that shows that the benefits of 
screening and monitoring, as represented in the clinical management guidelines, 
are only forthcoming when the preventive interventions are initiated early and 
sustained over the duration of diabetes.12 In the absence of diagnosis there is no 
means by which diabetes management and the prevention of complications can 
occur.  
 
With regard to the factors associated with delayed diagnosis, the study points to a 
number of possible explanations. Firstly, the level of health care utilisation 
among cases was much lower than that of controls, pointing to a reduced 
opportunity for cases to obtain a diagnosis. In addition, practitioner related 
factors such as the characteristics of GPs may have played a role. In the studies 
in Chapters 4 to 10, there were signs that the practitioners of cases were less 
knowledgeable and skilled with regard to diabetes.41, 353 In addition, they may 
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have had limited incentives to identify diabetes especially where this condition is 
not the presenting problem.38 In conventional medicine, where the system is 
structured around acute illnesses, GPs tend to deal with the problem at hand thus 
limiting opportunities for more holistic or preventive health care.38  The thesis 
also points to the significance of lower socio-economic status being a factor in 
delaying diagnosis, which is discussed below.  
 
Whilst the majority of people with diabetes in Australia received timely 
diagnosis, as indicated by the more even spread of earliest HbA1c testing in 
control subjects across the study years in Table 4.2, there appears to be a sizeable 
minority of patients who are disadvantaged because their diagnosis was delayed. 
This group would potentially benefit from strategies to bring forward the time of 
diagnosis, thus enabling diabetes management to be initiated earlier.357, 360    
 
This is the first time a population-based study has shown a link between delayed 
diagnosis, health care utilisation and the development of an advanced diabetes 
complication in Australia. Whilst the study shows that delayed diagnosis 
represents a considerable threat to the health of people with diabetes, it also 
shows that it is not a general problem across the diabetes population. This 
suggests that programs promoting early diagnosis could be targeted at high-risk 
populations.    
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EQUITY AND DIABETES MANAGEMENT  
 
This thesis examined in detail two important dimensions of equity in respect of 
the development of advanced diabetes complications: socio-economic status and 
geographic isolation. A third aspect of equity, Aboriginal and Torres Strait 
Islander health was also investigated, although in a more limited way.  
 
A number of studies in the thesis investigated the relationship between socio-
economic status and the development of advanced diabetes complications, but 
perhaps the most significant findings occurred in Chapters 6 and 7.   
 
In these chapters socio-economic status was entered into a logistic regression 
analysis in order to explore its significance as a risk factor for advanced diabetes 
complications. In the study in Chapter 7, which examined patients whose 
diagnosis had been delayed, lower socio-economic status was found to be an 
important risk factor for the development of advanced complications. Indeed, 
patients of lower socio-economic status and who received a delayed diagnosis 
were almost twice as likely to develop advanced diabetes complications than 
similar patients of higher socio-economic status.  
 
Some of the factors that may account for socio-economic differences in the risk 
of advanced complications include the quality of care, as lower socio-economic 
groups have been found to attend specialists less often,22 to rely more on 
conventional doctor-patient relationships305 and are less likely to attend for 
preventive care.317, 318 In addition, there are class based cultural and value 
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differences between GPs and socially deprived patients that can also impact on 
the quality of care.41 By contrast, in Chapter 6, which investigated an early-
diagnosed group, the risk of advanced complications was found not to be related 
to socio-economic status.  
 
This suggests that much of the greater burden of diabetes complications in low 
socio-economic groups may be related to delayed diagnosis, and points to the 
need for the implementation of early diagnosis strategies among low socio-
economic groups.357 Moreover, and perhaps surprisingly, it indicates that the 
management of diabetes as it was conducted in the 1990s was able to overcome 
important social inequalities in diabetes once diabetes had been diagnosed.  
 
The lack of significance of socio-economic status in Table 6.4 suggests that 
among those who had been diagnosed early, both higher and lower socio-
economic groups were able to obtain similar levels of health care for the 
management of diabetes. It seems likely that the Medicare system, with its goal 
of equal access to care for equal need, was at work here.258 As lower socio-
economic groups can be vulnerable to high health care costs the subsidies 
provided by the Medicare system allowed poorer patients access to health care.366 
That this has resulted in comparable levels of risk of advanced diabetes 
complications across socio-economic groups, points to the value of maintaining 
the Medicare system as the basis of diabetes management.   
 
With regard to addressing socio-economic disadvantage and diabetes, strategies 
to improve timely diagnosis should be prioritised. Whilst population screening 
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for diabetes is often seen as an inappropriate strategy for identifying diabetes,357 
there is some evidence that it may be effective in high-risk groups, such as the 
low socio-economic patients studied here. Pro-active case finding could be 
encouraged through programs targeting medical practitioners to get them to more 
effectively diagnose diabetes.360 
 
Even though the thesis may be showing that socio-economic differentials in the 
risk of vision-threatening retinopathy were addressed by the Australian health 
care system, the level of diabetes management in the population still appeared to 
be below that recommended by the clinical management guidelines.74 This 
suggests that the population remained at risk of developing advanced diabetes 
complications, even though for most vision-threatening retinopathy had been 
avoided in 2000.12  
 
Whilst a number of studies have shown that low socio-economic groups have a 
higher risk of diabetes complications,32, 161 as well as lower levels of health care 
utilisation,22 this is the first study to show that these two factors are linked. 
Further research on the specific factors at play in preventing people of low socio-
economic status being diagnosed with diabetes should inform the development of 
appropriate strategies to address this inequality in diabetes care. 
 
The second aspect of equity examined in the thesis concerns geographic 
isolation. The role of geographic isolation as a risk factor for the development of 
advanced diabetes complications was investigated in Chapter 9, where people 
with diabetes who lived in remote localities were found to be at twice the risk of 
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complications than patients who lived in metropolitan or other localities. In 
addition, the analyses showed that differences between cases and controls found 
in the earlier studies in this thesis were broadly consistent across all geographic 
areas. This suggests that the factors leading to the development of complications 
in remote localities were similar to those that account for complications in 
metropolitan areas.    
 
However, the study also found that some aspects of health care utilisation, such 
as delayed diagnosis, were not determined by geographic isolation. This suggests 
that whilst highly significant, proximity to health care services may not be the 
absolute barrier to health care that it is often assumed to be.367, 368 
  
The introduction of the Chronic Care Model within geographically remote areas 
represents a significant challenge to the health care system, but if advanced 
diabetes complications are to be prevented equitably, ways in which to introduce 
at least some of the model must be found. In the literature review the significance 
of information technology for improving the quality of care in remote or 
disadvantaged localities was suggested as one way in which the management of 
diabetes could be improved in these settings.249 
 
Whilst only a relatively opaque examination of the role of patterns of care and 
the development of complications among Aboriginals and Torres Strait Islanders 
was able to be conducted due to limitations in the Medicare data, the findings 
reaffirm that this population is particularly disadvantaged with regard to 
diabetes.30 Of most concern was the younger age of people with diabetes in the 
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Northern Territory, as well as the lower level of health care utilisation in cases in 
this jurisdiction.  
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Section 3: Conclusion: How the studies add to the understanding of 
diabetes management  
 
Having examined such issues as whether diabetes management was adequate 
during the 1990s, whether the health care system should focus on the 
management of diabetes or on screening, whether interventions should be 
concentrated on primary or tertiary care, whether programs should be introduced 
to promote equity in how diabetes is addressed, and whether medical 
practitioners need to be better skilled in diabetes care, the studies comprising this 
thesis have important implications for the management of diabetes in Australia,       
  
Since the findings of the DCCT were published in 1993,3 the evidence 
concerning the efficacy of clinical interventions to prevent advanced 
complications has been very strong.12 However, because population-based 
studies of diabetes interventions are rare, it has not been established whether 
clinical interventions when provided across a population, can be effective in 
preventing diabetes complications in a national population.11 This thesis has 
addressed that gap by showing an association between clinically effective 
interventions and the prevention of complications.  
 
In addition, in conducting a public health analysis of the effectiveness of clinical 
interventions, the thesis was able to identify problems with the management of 
diabetes across the Australia health care system. These problems were found to 
be related to the standard of diabetes management, as indicated by the patterns of 
care. In addition, significant equity issues in respect of diabetes care and 
 349
outcomes were identified, suggesting the need for particular segments of the 
population to be prioritised in the provision of diabetes care. Further, in 
identifying these problems, the studies also pointed to potential strategies by 
which they could be addressed, such as early diagnosis strategies in lower-socio-
economic groups.  
 
Perhaps the strongest finding was the broad need for improvements in the 
implementation of diabetes management in Australia. The findings were clear 
that improvements are required in both the quality and quantity of diabetes care. 
Those subjects that did not develop complications were more likely to utilise care 
more and to show indicators of having received better quality care. Importantly, 
whilst cases were shown to be a particularly disadvantaged group in respect of 
care, the level of health care utilisation in controls indicated that they also 
received inadequate diabetes management. Whilst the thesis suggested ways in 
which the diabetes management for cases could be improved, at least to the level 
of controls, it was not able to determine how the level of management could be 
optimised across the diabetes population. However, it did demonstrate a need for 
such improvement. 
 
Some of the most significant factors to consider with regard to reducing the risk 
of complications concerned low socio-economic status. With regard to 
addressing this risk factor, the studies suggested that there may be a need for 
early intervention programs, with a particular focus on low socio-economic 
groups to ensure more equitable diabetes outcomes in Australia.  
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In addition, the pre-diagnosis period was found to be highly significant in the 
development of advanced complications, and two types of strategies were 
suggested by the findings. For people with diabetes, strategies that promoted 
timely diagnosis were supported. For the general population, health promotion 
programs focused on cardiovascular risk factors were also supported as being of 
potential benefit to people with diabetes. 
 
Some implications also emerged in relation to GP characteristics. While findings 
suggest that the practitioners of cases may have been less able to manage 
diabetes than the practitioners of controls, this analysis was not definitive. 
Moreover, the consistent differences in the patterns of care shown in the studies 
suggest that the major problem in Australia lies with the health care system and 
not with the characteristics of practitioners. These findings accord with overseas 
studies showing that when the health care system is re-oriented towards the 
provision of chronic disease, the quality of care improves.277 They also suggest 
that practitioners are generally capable of providing effective diabetes 
management if the appropriate structures and incentives are put in place.197   
  
Having provided strong epidemiological evidence in support of the need for 
effective and equitable diabetes management, the task now turns to how the 
Chronic Care Model can be implemented in Australia. In the literature review, it 
was argued that the scope of the reform required would represent a significant 
barrier to the introduction of the model.258 However, given the findings of these 
studies, it may have become a bit easier to advocate for its introduction to health 
care policy makers and professionals.  
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With regard to addressing diabetes in Australia and the need to focus on 
particular risk groups, the literature review identified potential problems 
associated with the implementation of the Chronic Care Model in disadvantaged 
populations.237 However, the findings of the studies in this thesis suggest that a 
focus on socio-economic status may not be necessary with regard to diabetes 
management (except in respect of promoting earlier diagnosis) as long as access 
to health care remains comparably equal across socio-economic groups, as is 
currently enabled through the Medicare system. Whilst establishing the Chronic 
Care Model in isolated populations will remain a substantial challenge, the 
findings point to proximity to health services not being an absolute barrier to 
access to diabetes care that it often assumed to be. This may mean that there is 
considerable scope for improving the management of diabetes in isolated 
populations through the health care system as it currently operates.  
 
There is a great opportunity to use diabetes and its related microvascular and 
macrovascular complications as a vehicle to establish integrated health care 
models of care. By their very nature these systems would incorporate 
Commonwealth and state governments and create chronic disease centres that 
would link the activities of primary and secondary care settings. These centres 
would also provide the key IT infrastructure that would facilitate communication, 
information transfer, scheduling and recall systems. A necessary component of 
these centres would be the provision of training in chronic disease self-
management for patients as well as allied health staff that would assist general 
practice. Finally, this approach would allow for innovative funding models that 
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would enable and provide incentives to optimise best practice care. If there is no 
structural reform then the cost of diabetes, secondary to complications of 
blindness, kidney disease, stroke and heart disease will continue to rise 
inexorably.  
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